inchikey	drugbank_id	drug_name	groups	atc_codes	description	cas_number
XEEQGYMUWCZPDN-SWLSCSKDSA-N	DB05636	(+)-Mefloquine	investigational	nan	(+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to compare the efficacy of (+) Mefloquine vs. racemic [Mefloquine].	51688-68-7
MPBUFKZCEBTBSK-UHFFFAOYSA-N	DB07409	(1-HYDROXY-1-PHOSPHONO-2-[1,1';4',1'']TERPHENYL-3-YL-ETHYL)-PHOSPHONIC ACID	experimental	nan	nan	nan
IJEGNOYPWRBKAE-UHFFFAOYSA-N	DB06830	(1-HYDROXYHEPTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)	experimental	nan	nan	nan
COHUUYPEYRMWTH-UHFFFAOYSA-N	DB06931	(1-HYDROXYNONANE-1,1-DIYL)BIS(PHOSPHONIC ACID)	experimental	nan	nan	nan
VZBQJKIOAOUYJL-UHFFFAOYSA-N	DB03062	(1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone	experimental	nan	nan	nan
CMWRPDHVGMHLSZ-GFCCVEGCSA-N	DB07430	(10R)-10-methyl-3-(6-methylpyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one	experimental	nan	nan	nan
NTSPHKOMJMBWOU-NNKXXINSSA-N	DB07596	(17beta)-17-(cyanomethyl)-2-methoxyestra-1(10),2,4-trien-3-yl sulfamate	experimental	nan	nan	nan
KWEFZSZCLBHIEQ-YYADALCUSA-N	DB08553	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime	experimental	nan	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.	nan
BZVYQWLRCHLAGK-QGZVFWFLSA-N	DB07772	(1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid	experimental	nan	nan	nan
AYFCYVLVRYQGME-QGZVFWFLSA-N	DB08170	(1R)-N,6-DIHYDROXY-7-METHOXY-2-[(4-METHOXYPHENYL)SULFONYL]-1,2,3,4-TETRAHYDROISOQUINOLINE-1-CARBOXAMIDE	experimental	nan	nan	nan
VCOUEHUEFUDZIS-PMACEKPBSA-N	DB08244	(1S)-1-CYCLOPROPYL-2-[(2S)-4-(2,5-DIFLUOROPHENYL)-2-PHENYL-2,5-DIHYDRO-1H-PYRROL-1-YL]-2-OXOETHANAMINE	experimental	nan	nan	nan
BZVYQWLRCHLAGK-KRWDZBQOSA-N	DB07713	(1S)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid	experimental	nan	nan	nan
SGHXFHRRWFLILP-XJDXJNMNSA-N	DB07107	(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE	experimental	nan	nan	nan
NKBDSMREMMRFSI-INIZCTEOSA-N	DB08497	(1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate	experimental	nan	nan	nan
ULDXUWXTVRRUND-SWLSCSKDSA-N	DB02367	(1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine	experimental	nan	nan	nan
USPFJPDEADLGIG-HSZRJFAPSA-N	DB08674	(20S)-19,20,21,22-TETRAHYDRO-19-OXO-5H-18,20-ETHANO-12,14-ETHENO-6,10-METHENO-18H-BENZ[D]IMIDAZO[4,3-K][1,6,9,12]OXATRIAZA-CYCLOOCTADECOSINE-9-CARBONITRILE	experimental	nan	nan	nan
UFQOXIMRSMFQRI-BQYQJAHWSA-N	DB07350	(2E)-N-hydroxy-3-[1-methyl-4-(phenylacetyl)-1H-pyrrol-2-yl]prop-2-enamide	experimental	nan	nan	nan
ZCIXBBSRVLSRJQ-QPJJXVBHSA-N	DB08564	(2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide	experimental	nan	nan	nan
GNLAGGCSJGJECE-MRXNPFEDSA-N	DB07750	(2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol	experimental	nan	nan	nan
YMJHMJLNQLVUAV-GHYUOPHCSA-N	DB07211	(2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE	experimental	nan	nan	nan
HOCBJBNQIQQQGT-LJQANCHMSA-N	DB08463	(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol	experimental	nan	nan	nan
LUCFRFDOOYLALP-CYBMUJFWSA-N	DB07290	(2R)-2-{[(4-FLUORO-3-METHYLPHENYL)SULFONYL]AMINO}-N-HYDROXY-2-TETRAHYDRO-2H-PYRAN-4-YLACETAMIDE	experimental	nan	nan	nan
SQUNOCMDMIQIQK-OAHLLOKOSA-N	DB08285	(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol	experimental	nan	nan	nan
ZLZXUNHJWVLGTE-DLBZAZTESA-N	DB07592	(2R)-3-Methyl-1-phenyl-2-butanyl [(2S)-1-oxo-2-hexanyl]carbamate	experimental	nan	nan	nan
YDMIPBHQKFOFQW-NSYGIPOTSA-N	DB07145	(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE	experimental	nan	nan	nan
XSBZZZGVAIXJLD-YUMQZZPRSA-N	DB07482	(2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE	experimental	nan	nan	nan
MMOUXLMPQFMDRD-JOCHJYFZSA-N	DB07861	(2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide	experimental	nan	nan	nan
VXDKQRWTOJFQKH-BJZITVGISA-N	DB06837	(2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide	experimental	nan	nan	nan
FTSCEGKYKXESFF-LXTVHRRPSA-N	DB08283	(2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL	experimental	nan	nan	nan
XPVKGTWRXBSJKO-LHXLBICKSA-N	DB07567	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL	experimental	nan	nan	nan
YWTBGJGMTBHQTM-IBGZPJMESA-N	DB08073	(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	experimental	nan	nan	nan
MEIJADBULOETOV-KRWDZBQOSA-N	DB07501	(2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol	experimental	nan	nan	nan
TUOXPJFCQDMQOX-YFKPBYRVSA-N	DB07003	(2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine	experimental	nan	nan	nan
PAWOPJKHTZCKMT-QFIPXVFZSA-N	DB06908	(2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID	experimental	nan	nan	nan
QELOIXSGJMIHBZ-MSOLQXFVSA-N	DB07448	(2S)-3-[(R)-[(1S)-1-amino-3-phenylpropyl](hydroxy)phosphoryl]-2-benzylpropanoic acid	experimental	nan	nan	nan
WFFMEXQHWXEKBV-SFHVURJKSA-N	DB08246	(2S)-4-(2,5-DIFLUOROPHENYL)-N,N-DIMETHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE	experimental	nan	nan	nan
NKLVBHMAIMEVEH-QFIPXVFZSA-N	DB08239	(2S)-4-(2,5-DIFLUOROPHENYL)-N-METHYL-2-PHENYL-N-PIPERIDIN-4-YL-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE	experimental	nan	nan	nan
IOSAAWHGJUZBOG-WDEREUQCSA-N	DB07711	(2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol	experimental	nan	nan	nan
XCCSSVMRGIQMGF-LPHOPBHVSA-N	DB06994	(2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine	experimental	nan	nan	nan
YUDQXOMZBLEWBH-KAMYIIQDSA-N	DB08172	(2Z)-N-(3-chloro-2'-methoxybiphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide	experimental	nan	nan	nan
YDWPQZUWZDRRSE-AATRIKPKSA-N	DB02139	(2e)-N-Allyl-4-{[3-(4-Bromophenyl)-5-Fluoro-1-Methyl-1h-Indazol-6-Yl]Oxy}-N-Methyl-2-Buten-1-Amine	experimental	nan	nan	nan
QJSMFUTULGSHNQ-ZOBUZTSGSA-N	DB07638	(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL	experimental	nan	nan	nan
FSYFYSFYUHBIHE-GLJUWKHASA-N	DB08737	(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL	experimental	nan	nan	nan
RHQLNMNKTIOREN-AOIWGVFYSA-N	DB08020	(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL	experimental	nan	nan	nan
TXYKBKYDFZQOCB-SSDOTTSWSA-N	DB07431	(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one	experimental	nan	nan	nan
UDFXWCLBONUMNA-CYBMUJFWSA-N	DB07007	(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine	experimental	nan	nan	nan
NTHMDFGHOCNNOE-ZJUUUORDSA-N	DB08606	(3R,4S)-1-[(4-AMINO-5H-PYRROLO[3,2-D]PYRIMIDIN-7-YL)METHYL]-4-[(METHYLSULFANYL)METHYL]PYRROLIDIN-3-OL	experimental	nan	nan	nan
CVZIHNYAZLXRRS-HNNXBMFYSA-N	DB07964	(3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE	experimental	nan	nan	nan
JIIBOYBTIWHZFJ-ZETCQYMHSA-N	DB07001	(3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine	experimental	nan	nan	nan
DDHASJXGNUWZTM-ZLEWNXFRSA-N	DB08010	(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime	experimental	nan	nan	nan
AYSXURJZVXBSRV-WJDWOHSUSA-N	DB07078	(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE	experimental	nan	nan	nan
LOGJQOUIVKBFGH-YBEGLDIGSA-N	DB08039	(3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE	experimental	nan	nan	nan
GPFRMIHXGMVMGF-BZSNNMDCSA-N	DB07036	(3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol	experimental	nan	nan	nan
YATCZCSDJCQNAL-UHFFFAOYSA-N	DB03234	(4'-{[Allyl(Methyl)Amino]Methyl}-1,1'-Biphenyl-4-Yl)(4-Bromophenyl)Methanone	experimental	nan	nan	nan
JAZMZJDLZUDIDG-NSCUHMNNSA-N	DB08458	(4-BROMOPHENYL)[4-({(2E)-4-[CYCLOPROPYL(METHYL)AMINO]BUT-2-ENYL}OXY)PHENYL]METHANONE	experimental	nan	nan	nan
ZMWYSLJBNJUCRK-UHFFFAOYSA-N	DB08137	(4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide	experimental	nan	nan	nan
SQBOSZXDOHQFAA-ZRTHHSRSSA-N	DB01732	(4R,5S,6S,7R)-1,3-dibenzyl-4,7-bis(phenoxymethyl)-5,6-dihydroxy-1,3 diazepan-2-one	experimental	nan	nan	nan
INSBKYCYLCEBOD-UHFFFAOYSA-N	DB01765	(5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid	experimental	nan	nan	391670-48-7
FNWHPLLNMLOZTL-UHFFFAOYSA-N	DB07213	(5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL	experimental	nan	nan	nan
LCBAQTCTQXHTJG-ZETCQYMHSA-N	DB07149	(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one	experimental	nan	nan	nan
AQSNIXKAKUZPSI-SSTWWWIQSA-N	DB08416	(9BETA,13ALPHA,14BETA,17ALPHA)-2-METHOXYESTRA-1,3,5(10)-TRIENE-3,17-DIYL DISULFAMATE	experimental	nan	nan	nan
FQVDJZWFSZSGGA-QGZVFWFLSA-N	DB07472	(R)-(+)9B-(3-METHYL)PHENYL-2,3-DIHYDROTHIAZOLO[2,3-A]ISOINDOL-5(9BH)-ONE	experimental	nan	nan	nan
LKJPYSCBVHEWIU-KRWDZBQOSA-N	DB02932	(R)-Bicalutamide	experimental	nan	nan	113299-40-4
RTHCYVBBDHJXIQ-MRXNPFEDSA-N	DB08472	(R)-Fluoxetine	experimental	nan	An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has R configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).	100568-03-4
HJORMJIFDVBMOB-LBPRGKRZSA-N	DB04149	(R)-Rolipram	investigational	nan	The (R)-enantiomer of rolipram, it is a phosphodiesterase inhibitor with antidepressant properties.	85416-75-7
BMHZAHGTGIZZCT-LJQANCHMSA-N	DB07450	(R)-minalrestat	experimental	nan	nan	nan
COVPLULNDBDXTN-KYJUHHDHSA-N	DB04724	(S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide	experimental	nan	nan	nan
AWDORCFLUJZUQS-ZDUSSCGKSA-N	DB07876	(S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE	experimental	nan	nan	nan
WUZIMDSVRIBNNI-DEOSSOPVSA-N	DB04270	(S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid	experimental	nan	nan	nan
UUDAMDVQRQNNHZ-YFKPBYRVSA-N	DB02057	(S)-AMPA	experimental	nan	AMPA is a specific agonist for the AMPA receptor.	83643-88-3
NDDAHWYSQHTHNT-JTQLQIEISA-N	DB07467	(S)-Indapamide	experimental	nan	nan	77083-53-5
YMUYGRBBEDYUOP-HXUWFJFHSA-N	DB07264	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	experimental	nan	nan	nan
HJORMJIFDVBMOB-GFCCVEGCSA-N	DB03606	(S)-Rolipram	experimental	nan	A phosphodiesterase inhibitor with antidepressant properties. [PubChem]	85416-73-5
PVALLOSAENRPQO-INIZCTEOSA-N	DB07985	+/-METHYL 4-(AMINOIMINOMETHYL)-BETA-[3- INH (AMINOIMINO)PHENYL]BENZENE PENTANOATE	experimental	nan	nan	nan
WMQHRXUKAYSPPK-UHFFFAOYSA-N	DB08612	1,1,1-TRIFLUORO-3-(OCTYLTHIO)ACETONE	experimental	nan	nan	nan
GWEHVDNNLFDJLR-UHFFFAOYSA-N	DB07496	1,3-diphenylurea	experimental	nan	nan	102-07-8
ZOHCDJRFYXKEQW-UHFFFAOYSA-N	DB02170	1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One	experimental	nan	nan	nan
CAWXCABXSPTFRN-UHFFFAOYSA-N	DB07439	1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE	experimental	nan	nan	nan
GEZALMMCQYDFML-UHFFFAOYSA-N	DB08054	1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine	experimental	nan	nan	nan
YAWZIQKDHQIHOS-UHFFFAOYSA-N	DB02873	1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One	experimental	nan	nan	nan
XQCKNCFQOJFQFK-UHFFFAOYSA-N	DB03807	1-(2-Chlorophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	experimental	nan	nan	nan
QEMCDXCXSVPAAB-UHFFFAOYSA-N	DB08278	1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone	experimental	nan	nan	477931-14-9
KRKQVGZXTNLQSV-UHFFFAOYSA-N	DB07622	1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA	experimental	nan	nan	nan
CEAYRKIZESVQSN-UHFFFAOYSA-N	DB08590	1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE	experimental	nan	nan	nan
OBSFXHDOLBYWRJ-UHFFFAOYSA-N	DB06896	1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide	experimental	nan	nan	nan
FWIJKWMXNHRSRO-UHFFFAOYSA-N	DB02277	1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea	experimental	nan	nan	nan
GIZYIOOBBUHOBS-UHFFFAOYSA-N	DB07405	1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE	experimental	nan	nan	nan
ONABDOMWRCXLPX-KRWDZBQOSA-N	DB07593	1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE	experimental	nan	nan	nan
DLYMRVCQTVOYEW-UHFFFAOYSA-N	DB08369	1-(biphenyl-4-ylmethyl)-1H-imidazole	experimental	nan	nan	nan
GKGJFUXSTSUKPB-UHFFFAOYSA-N	DB02177	1-Acetyl-4-(4-{4-[(2-Ethoxyphenyl)Thio]-3-Nitrophenyl}Pyridin-2-Yl)Piperazine	experimental	nan	nan	nan
ADEBPBSSDYVVLD-HXUWFJFHSA-N	DB07701	1-BENZYL-4-[(5,6-DIMETHOXY-1-INDANON-2-YL)METHYL]PIPERIDINE	experimental	nan	nan	nan
SUSMVCKSLVPRCL-QGZVFWFLSA-N	DB04140	1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide	experimental	nan	nan	nan
YHEHVRSGKUYDON-UHFFFAOYSA-N	DB07119	1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL	experimental	nan	nan	nan
NVUDDRWKCUAERS-PNHWDRBUSA-N	DB04218	1-Deaza-Adenosine	experimental	nan	nan	nan
PFAYCUAUBOGVDX-AWEZNQCLSA-N	DB08213	1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE	experimental	nan	nan	nan
QYEMNJMSULGQRD-UHFFFAOYSA-N	DB04580	1-Methyl-2-quinolone	experimental	nan	nan	606-43-9
UXBCHTZINZNVRG-UHFFFAOYSA-N	DB04763	1-N-(4-SULFAMOYLPHENYL-ETHYL)-2,4,6-TRIMETHYLPYRIDINIUM	experimental	nan	nan	nan
ZVPDNRVYHLRXLX-UHFFFAOYSA-N	DB01809	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	experimental	nan	nan	nan
HJWMLCDGRWWLAQ-UHFFFAOYSA-N	DB06882	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea	experimental	nan	nan	nan
DHNYNLNKNQJSHF-UHFFFAOYSA-N	DB06883	1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea	experimental	nan	nan	nan
KCWPSUKJCKZEAO-UHFFFAOYSA-N	DB08149	1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	experimental	nan	nan	nan
QOZMRRGNAZNWDN-UHFFFAOYSA-N	DB08148	1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine	experimental	nan	nan	nan
HGAKLLFPOGATII-UHFFFAOYSA-N	DB08527	1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE	experimental	nan	nan	nan
DDDLGNOZDKDSEG-UHFFFAOYSA-N	DB08043	1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA	experimental	nan	nan	nan
KKKDZZRICRFGSD-UHFFFAOYSA-N	DB04581	1-benzylimidazole	experimental	nan	1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.	4238-71-5
ITOYZJGFTNTKKR-UHFFFAOYSA-N	DB08053	1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine	experimental	nan	nan	nan
UOKGZPYGRJDACN-UHFFFAOYSA-N	DB08300	1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine	experimental	nan	nan	nan
ZOBRPBVIEUWYJR-UHFFFAOYSA-N	DB08355	1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid	experimental	nan	nan	nan
BDLMBQRBNPDCSS-UHFFFAOYSA-N	DB07974	1-{2-[(4-CHLOROPHENYL)AMINO]-2-OXOETHYL}-N-(1-ISOPROPYLPIPERIDIN-4-YL)-1H-INDOLE-2-CARBOXAMIDE	experimental	nan	nan	nan
FGZIONRFHVNRJB-UHFFFAOYSA-N	DB04727	1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea	experimental	nan	nan	nan
JJHXPDTVQKWKHA-UHFFFAOYSA-N	DB07360	1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea	experimental	nan	nan	nan
NVINUNQBDNEMSY-UHFFFAOYSA-N	DB06932	10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine	experimental	nan	nan	nan
LTKHPMDRMUCUEB-IBGZPJMESA-N	DB03541	10-Propargyl-5,8-Dideazafolic Acid	experimental	nan	nan	nan
MMWCIQZXVOZEGG-XJTPDSDZSA-N	DB03401	1D-myo-inositol 1,4,5-trisphosphate	experimental	nan	Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.	85166-31-0
OAKPWEUQDVLTCN-NKWVEPMBSA-N	DB02189	2',3'-Dideoxyadenosine triphosphate	experimental	nan	nan	24027-80-3
AFZSMODLJJCVPP-UHFFFAOYSA-N	DB14201	2,2'-Dibenzothiazyl disulfide	approved	nan	2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.	120-78-5
FFYBYVPVYLMLAR-KBPBESRZSA-N	DB02154	2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid	experimental	nan	nan	nan
QUIQCYFSBGOBKE-UHFFFAOYSA-N	DB07146	2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE	experimental	nan	nan	nan
XREDUPOVEQDQQS-UHFFFAOYSA-N	DB07577	2,4-Diamino-5-phenyl-6-ethylpyrimidine	experimental	nan	nan	27653-49-2
YBJANOUTWRTBDK-UHFFFAOYSA-N	DB02427	2,4-Diamino-6-[N-(2',5'-Dimethoxybenzyl)-N-Methylamino]Quinazoline	experimental	nan	nan	nan
ZOBPZXTWZATXDG-UHFFFAOYSA-N	DB11898	2,4-thiazolidinedione	investigational	nan	Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2.	2295-31-0
HXJKWPGVENNMCC-UHFFFAOYSA-N	DB01467	2,5-Dimethoxy-4-ethylamphetamine	experimental;illicit	nan	nan	22004-32-6
MCYCODJKXUJSAT-UHFFFAOYSA-N	DB13940	2,5-Dimethoxy-4-ethylthioamphetamine	experimental	nan	2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.	185562-00-9
LATVFYDIBMDBSY-UHFFFAOYSA-N	DB01465	2,5-Dimethoxyamphetamine	experimental;illicit	nan	nan	2801-68-5
PAHKYLUYTGBFNW-CMDGGOBGSA-N	DB08100	2,6-dimethyl-4-[(E)-2-phenylethenyl]phenol	experimental	nan	nan	nan
KGMVTZZDGKDTEU-UHFFFAOYSA-N	DB08083	2-(1,3-thiazol-4-yl)-1H-benzimidazole-5-sulfonamide	experimental	nan	nan	nan
IYTGPPNUOLLGBE-UHFFFAOYSA-N	DB08065	2-(1H-pyrazol-3-yl)-1H-benzimidazole	experimental	nan	nan	nan
JPGNPKIYCTXJPG-UHFFFAOYSA-O	DB02463	2-(2-Hydroxy-Phenyl)-1h-Indole-5-Carboxamidine	experimental	nan	nan	nan
OWFLADWRSCINST-UHFFFAOYSA-N	DB08358	2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	experimental	nan	nan	nan
URJKRCBBKTXOHS-UHFFFAOYSA-O	DB02287	2-(2-hydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine	experimental	nan	nan	nan
JZCUVYNOSDWORZ-UHFFFAOYSA-N	DB08701	2-(3-BROMOPHENYL)-6-[(2-HYDROXYETHYL)AMINO]-1H-BENZO[DE]ISOQUINOLINE-1,3(2H)-DIONE	experimental	nan	nan	nan
AITZHKQVQNLKHI-UHFFFAOYSA-N	DB07618	2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE	experimental	nan	nan	nan
CKSIVONWCYACAP-UHFFFAOYSA-N	DB07207	2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE	experimental	nan	nan	nan
SNNNDCMXZYWCCI-UHFFFAOYSA-N	DB07032	2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL	experimental	nan	nan	nan
OLKQIWCQICCYQS-UHFFFAOYSA-N	DB08767	2-(4-METHOXYPHENYL)ACETAMIDE	experimental	nan	nan	nan
MDGWZLQPNOETLH-UHFFFAOYSA-N	DB08773	2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol	experimental	nan	nan	63676-22-2
IAUZEBLXCOCAFL-JSGCOSHPSA-N	DB07277	2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE	experimental	nan	nan	nan
JHOZVRGNIYFYHE-UHFFFAOYSA-N	DB07009	2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL	experimental	nan	nan	nan
JXHWVKOKYDAROD-UHFFFAOYSA-N	DB07548	2-(6-Chloro-3-{[2,2-difluoro-2-(2-pyridinyl)ethyl]amino}-2-oxo-1(2H)-pyrazinyl)-N-[(2-fluoro-6-pyridinyl)methyl]acetamide	experimental	nan	nan	312904-60-2
ZIBMATWHOAGNTR-UHFFFAOYSA-N	DB03670	2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid	experimental	nan	nan	nan
BIASYWBGUYOWJR-UHFFFAOYSA-N	DB06954	2-(cycloheptylmethyl)-1,1-dioxido-1-benzothiophen-6-yl sulfamate	experimental	nan	nan	nan
PPDLAUCFAOODER-UHFFFAOYSA-N	DB08659	2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide	experimental	nan	nan	nan
QHPKKGUGRGRSGA-UHFFFAOYSA-N	DB07268	2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE	experimental	nan	nan	nan
UYJNQQDJUOUFQJ-UHFFFAOYSA-N	DB07460	2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE	experimental	nan	nan	nan
XZEFMZCNXDQXOZ-UHFFFAOYSA-N	DB08325	2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol	experimental	nan	nan	212779-48-1
SWGDXLAZBZDUBR-UHFFFAOYSA-N	DB08528	2-AMINO-6-(3,5-DIMETHYLPHENYL)SULFONYLBENZONITRILE	experimental	nan	nan	nan
XWWRLKIBRPJQJX-UHFFFAOYSA-N	DB06948	2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE	experimental	nan	nan	nan
REGFWZVTTFGQOJ-UHFFFAOYSA-N	DB02335	2-Aminothiazoline	experimental	nan	nan	1779-81-3
ASEJDWRSZYAIOT-GJZGRUSLSA-N	DB02450	2-Benzo[1,3]Dioxol-5-Ylmethyl-3-Benzyl-Succinic Acid	experimental	nan	nan	nan
LISFMEBWQUVKPJ-UHFFFAOYSA-N	DB04745	2-Hydroxyquinoline	experimental	nan	nan	59-31-4
FMWVCTJKLAVRPB-MUUNZHRXSA-N	DB04471	2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol	experimental	nan	nan	nan
ZUEBVBPVXLQMQR-SECBINFHSA-N	DB02953	2-Thiomethyl-3-Phenylpropanoic Acid	experimental	nan	nan	nan
INAZPZCJNPPHGV-UHFFFAOYSA-N	DB07620	2-[(2,4-DICHLORO-5-METHYLPHENYL)SULFONYL]-1,3-DINITRO-5-(TRIFLUOROMETHYL)BENZENE	experimental	nan	nan	nan
XJLATMLVMSFZBN-VYDXJSESSA-N	DB04310	2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide	experimental	nan	nan	13434-13-4
XJJYJNMNYDNXNO-UHFFFAOYSA-N	DB07728	2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE	experimental	nan	nan	nan
RKWXKADYTDWZIJ-VIFPVBQESA-N	DB07390	2-[3-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-ureido]-N-methyl-3-phenyl-propionamide	experimental	nan	nan	nan
HZAXNPDJVFUGDS-BYPYZUCNSA-N	DB07988	2-[3-(5-Mercapto-[1,3,4]thiadiazol-2yl)-ureido]-N-methyl-3-pentafluorophenyl-propionamide	experimental	nan	nan	nan
XUJQPDQURBZEGJ-KXQOOQHDSA-N	DB04016	2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid	experimental	nan	nan	nan
JTVILUUAQWQWBK-IYARVYRRSA-N	DB04288	2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine	experimental	nan	nan	nan
JTJBRKLISQICDU-DEOSSOPVSA-N	DB04088	2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid	experimental	nan	nan	nan
JIVPVXMEBJLZRO-AWEZNQCLSA-N	DB08046	2-chloro-5-[(1S)-1-hydroxy-3-oxo-2H-isoindol-1-yl]benzenesulfonamide	experimental	nan	nan	1441368-51-9
JINJZWSZQKHCIP-UFGQHTETSA-N	DB03991	2-deoxy-2,3-dehydro-N-acetylneuraminic acid	experimental	nan	nan	24967-27-9
VNDWQCSOSCCWIP-UHFFFAOYSA-N	DB04716	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one	experimental	nan	nan	457081-03-7
PEGXADGTBNRSGV-ZDUSSCGKSA-N	DB07194	2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide	experimental	nan	nan	nan
LMGQGPVCSYOMNS-UHFFFAOYSA-N	DB01725	2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide	experimental	nan	nan	nan
ZXWVCCFKIRBLDP-UHFFFAOYSA-N	DB04689	2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID	experimental	nan	nan	nan
TWVYNPULGKGJOS-UHFFFAOYSA-N	DB07053	2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID	experimental	nan	nan	nan
NZNTWOVDIXCHHS-LSDHHAIUSA-N	DB08361	2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide	experimental	nan	nan	nan
INBGSXNNRGWLJU-ZHHJOTBYSA-N	DB04705	25-Hydroxycholesterol	experimental	nan	nan	2140-46-7
JLFSBHQQXIAQEC-UHFFFAOYSA-N	DB16063	2X-121	investigational	nan	2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).	1140964-99-3
WGTASENVNYJZBK-UHFFFAOYSA-N	DB01516	3,4,5-Trimethoxyamphetamine	experimental;illicit	nan	nan	1082-88-8
SUGXUUGGLDCZKB-UHFFFAOYSA-N	DB04459	3,4-Dichloroisocoumarin	experimental	nan	nan	nan
MSYGAHOHLUJIKV-UHFFFAOYSA-N	DB01959	3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	experimental	nan	nan	nan
MQFPIRFODWNQIO-UHFFFAOYSA-N	DB07275	3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)quinolin-2(1H)-one	experimental	nan	nan	nan
JTKFRFMSUBOCIQ-UHFFFAOYSA-N	DB07959	3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE	experimental	nan	nan	nan
BFNBJSXMXXQLAW-UHFFFAOYSA-N	DB08602	3-(2,6-difluorophenyl)-2-(methylthio)quinazolin-4(3H)-one	experimental	nan	nan	nan
YEIASMOUYNOXGA-UHFFFAOYSA-N	DB06925	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	experimental	nan	nan	nan
LHLGUOHREUTYTO-UHFFFAOYSA-N	DB07514	3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one	experimental	nan	nan	nan
HXUZQEYFKAZBPX-UHFFFAOYSA-N	DB07528	3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one	experimental	nan	nan	nan
BKDUVKJYBJDZQW-UHFFFAOYSA-N	DB08248	3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE	experimental	nan	nan	nan
LCGSYJVWLGYWTD-UHFFFAOYSA-N	DB07236	3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL	experimental	nan	nan	nan
JDARUOOLJCFUOY-UHFFFAOYSA-N	DB07265	3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID	experimental	nan	nan	nan
KLSZVPNVFKKIRD-FNORWQNLSA-N	DB07486	3-({4-[(1E)-3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-2,3-bis(trifluoromethyl)phenyl}sulfanyl)aniline	experimental	nan	nan	nan
DHPCBFMFERFZLR-UHFFFAOYSA-N	DB07230	3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE	experimental	nan	nan	nan
NFSTZPMYAZRZPC-UHFFFAOYSA-N	DB01997	3-Bromo-7-Nitroindazole	experimental	nan	nan	nan
QTPHSDHUHXUYFE-NWDGAFQWSA-N	DB04114	3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine	experimental	nan	nan	nan
UQTZMGFTRHFAAM-ZETCQYMHSA-N	DB01758	3-Iodo-Tyrosine	experimental	nan	nan	70-78-0
NHOACLCXCKJMAK-UHFFFAOYSA-N	DB03490	3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole	experimental	nan	nan	nan
CAVCWRXFMNCBCM-UHFFFAOYSA-N	DB07903	3-[(2,2-DIMETHYLPROPANOYL)AMINO]-N-1,3-THIAZOL-2-YLPYRIDINE-2-CARBOXAMIDE	experimental	nan	nan	nan
JNDVEAXZWJIOKB-JYRVWZFOSA-N	DB08577	3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE	experimental	nan	nan	nan
XZWFHJUEAVOHHG-UHFFFAOYSA-N	DB08030	3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide	experimental	nan	nan	nan
QBZAPFWYAPXRGQ-KRWDZBQOSA-N	DB03996	3-[(5s)-1-Acetyl-3-(2-Chlorophenyl)-4,5-Dihydro-1h-Pyrazol-5-Yl]Phenol	experimental	nan	nan	nan
APYXQTXFRIDSGE-UHFFFAOYSA-N	DB07457	3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE	experimental	nan	nan	nan
RPGZQOOZHIEPJW-HNNXBMFYSA-N	DB01772	3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione	experimental	nan	nan	nan
JJDRRZFRTKZLFT-UHFFFAOYSA-N	DB04518	3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol	experimental	nan	nan	nan
JUEONDBIBADVGD-UHFFFAOYSA-N	DB08156	3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID	experimental	nan	nan	nan
MWYBBCLGEHZSCP-UHFFFAOYSA-N	DB07335	3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL	experimental	nan	nan	nan
GLTRPHMPCVLOJS-UHFFFAOYSA-N	DB07474	3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE	experimental	nan	nan	nan
OHQMEDBYNUAVNE-UHFFFAOYSA-N	DB08446	3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile	experimental	nan	nan	nan
CGBDAHCDSVOMCF-FYZVQMPESA-N	DB03076	3-[[(3R,4S,5S,6R)-7-Benzyl-4,5-dihydroxy-1,1-dioxo-3,6-bis(phenoxymethyl)-1,2,7-thiadiazepan-2-yl]methyl]-N-methylbenzamide	experimental	nan	nan	nan
WHCLIFOVZDANCU-UHFFFAOYSA-N	DB08154	3-chloro-5-[2-chloro-5-(1H-indazol-3-ylmethoxy)phenoxy]benzonitrile	experimental	nan	nan	nan
SVMHTBVIPYVDIL-UHFFFAOYSA-N	DB08459	3-chloro-5-[2-chloro-5-(1H-pyrazolo[3,4-b]pyridin-3-ylmethoxy)phenoxy]benzonitrile	experimental	nan	nan	nan
MINVOLKUPZPDNX-UHFFFAOYSA-N	DB07229	3-{5-[AMINO(IMINIO)METHYL]-1H-INDOL-2-YL}-5-METHOXY-1,1'-BIPHENYL-2-OLATE	experimental	nan	nan	nan
RZXQBIKGWSLVEK-JCNLHEQBSA-N	DB08279	3-{ISOPROPYL[(TRANS-4-METHYLCYCLOHEXYL)CARBONYL]AMINO}-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID	experimental	nan	nan	nan
MCBPNFWHHNJTGN-LLVKDONJSA-N	DB07234	3-{[(1R)-1-phenylethyl]amino}-4-(pyridin-4-ylamino)cyclobut-3-ene-1,2-dione	experimental	nan	nan	nan
FTQYGMLRLRXBPT-IDUWFGFVSA-N	DB08124	3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one	experimental	nan	nan	nan
DMCRNUMVSATRTP-LCYFTJDESA-N	DB08126	3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole	experimental	nan	nan	nan
CARKQNSZFCLNKM-UHFFFAOYSA-N	DB07079	3-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiol	experimental	nan	nan	nan
RAKYKJWUUUKCCW-MPLBGYFPSA-N	DB03737	4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One	experimental	nan	nan	nan
LCTWZJKHOGKNMX-UHFFFAOYSA-N	DB02840	4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid	experimental	nan	nan	nan
ATORUNMAUREKMH-UHFFFAOYSA-N	DB03749	4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole	experimental	nan	nan	nan
FXNSVEQMUYPYJS-UHFFFAOYSA-N	DB08782	4-(2-AMINOETHYL)BENZENESULFONAMIDE	experimental	nan	nan	nan
AIBKIFHSQQYXLG-UHFFFAOYSA-N	DB04020	4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol	experimental	nan	nan	nan
IBCXZJCWDGCXQT-UHFFFAOYSA-N	DB03921	4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline	experimental	nan	nan	nan
LZMOSYUFVYJEPY-UHFFFAOYSA-N	DB07859	4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE	experimental	nan	nan	nan
ROKOFZNQCIIJMI-UHFFFAOYSA-N	DB08522	4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE	experimental	nan	nan	nan
VYQQTWUZKPWPRL-WOJGMQOQSA-N	DB07150	4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME	experimental	nan	nan	nan
GGEWEQJWGGJUHO-UHFFFAOYSA-N	DB08178	4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	experimental	nan	nan	nan
ZHMRPXZRUZLCNL-UHFFFAOYSA-N	DB08182	4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine	experimental	nan	nan	nan
KSFDVNIKNYXUIP-UHFFFAOYSA-N	DB08191	4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid	experimental	nan	nan	nan
RUUOIINPNMNPIU-UHFFFAOYSA-N	DB08241	4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE	experimental	nan	nan	nan
NBTXJDAHLMMIGY-UHFFFAOYSA-N	DB06937	4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL	experimental	nan	nan	nan
CWQKPKYIMQTGJK-UHFFFAOYSA-N	DB08136	4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide	experimental	nan	nan	nan
MXWDSZWTBOCWBK-UHFFFAOYSA-N	DB02565	4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide	experimental	nan	nan	251456-60-7
IWFSHKKFDSWNLZ-BWACUDIHSA-N	DB08608	4-({(2R,5S)-2,5-DIMETHYL-4-[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]PIPERAZIN-1-YL}CARBONYL)BENZONITRILE	experimental	nan	nan	nan
AANXPIMDONQTQF-HNNXBMFYSA-N	DB07121	4-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDE	experimental	nan	nan	nan
LVRKQJAEQWVSCM-HAQNSBGRSA-N	DB07687	4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE	experimental	nan	nan	nan
YMHOBZXQZVXHBM-UHFFFAOYSA-N	DB01537	4-Bromo-2,5-dimethoxyphenethylamine	illicit;investigational	nan	nan	66142-81-2
BDFJIEMVNDLSTB-UHFFFAOYSA-N	DB06957	4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL	experimental	nan	nan	nan
IBRWUZLLHSXPKL-UHFFFAOYSA-N	DB02401	4-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid	experimental	nan	nan	66313-36-8
NTJQREUGJKIARY-UHFFFAOYSA-N	DB01528	4-Methyl-2,5-dimethoxyamphetamine	experimental;illicit	nan	A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.	15588-95-1
XZKIHKMTEMTJQX-UHFFFAOYSA-N	DB04214	4-Nitrophenyl Phosphate	experimental	nan	nan	330-13-2
JJQQOJRGUHNREK-PWNYCUMCSA-N	DB04496	4-Phospho-D-erythronohydroxamic acid	experimental	nan	nan	718599-64-5
GHDKYBCUDPSXGJ-UHFFFAOYSA-N	DB04600	4-[(3-BROMO-4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE	experimental	nan	nan	nan
DTDZLJHKVNTQGZ-GOSISDBHSA-N	DB07403	4-[(3-CHLORO-4-{[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]AMINO}PHENYL)SULFONYL]-N,N-DIMETHYLBENZAMIDE	experimental	nan	nan	nan
NKORVPQBJCGYEC-UHFFFAOYSA-N	DB02197	4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide	experimental	nan	nan	nan
JHMBUEWQJDGKGS-UHFFFAOYSA-N	DB04739	4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE	experimental	nan	nan	nan
WEXGHQDVDVWOIU-UHFFFAOYSA-N	DB04601	4-[(4-O-SULFAMOYLBENZYL)(4-CYANOPHENYL)AMINO]-4H-[1,2,4]-TRIAZOLE	experimental	nan	nan	nan
FVFVVRPJERUECT-UHFFFAOYSA-N	DB03307	4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide	experimental	nan	nan	nan
ZDUDMCQPFKPISO-UHFFFAOYSA-N	DB08047	4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol	experimental	nan	nan	nan
HGEPGGJUGUMFHT-UHFFFAOYSA-N	DB08058	4-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one	experimental	nan	nan	nan
GYPHGCGOSZJXOT-UHFFFAOYSA-N	DB07336	4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL	experimental	nan	nan	nan
BILJSHVAAVZERY-UHFFFAOYSA-N	DB07829	4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE	experimental	nan	nan	nan
BNDYIYYKEIXHNK-UHFFFAOYSA-N	DB03365	4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline	experimental	nan	nan	nan
CJSSYVIHFXDFFC-UHFFFAOYSA-N	DB02491	4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine	experimental	nan	nan	nan
OTMLAWRVLMYMDF-UHFFFAOYSA-N	DB04407	4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol	experimental	nan	nan	nan
QICPQLFMWYQJGX-SFHVURJKSA-N	DB01761	4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine	experimental	nan	nan	nan
QTNUWEKKZHSUQO-UHFFFAOYSA-N	DB08299	4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid	experimental	nan	nan	nan
ZJLSMLDOCGOURY-UHFFFAOYSA-N	DB06938	4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide	experimental	nan	nan	nan
LZACPHWPRDKUPK-UHFFFAOYSA-N	DB07502	4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol	experimental	nan	nan	nan
JLIRVZVVCCIAKG-UHFFFAOYSA-N	DB07601	4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol	experimental	nan	nan	nan
SXTSBZBQQRIYCU-UHFFFAOYSA-N	DB02459	4-guanidinobenzoic acid	experimental	nan	nan	16060-65-4
FJKROLUGYXJWQN-UHFFFAOYSA-N	DB04242	4-hydroxybenzoic acid	experimental	nan	nan	99-96-7
YUDPTGPSBJVHCN-YMILTQATSA-N	DB13177	4-methylumbelliferyl beta-D-glucoside	experimental	nan	nan	18997-57-4
FVZITYNLUYJDOE-UHFFFAOYSA-N	DB03162	4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid	experimental	nan	nan	45654-48-6
PWTBZOIUWZOPFT-UHFFFAOYSA-N	DB08770	4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol	experimental	nan	nan	nan
VKQPTVJDZIILPG-UHFFFAOYSA-N	DB07832	4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde	experimental	nan	nan	nan
AKFVRSQELXTCFW-JYRVWZFOSA-N	DB07540	4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE	experimental	nan	nan	nan
RGVVHQNJKUNSFQ-WDZFZDKYSA-N	DB07538	4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE	experimental	nan	nan	nan
FJJJERLTHDXEPT-JYRVWZFOSA-N	DB07533	4-{5-[(Z)-(2-Imino-4-Oxo-1,3-Thiazolidin-5-Ylidene)methyl]-2-Furyl}-N-Methylbenzenesulfonamide	experimental	nan	nan	nan
BKUMVXIXUVYKDQ-GHXNOFRVSA-N	DB07534	4-{5-[(Z)-(2-Imino-4-Oxo-1,3-Thiazolidin-5-Ylidene)methyl]furan-2-Yl}benzenesulfonamide	experimental	nan	nan	nan
KOMNQBZWMCFDTQ-VIFPVBQESA-N	DB08141	4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide	experimental	nan	nan	nan
BOMPRXSVSIPRDT-PTNGSMBKSA-N	DB08125	4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide	experimental	nan	nan	nan
IRKPNOLLMNHSOU-UHFFFAOYSA-N	DB02354	4-{[1-Methyl-5-(2-Methyl-Benzoimidazol-1-Ylmethyl)-1h-Benzoimidazol-2-Ylmethyl]-Amino}-Benzamidine	experimental	nan	nan	nan
YBKLJTXDSBEVRV-UHFFFAOYSA-N	DB08572	4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE	experimental	nan	nan	nan
VPOGRVWIIVMWRI-UHFFFAOYSA-N	DB07686	4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	experimental	nan	nan	nan
RPJIMTALCNCQLV-UHFFFAOYSA-N	DB07688	4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE	experimental	nan	nan	nan
ARMFMDYRYOKSOW-UHFFFAOYSA-N	DB08005	4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide	experimental	nan	nan	nan
FTSDEWPMACCNGN-YTMOPEAISA-N	DB02684	5'-O-(L-Cysteinylsulfamoyl)adenosine	experimental	nan	nan	nan
LKVJEMXWEODCAY-JVEUSOJLSA-N	DB02510	5'-O-(L-Prolylsulfamoyl)adenosine	experimental	nan	nan	nan
UPVAPSGKXAAHBG-CKTDUXNWSA-N	DB03355	5'-O-(L-Threonylsulfamoyl)adenosine	experimental	nan	nan	nan
WUUGFSXJNOTRMR-IOSLPCCCSA-N	DB02282	5'-S-methyl-5'-thioadenosine	investigational	nan	nan	2457-80-9
DZXMARZBAUMWLK-UHFFFAOYSA-N	DB07073	5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one	experimental	nan	nan	nan
PTILEOLOGGMFCS-UHFFFAOYSA-N	DB07297	5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE	experimental	nan	nan	nan
BGKFPRIGXAVYNX-UHFFFAOYSA-N	DB01931	5,7-Dichlorokynurenic acid	experimental	nan	nan	131123-76-7
XRSYNYGEEYTXJV-UHFFFAOYSA-N	DB08388	5-(2-ETHOXYETHYL)-5-[4-(4-FLUOROPHENOXY)PHENOXY]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE	experimental	nan	nan	nan
XVECMUKVOMUNLE-UHFFFAOYSA-N	DB07794	5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE	experimental	nan	nan	nan
PZVGOWIIHCUHAO-UHFFFAOYSA-N	DB07632	5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide	experimental	nan	nan	nan
BDVFVCGFMNCYPV-UHFFFAOYSA-N	DB07996	5-(2-methylpiperazine-1-sulfonyl)isoquinoline	experimental	nan	nan	84477-87-2
STWVLEKJQQRGMO-GUYCJALGSA-N	DB18065	5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine	investigational	nan	nan	2088453-21-6
HUNAOTXNHVALTN-UHFFFAOYSA-N	DB07495	5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE	experimental	nan	nan	nan
JXPCDMPJCKNLBY-UHFFFAOYSA-N	DB06964	5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE	experimental	nan	nan	nan
APGOABVITLQCKW-UHFFFAOYSA-N	DB06961	5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide	experimental	nan	nan	nan
IEQQJQHHJMQETK-YPKPFQOOSA-N	DB07493	5-Bromoindirubin	experimental	nan	nan	60874-72-8
USWKTQVAABDFSY-UHFFFAOYSA-N	DB07018	5-ETHYL-3-[(2-METHOXYETHYL)METHYLAMINO]-6-METHYL-4-(3-METHYLBENZYL)PYRIDIN-2(1H)-ONE	experimental	nan	nan	nan
GGEKOZPXKBYLNK-UHFFFAOYSA-N	DB07198	5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE	experimental	nan	nan	nan
AKWKBACKRMYPRV-NQIIRXRSSA-N	DB08493	5-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YLCARBAMOYL)-HEXANOIC ACID	experimental	nan	nan	nan
DNBPMBJFRRVTSJ-UHFFFAOYSA-N	DB01441	5-Methoxy-N,N-diisopropyltryptamine	experimental;illicit	nan	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine, N,N-diethyltryptamine, bufotenine, psilocybin and psilocin. Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects.	4021-34-5
RTBMLCLTYAPKIF-UHFFFAOYSA-N	DB03368	5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione	experimental	nan	nan	nan
OJLYTHOKCYLPMA-UHFFFAOYSA-N	DB07178	5-PENTYL-2-PHENOXYPHENOL	experimental	nan	nan	nan
BUFDQCGCADQQQY-UHFFFAOYSA-N	DB04163	5-Phenylsulfanyl-2,4-Quinazolinediamine	experimental	nan	nan	nan
SQWZFLMPDUSYGV-POHAHGRESA-N	DB04769	5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE	experimental	nan	nan	nan
SAAYRHKJHDIDPH-UHFFFAOYSA-N	DB07970	5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide	experimental	nan	nan	nan
ATFDKOLABYIYCC-INIZCTEOSA-N	DB07142	5-[(3R)-3-(5-methoxy-3',5'-dimethylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine	experimental	nan	nan	nan
QVXYJVHNRPNRJL-HNNXBMFYSA-N	DB07141	5-[(3R)-3-(5-methoxy-4'-methylbiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine	experimental	nan	nan	nan
JPENSYBRTSIYGO-AWEZNQCLSA-N	DB07140	5-[(3R)-3-(5-methoxybiphenyl-3-yl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine	experimental	nan	nan	nan
UOJFGEAPSYQDIP-UHFFFAOYSA-N	DB04306	5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine	experimental	nan	nan	nan
JYAHFMKZJRVTDT-UHFFFAOYSA-N	DB07935	5-[(5-fluoro-3-methyl-1H-indazol-4-yl)oxy]benzene-1,3-dicarbonitrile	experimental	nan	nan	nan
NNFDQABYXZBKRK-UHFFFAOYSA-N	DB08234	5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine	experimental	nan	nan	nan
UHCHLTQBLNUYRT-GFCCVEGCSA-N	DB07471	5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE	experimental	nan	nan	nan
HWJPWWYTGBZDEG-AWEZNQCLSA-N	DB08741	5-[[(2R)-2-cyclopropyl-7,8-dimethoxy-2H-chromen-5-yl]methyl]pyrimidine-2,4-diamine	experimental	nan	nan	nan
UVERBUNNCOKGNZ-CQSZACIVSA-N	DB08656	5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide	experimental	nan	nan	nan
MEFJFXHHHNDHEN-UHFFFAOYSA-N	DB08021	5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide	experimental	nan	nan	nan
FURUXTVZLHCCNA-AWEZNQCLSA-N	DB03601	5-deoxyflavanone	experimental	nan	5-deoxyflavanone is a solid. This compound belongs to the flavanones. These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.	578-86-9
HFEKDTCAMMOLQP-RRKCRQDMSA-N	DB03761	5-fluoro-2'-deoxyuridine-5'-monophosphate	experimental	nan	nan	134-46-3
WHSIXKUPQCKWBY-IOSLPCCCSA-N	DB04604	5-iodotubercidin	experimental	nan	nan	24386-93-4
ZSTKHSQDNIGFLM-UHFFFAOYSA-N	DB14010	5-methoxy-N,N-dimethyltryptamine	illicit;investigational	nan	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a tryptamine with psychedelic properties. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. This drug, as well as [dimethyltryptamine] and [bufotenin], have been registered to be used in South America in religious and spiritual rituals.	1019-45-0
LRHHXKBKRNNFRV-UHFFFAOYSA-N	DB08008	5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine	experimental	nan	nan	nan
HOLJYLOVIHBQHO-UHFFFAOYSA-N	DB06891	5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE	experimental	nan	nan	nan
YCFJZPGDTZVVSM-UHFFFAOYSA-N	DB08665	6,11-DIHYDRO-11-ETHYL-6-METHYL-9-NITRO-5H-PYRIDO[2,3-B][1,5]BENZODIAZEPIN-5-ONE	experimental	nan	nan	nan
MJZJYWCQPMNPRM-UHFFFAOYSA-N	DB08734	6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE	experimental	nan	nan	nan
MEXUTNIFSHFQRG-UHFFFAOYSA-N	DB08036	6,7,12,13-tetrahydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one	experimental	nan	nan	nan
UPTQSRGSSJRBKJ-LJQANCHMSA-N	DB08389	6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE	experimental	nan	nan	nan
XQKJVNGGVLHNLA-UHFFFAOYSA-N	DB07612	6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE	experimental	nan	nan	nan
RXSSKAZHCZWJPP-UHFFFAOYSA-N	DB07319	6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE	experimental	nan	nan	nan
QNURTFDBHAQRSI-OAHLLOKOSA-N	DB01640	6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one	experimental	nan	nan	nan
AECPTICWHONWNW-UHFFFAOYSA-N	DB01977	6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine	experimental	nan	nan	nan
OGODDSLNRULSMM-UHFFFAOYSA-N	DB07965	6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile	experimental	nan	nan	nan
KSAAUHMSLCPIEX-UHFFFAOYSA-N	DB08634	6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL	experimental	nan	nan	nan
AWSQADBSXFTFKL-UHFFFAOYSA-N	DB08441	6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE	experimental	nan	nan	nan
LMJSLTNSBFUCMU-MRVPVSSYSA-N	DB08645	6-CHLORO-3-(DICHLOROMETHYL)-3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE	experimental	nan	nan	nan
OQCFORGSZJSAEL-UHFFFAOYSA-N	DB07871	6-CHLORO-4-(CYCLOHEXYLOXY)-3-ISOPROPYLQUINOLIN-2(1H)-ONE	experimental	nan	nan	nan
BNZHKKGOSYAQSW-UHFFFAOYSA-N	DB07867	6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE	experimental	nan	nan	nan
CLKFNGKDJYMUPK-UHFFFAOYSA-N	DB07868	6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE	experimental	nan	nan	nan
OUEGMEMDEAOAEG-UHFFFAOYSA-N	DB07203	6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE	experimental	nan	nan	nan
RFSDQDHHBKYQOD-UHFFFAOYSA-N	DB08233	6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE	experimental	nan	nan	nan
DGWXOLHKVGDQLN-UHFFFAOYSA-N	DB08312	6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE	experimental	nan	nan	nan
FEKRWNWZMOSVBX-UHFFFAOYSA-O	DB03865	6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine	experimental	nan	nan	nan
HUYQYLFFFNSAAX-BUXKBTBVSA-N	DB06856	6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE	experimental	nan	nan	nan
NOOBQTYVTDBXTL-UHFFFAOYSA-N	DB08765	6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE	experimental	nan	nan	nan
MWGXGTJJAOZBNW-UHFFFAOYSA-N	DB02407	6-O-Cyclohexylmethyl Guanine	experimental	nan	nan	nan
PRIGRJPRGZCFAS-UHFFFAOYSA-N	DB07364	6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE	experimental	nan	nan	nan
FWTQOPWAMQXIMI-UHFFFAOYSA-N	DB07076	6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE	experimental	nan	nan	nan
CSWQJKHBMACTGB-UHFFFAOYSA-N	DB03082	6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide	experimental	nan	nan	nan
FQYJTHIYAQQJAB-UHFFFAOYSA-N	DB08352	6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine	experimental	nan	nan	nan
DARQQJKHXPXSRO-QFIPXVFZSA-N	DB02705	6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	nan	nan	nan
XRHANBWAKSYPEN-UHFFFAOYSA-N	DB02473	6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	nan	nan	nan
LVNMYQLXKMSQTG-AWEZNQCLSA-N	DB02551	6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine	experimental	nan	nan	nan
LRVZOSYMNMNQFR-SHUUEZRQSA-N	DB03718	6-aza uridine 5'-monophosphate	experimental	nan	nan	2018-19-1
DDLZLOKCJHBUHD-WAVHTBQISA-N	DB03444	6-bromoindirubin-3'-oxime	experimental	nan	nan	667463-62-9
FEGRQUWSKADGSP-UHFFFAOYSA-N	DB07326	6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide	experimental	nan	nan	nan
FJNFXXGWYVMQNA-UHFFFAOYSA-N	DB07153	6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine	experimental	nan	nan	nan
HPWBHQIUIBFTQC-UHFFFAOYSA-N	DB07856	6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE	experimental	nan	nan	nan
WFPUBEDBBOGGIQ-UHFFFAOYSA-N	DB08550	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	experimental	nan	Potent reversible inhibitor of phenylethanolamine N-methyltransferase.	61563-24-4
GCPJCLJGTVTGRF-UHFFFAOYSA-N	DB07862	7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE	experimental	nan	nan	nan
FFCFXJXBXUOFIU-UHFFFAOYSA-N	DB03824	7-Iodo-1,2,3,4-Tetrahydro-Isoquinoline	experimental	nan	nan	nan
YENZSPIOXMNEFF-UHFFFAOYSA-N	DB07248	7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE	experimental	nan	nan	nan
OYXZMSRRJOYLLO-KGZHIOMZSA-N	DB04706	7beta-hydroxycholesterol	experimental	nan	nan	566-27-8
MWGWLDJLENCVRQ-UHFFFAOYSA-N	DB07877	8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE	experimental	nan	nan	nan
GRQLDCHTDNYVQI-UHFFFAOYSA-N	DB04059	8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide	experimental	nan	nan	nan
KRZHNRULRHECRF-JQCUSGDOSA-N	DB08648	8-Hydroxy-2-oxa-bicyclo[3.3.1]non-6-ene-3,5-dicarboxylic acid	experimental	nan	nan	nan
QNDVLZJODHBUFM-WFXQOWMNSA-N	DB02169	9,10-Deepithio-9,10-Didehydroacanthifolicin	experimental	nan	A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41)	78111-17-8
KRCXZGYVOZSCSF-UHFFFAOYSA-N	DB07553	9,9,9-TRIFLUORO-8-OXO-N-PHENYLNONANAMIDE	experimental	nan	nan	nan
JHBXNPBKSPYOFT-UHFFFAOYSA-N	DB02495	9-(4-hydroxybutyl)-N2-phenylguanine	experimental	nan	9-(4-hydroxybutyl)-N2-phenylguanine is a solid. This compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.	nan
RPJPZDVUUKWPGT-FOIHOXPVSA-N	DB13068	9-(N-methyl-L-isoleucine)-cyclosporin A	investigational	nan	9-(N-methyl-L-isoleucine)-cyclosporin A (NIM811) has been used in trials studying the treatment of Chronic Hepatitis C Genotype-1 Relapse.	143205-42-9
JJNKDTWKWYLERH-UHFFFAOYSA-N	DB07967	9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE	experimental	nan	nan	nan
IAUZTOZLTFSMIE-UHFFFAOYSA-N	DB04608	9-HYDROXY-4-PHENYL-6H-PYRROLO[3,4-C]CARBAZOLE-1,3-DIONE	experimental	nan	nan	nan
AOGOZJCRIFBTTN-UHFFFAOYSA-N	DB07006	9-HYDROXY-6-(3-HYDROXYPROPYL)-4-(2-METHOXYPHENYL)PYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE	experimental	nan	nan	nan
KXSIHXHEHABEJX-UHFFFAOYSA-N	DB07330	A-620223	experimental	nan	nan	272769-49-0
BPNUQXPIQBZCMR-IBGZPJMESA-N	DB08568	A-674563	experimental	nan	nan	552325-73-2
KVMLMFRXRZLEGU-UHFFFAOYSA-N	DB17199	AAG-1	experimental	nan	nan	1204408-18-3
GOQBSVFOBGVWTA-UHFFFAOYSA-N	DB18296	AB-22	experimental	nan	nan	1463913-43-0
OEDSFMUSNZDJFD-UHFFFAOYSA-N	DB19199	ABBV-744	investigational	nan	nan	2138861-99-9
HPLNQCPCUACXLM-PGUFJCEWSA-N	DB17023	ABT-737	experimental	nan	An inhibitor of members of the Bcl‑2 family of apoptosis regulators.[A252977]	852808-04-9
URCVCIZFVQDVPM-UHFFFAOYSA-N	DB12254	ABT-751	investigational	nan	ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.	141430-65-1
SQZJGTOZFRNWCX-UHFFFAOYSA-N	DB16036	ABX-1431	investigational	nan	ABX-1431 is under investigation in clinical trial NCT03625453 (Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder).	1446817-84-0
OONFNUWBHFSNBT-HXUWFJFHSA-N	DB12558	AEE-788	investigational	nan	AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.	497839-62-0
MEKASOQEXYKAKM-UHFFFAOYSA-N	DB13035	AG-24322	investigational	nan	AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.	837364-57-5
WMBYSCVMFMNUQV-LBPRGKRZSA-N	DB18023	AGF-94	experimental	nan	nan	136784-51-5
HEAIZQNMNCHNFD-UHFFFAOYSA-N	DB08079	AMG-208	investigational	nan	AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.	1002304-34-8
KWRYMZHCQIOOEB-LBPRGKRZSA-N	DB16879	AMG-319	investigational	nan	nan	1608125-21-8
IVUGFMLRJOCGAS-UHFFFAOYSA-N	DB17197	AMG-900	experimental	nan	nan	945595-80-2
LAMIXXKAWNLXOC-INIZCTEOSA-N	DB12707	AR-42	investigational	nan	AR-42 has been used in trials studying the treatment of Meningioma, Acoustic Neuroma, Testicular Lymphoma, Intraocular Lymphoma, and Vestibular Schwannoma, among others.	935881-37-1
HUDQLWBKJOMXSZ-UHFFFAOYSA-N	DB06345	AR-9281	investigational	nan	AR-9281 inhibits soluble epoxide hydrolase.	913548-29-5
YAEMHJKFIIIULI-UHFFFAOYSA-N	DB01950	AR-AO-14418	experimental	nan	nan	487021-52-3
MGGBYMDAPCCKCT-UHFFFAOYSA-N	DB12729	ASP-3026	investigational	nan	ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS.	1097917-15-1
OVPNQJVDAFNBDN-UHFFFAOYSA-N	DB08142	AT-7519	investigational	nan	AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.	844442-38-2
LOLPPWBBNUVNQZ-UHFFFAOYSA-N	DB05169	AT9283	investigational	nan	AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.	896466-04-9
ZKHQWZAMYRWXGA-KQYNXXCUSA-N	DB00171	ATP	investigational;nutraceutical	nan	An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.	56-65-5
WHJIHZSXTQRCNX-UHFFFAOYSA-N	DB18114	AUM-302	experimental	nan	nan	1414455-21-2
WLYWTGDTMWWNNG-UHFFFAOYSA-N	DB11881	AUY922	investigational	nan	AUY922 has been used in trials studying the treatment of Lymphoma, Breast Cancer, Metastatic Disease, Advanced Solid Tumors, and Hematologic Neoplasms, among others.	747412-64-2
OCKIPDMKGPYYJS-ZDUSSCGKSA-N	DB12145	AZD-0328	investigational	nan	AZD0328 has been used in trials studying the treatment and basic science of Schizophrenia and Alzheimer's Disease.	220099-91-2
PDOQBOJDRPLBQU-QMMMGPOBSA-N	DB12588	AZD-1480	investigational	nan	AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF), and Essential Thrombocythaemia Myelofibrosis.	935666-88-9
ZAGGGZCIFUQHOH-UHFFFAOYSA-N	DB17077	AZD-1940	investigational	nan	nan	881413-29-2
JWYIGNODXSRKGP-UHFFFAOYSA-N	DB11946	AZD-1981	investigational	nan	AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.	802904-66-1
MRXBCEQZNKUUIP-DEOSSOPVSA-N	DB12368	AZD-3839	investigational	nan	AZD3839 has been used in trials studying the basic science of Safety, Tolerability, Alzheimer's Disease, and Blood Concentration.	1227163-84-9
QZECRCLSIGFCIO-RISCZKNCSA-N	DB16822	AZD-5069	investigational	nan	nan	878385-84-3
RSMYFSPOTCDHHJ-GOSISDBHSA-N	DB17018	AZD-5153	investigational	nan	nan	1869912-39-9
NVWCZRPXYVDQEE-UHFFFAOYSA-N	DB12210	AZD-6280	investigational	nan	AZD6280 has been used in trials studying the basic science of Anxiety.	942436-93-3
IRTDIKMSKMREGO-OAHLLOKOSA-N	DB14980	AZD-6482	investigational	nan	AZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).	1173900-33-8
ZJKUETLEJYCOBO-UHFFFAOYSA-N	DB19203	AZD-7268	investigational	nan	AZD-7268 is under investigation in clinical trial NCT01020799 (AZD7268 Safety and Tolerability Study).	1018988-00-5
KYDURMHFWXCKMW-UHFFFAOYSA-N	DB13994	AZD-7325	investigational	nan	AZD7325 is a high affinity, selective modulator of the GABAA receptor system. [L2936]	942437-37-8
XISVSTPEXYIKJL-UHFFFAOYSA-N	DB16834	AZD-7648	investigational	nan	nan	2230820-11-6
YXFNPRHZMOGREC-SHTZXODSSA-N	DB14949	AZD-7687	investigational	nan	AZD-7687 is under investigation in clinical trial NCT01119352 (AZD7687 Multiple Ascending Dose Study).	1166827-44-6
IAYGCINLNONXHY-LBPRGKRZSA-N	DB12242	AZD-7762	investigational	nan	AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.	860352-01-8
KVLFRAWTRWDEDF-IRXDYDNUSA-N	DB12774	AZD-8055	investigational	nan	AZD8055 has been used in trials studying the treatment of Cancer, Lymphomas, Solid Tumors, MALIGNANT GLIOMA, and brainstem glioma, among others.	1009298-09-2
LMJFJIDLEAWOQJ-CQSZACIVSA-N	DB15029	AZD-8186	investigational	nan	AZD-8186 is under investigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery).	1627494-13-6
RWEVIPRMPFNTLO-UHFFFAOYSA-N	DB06061	AZD-8330	investigational	nan	AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.	869357-68-6
MCGSCOLBFJQGHM-SCZZXKLOSA-N	DB01048	Abacavir	approved;investigational	J05AR13;J05AR02;J05AR04;J05AF06	Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.	136470-78-5
ANZIISNSHPKVRV-UHFFFAOYSA-N	DB20666	Abanoquil	experimental	nan	Abanoquil is a small molecule drug. Abanoquil has a monoisotopic molecular weight of 395.18 Da.	90402-40-7
ICAXEUYZCLRXKY-UHFFFAOYSA-N	DB19867	Abaperidone	experimental	nan	Abaperidone is a small molecule drug. Abaperidone has a monoisotopic molecular weight of 452.17 Da.	183849-43-6
UZWDCWONPYILKI-UHFFFAOYSA-N	DB12001	Abemaciclib	approved;investigational	L01EF03	Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has u	1231929-97-7
MAUCONCHVWBMHK-UHFFFAOYSA-N	DB12565	Abexinostat	investigational	nan	Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.	783355-60-2
FTIFIZZEWIBTMR-UHFFFAOYSA-N	DB21596	Abimtrelvir	experimental	nan	Abimtrelvir is a small molecule drug. The usage of the INN stem '-trelvir' in the name indicates that Abimtrelvir is a antiviral 3CL protease inhibitor. Abimtrelvir has a monoisotopic molecular weight of 527.11 Da.	2647530-75-2
GZOSMCIZMLWJML-VJLLXTKPSA-N	DB05812	Abiraterone	approved;investigational	L01XK52;L02BX53;L02BX03	Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively. It is used to treat metastatic castration-resistant prostate cancer, hormone-sensitive high-risk metastatic prostate cancer. [L40968, L40	154229-19-3
IUEWXNHSKRWHDY-PHIMTYICSA-N	DB14973	Abrocitinib	approved;investigational	D11AH08	Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function.[L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, including atopic dermatitis, a chronic inflammatory skin disease with complex pathogenesis. Atopi	1622902-68-4
WDENQIQQYWYTPO-IBGZPJMESA-N	DB11703	Acalabrutinib	approved;investigational	L01EL02	To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least o	1420477-60-6
GOEMGAFJFRBGGG-UHFFFAOYSA-N	DB01193	Acebutolol	approved;investigational	C07AB04;C07BB04	A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.	37517-30-9
QCXJEYYXVJIFCE-UHFFFAOYSA-N	DB04500	Acedoben	experimental	nan	nan	556-08-1
FSQKKOOTNAMONP-UHFFFAOYSA-N	DB13783	Acemetacin	approved	M01AB11	Acemetacin is a carboxymethyl ester of indometacin. It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin.[A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E. Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestina	53164-05-9
BZKPWHYZMXOIDC-UHFFFAOYSA-N	DB00819	Acetazolamide	approved;investigational;vet_approved	G01AE10;S01EC01	One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an	59-66-5
FTQDJVZNPJRVPG-XWEVEMRCSA-N	DB13640	Acetoxolone	experimental	A02BX09	nan	6277-14-1
RAUGYAOLAMRLLZ-UHFFFAOYSA-N	DB20978	Acetryptine	experimental	nan	Acetryptine is a small molecule drug. Acetryptine has a monoisotopic molecular weight of 202.11 Da.	3551-18-6
OIPILFWXSMYKGL-UHFFFAOYSA-N	DB03128	Acetylcholine	approved;investigational	S01EB09	A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.	51-84-3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N	DB00945	Acetylsalicylic acid	approved;investigational;vet_approved	B01AC06;C07FX04;C10BX04;M01BA03;C10BX02;N02BA71;B01AC56;N02AJ07;N02AJ02;N02BA01;B01AF51;C10BX05;N02BA51;A01AD05;C10BX01;C07FX03;N02AJ18;C10BX12;C10BX08;C10BX06;C07FX02	Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, i	50-78-2
ASMXXROZKSBQIH-VITNCHFBSA-N	DB08897	Aclidinium	approved	R03BB05;R03AL05	Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.	727649-81-2
DUYNJNWVGIWJRI-LJAQVGFWSA-N	DB16080	Acolbifene	investigational	nan	Acolbifene is under investigation in clinical trial NCT01452373 (Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women).	182167-02-8
PEMUGDMSUDYLHU-ZEQRLZLVSA-N	DB15568	Adagrasib	approved;investigational	L01XX77	Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding pocket.[A187559] Adagrasib targets KRAS<sup>G12C</sup>, one of the most common KRAS mutation	2326521-71-3
LZCDAPDGXCYOEH-UHFFFAOYSA-N	DB00210	Adapalene	approved;investigational	D10AD03;D10AD53	Acne vulgaris is a multifactorial disorder of the pilosebaceous unit involving increased sebum production, inflammation, and hyperproliferation/hyperkeratinization of the follicular infundibulum. It is also associated with _Cutibacterium acnes_ (also known as _Propionibacterium acnes_). Adapalene is a third-generation topical retinoid used for the treatment of acne vulgaris.[A193518] Adapalene has similar efficacy but a superior safety profile compared to tretinoin.[A193521] [Tazarotene] is more	106685-40-9
OIRDTQYFTABQOQ-KQYNXXCUSA-N	DB00640	Adenosine	approved;investigational	C01EB10	The structure of adenosine was first described in 1931,[A229823] though the vasodilating effects were not described in literature until the 1940s.[A229828] Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy,[L31983] though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia.[L31998] Adenosine was granted FDA approv	58-61-7
XTWYTFMLZFPYCI-KQYNXXCUSA-N	DB16833	Adenosine disphosphate	experimental	nan	nan	58-64-0
UDMBCSSLTHHNCD-KQYNXXCUSA-N	DB00131	Adenosine phosphate	approved;investigational;nutraceutical;withdrawn	nan	Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2&#39;-, 3&#39;-, or 5&#39;-position. Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]	61-19-8
UFZTZBNSLXELAL-IOSLPCCCSA-N	DB03909	Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate	experimental	nan	nan	nan
JIAJERGOUFOENU-LNAOLWRRSA-N	DB03186	Adenylate-3'-phosphate-[[2'-deoxy-uridine-5'-phosphate]-3'-phosphate]	experimental	nan	nan	nan
TVLQBBHUNDMTEC-UHFFFAOYSA-N	DB20623	Adibendan	experimental	nan	Adibendan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Adibendan is a cardiac stimulant, pimobendan derivative. Adibendan has a monoisotopic molecular weight of 278.12 Da.	100510-33-6
IUVSEUFHPNITEQ-UHFFFAOYSA-N	DB20244	Adoprazine	experimental	nan	Adoprazine is a small molecule drug. Adoprazine has a monoisotopic molecular weight of 405.19 Da.	222551-17-9
ISBHYKVAFKTATD-SNVBAGLBSA-N	DB15027	Adriforant	investigational	nan	Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).	943057-12-3
QGXBDMJGAMFCBF-BNSUEQOYSA-N	DB02854	Aetiocholanolone	experimental	nan	The 5-beta-reduced isomer of androsterone. Etiocholanolone is a major metabolite of testosterone and androstenedione in many mammalian species including humans. It is excreted in the urine. [PubChem]	53-42-9
UAHFGYDRQSXQEB-LEBBXHLNSA-N	DB04931	Afamelanotide	approved;investigational	D02BB02	Afamelanotide is a first-in-class, synthetic, 13-amino acid peptide analogue of the endogenous alpha melanocyte-stimulating hormone (α-MSH).[L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer biological half-life.[A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria,	75921-69-6
ULXXDDBFHOBEHA-CWDCEQMOSA-N	DB08916	Afatinib	approved;investigational	L01EB03	Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [L2939]. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim [L2939].	850140-72-6
QPYJXFZUIJOGNX-HSUXUTPPSA-N	DB04545	Afegostat	investigational	nan	nan	169105-89-9
SNFVHLQYHFQOEP-UHFFFAOYSA-N	DB16580	Afimetoran	investigational	nan	Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).	2171019-55-7
TXUZVZSFRXZGTL-QPLCGJKRSA-N	DB04468	Afimoxifene	investigational	nan	Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by Ascent Therapeutics.	68392-35-8
AFJRDFWMXUECEW-LBPRGKRZSA-N	DB11648	Afuresertib	investigational	nan	Afuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.	1047644-62-1
DKNUPRMJNUQNHR-UHFFFAOYSA-N	DB15068	Agerafenib	investigational	nan	Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).	1188910-76-0
YJYPHIXNFHFHND-UHFFFAOYSA-N	DB06594	Agomelatine	approved;investigational	N06AX22	Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization on 27 July 2006. The major concern was that efficacy had not b	138112-76-2
PZLYYZPXSSNGJS-UHFFFAOYSA-N	DB03262	Al-6619, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Hydroxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]	experimental	nan	nan	nan
XSUAVPPTKHUTDX-UHFFFAOYSA-N	DB03598	Al-6629, [2h-Thieno[3,2-E]-1,2-Thiazine-6-Sulfonamide,2-(3-Methoxyphenyl)-3-(4-Morpholinyl)-, 1,1-Dioxide]	experimental	nan	nan	nan
UHIXWHUVLCAJQL-MPBGBICISA-N	DB12073	Albaconazole	investigational	nan	Albaconazole has been used in trials studying the basic science of Onychomycosis.	187949-02-6
PQSUYGKTWSAVDQ-ZVIOFETBSA-N	DB04630	Aldosterone	investigational	H02AA01	A hormone secreted by the adrenal cortex that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.	52-39-1
CMLVKUWQFZQPPS-YUNKPMOVSA-N	DB18824	Aldumastat	investigational	nan	nan	1957278-93-1
KDGFLJKFZUIJMX-UHFFFAOYSA-N	DB11363	Alectinib	approved;investigational	L01ED03	Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved unde	1256580-46-7
DAYKLWSKQJBGCS-NRFANRHFSA-N	DB08915	Aleglitazar	investigational	nan	Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was a	475479-34-6
OGSPWJRAVKPPFI-UHFFFAOYSA-N	DB00630	Alendronic acid	approved;investigational	M05BB03;M05BA04;M05BB06;M05BB05	Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].	66376-36-1
WNMJYKCGWZFFKR-UHFFFAOYSA-N	DB00346	Alfuzosin	approved	G04CA01;G04CA51	Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70.[A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.[L31593] It was	81403-80-7
ZLHFILGSQDJULK-UHFFFAOYSA-N	DB05220	Alisertib	investigational	nan	Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.	1028486-01-2
UXOWGYHJODZGMF-QORCZRPOSA-N	DB09026	Aliskiren	approved;investigational	C09XA54;C09XA53;C09DX02;C09XA02;C09XA52	Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]	173334-57-1
OLROWHGDTNFZBH-XEMWPYQTSA-N	DB12139	Alisporivir	investigational	nan	Alisporivir has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C.	254435-95-5
SHGAZHPCJJPHSC-ZVCIMWCZSA-N	DB00523	Alitretinoin	approved	L01XF02;D11AH04	An important regulator of gene expression during growth and development, and in neoplasms. Tretinoin, also known as retinoic acid and derived from maternal vitamin A, is essential for normal growth; and embryonic development. An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute).	5300-03-8
JDLKFOPOAOFWQN-UHFFFAOYSA-N	DB11780	Allicin	investigational	nan	Allicin has been used in trials studying the treatment of Follicular Lymphoma.	539-86-6
MVZGYPSXNDCANY-UHFFFAOYSA-N	DB18840	Allitinib	experimental	nan	Allitinib is under investigation in clinical trial NCT04671303 (To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer).	897383-62-9
MDWNFWDBQGOKNZ-XYUDZHFQSA-N	DB04628	Allosamidin	experimental	nan	Allosamidin exhibits extremely potent inhibitory activity against chitinases from a number of sources, particularly from <i>Candida albicans</i>, and can be utilized as potent antifungal agent.	103782-08-7
KCNKJCHARANTIP-SNAWJCMRSA-N	DB03771	Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine	experimental	nan	nan	nan
JYNZIOFUHBJABQ-UHFFFAOYSA-N	DB02339	Allyl-{6-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-Hexyl-}-Methyl-Amin	experimental	nan	nan	nan
DKMACHNQISHMDN-RPLLCQBOSA-N	DB06673	Almorexant	investigational	nan	nan	871224-64-5
QVSXOXCYXPQXMF-OAHLLOKOSA-N	DB20494	Alniditan	experimental	nan	Alniditan is a small molecule drug. Alniditan has a monoisotopic molecular weight of 302.21 Da.	152317-89-0
ACZCJTHHWMBFKC-UHFFFAOYSA-N	DB18708	Alogabat	investigational	nan	nan	2230009-48-8
JSWZEAMFRNKZNL-UHFFFAOYSA-N	DB00969	Alosetron	approved;withdrawn	A03AE01	Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002,	122852-42-0
STUWGJZDJHPWGZ-LBPRGKRZSA-N	DB12015	Alpelisib	approved;investigational	L01EM03	Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.[A179209] There are severa	1217486-61-7
VREFGVBLTWBCJP-UHFFFAOYSA-N	DB00404	Alprazolam	approved;illicit;investigational	N05BA12	Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.[A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.[A18125] Alprazolam has been mixed with alcoh	28981-97-7
PAZJSJFMUHDSTF-UHFFFAOYSA-N	DB00866	Alprenolol	approved;withdrawn	C07AA01	One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.	13655-52-2
OLUKILHGKRVDCT-UHFFFAOYSA-N	DB04014	Alsterpaullone	experimental	nan	nan	nan
SMYALUSCZJXWHG-UHFFFAOYSA-N	DB19972	Altanserin	investigational	nan	Altanserin is a small molecule drug. The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist. Altanserin is under investigation in clinical trial NCT03970239 (Serotonin in Impulse Control Disorders in Parkinson's Disease). Altanserin has a monoisotopic molecular weight of 411.14 Da.	76330-71-7
GNNDEPIMDAZHRQ-UHFFFAOYSA-N	DB17191	Altiratinib	investigational	nan	nan	1345847-93-9
UPNUIXSCZBYVBB-JVFUWBCBSA-N	DB06274	Alvimopan	approved;investigational	A06AH02	Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.	156053-89-3
BIIVYFLTOXDAOV-YVEFUNNKSA-N	DB03496	Alvocidib	investigational	nan	Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.	146426-40-6
DKNWSYNQZKUICI-UHFFFAOYSA-N	DB00915	Amantadine	approved;investigational	N04BB01	An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.	768-94-5
OUJTZYPIHDYQMC-LJQANCHMSA-N	DB06403	Ambrisentan	approved;investigational	C02KX02;C02KX52	Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of 	177036-94-1
WKDBRCUUDXLTIM-NSHDSACASA-N	DB21514	Amdizalisib	investigational	nan	Amdizalisib is a small molecule drug. Amdizalisib is under investigation in clinical trial NCT05713110 (A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma). Amdizalisib has a monoisotopic molecular weight of 390.11 Da.	1894229-05-0
XSDQTOBWRPYKKA-UHFFFAOYSA-N	DB00594	Amiloride	approved;investigational	C03DB01	A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)	2609-46-3
NQRKYASMKDDGHT-UHFFFAOYSA-N	DB02079	Aminooxyacetic acid	experimental	nan	A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues. [PubChem]	645-88-5
TVZGACDUOSZQKY-LBPRGKRZSA-N	DB08878	Aminopterin	approved;withdrawn	nan	Aminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia. In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis. Clinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate.	54-62-6
IYIKLHRQXLHMJQ-UHFFFAOYSA-N	DB01118	Amiodarone	approved;investigational	C01BD01	Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings.[A36817] Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]	1951-25-3
NTJOBXMMWNYJFB-UHFFFAOYSA-N	DB06288	Amisulpride	approved;investigational	N05AL05	Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression.[A6755] Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to othe	71675-85-9
BSMNRYCSBFHEMQ-KCJUWKMLSA-N	DB05964	Amitifadine	investigational	nan	nan	410074-73-6
HTIQEAQVCYTUBX-UHFFFAOYSA-N	DB00381	Amlodipine	approved;investigational	C09BB13;C09BB04;C10BX18;C07FB12;C09DB05;C09XA53;C10BX03;C09BX04;C09DB07;C09DX06;C09BX01;C10BX11;C09DB02;C10BX09;C09DX01;C10BX19;C09DB01;C09XA54;C10BX07;C09BB03;C07FB07;C09DB06;C07FB13;C09DX08;C08CA01;C09BX06;C09BX03;C09DB04;C09DX03;C08GA02;C08CA51;C09DB09;C10BX14;C09BB07;C09DX07	Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers [A175327]. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlo	88150-42-9
QWGDMFLQWFTERH-UHFFFAOYSA-N	DB00543	Amoxapine	approved	N06AA17	Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and n	14028-44-5
LSQZJLSUYDQPKJ-NJBDSQKTSA-N	DB01060	Amoxicillin	approved;investigational;vet_approved	A02BD12;J01CR50;A02BD14;A02BD04;A02BD07;A02BD13;A02BD10;A02BD05;A02BD03;A02BD01;A02BD15;A02BD06;J01CA04;A02BD17;A02BD16;A02BD11	Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972.[A190648] Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin.[A190648] Amoxicillin was granted FDA approval on 18 January 1974.[L11644]	26787-78-0
YMARZQAQMVYCKC-OEMFJLHTSA-N	DB00701	Amprenavir	approved;withdrawn	J05AE05	Amprenavir is a protease inhibitor used to treat HIV infection.	161814-49-9
JLUUVUUYIXBDCG-UHFFFAOYSA-N	DB21566	Amredobresib	investigational	nan	Amredobresib is a small molecule drug. The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic. Amredobresib is under investigation in clinical trial NCT02516553 (BI 894999 First in Human Dose Finding Study in Advanced Malignancies). Amredobresib has a monoisotopic molecular weight of 467.25 Da.	1610044-98-8
FOFDIMHVKGYHRU-UHFFFAOYSA-N	DB12742	Amuvatinib	investigational	nan	Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.	850879-09-3
LDXYBEHACFJIEL-HNNXBMFYSA-N	DB12417	Anagliptin	investigational	nan	Anagliptin is under investigation for the treatment of LDL Cholesterol, Coronary Disease, Diabetes Mellitus, Glycosylated Hemoglobin, and Dipeptidyl-Peptidase 4 Inhibitors.	739366-20-2
OTBXOEAOVRKTNQ-UHFFFAOYSA-N	DB00261	Anagrelide	approved;investigational	L01XX35	Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]	68475-42-3
QADHLRWLCPCEKT-LOVVWNRFSA-N	DB01524	Androstenediol	experimental;illicit	nan	Androstenediol is an intermediate in [testosterone] biosynthesis, found in the testis or the adrenal glands. Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group to a 3-keto group (3-hydroxysteroid dehydrogenases).	521-17-5
AEMFNILZOJDQLW-QAGGRKNESA-N	DB01536	Androstenedione	illicit;investigational	nan	A delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.	63-05-8
YKJYKKNCCRKFSL-RDBSUJKOSA-N	DB07374	Anisomycin	experimental	nan	Anisomycin (sometimes known as flagecidin), is an antibiotic retrieved from the bacteria _Streptomyces griseolus_. This drug acts to inhibit bacterial protein and DNA synthesis.	22862-76-6
KSMZEXLVHXZPEF-UHFFFAOYSA-N	DB11885	Anlotinib	investigational	nan	Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.	1058156-90-3
QKYBZJLEMOZFFU-UHFFFAOYSA-N	DB15052	Ansofaxine	investigational	nan	Ansofaxine is under investigation in clinical trial NCT02271412 (Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005).	916918-80-4
NUZWLKWWNNJHPT-UHFFFAOYSA-N	DB11157	Anthralin	approved	D05AC01;D05AC51	Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin [A27277]. This specific property of the molecule inspired workers to study details of its pharmacology. It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not b	1143-38-0
NETXMUIMUZJUTB-UHFFFAOYSA-N	DB12000	Apabetalone	investigational	nan	Apabetalone has been investigated for the treatment of Diabetes, Atherosclerosis, and Coronary Artery Disease.	1044870-39-4
FLEVIENZILQUKB-XTWQNQIISA-N	DB05009	Apadenoson	investigational	nan	Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.	250386-15-3
NOFOAYPPHIUXJR-APNQCZIXSA-N	DB17742	Aphidicolin	experimental	nan	Aphidicolin is an antimitotic and antiviral metabolite of the mould _Cephalosporium aphidicola_. It inhibits DNA polymerase alpha and blocks DNA replication.[A259157, A259162]	38966-21-1
KZNIFHPLKGYRTM-UHFFFAOYSA-N	DB07352	Apigenin	investigational	nan	nan	520-36-5
LSYANGLAZUZYFX-UHFFFAOYSA-N	DB16241	Apinocaltamide	investigational	nan	Apinocaltamide is under investigation in clinical trial NCT03239691 (A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients).	1838651-58-3
YOVVNQKCSKSHKT-HNNXBMFYSA-N	DB12180	Apitolisib	investigational	nan	Apitolisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, and Endometrial Carcinoma, among others.	1032754-93-0
IEJXVRYNEISIKR-UHFFFAOYSA-N	DB00964	Apraclonidine	approved	S01EA03	Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.	66711-21-5
MAVDNGWEBZTACC-HNNXBMFYSA-N	DB13020	Apratastat	investigational	nan	Tmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).	287405-51-0
IMOZEMNVLZVGJZ-QGZVFWFLSA-N	DB05676	Apremilast	approved;investigational	L04AA32	Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood	608141-41-9
ATALOFNDEOCMKK-OITMNORJSA-N	DB00673	Aprepitant	approved;investigational	A04AD12	Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the t	170729-80-3
DKULOVKANLVDEA-UHFFFAOYSA-N	DB15059	Aprocitentan	approved	C02KN01	Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan]. Approximately 10-15% of patients with hypertension have resistant hypertension, defined as uncontrolled high blood pressure despite the combined use of a renin-angiotensin system blocker, a calcium channel blocker, and a diuretic at maximally tolerated doses.[A263386] Patients with resistant hypertension are at an increased risk of cardiovascul	1103522-45-7
YZXBAPSDXZZRGB-DOFZRALJSA-N	DB04557	Arachidonic Acid	approved;investigational;withdrawn	nan	An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. [PubChem]	506-32-1
PLWROONZUDKYKG-DOFZRALJSA-N	DB17022	Arachidonyltrifluoromethane	experimental	nan	Specific inhibitor of phospholipase A2.[A252972]	149301-79-1
KPYSYYIEGFHWSV-QMMMGPOBSA-N	DB08891	Arbaclofen	investigational	nan	Arbaclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind, placebo controlled trials. It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. Arbaclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with d	69308-37-8
HJJPJSXJAXAIPN-UHFFFAOYSA-N	DB04365	Arecoline	experimental	nan	An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.	63-75-2
FOZYKTUSOWWQGR-KNPYFFGGSA-N	DB04350	Argadin	experimental	nan	nan	289665-92-5
UHBHXSDKGLPPGO-HTDHLNIYSA-N	DB03632	Argifin	experimental	nan	nan	243975-37-3
CEUORZQYGODEFX-UHFFFAOYSA-N	DB01238	Aripiprazole	approved;investigational	N05AX12	Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's.[L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.[L45859] Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on Nove	129722-12-9
YFGHCGITMMYXAQ-LJQANCHMSA-N	DB06413	Armodafinil	approved;investigational	N06BA13	Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cep	112111-43-0
FOIVPCKZDPCJJY-JQIJEIRASA-N	DB02877	Arotinoid acid	experimental	nan	Arotinoid acid is a retinoic acid analog which acts as a selective RAR agonist.	71441-28-6
BHIAIPWSVYSKJS-UHFFFAOYSA-N	DB09204	Arotinolol	investigational	nan	Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.[T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]	68377-92-4
MCGDSOGUHLTADD-UHFFFAOYSA-N	DB06249	Arzoxifene	approved;withdrawn	nan	nan	182133-25-1
VOVZXURTCKPRDQ-CQSZACIVSA-N	DB12597	Asciminib	approved;investigational	L01EA06	Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.[L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wi	1492952-76-7
VSWBSWWIRNCQIJ-UHFFFAOYSA-N	DB06216	Asenapine	approved;investigational	N05AH05	Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.	65576-45-6
GAIOPWBQKZMUNO-UHFFFAOYSA-N	DB21530	Asnuciclib	experimental	nan	Asnuciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Asnuciclib is a cyclin dependant kinase inhibitor. Asnuciclib has a monoisotopic molecular weight of 394.07 Da.	1421693-22-2
GJMNAFGEUJBOCE-MEQIQULJSA-N	DB06680	Asoprisnil	investigational	nan	Asoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.	199396-76-4
GXDALQBWZGODGZ-UHFFFAOYSA-N	DB00637	Astemizole	approved;withdrawn	R06AX11	Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.	68844-77-9
XRWSZZJLZRKHHD-WVWIJVSJSA-N	DB11586	Asunaprevir	approved;withdrawn	J05AP06;J05AP58	Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.[A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]	630420-16-5
XYWIPYBIIRTJMM-IBGZPJMESA-N	DB19088	Asundexian	investigational	nan	Asundexian is under investigation in clinical trial NCT05686070 (A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke).	2064121-65-7
VLLFGVHGKLDDLW-SFHVURJKSA-N	DB15307	Atabecestat	investigational	nan	Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates).	1200493-78-2
OOUGLTULBSNHNF-UHFFFAOYSA-N	DB05016	Ataluren	approved;withdrawn	M09AX03	Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene. This drug does not yet have approval by the US Food and Drug Administration or by Health C	775304-57-9
UQZCQKXJAXKZQH-LBPRGKRZSA-N	DB19028	Atamparib	investigational	nan	Atamparib is under investigation in clinical trial NCT05127590 (RBN-2397 in Combination With Pembrolizumab in Patients With SCCL).	2381037-82-5
AXRYRYVKAWYZBR-GASGPIRDSA-N	DB01072	Atazanavir	approved;investigational	J05AE08;J05AR15;J05AR23	Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only 	198904-31-3
METKIMKYRPQLGS-UHFFFAOYSA-N	DB00335	Atenolol	approved;investigational	C07CB53;C07AB03;C07FB03;C07DB01;C07BB03;C07CB03	Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize.[A178429] Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure 	29122-68-7
UCPOMLWZWRTIAA-UHFFFAOYSA-N	DB12264	Atevirdine	investigational	nan	Atevirdine has been used in trials studying the treatment of HIV Infections.	136816-75-6
ZHPMYDSXGRRERG-DEOSSOPVSA-N	DB12341	Aticaprant	investigational	nan	Aticaprant has been used in trials studying the health services research and basic science of Anxiety Disorders and Alcohol Dependence.	1174130-61-0
PRQMBGDYXWVEHE-SKDRFNHKSA-N	DB21558	Atinvicitinib	experimental	nan	Atinvicitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Atinvicitinib is a Janus kinase inhibitor. Atinvicitinib has a monoisotopic molecular weight of 360.13 Da.	2169273-59-8
HSWPZIDYAHLZDD-UHFFFAOYSA-N	DB11481	Atipamezole	investigational;vet_approved	nan	Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. It has also been undergone research as a potential anti-Parkinsonian drug for humans.	104054-27-5
QYJLBHRAPDJOSO-NVXWUHKLSA-N	DB21733	Atirmociclib	investigational	nan	Atirmociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Atirmociclib is a cyclin dependant kinase inhibitor. Atirmociclib is under investigation in clinical trial NCT06760637 (Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease). Atirmociclib has a monoisotopic molecular weight of 463.18 Da.	2380321-51-5
QIVUCLWGARAQIO-OLIXTKCUSA-N	DB16098	Atogepant	approved;investigational	N02CD07	Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.[L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is novel in that it is the first and only oral CGRP anta	1374248-81-3
VHGCDTVCOLNTBX-QGZVFWFLSA-N	DB00289	Atomoxetine	approved;investigational	N06BA09	Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pa	83015-26-3
XUKUURHRXDUEBC-KAYWLYCHSA-N	DB01076	Atorvastatin	approved;investigational	C10BA05;C10BX11;C10BX12;C10BX19;C10BX18;C10AA05;C10BX15;C10BX03;C10BX08;C10BX06	Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical 	134523-00-5
VWXRQYYUEIYXCZ-OBIMUBPZSA-N	DB09059	Atosiban	approved;investigational	G02CX01	Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult wome	90779-69-4
MOTJMGVDPWRKOC-QPVYNBJUSA-N	DB06199	Atrasentan	approved;investigational	nan	Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist to be approved for this condition.[L52855,L52900]	173937-91-2
RKUNBYITZUJHSG-SPUOUPEWSA-N	DB00572	Atropine	approved;investigational;vet_approved	S01FA01;A03CB03;V03AB54;A03BA01	Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products.[A251660,L42840] Atropine is a competitive, reversible antagonist of muscarinic re	51-55-8
ROTWSDMXHVGAHZ-QZTJIDSGSA-N	DB19029	Atuliflapon	investigational	nan	Atuliflapon is under investigation in clinical trial NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-severe Uncontrolled Asthma).	2041075-86-7
QJRFBKYETDVAJQ-ZEQKJWHPSA-N	DB23608	Atumelnant	investigational	nan	nan	2392970-97-5
ACWKGTGIJRCOOM-HHHXNRCGSA-N	DB20084	Atuveciclib	investigational	nan	Atuveciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Atuveciclib is a cyclin dependant kinase inhibitor. Atuveciclib is under investigation in clinical trial NCT02345382 (Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia). Atuveciclib has a monoisotopic molecular weight of 387.12 Da.	1414943-94-4
OLIMBXKACVCIMM-HNNXBMFYSA-N	DB19030	Atuzaginstat	investigational	nan	Atuzaginstat is under investigation in clinical trial NCT03823404 (GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease).	2211981-76-7
RSNPAKAFCAAMBH-UHFFFAOYSA-N	DB14857	Avadomide	investigational	nan	Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).	1015474-32-4
XEAOPVUAMONVLA-QGZVFWFLSA-N	DB11893	Avagacestat	investigational	nan	Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease.	1146699-66-2
DWYRIWUZIJHQKQ-SANMLTNESA-N	DB15233	Avapritinib	approved;investigational	L01EX18	Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] an	1703793-34-3
NDCUAPJVLWFHHB-UHNVWZDZSA-N	DB09060	Avibactam	approved;investigational	nan	Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens. As there is limited clini	1192500-31-4
YBWLTKFZAOSWSM-UHFFFAOYSA-N	DB20899	Avosentan	experimental	nan	Avosentan is a small molecule drug. The usage of the INN stem '-entan' in the name indicates that Avosentan is a endothelin receptor antagonist. Avosentan has a monoisotopic molecular weight of 479.13 Da.	290815-26-8
VFVAQKKPFOPZEA-UHFFFAOYSA-N	DB16652	Avotaciclib	investigational	nan	Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer).	1983983-41-0
LMMJFBMMJUMSJS-UHFFFAOYSA-N	DB15254	Avutometinib	approved;investigational	nan	Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.[L53203,L53198] The MAPK pathway is implicated in variety of cancers, playing a key role in tumor cell proliferation, differentiation and survival.[L53203] It has been under investigation in humans since at least 2012.[A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recu	946128-88-7
ATLYLVPZNWDJBW-KIHHCIJBSA-N	DB12013	Axelopran	investigational	nan	Axelopran has been used in trials studying the treatment of OIC and Opioid-induced Constipation.	949904-48-7
RITAVMQDGBJQJZ-FMIVXFBMSA-N	DB06626	Axitinib	approved;investigational	L01EK01	Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is avail	319460-85-0
VYNIUBZKEWJOJP-UNMCSNQZSA-N	DB19741	Azalanstat	experimental	nan	Azalanstat is a small molecule drug. Azalanstat has a monoisotopic molecular weight of 429.13 Da.	143393-27-5
XTKDAFGWCDAMPY-UHFFFAOYSA-N	DB11376	Azaperone	investigational;vet_approved	nan	Azaperone is a pyridinylpiperazine and butyrophenone agent that is capable of eliciting neuroleptic sedative and antiemetic effects. It is subsequently employed predominantly as a veterinary tranquilizer and mainly for pigs and elephants. At the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.	1649-18-9
NYGHGTMKALXFIA-UHFFFAOYSA-N	DB13727	Azapetine	experimental	C04AX30	nan	146-36-1
MBUVEWMHONZEQD-UHFFFAOYSA-N	DB00972	Azelastine	approved;investigational	R06AX19;S01GX07;R01AC03	Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.[L8240,L8270] Azelastine is also available in combination with fluticasone propionate as a nasal spray marketed unde	58581-89-8
MQTOSJVFKKJCRP-BICOPXKESA-N	DB00207	Azithromycin	approved;investigational	J01RA07;S01AA26;J01FA10;J01RA16	Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration [A174172]. It was initially approved by the FDA in 1991 [A174175]. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin [A174169]. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of 	83905-01-5
WZPBZJONDBGPKJ-VEHQQRBSSA-N	DB00355	Aztreonam	approved;investigational	J01DF01	A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.	78110-38-0
BKLJDIJJOOQUFG-UHFFFAOYSA-N	DB16758	BAY-876	experimental	nan	nan	1799753-84-6
JNLSTLQFDDAULK-UHFFFAOYSA-N	DB16035	BFH772	investigational	nan	BFH772 is under investigation in clinical trial NCT01449591 (Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients).	890128-81-1
DVWARFPIVDNTDK-UHFFFAOYSA-N	DB17104	BG-P400-TAT	experimental	nan	nan	nan
XQVVPGYIWAGRNI-JOCHJYFZSA-N	DB16107	BI 2536	investigational	nan	BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).	755038-02-9
HTLWMOKBJQKDIJ-WJOKGBTCSA-N	DB16037	BI 44370 TA	investigational	nan	BI 44370 TA is under investigation in clinical trial NCT00751803 (BI 44370 TA in Acute Migraine Attack).	866086-05-7
QULDDKSCVCJTPV-UHFFFAOYSA-N	DB12359	BIIB021	investigational	nan	BIIB021 has been investigated for the treatment of Tumors and Lymphoma.	848695-25-0
KBOGUFFJCBPJEH-SQGSUPJISA-N	DB04651	BIOTINOL-5-AMP	experimental	nan	nan	nan
TXEBNKKOLVBTFK-UHFFFAOYSA-N	DB17985	BLU-9931	experimental	nan	nan	1538604-68-0
ADZBMFGQQWPHMJ-RHSMWYFYSA-N	DB16838	BLZ-945	investigational	nan	nan	953769-46-5
ZXQHMEUGMCXKLO-KPKJPENVSA-N	DB02466	BMS-181156	experimental	nan	nan	110368-35-9
OLCWFLWEHWLBTO-HSZRJFAPSA-N	DB12234	BMS-214662	investigational	nan	BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3), among others.	195987-41-8
GDTQLZHHDRRBEB-UHFFFAOYSA-N	DB12696	BMS-582949	investigational	nan	BMS-582949 has been investigated for the treatment of Psoriasis.	623152-17-0
LUJZZYWHBDHDQX-QFIPXVFZSA-N	DB12318	BMS-599626	investigational	nan	BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.	714971-09-2
CSGQVNMSRKWUSH-IAGOWNOFSA-N	DB11665	BMS-690514	investigational	nan	BMS-690514 has been investigated for the treatment of Breast Cancer.	859853-30-8
PJTGSIKANITYOO-RCOXNQKVSA-N	DB19004	BMS-741672	investigational	nan	BMS-741672 is under investigation in clinical trial NCT00699790 (Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance).	1386991-77-0
LQVXSNNAFNGRAH-QHCPKHFHSA-N	DB15399	BMS-754807	investigational	nan	BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).	1001350-96-4
VNBRGSXVFBYQNN-UHFFFAOYSA-N	DB12064	BMS-777607	investigational	nan	BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.	1025720-94-8
CMVHFGNTABZQJU-HCXYKTFWSA-N	DB16240	BMS-813160	investigational	nan	BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).	1286279-29-5
JJWLXRKVUJDJKG-VIFPVBQESA-N	DB12357	BMS-863233	investigational	nan	BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.	1169558-38-6
JCINBYQJBYJGDM-UHFFFAOYSA-N	DB12591	BMS-911543	investigational	nan	BMS-911543 has been used in trials studying the treatment of Cancer.	1271022-90-2
XDMUFNNPLXHNKA-ZTESCHFWSA-N	DB15193	BMS-955176	investigational	nan	BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).	1392312-45-6
GQBRZBHEPUQRPL-LJQANCHMSA-N	DB14948	BMS-986020	investigational	nan	BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).	1257213-50-5
KEEBLYWBELVGPQ-UHFFFAOYSA-N	DB14942	BMS-986141	investigational	nan	BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).	1478711-48-6
ZRYMMWAJAFUANM-INIZCTEOSA-N	DB15291	BMS-986142	investigational	nan	BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).	1643368-58-4
KGERZPVQIRYWRK-GDLZYMKVSA-N	DB15435	BMS-986158	investigational	nan	BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).	1800340-40-2
AYAJZQYENGWICE-QHCPKHFHSA-N	DB03466	BMS184394	experimental	nan	nan	nan
SGWLRDAOCLITOM-UHFFFAOYSA-N	DB15498	BOS172722	investigational	nan	BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent.[A187123] Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication. The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects.[A187120] An in vivo study combined BOS172722 with [Paclitaxel] for the treatment of triple hormone receptor negative 	1578245-44-9
YXQQNSYZOQHKHD-UHFFFAOYSA-N	DB07404	BPH-608	experimental	nan	nan	nan
KPYSYYIEGFHWSV-UHFFFAOYSA-N	DB00181	Baclofen	approved;investigational	M03BX01	Baclofen is a gamma-aminobutyric acid (GABA) agonist used as a skeletal muscle relaxant. Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients.[A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.[A245323, A245338] Baclofen is used to manage severe muscle spasms of cerebral or spinal cord origins, including multiple	1134-47-0
ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	DB11851	Bafetinib	investigational	nan	Bafetinib has been used in trials studying the treatment of Adult Gliosarcoma, Adult Mixed Glioma, Adult Glioblastoma, Chronic Myeloid Leukemia, and Acute Lymphocytic Leukemia, among others.	859212-16-1
XDHNQDDQEHDUTM-JQWOJBOSSA-N	DB06733	Bafilomycin A1	experimental	nan	The bafilomycins refer to a category of toxic macrolide antibiotics that are derivatives of Streptomyces griseus. These compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase). The most commonly utilized bafilomycin is bafilomycin A1. This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.	88899-55-2
XYUFCXJZFZPEJD-PGRDOPGGSA-N	DB04098	Balanol	experimental	nan	nan	nan
LLCRBOWRJOUJAE-UHFFFAOYSA-N	DB12239	Balicatib	investigational	nan	Balicatib has been used in trials studying the treatment of Osteoporosis and Knee Osteoarthritis.	354813-19-7
FIDLLEYNNRGVFR-CTNGQTDRSA-N	DB15675	Baloxavir	investigational	nan	Baloxavir is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)).	1985605-59-1
GBJVVSCPOBPEIT-UHFFFAOYSA-N	DB11747	Barasertib	investigational	nan	Barasertib has been used in trials studying the treatment of Tumors, Lymphoma, Solid Tumors, Solid Tumours, and Myeloid Leukemia, among others.	722543-31-9
XUZMWHLSFXCVMG-UHFFFAOYSA-N	DB11817	Baricitinib	approved;investigational	L04AF02	Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A24	1187594-09-7
VCGRFBXVSFAGGA-UHFFFAOYSA-N	DB11877	Basmisanil	investigational	nan	Basmisanil has been used in trials studying the treatment and basic science of Down Syndrome.	1159600-41-5
URWYQGVSPQJGGB-DHUJRADRSA-N	DB12526	Batefenterol	investigational	nan	Batefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.	743461-65-6
XFILPEOLDIKJHX-QYZOEREBSA-N	DB03880	Batimastat	experimental	nan	nan	130370-60-4
UCJGJABZCDBEDK-UHFFFAOYSA-N	DB06401	Bazedoxifene	approved;investigational	G03XC02;G03CC07	Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. In 2013, the combination product containing conjugated estrogens and bazedox	198481-32-2
AVDLWYHBABSSHC-CHWSQXEVSA-N	DB04368	Bb-3497	experimental	nan	nan	235784-88-0
ZTTKEBYSXUCBSE-QDFUAKMASA-N	DB12225	Beclabuvir	investigational	J05AP58	Beclabuvir has been used in trials studying the treatment of Hepatitis C, Chronic.	958002-33-0
QUIJNHUBAXPXFS-XLJNKUFUSA-N	DB08903	Bedaquiline	approved;investigational	J04AK05	Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity.[A261866] Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP.[A261866] Consequently, bedaquiline can be used to treat mycoba	843663-66-1
PSXOKXJMVRSARX-SCSAIBSYSA-N	DB12263	Begacestat	investigational	nan	Begacestat has been used in trials studying the treatment and basic science of Alzheimer Disease.	769169-27-9
NCNRHFGMJRPRSK-MDZDMXLPSA-N	DB05015	Belinostat	approved;investigational	L01XH04	Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-da	866323-14-0
GKHIVNAUVKXIIY-UHFFFAOYSA-N	DB16703	Belumosudil	approved;investigational	L04AA48	Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension.[A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC<sub>50</sub> 100 nM vs. 3 μM, respectively).[L34749] In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hemato	911417-87-3
KVCQTKNUUQOELD-UHFFFAOYSA-N	DB17568	Belvarafenib	investigational	nan	nan	1446113-23-0
KXMZDGSRSGHMMK-VWLOTQADSA-N	DB12411	Bemcentinib	investigational	nan	Bemcentinib has been investigated for the treatment of Non-Small Cell Lung Cancer.	1037624-75-1
YTKUWDBFDASYHO-UHFFFAOYSA-N	DB06769	Bendamustine	approved;investigational	L01AA09	Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent c	16506-27-7
FEBOTPHFXYHVPL-UHFFFAOYSA-N	DB12867	Benperidol	approved;withdrawn	N05AD07	Benperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.	2062-84-2
XCPPIJCBCWUBNT-UHFFFAOYSA-N	DB16851	Bentamapimod	investigational	nan	nan	848344-36-5
GIJXKZJWITVLHI-PMOLBWCYSA-N	DB00245	Benzatropine	approved;investigational	N04AC01	Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in	86-13-5
WHQCHUCQKNIQEC-UHFFFAOYSA-N	DB12319	Benzbromarone	approved;investigational;withdrawn	M04AB03	Benzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.	3562-84-3
SIYLLGKDQZGJHK-UHFFFAOYSA-N	DB11125	Benzethonium	approved	D08AJ58;R02AA09;D08AJ08	Benzethonium is a synthetic quaternary ammonium salt with surfactant, antiseptic, and broad spectrum antimicrobial properties. Its salt form, benzethonium chloride, is primarily used as a skin disinfectant at concentrations of 0.1-0.2 %, which are safe and effective concentrations for the compound specified by the U.S. Food and Drug Administration (FDA). It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. It is shown to be effective in mediating its 	10172-60-8
YNCYPMUJDDXIRH-UHFFFAOYSA-N	DB04360	Benzo[B]Thiophene-2-Boronic Acid	experimental	nan	nan	nan
PWDGTQXZLNDOKS-UHFFFAOYSA-N	DB07050	Benzolamide	investigational	nan	nan	nan
WGQKYBSKWIADBV-UHFFFAOYSA-N	DB02464	Benzylamine	investigational	nan	nan	100-46-9
POQDXIFVWVZVML-UHFFFAOYSA-N	DB09182	Benzylfentanyl	experimental;illicit	nan	Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. In 2010 it was removed from the list after it was found to have minimal opioid activity. Benzylfentanyl has a Ki of 213nM at the mu opioid receptor, binding around 200x less strongly than fentanyl itself.	1474-02-8
JGSARLDLIJGVTE-MBNYWOFBSA-N	DB01053	Benzylpenicillin	approved;investigational;vet_approved	J01CR50;J01CE01;S01AA14;J01CE08	Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms. Natural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, g	61-33-6
HLIBJQGJVDHCNB-UHFFFAOYSA-N	DB20479	Benzylsulfamide	experimental	nan	Benzylsulfamide is a small molecule drug. Benzylsulfamide has a monoisotopic molecular weight of 262.08 Da.	104-22-3
UIEATEWHFDRYRU-UHFFFAOYSA-N	DB01244	Bepridil	approved;investigational;withdrawn	C08EA02	A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).	64706-54-3
DFOCUWZXJBAUSQ-URLMMPGGSA-N	DB18146	Berbamine	experimental	nan	nan	478-61-5
YBHILYKTIRIUTE-UHFFFAOYSA-N	DB04115	Berberine	approved;investigational;withdrawn	nan	An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.	2086-83-1
BGEBZHIAGXMEMV-UHFFFAOYSA-N	DB12216	Bergapten	investigational	D05BA03	Bergapten is under investigation in clinical trial NCT00533195 (Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis).	484-20-8
JZCWLJDSIRUGIN-UHFFFAOYSA-N	DB11794	Berzosertib	investigational	nan	Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.	1232416-25-9
WHGYBXFWUBPSRW-FOUAGVGXSA-N	DB03995	Betadex	investigational	nan	nan	7585-39-9
NWIUTZDMDHAVTP-UHFFFAOYSA-N	DB00195	Betaxolol	approved;investigational	S01ED02;C07AB05;S01ED52	A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.	63659-18-7
NZUPCNDJBJXXRF-UHFFFAOYSA-O	DB01019	Bethanechol	approved	N07AB02	Bethanechol is a synthetic ester that was initially synthesized in 1935.[A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous system is necessary.[A232905,L32539] For example, bethanechol is readily used to treat postoperative or postpartum urinary retention. An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded	674-38-4
XHOLNRLADUSQLD-UHFFFAOYSA-N	DB12364	Betrixaban	approved	B01AF04	Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [A27285	330942-05-7
BTCRKOKVYTVOLU-SJSRKZJXSA-N	DB12236	Bexagliflozin	approved;investigational	A10BK08	Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.[A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge.[A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.[A256408] By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose an	1118567-05-7
NAVMQTYZDKMPEU-UHFFFAOYSA-N	DB00307	Bexarotene	approved;investigational	L01XF03	Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.	153559-49-0
WQBIOEFDDDEARX-CHWSQXEVSA-N	DB19798	Bexlosteride	experimental	nan	Bexlosteride is a small molecule drug. The usage of the INN stem '-steride' in the name indicates that Bexlosteride is a androgen/anabolic steroid. Bexlosteride has a monoisotopic molecular weight of 249.09 Da.	148905-78-6
OFYVIGTWSQPCLF-UHFFFAOYSA-N	DB04889	Bicifadine	investigational	nan	Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.	71195-57-8
SOLUWJRYJLAZCX-LYOVBCGYSA-N	DB11799	Bictegravir	approved;investigational	J05AR20	Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677]	1611493-60-7
CYGODHVAJQTCBG-UHFFFAOYSA-N	DB04888	Bifeprunox	investigational	nan	Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.	350992-10-8
OCAPBUJLXMYKEJ-UHFFFAOYSA-N	DB04794	Bifonazole	approved	D01AC10;D01AC60	Bifonazole is an azole antifungal drug.	60628-96-8
ADGGYDAFIHSYFI-UHFFFAOYSA-N	DB14846	Bimiralisib	investigational	nan	Bimiralisib is under investigation in clinical trial NCT02723877 (PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)).	1225037-39-7
ACWZRVQXLIRSDF-UHFFFAOYSA-N	DB11967	Binimetinib	approved;investigational	L01EE03	Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.[L3335]	606143-89-9
XJFMHMFFBSOEPR-DNZQAUTHSA-N	DB04853	Binodenoson	investigational	nan	Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion.	144348-08-3
WUADCCWRTIWANL-UHFFFAOYSA-N	DB15334	Biochanin A	experimental	nan	Biochanin A is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).	491-80-5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N	DB00121	Biotin	approved;investigational;nutraceutical	A11HA05	A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.	58-85-5
YSXKPIUOCJLQIE-UHFFFAOYSA-N	DB00810	Biperiden	approved;investigational;withdrawn	N04AA02	A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.	514-65-8
GNMUEVRJHCWKTO-FQEVSTJZSA-N	DB15189	Birabresib	investigational	nan	Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).	202590-98-5
KHOITXIGCFIULA-UHFFFAOYSA-N	DB09020	Bisacodyl	approved;investigational	A06AB52;A06AB02;A06AG02	Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300]	603-50-9
QMGUOJYZJKLOLH-UHFFFAOYSA-N	DB03777	Bisindolylmaleimide I	experimental	nan	nan	133052-90-1
UQHKJRCFSLMWIA-UHFFFAOYSA-N	DB01946	Bisindolylmaleimide VIII	experimental	nan	nan	125313-65-7
VHYCDWMUTMEGQY-UHFFFAOYSA-N	DB00612	Bisoprolol	approved;investigational	C07FX04;C07BB07;C07AB07;C09BX05;C09BX02;C09BX04;C09BX06;C07FB07	Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs.[A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be	66722-44-9
IISBACLAFKSPIT-UHFFFAOYSA-N	DB06973	Bisphenol A	experimental	nan	nan	80-05-7
SDDLEVPIDBLVHC-UHFFFAOYSA-N	DB07485	Bisphenol Z	experimental	nan	nan	843-55-0
JFIOVJDNOJYLKP-UHFFFAOYSA-N	DB04813	Bithionol	approved;withdrawn	D10AB01;P02BX01	Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).	97-18-7
XVGOZDAJGBALKS-UHFFFAOYSA-N	DB09223	Blonanserin	investigational	nan	Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.	132810-10-7
LHHCSNFAOIFYRV-DOVBMPENSA-N	DB08873	Boceprevir	approved;withdrawn	J05AP03	Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of 	394730-60-0
HPKJGHVHQWJOOT-ZJOUEHCJSA-N	DB21501	Bofutrelvir	experimental	nan	Bofutrelvir is a small molecule drug. The usage of the INN stem '-trelvir' in the name indicates that Bofutrelvir is a antiviral 3CL protease inhibitor. Bofutrelvir has a monoisotopic molecular weight of 452.24 Da.	2103278-86-8
QXZBMSIDSOZZHK-DOPDSADYSA-N	DB11724	Bombesin	investigational	nan	Bombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers).	31362-50-2
UUOJIACWOAYWEZ-UHFFFAOYSA-N	DB08807	Bopindolol	experimental	C07AA17;C07CA17	Bopindolol (INN) is an ester prodrug for the beta blocker [pindolol].	62658-63-3
GXJABQQUPOEUTA-RDJZCZTQSA-N	DB00188	Bortezomib	approved;investigational	L01XG01	Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity	179324-69-7
GJPICJJJRGTNOD-UHFFFAOYSA-N	DB00559	Bosentan	approved;investigational	G01AE10;C02KX01	Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.	147536-97-8
UBPYILGKFZZVDX-UHFFFAOYSA-N	DB06616	Bosutinib	approved;investigational	L01EA04	Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; ho	380843-75-4
QXZGBUJJYSLZLT-FDISYFBBSA-N	DB12126	Bradykinin	investigational	nan	Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.	58-82-2
VJPPLCNBDLZIFG-ZDUSSCGKSA-N	DB15347	Branebrutinib	investigational	nan	Branebrutinib is under investigation in clinical trial NCT02705989 (Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects).	1912445-55-6
JORVRJNILJXMMG-OLNQLETPSA-N	DB04887	Brecanavir	investigational	nan	Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.	313682-08-5
BUWBRTXGQRBBHG-MJBXVCDLSA-N	DB15003	Brepocitinib	investigational	nan	PF-06700841 is under investigation in clinical trial NCT03236493 (Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers).	1883299-62-4
PHEZJEYUWHETKO-UHFFFAOYSA-N	DB03523	Brequinar	investigational	nan	nan	96187-53-0
LWUDDYHYYNNIQI-ZDUSSCGKSA-N	DB21038	Bretazenil	experimental	nan	Bretazenil is a small molecule drug. The usage of the INN stem '-nil' in the name indicates that Bretazenil is a benzodiazepine receptor antagonist/agonist. Bretazenil has a monoisotopic molecular weight of 417.07 Da.	84379-13-5
AURFZBICLPNKBZ-SYBPFIFISA-N	DB11859	Brexanolone	approved;investigational	N06AX29	As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females [F4066]. Since PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening conditi	516-54-1
ZKIAIYBUSXZPLP-UHFFFAOYSA-N	DB09128	Brexpiprazole	approved;investigational	N05AX16	Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors.[L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extr	913611-97-9
AILRADAXUVEEIR-UHFFFAOYSA-N	DB12267	Brigatinib	approved;investigational	L01ED04	Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary	1197953-54-0
BURHGPHDEVGCEZ-KJGLQBJMSA-N	DB12253	Brilanestrant	investigational	nan	ARN-810 has been used in trials studying the basic science and treatment of Breast Cancer.	1365888-06-7
PMKMNTBZJOXTJW-UHFFFAOYSA-N	DB09226	Brilaroxazine	investigational	nan	Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III cl	1239729-06-6
XYLJNLCSTIOKRM-UHFFFAOYSA-N	DB00484	Brimonidine	approved;investigational	D11AX21;S01EA55;S01GA07;S01EA05	Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996.[A178951] It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors.[A179002] Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors than [clonidine] or [apraclonidine], which are also alpha-2 adrenergic agonists.[A178969] Alpha-2 adrenergic agonists are mem	59803-98-4
HCRKCZRJWPKOAR-JTQLQIEISA-N	DB01194	Brinzolamide	approved;investigational	S01EC54;S01EC04;G01AE10	Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.[L35310] Although the exact pathophysiology of glaucoma is still unknown, one of the main hallmarks of this disease is vascular dysregulation and abnormalities.[A2049,A2051] The resulting vascular resistance increases intraocular pressure, thus impairing ocular perfusion.[A2049,A2051] Although system	138890-62-7
WCWUXEGQKLTGDX-LLVKDONJSA-N	DB11958	Brivanib	investigational	nan	Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).	649735-46-6
ODZBBRURCPAEIQ-PIXDULNESA-N	DB03312	Brivudine	approved;investigational	J05AB15	Brivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.	69304-47-8
DAVPSCAAXXVSFU-ALEPSDHESA-N	DB20131	Brobactam	experimental	nan	Brobactam is a small molecule drug. The usage of the INN stem '-bactam' in the name indicates that Brobactam is a ẞ-lactamase inhibitor. Brobactam has a monoisotopic molecular weight of 278.96 Da.	26631-90-3
BFCRRLMMHNLSCP-UHFFFAOYSA-N	DB13795	Brodimoprim	experimental	J01EA02	nan	56518-41-3
FXMWUTGUCAKGQL-UHFFFAOYSA-N	DB01484	Brolamfetamine	experimental;illicit	nan	nan	32156-26-6
OJGDCBLYJGHCIH-UHFFFAOYSA-N	DB09019	Bromhexine	approved	R05CB02	Bromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion. It is derived from the Adhatoda vasica plant and aids in the clearance of excess mucus, improving breathing and reducing cough. It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries.[A233240] Recently, bromhexine and its metabolite [ambroxol] have garnered interest for the potential prevention and treatment of COVID-19 du	3572-43-8
AEKIJKSVXKWGRJ-BYPYZUCNSA-N	DB04000	Bromo-Willardiine	experimental	nan	nan	nan
OZVBMTJYIDMWIL-AYFBDAFISA-N	DB01200	Bromocriptine	approved;investigational;withdrawn	N04BC01;G02CB01	Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some p	25614-03-3
RKLNONIVDFXQRX-UHFFFAOYSA-N	DB12401	Bromperidol	approved;withdrawn	N05AD06	Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.	10457-90-6
ZDIGNSYAACHWNL-UHFFFAOYSA-N	DB00835	Brompheniramine	approved	R06AB51;R06AB01	Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.	86-22-6
ZDASUJMDVPTNTF-UHFFFAOYSA-N	DB13536	Broxyquinoline	experimental	P01AA01;A07AX01;G01AC06	nan	521-74-4
MJQUEDHRCUIRLF-TVIXENOKSA-N	DB11752	Bryostatin 1	investigational	nan	Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.	83314-01-6
VOVIALXJUBGFJZ-KWVAZRHASA-N	DB01222	Budesonide	approved;investigational	R03AK15;R03AL11;D07AC09;R01AD05;R03AK07;A07EA06;R03BA02;R03AK12	Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994.[L10598] It is also available in a combination product with [formoterol].[L10619]	51333-22-3
OWYLAEYXIQKAOL-UHFFFAOYSA-N	DB13510	Buflomedil	experimental	C04AX20	nan	55837-25-7
VTTONGPRPXSUTJ-UHFFFAOYSA-N	DB01445	Bufotenine	experimental;illicit	nan	A hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a tool in CNS studies and misused as a psychedelic.	487-93-4
MAEIEVLCKWDQJH-UHFFFAOYSA-N	DB00887	Bumetanide	approved;investigational	G01AE10;C03CB02;C03EB02;C03CA02	Bumetanide is a sulfamyl diuretic.	28395-03-1
RHLJLALHBZGAFM-UHFFFAOYSA-N	DB12230	Bunazosin	investigational	nan	Bunazosin has been used in trials studying the treatment of High Blood Pressure.	80755-51-7
CWHUFRVAEUJCEF-UHFFFAOYSA-N	DB11666	Buparlisib	investigational	nan	Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.	944396-07-0
HQIRNZOQPUAHHV-UHFFFAOYSA-N	DB08808	Bupranolol	experimental	C07AA19	Bupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.	14556-46-8
SNPPWIUOZRMYNY-UHFFFAOYSA-N	DB01156	Bupropion	approved;investigational	N06AX62;A08AA62;N06AX12	Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the ne	34911-55-2
QWCRAEMEVRGPNT-UHFFFAOYSA-N	DB00490	Buspirone	approved;investigational	N05BE01	Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs.[L4478] Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteri	36505-84-7
ABJKWBDEJIDSJZ-UHFFFAOYSA-N	DB01091	Butenafine	approved	D01AE23	Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.	101828-21-1
IFKLAQQSCNILHL-QHAWAJNXSA-N	DB00611	Butorphanol	approved;illicit;investigational;vet_approved	N02AF01	A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.	42408-82-2
NLZUEZXRPGMBCV-UHFFFAOYSA-N	DB16863	Butylated hydroxytoluene	investigational	nan	nan	128-37-0
RDALZZCKQFLGJP-UHFFFAOYSA-N	DB16874	CB-5083	investigational	nan	nan	1542705-92-9
GMYLVKUGJMYTFB-UHFFFAOYSA-N	DB12740	CC-115	investigational	nan	CC-115 has been used in trials studying the treatment of Prostate Cancer, Neoplasm Metastasis, Ewing's Osteosarcoma, Glioblastoma Multiforme, and Chronic Lymphocytic Leukemia, among others.	1228013-15-7
XDJCLCLBSGGNKS-UHFFFAOYSA-N	DB12432	CC-401	investigational	nan	CC-401 has been used in trials studying the treatment of Myeloid Leukemia.	395104-30-0
QBBRJRLJWXRSHQ-CKYFFXLPSA-N	DB18445	CC-90001	investigational	nan	nan	1403859-14-2
OWPMENVYXDJDOW-UHFFFAOYSA-N	DB07594	CCT-018159	experimental	nan	nan	171009-07-7
RWYREGSYPCNZTL-UHFFFAOYSA-N	DB02741	CD564	experimental	nan	nan	nan
UBNMGTSDHSQBEL-PMERELPUSA-N	DB12694	CE-326597	investigational	nan	CE-326,597 has been used in trials studying the treatment of Obesity.	870615-40-0
BCSHRERPHLTPEE-NRFANRHFSA-N	DB13060	CEP-37440	investigational	nan	CEP-37440 has been used in trials studying the treatment of Solid Tumors.	1391712-60-9
CTLOSZHDGZLOQE-UHFFFAOYSA-N	DB14882	CEP-9722	investigational	nan	CEP-9722 is under investigation in clinical trial NCT01345357 (Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma).	916574-83-9
BSIZUMJRKYHEBR-QGZVFWFLSA-N	DB07556	CGS-27023	experimental	nan	nan	161314-70-1
JEGHXKRHKHPBJD-UHFFFAOYSA-N	DB13051	CH-5132799	investigational	nan	CH5132799 has been used in trials studying the treatment of Solid Tumors.	1007207-67-1
BOIPLTNGIAPDBY-UHFFFAOYSA-N	DB12980	CHS-828	investigational	nan	CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.	200484-11-3
GFMMXOIFOQCCGU-UHFFFAOYSA-N	DB12429	CI-1040	investigational	nan	CI-1040 has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Breast Neoplasms, Pancreatic Cancer, and Colorectal Cancer, among others.	212631-79-3
QQMKTHUGOQDEIL-UHFFFAOYSA-N	DB16466	CM4620	investigational	nan	CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and NCT04661540 (critical COVID-19 pneumonia).	1713240-67-5
JHVHEDNLONERHY-UHFFFAOYSA-N	DB05824	CNS-5161	experimental	nan	CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.	nan
ZIWFCOIGUNPHPM-HKUYNNGSSA-N	DB05421	CP-122721	experimental	nan	CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.	145742-28-5
NZQDWKCNBOELAI-KSFYIVLOSA-N	DB13053	CP-195543	investigational	nan	CP-195,543 has been used in trials studying the treatment of Arthritis, Rheumatoid.	204981-48-6
YDCGVASFVACWKF-NRFANRHFSA-N	DB03383	CP-320626	experimental	nan	nan	186430-23-9
HXHAJRMTJXHJJZ-UHFFFAOYSA-N	DB12962	CP-547632	investigational	nan	CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.	252003-65-9
LLVZBTWPGQVVLW-SNAWJCMRSA-N	DB12302	CP-724714	investigational	nan	CP-724,714 has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasm Metastasis.	537705-08-1
ZBVPUFSKFGYNLC-FIDNPTQWSA-N	DB12196	CP-866087	investigational	nan	CP-866,087 has been used in trials studying the treatment of Obesity, Alcoholism, and Sexual Dysfunction, Physiological.	519052-02-9
XKCHOMIJYLHXLI-UHFFFAOYSA-N	DB02288	CRA-9334	experimental	nan	nan	nan
CFSQPEBVGUSQII-UHFFFAOYSA-N	DB03173	CRA_10433	experimental	nan	nan	nan
WCFWDBPDMBXMTQ-UHFFFAOYSA-N	DB02526	CRA_10655	experimental	nan	nan	nan
HSHVHNIOQTZSOQ-UHFFFAOYSA-N	DB04470	CRA_10656	experimental	nan	nan	nan
CMCDWLMEDRBWIR-GTNSWQLSSA-N	DB03555	CRA_11092	experimental	nan	nan	nan
SJMNJNRKVVVGRB-SECBINFHSA-L	DB02063	CRA_16847	experimental	nan	nan	nan
YYUZFCLHOQHMPT-UHFFFAOYSA-O	DB04246	CRA_23653	experimental	nan	nan	nan
GAVRMVQHHVMXFD-UHFFFAOYSA-N	DB03159	CRA_8696	experimental	nan	nan	nan
BVTBOJXEAPSOEB-UHFFFAOYSA-N	DB04215	CRA_9076	experimental	nan	nan	nan
ROSNVSQTEGHUKU-UHFFFAOYSA-N	DB08490	CTS-1027	investigational	nan	CTS-1027 has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C Virus Infection.	193022-04-7
PLIVFNIUGLLCEK-UHFFFAOYSA-N	DB12174	CUDC-101	investigational	nan	CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.	1012054-59-9
KORNTPPJEAJQIU-KJXAQDMKSA-N	DB00248	Cabergoline	approved;investigational	N04BC06;G02CB03	Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.	81409-90-7
WCWSTNLSLKSJPK-LKFCYVNXSA-N	DB11751	Cabotegravir	approved;investigational	J05AJ04	Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine].[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir],[A227668] which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to tr	1051375-10-0
ONIQOQHATWINJY-UHFFFAOYSA-N	DB08875	Cabozantinib	approved;investigational	L01EX07	Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.[L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously trea	849217-68-1
VHRGRCVQAFMJIZ-UHFFFAOYSA-N	DB03854	Cadaverine	experimental	nan	Cadaverine is a foul-smelling diamine formed by bacterial decarboxylation of lysine.	462-94-2
NIDRYBLTWYFCFV-FMTVUPSXSA-N	DB04886	Calanolide A	investigational	nan	Calanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. Both drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.	142632-32-4
GMRQFYUYWCNGIN-NKMMMXOESA-N	DB00136	Calcitriol	approved;investigational;nutraceutical	D05AX03;A11CC04	Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to [DB00169] (vitamin D3) in the skin, which is then converted to [DB00146] in the liver and kidneys. [DB00146] undergoes hydroxylation	32222-06-3
FKAWLXNLHHIHLA-YCBIHMBMSA-N	DB02860	Calyculin A	experimental	nan	nan	101932-71-2
WDHOIABIERMLGY-CMJOXMDJSA-N	DB19218	Camizestrant	investigational	nan	Camizestrant is under investigation in clinical trial NCT05952557 (An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)).	2222844-89-3
XASIMHXSUQUHLV-UHFFFAOYSA-N	DB13729	Camostat	investigational	B02AB04	Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice.[A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.[A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197]	59721-28-7
VSJKWCGYPAHWDS-FQEVSTJZSA-N	DB04690	Camptothecin	investigational	nan	Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, <i>Camptotheca acuminata</i>. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.	7689-03-4
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	DB08907	Canagliflozin	approved;investigational	A10BD16;A10BK02	Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus [L5897], [FDA label]. Canagliflozin is the first oral antid	842133-18-0
HTQMVQVXFRQIKW-UHFFFAOYSA-N	DB13919	Candesartan	investigational	C09DA06;C09DB07;C09DX06;C09CA06;C10BX19	Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of [candesartan cilexetil].	139481-59-7
OMZCMEYTWSXEPZ-UHFFFAOYSA-N	DB05424	Canertinib	investigational	nan	Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.	267243-28-7
UVOLYTDXHDXWJU-UHFFFAOYSA-N	DB14735	Cannabichromene	investigational	nan	A natural product found in Cannabis sativa and Helichrysum species.	20675-51-8
QHMBSVQNZZTUGM-ZWKOTPCHSA-N	DB09061	Cannabidiol	approved;investigational	N03AX24	Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvu	13956-29-1
REOZWEGFPHTFEI-JKSUJKDBSA-N	DB14050	Cannabidivarin	investigational	nan	Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within [DB14009]. It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana [A32584]. Compared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain. Notably, both [DB09061] and CBDV have demonstrated anticonvulsant activity in animal and human models and are demonstrating promising cli	24274-48-4
QXACEHWTBCFNSA-SFQUDFHCSA-N	DB14734	Cannabigerol	investigational	nan	A natural product found in Cannabis sativa and Helichrysum species.	25654-31-3
VBGLYOIFKLUMQG-UHFFFAOYSA-N	DB14737	Cannabinol	investigational	nan	Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.	521-35-7
GSTZHANFXAKPSE-MXTREEOPSA-N	DB05048	Cannabinor	experimental	nan	Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.	573981-31-4
DHZBEENLJMYSHQ-XCVPVQRUSA-N	DB12328	Cantharidin	approved;investigational	nan	Cantharidin is a naturally occurring odorless, colorless fatty substance of the terpenoid class that is produced as an oral fluid in the alimentary canal of the male blister beetle.[A32891, A32892] For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating. Post-copulation, the female beetle places the cantharidin over her eggs as protection against any potential predators.[A32891, A32892] Topical cantharidin produ	56-25-7
JDUBGYFRJFOXQC-KRWDZBQOSA-N	DB12218	Capivasertib	approved;investigational	L01EX27	Hormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. Therefore, significant research has been put into developing genetically targeted treatments.[A262021] The PIK3/AKT pathway is one of	1143532-39-1
YQXCVAGCMNFUMQ-UHFFFAOYSA-N	DB08502	Capravirine	investigational	nan	nan	178979-85-6
YKPUWZUDDOIDPM-SOFGYWHQSA-N	DB06774	Capsaicin	approved;investigational	M02AB01;N01BX04	Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgi	404-86-4
FAKRSMQSSFJEIM-RQJHMYQMSA-N	DB01197	Captopril	approved;investigational	C09AA01;C09BA01	Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.	62571-86-2
OFAIGZWCDGNZGT-UHFFFAOYSA-N	DB11504	Caramiphen	experimental;vet_approved	nan	Caramiphen is a cholinergic antagonist used in Parkinson's disease. Additionally, it is used, in combination with [phenylpropanolamine], as a cough suppressant and nasal decongestant for the symptomatic treatment of seasonal respiratory conditions.	77-22-5
VPJXQGSRWJZDOB-UHFFFAOYSA-O	DB00411	Carbamoylcholine	approved	N07AB01;S01EB02	Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932.[A226315] Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and other parasympathetic effects. Carbamoylcholine was granted FDA approval on 28 September 1972.[L30245]	462-58-8
HQAKVYGASUTQHH-UHFFFAOYSA-N	DB03851	Carbazole Butanoic Acid	experimental	nan	nan	nan
OBZHEBDUNPOCJG-WBXJDKIVSA-N	DB02329	Carbenoxolone	experimental	A02BX01;A02BX71;A02BX51	An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]	5697-56-3
YDBLKRPLXZNVNB-UHFFFAOYSA-N	DB05416	Cardarine	investigational	nan	Cardarine (GW-501516) is a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Cardarine has been investigated for the treatment of Obesity, Lipid Disorders, and Cardiovascular Disease.	317318-70-0
YDSDEBIZUNNPOB-UHFFFAOYSA-N	DB01535	Carfentanil	illicit;investigational;vet_approved	nan	Carfentanil or carfentanyl (Wildnil) is an analogue of the popular synthetic opioid analgesic fentanyl, and is one of the most potent opioids known (also the most potent opioid used commercially). Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. It has a quantitative potency approximately 10,000 times that of morphine and 100 times that of fentanyl, with activity in humans starting at about 1 microgram. It is marketed under the	59708-52-0
BLMPQMFVWMYDKT-NZTKNTHTSA-N	DB08889	Carfilzomib	approved;investigational	L01XG02	Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]	868540-17-4
KPWSJANDNDDRMB-QAQDUYKDSA-N	DB06016	Cariprazine	approved;investigational	N05AX15	Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.[A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors.[L40198] Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the	839712-12-8
AOCCBINRVIKJHY-UHFFFAOYSA-N	DB09010	Carmofur	approved;withdrawn	L01BC04	Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.	61422-45-5
NWPJLRSCSQHPJV-UHFFFAOYSA-N	DB20320	Carpipramine	experimental	nan	Carpipramine is a small molecule drug. The usage of the INN stem '-pramine' in the name indicates that Carpipramine is a substance of the imipramine group. Carpipramine has a monoisotopic molecular weight of 446.3 Da.	5942-95-0
PUXBGTOOZJQSKH-UHFFFAOYSA-N	DB00821	Carprofen	approved;vet_approved;withdrawn	nan	Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human u	53716-49-7
IQNQAOGGWGCROX-UHFFFAOYSA-N	DB20334	Cartazolate	experimental	nan	Cartazolate is a small molecule drug. Cartazolate has a monoisotopic molecular weight of 290.17 Da.	34966-41-1
OGHNVEJMJSYVRP-UHFFFAOYSA-N	DB01136	Carvedilol	approved;investigational	C07AG02;C07FX06	Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hyper	72956-09-3
UCAGLBKTLXCODC-UHFFFAOYSA-N	DB19764	Carzenide	experimental	nan	Carzenide is a small molecule drug. Carzenide has a monoisotopic molecular weight of 201.01 Da.	138-41-0
CSMVOZKEWSOFER-RQNOJGIXSA-N	DB12830	Cebranopadol	investigational	nan	Cebranopadol has been used in trials studying the treatment of Pain, Neoplasms, and Chronic Pain.	863513-91-1
XXJWYDDUDKYVKI-UHFFFAOYSA-N	DB04849	Cediranib	investigational	L01EK02	The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.	288383-20-0
XIURVHNZVLADCM-IUODEOHRSA-N	DB00456	Cefalotin	approved;vet_approved;withdrawn	J01DB03	Cefalotin is a cephalosporin antibiotic.	153-61-7
OLVCFLKTBJRLHI-AXAPSJFSSA-N	DB01326	Cefamandole	approved;withdrawn	J01DC03	Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate]. It is no longer marketed in the United States.	34444-01-4
MLYYVTUWGNIJIB-BXKDBHETSA-N	DB01327	Cefazolin	approved;investigational	J01DB04	A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.	25953-19-9
GPRBEKHLDVQUJE-QSWIMTSFSA-N	DB00493	Cefotaxime	approved;investigational	J01DD01	Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).	63527-52-6
WZOZEZRFJCJXNZ-ZBFHGGJFSA-N	DB01331	Cefoxitin	approved;investigational	J01DC01	Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.	35607-66-0
ZCCUWMICIWSJIX-NQJJCJBVSA-N	DB06590	Ceftaroline fosamil	approved;investigational	J01DI02	Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneumonia.	229016-73-3
VAAUVRVFOQPIGI-SPQHTLEESA-N	DB01212	Ceftriaxone	approved;investigational	J01DD04;J01DD54	Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resist	73384-59-5
JFPVXVDWJQMJEE-IZRZKJBUSA-N	DB01112	Cefuroxime	approved;investigational	S01AA27;J01DC02;J01RA03	Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.	55268-75-2
KQJSQWZMSAGSHN-JJWQIEBTSA-N	DB18736	Celastrol	experimental	nan	Celastrol is a pentacyclic triterpenoid isolated from the root extracts of _Tripterygium wilfordii_.[L50567]	34157-83-0
RZEKVGVHFLEQIL-UHFFFAOYSA-N	DB00482	Celecoxib	approved;investigational	N02AJ16;M01AH01;G01AE10;L01XX33;C08CA51	Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604] Interesti	169590-42-5
PNDKCRDVVKJPKG-WHERJAGFSA-N	DB11758	Cenicriviroc	investigational	nan	Cenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor Complex.	497223-25-3
QDDQIPUKAXBMBX-UHFFFAOYSA-N	DB16123	Ceralifimod	investigational	nan	Ceralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).	891859-12-4
VERWOWGGCGHDQE-UHFFFAOYSA-N	DB09063	Ceritinib	approved;investigational	L01ED02	Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogene	1032900-25-6
NEUSVAOJNUQRTM-UHFFFAOYSA-N	DB11073	Cetylpyridinium	approved;investigational	D08AJ03;A01AB53;B05CA01;R02AA06;D09AA07	Cetylpyridinium is a quaternary ammonium with broad-spectrum antiseptic properties. Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays. In these products, it generally mediates an antiseptic activity and protective action against dental plaque and reducing gingivitis.	7773-52-6
LLEJIEBFSOEYIV-UHFFFAOYSA-N	DB17024	Chelerythrine	experimental	nan	A benzophenanthridine alkaloid evaluated as a kinase-inhibitor.[A252982]	34316-15-9
WIIZWVCIJKGZOK-RKDXNWHRSA-N	DB00446	Chloramphenicol	approved;vet_approved;withdrawn	D06AX02;S02AA01;D10AF03;S01AA01;G01AA05;J01BA01;S03AA08	An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this speci	56-75-7
ANTSCNMPPGJYLG-UHFFFAOYSA-N	DB00475	Chlordiazepoxide	approved;illicit	N05BA02	An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.	58-25-3
GHXZTYHSJHQHIJ-UHFFFAOYSA-N	DB00878	Chlorhexidine	approved;investigational;vet_approved;withdrawn	R02AA05;S03AA04;D08AC52;A01AB53;S01AX09;D08AC02;D09AA12;B05CA02;A01AB03;S02AA09	Chlorhexidine is a broad-spectrum antimicrobial biguanide used as a topical antiseptic and in dental practice for the treatment of inflammatory dental conditions caused by microorganisms.[L11512] It is one of the most common skin and mucous membrane antiseptic agents in use today.[A190417] The molecule itself is a cationic bis-guanide consisting of two 4-chlorophenyl rings and two biguanide groups joined by a central hexamethylene chain.[A190453] Topical chlorhexidine for disinfection, as well a	55-56-1
WHTVZRBIWZFKQO-UHFFFAOYSA-N	DB00608	Chloroquine	approved;investigational;vet_approved	P01BB52;P01BA01	Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432] **The FDA emergency use 	54-05-7
DBOUGBAQLIXZLV-UHFFFAOYSA-N	DB13382	Chlorproethazine	experimental	N05AA07	nan	84-01-5
ZPEIMTDSQAKGNT-UHFFFAOYSA-N	DB00477	Chlorpromazine	approved;investigational;vet_approved	N05AA01	The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.	50-53-3
JIVPVXMEBJLZRO-UHFFFAOYSA-N	DB00310	Chlorthalidone	approved;investigational	G01AE10;C03EA06;C03BB04;C03BA04	Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in the kidney. The exact mechanism of chlorthalidone's anti-hypertensive effect is under debate, however, it is thought that increased diuresis 	77-36-1
HVYWMOMLDIMFJA-DPAQBDIFSA-N	DB04540	Cholesterol	approved;investigational;withdrawn	nan	The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.	57-88-5
RTIXKCRFFJGDFG-UHFFFAOYSA-N	DB15581	Chrysin	investigational	nan	nan	480-40-0
SCZVLDHREVKTSH-UHFFFAOYSA-N	DB17283	Chrysoeriol	experimental	nan	nan	491-71-4
MRXDGVXSWIXTQL-HYHFHBMOSA-N	DB01683	Chymostatin	experimental	nan	nan	9076-44-2
ODQWQRRAPPTVAG-BOPFTXTBSA-N	DB14750	Cidoxepin	experimental	nan	nan	3607-18-9
KURQKNMKCGYWRJ-HNNXBMFYSA-N	DB16125	Ciforadenant	investigational	nan	Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).	1202402-40-1
YZFWTZACSRHJQD-UHFFFAOYSA-N	DB09201	Ciglitazone	experimental	nan	Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market. Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstim	74772-77-3
AMLYAMJWYAIXIA-VWNVYAMZSA-N	DB11890	Cilengitide	investigational	nan	Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.	188968-51-6
CFBUZOUXXHZCFB-OYOVHJISSA-N	DB03849	Cilomilast	investigational	nan	Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.	153259-65-5
UIAYVIIHMORPSJ-UHFFFAOYSA-N	DB19897	Cilostamide	experimental	nan	Cilostamide is a small molecule drug. Cilostamide has a monoisotopic molecular weight of 342.19 Da.	68550-75-4
RRGUKTPIGVIEKM-UHFFFAOYSA-N	DB01166	Cilostazol	approved;investigational	B01AC23	Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.	73963-72-1
PJZPDFUUXKKDNB-KNINVFKUSA-N	DB05868	Ciluprevir	investigational	nan	The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.	300832-84-2
AQIXAKUUQRKLND-UHFFFAOYSA-N	DB00501	Cimetidine	approved;investigational	A02BA51;A02BA01	A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.	51481-61-9
VDHAWDNDOKGFTD-MRXNPFEDSA-N	DB01012	Cinacalcet	approved;investigational	H05BX01	Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.	226256-56-0
WBYWAXJHAXSJNI-VOTSOKGWSA-N	DB18313	Cinnamic acid	experimental	nan	nan	140-10-3
DERZBLKQOCDDDZ-JLHYYAGUSA-N	DB00568	Cinnarizine	approved;investigational	N07CA52;N07CA02	First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due	298-57-7
GFUITADOEPNRML-SJORKVTESA-N	DB19468	Cipemastat	experimental	nan	Cipemastat is a small molecule drug. The usage of the INN stem '-mastat' in the name indicates that Cipemastat is a matrix metalloproteinase inhibitor. Cipemastat has a monoisotopic molecular weight of 436.27 Da.	190648-49-8
CVKJAXCQPFOAIN-VXGBXAGGSA-N	DB19761	Cipralisant	experimental	nan	Cipralisant is a small molecule drug. The usage of the INN stem '-isant' in the name indicates that Cipralisant is a histamine H3​ receptor antagonist. Cipralisant has a monoisotopic molecular weight of 216.16 Da.	213027-19-1
MYSWGUAQZAJSOK-UHFFFAOYSA-N	DB00537	Ciprofloxacin	approved;investigational	J01RA11;S03AA07;J01MA02;S02AA15;J01RA10;J01RA12;S01AE03	Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]	85721-33-1
YAORIDZYZDUZCM-UHFFFAOYSA-N	DB09202	Cirazoline	experimental	nan	Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent. Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.	59939-16-1
BQWWOBKMDWACGC-UHFFFAOYSA-N	DB17269	Cirtuvivint	investigational	nan	Cirtuvivint is a first-in-class CDC-like kinase (CLK) inhibitor.	2143917-62-6
PVRYEWOXWGDQHA-URLMMPGGSA-N	DB02872	Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone	experimental	nan	nan	nan
WSEQXVZVJXJVFP-UHFFFAOYSA-N	DB00215	Citalopram	approved;investigational	N06AB04	Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reu	59729-33-8
VLIUIBXPEDFJRF-UHFFFAOYSA-N	DB15449	Citarinostat	investigational	nan	Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).	1316215-12-9
PTOAARAWEBMLNO-KVQBGUIXSA-N	DB00242	Cladribine	approved;investigational	L04AA40;L01BB04	Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and T lymphocytes.[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia.[A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]	4291-63-8
HZZVJAQRINQKSD-PBFISZAISA-N	DB00766	Clavulanic acid	approved;investigational;vet_approved	nan	Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections.[T665] Clavulanic acid is derived from the organism Streptomyces clavuligerus.[A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910]	58001-44-8
LFWCJABOXHSRGC-UHFFFAOYSA-N	DB06677	Clazosentan	investigational	C04AX33	nan	180384-56-9
BVPWJMCABCPUQY-UHFFFAOYSA-N	DB13511	Clebopride	investigational	A03FA06	nan	55905-53-8
YNNUSGIPVFPVBX-NHCUHLMSSA-N	DB00283	Clemastine	approved;investigational	D04AA14;R06AA54;R06AA04	An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.	15686-51-8
STJMRWALKKWQGH-UHFFFAOYSA-N	DB01407	Clenbuterol	approved;investigational;vet_approved	R03CC13;R03AC14;R03CC63	A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.	37148-27-9
LXZMHBHEXAELHH-UHFFFAOYSA-N	DB18956	Clesacostat	investigational	nan	Clesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)).	1370448-25-1
CBGUOGMQLZIXBE-XGQKBEPLSA-N	DB01013	Clobetasol propionate	approved;investigational	nan	Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]	25122-46-7
GDLIGKIOYRNHDA-UHFFFAOYSA-N	DB01242	Clomipramine	approved;investigational;vet_approved	N06AA04	Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary	303-49-1
DGBIGWXXNGSACT-UHFFFAOYSA-N	DB01068	Clonazepam	approved;illicit;investigational	N03AE01	A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 19	1622-61-3
GJSURZIOUXUGAL-UHFFFAOYSA-N	DB00575	Clonidine	approved;investigational	S01EA04;C02LC01;C02AC01;N02CX02;C02LC51	Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]	4205-90-7
GKTWGGQPFAXNFI-HNNXBMFYSA-N	DB00758	Clopidogrel	approved;investigational	B01AC04	Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular d	113665-84-2
VJGGHXVGBSZVMZ-QIZQQNKQSA-N	DB11507	Cloprostenol	experimental;vet_approved	nan	nan	54276-21-0
BTFHLQRNAMSNLC-UHFFFAOYSA-N	DB04017	Clorgiline	experimental	nan	An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.	17780-72-2
FJAQNRBDVKIIKK-LFLQOBSNSA-N	DB03966	Clorobiocin	experimental	nan	Clorobiocin is an aminocoumarin antibiotic, similar to [novobiocin] and coumermycin A1.	39868-96-7
XRYLGRGAWQSVQW-UHFFFAOYSA-N	DB15971	Clorotepine	experimental	nan	nan	13448-22-1
VNFPBHJOKIVQEB-UHFFFAOYSA-N	DB00257	Clotrimazole	approved;investigational;vet_approved	D01AC01;A01AB18;G01AF02;G01AF20	This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s [A174094]. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity [A174094]. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several 	23593-75-1
LQOLIRLGBULYKD-JKIFEVAISA-N	DB01147	Cloxacillin	approved;investigational;vet_approved	J01CR50;J01CF02	A semi-synthetic penicillin antibiotic which is a chlorinated derivative of [oxacillin].	61-72-3
CTQMJYWDVABFRZ-UHFFFAOYSA-N	DB15933	Cloxyquin	experimental	nan	nan	130-16-5
QZUDBNBUXVUHMW-UHFFFAOYSA-N	DB00363	Clozapine	approved;investigational	N05AH02	"Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent.[A256708] Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it ""atypical"".[A256723]. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia.[A185747] However, its promiscuity toward the muscarinic and adrenergic rece"	5786-21-0
BSMCAPRUBJMWDF-KRWDZBQOSA-N	DB05239	Cobimetinib	approved;investigational	L01EE02	Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.	934660-93-2
ZPUCINDJVBIVPJ-LJISPDSOSA-N	DB00907	Cocaine	approved;illicit;investigational	S01HA01;S02DA02;N01BC01;R02AD03	An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.	50-36-2
IAKHMKGGTNLKSZ-INIZCTEOSA-N	DB01394	Colchicine	approved;investigational	M04AC51;M04AC01	"Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or ""autumn crocus.""[A183611] Its use was first approved by the FDA in 1961.[L8192] Colchicine is used in the treatment of gout flares and Familial Mediterranean fever,[L8138] and prevention of major cardiovascular events.[L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602]"	64-86-8
HVXBOLULGPECHP-WAYWQWQTSA-N	DB14680	Combretastatin A4	experimental	nan	nan	117048-59-6
UZOOIPXOYYJULJ-RHLLTPQKSA-N	DB02715	Compound 18	experimental	nan	nan	31112-66-0
UZOOIPXOYYJULJ-BLIZRMSTSA-N	DB02615	Compound 19	experimental	nan	nan	nan
TWZNCTCQAGRUGQ-RRPNLBNLSA-N	DB03742	Compound 4-D	experimental	nan	nan	nan
GPLGAQQQNWMVMM-MYAJQUOBSA-N	DB20644	Conessine	experimental	nan	Conessine is a small molecule drug. Conessine has a monoisotopic molecular weight of 356.32 Da.	546-06-5
IKENVDNFQMCRTR-UHFFFAOYSA-N	DB00872	Conivaptan	approved	C03XA02	Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).	210101-16-9
PZBCKZWLPGJMAO-UHFFFAOYSA-N	DB12483	Copanlisib	approved;investigational	L01EM02	Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.[A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]	1032568-63-0
NLIHPCYXRYQPSD-BAJZRUMYSA-N	DB01860	Cordycepin Triphosphate	experimental	nan	nan	73-04-1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N	DB04652	Corticosterone	investigational	nan	An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 8th ed, p1437)	50-22-6
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	DB04665	Coumarin	investigational	nan	nan	91-64-5
AFGYODUJVVOZAX-CYFREDJKSA-N	DB21642	Crelosidenib	investigational	nan	Crelosidenib is a small molecule drug. Crelosidenib is under investigation in clinical trial NCT04603001 (Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations). Crelosidenib has a monoisotopic molecular weight of 504.28 Da.	2230263-60-0
DYNHJHQFHQTFTP-UHFFFAOYSA-N	DB11832	Crenolanib	investigational	nan	Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.	670220-88-9
USZAGAREISWJDP-UHFFFAOYSA-N	DB05219	Crisaborole	approved;investigational	D11AH06	Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin	906673-24-3
KTEIFNKAUNYNJU-GFCCVEGCSA-N	DB08865	Crizotinib	approved;investigational	L01ED01	Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT).[L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement.[A250785] Crizotinib	877399-52-5
AEFFENQISAXIKE-UHFFFAOYSA-N	DB18081	Crozbaciclib	experimental	nan	nan	2099128-41-1
LLFOBMRPWNABCB-UHFFFAOYSA-N	DB21600	Culmerciclib	experimental	nan	Culmerciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Culmerciclib is a cyclin dependant kinase inhibitor. Culmerciclib has a monoisotopic molecular weight of 446.23 Da.	2004705-28-4
VFLDPWHFBUODDF-FCXRPNKRSA-N	DB11672	Curcumin	approved;investigational	nan	Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [Curcuma xanthorrhiza oil]. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166]. Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and 	458-37-7
UVSWWUWQVAQPJR-UHFFFAOYSA-N	DB06618	Cutamesine	investigational	nan	nan	165377-43-5
SLFGIOIONGJGRT-UHFFFAOYSA-N	DB09000	Cyamemazine	experimental	N05AA06	Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).	3546-03-0
UVKZSORBKUEBAZ-UHFFFAOYSA-N	DB01176	Cyclizine	approved;withdrawn	R06AE03;R06AE53	A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)	82-92-8
QMNFFXRFOJIOKZ-UHFFFAOYSA-N	DB14763	Cycloguanil	approved	P01BB02	Cycloguanil is the active metabolite of [proguanil].	516-21-2
YPHMISFOHDHNIV-FSZOTQKASA-N	DB20401	Cycloheximide	experimental	nan	Cycloheximide is a small molecule drug. Cycloheximide has a monoisotopic molecular weight of 281.16 Da.	66-81-9
UQFRSHRWRKYNDE-UHFFFAOYSA-N	DB02388	Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	experimental	nan	nan	nan
XCTKFTOEAKJMII-UHFFFAOYSA-N	DB03084	Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine	experimental	nan	nan	nan
PMATZTZNYRCHOR-CGLBZJNRSA-N	DB00091	Cyclosporine	approved;investigational;vet_approved	L04AD01;S01XA18	Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_.[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]	59865-13-3
JJCFRYNCJDLXIK-UHFFFAOYSA-N	DB00434	Cyproheptadine	approved;investigational	R06AX02	Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors.[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.[A231274]	129-03-3
UWFYSQMTEOIJJG-FDTZYFLXSA-N	DB04839	Cyproterone acetate	approved;investigational	G03HB01;G03HA01	An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.	427-51-0
ANJTVLIZGCUXLD-DTWKUNHWSA-N	DB09028	Cytisine	investigational	N07BA04	Cytisine is an alkaloid naturally derived from the Fabaceae family of plants including the genera Laburnum and Cytisus. Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy. Also known as baptitoxine or sophorine, cytisine has been used as a smoking cessation treatment since 1964, and is relatively unknown in regions outside of central and Eastern Europe. Cytisine is a partial nicotinic acetylcholine a	485-35-8
GBOGMAARMMDZGR-TYHYBEHESA-N	DB16766	Cytochalasin B	experimental	nan	nan	14930-96-2
WHUUTDBJXJRKMK-GSVOUGTGSA-N	DB02517	D-Glutamic Acid	experimental	nan	Glutamic acid is the most common excitatory neurotransmitter in the central nervous system.	6893-26-1
CJHLRGCXPGIPCB-MOPGFXCFSA-N	DB06919	D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide	experimental	nan	nan	nan
ZHUJMSMQIPIPTF-IBURTVSXSA-N	DB08856	DADLE	experimental	nan	A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.	63631-40-3
SLPJGDQJLTYWCI-UHFFFAOYSA-N	DB04719	DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE	experimental	nan	nan	nan
FFBDFADSZUINTG-UHFFFAOYSA-N	DB12946	DPCPX	investigational	nan	CPX has been used in trials studying the treatment of Cystic Fibrosis.	102146-07-6
MCMMCRYPQBNCPH-WMIMKTLMSA-N	DB08861	DPDPE	experimental	nan	A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.	88373-73-3
OIZSVTOIBNSVOS-UHFFFAOYSA-N	DB12397	DSM-265	investigational	nan	DSM265 has been used in trials studying the prevention and treatment of Malaria.	1282041-94-4
AVSMSXHPIYIKIJ-UHFFFAOYSA-N	DB12741	DTP-348	investigational	nan	Dtp348 has been used in trials studying the treatment of Solid Tumors and Head and Neck Neoplasms.	1383370-92-0
YBSJFWOBGCMAKL-UHFFFAOYSA-N	DB14726	Dabigatran	approved;investigational	nan	Dabigatran is the active form of the orally bioavailable prodrug [dabigatran etexilate].	211914-51-1
BFSMGDJOXZAERB-UHFFFAOYSA-N	DB08912	Dabrafenib	approved;investigational	L01EC02	Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]	1195765-45-7
BWDQBBCUWLSASG-MDZDMXLPSA-N	DB17034	Dacinostat	experimental	nan	Dacinostat is a novel histone deacetylase inhibitor.[A253032]	404951-53-7
LVXJQMNHJWSHET-AATRIKPKSA-N	DB11963	Dacomitinib	approved;investigational	L01EB07	Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.[A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.[L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial	1110813-31-4
RJURFGZVJUQBHK-IIXSONLDSA-N	DB00970	Dactinomycin	approved;investigational	L01DA01	A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	50-76-0
JOGKUKXHTYWRGZ-UHFFFAOYSA-N	DB11651	Dactolisib	investigational	nan	Dactolisib has been used in trials studying the treatment of Cancer, Solid Tumor, Renal Cancer, Breast Cancer, and Cowden Syndrome, among others.	915019-65-7
ZQSIJRDFPHDXIC-UHFFFAOYSA-N	DB13182	Daidzein	investigational	nan	nan	486-66-8
POZRVZJJTULAOH-LHZXLZLDSA-N	DB01406	Danazol	approved;investigational	G03XA01	A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	17230-88-5
ZVTDLPBHTSMEJZ-JSZLBQEHSA-N	DB11779	Danoprevir	investigational	nan	Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.	850876-88-9
XKFTZKGMDDZMJI-HSZRJFAPSA-N	DB11778	Danusertib	investigational	nan	Danusertib has been used in trials studying the treatment of Leukemia.	827318-97-8
JVHXJTBJCFBINQ-ADAARDCZSA-N	DB06292	Dapagliflozin	approved;investigational	A10BK01;A10BD15;A10BD21;A10BD25;A10BD30;A10BD29	Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2.[A261596] When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria.[A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglyc	461432-26-8
RFWZESUMWJKKRN-UHFFFAOYSA-N	DB00298	Dapiprazole	approved	S01EX02	Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.	72822-12-9
ILAYIAGXTHKHNT-UHFFFAOYSA-N	DB08639	Dapivirine	investigational	G01AX17	Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.	244767-67-7
KPBNHDGDUADAGP-VAWYXSNFSA-N	DB12731	Daporinad	investigational	nan	Daporinad has been used in trials studying the treatment of Melanoma, Cutaneous T-cell Lymphoma, and B-cell Chronic Lymphocytic Leukemia.	658084-64-1
MQJKPEGWNLWLTK-UHFFFAOYSA-N	DB00250	Dapsone	approved;investigational	J04BA50;J04BA51;D10AX05;J04BA02	A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)	80-08-0
NBGABHGMJVIVBW-QHCPKHFHSA-N	DB15031	Daridorexant	approved;investigational	N05CJ03	Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression. Conventional treatments for insomnia include drugs targeting gamma-aminobutyric	1505484-82-1
HXGBXQDTNZMWGS-RUZDIDTESA-N	DB00496	Darifenacin	approved;investigational	G04BD10	Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.	133099-04-4
PTTQXDBPTFOCMT-UHFFFAOYSA-N	DB18966	Darigabat	investigational	nan	Darigabat is under investigation in clinical trial NCT05941442 (A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder).	1614245-70-3
XXJXHXJWQSCNPX-UHFFFAOYSA-N	DB16059	Darovasertib	investigational	nan	IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).	1874276-76-2
CJBJHOAVZSMMDJ-HEXNFIEUSA-N	DB01264	Darunavir	approved;investigational	J05AR14;G01AE10;J05AR22;J05AR26;J05AE10	Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as [ritonavir] for the effective management of HIV-1 infection.[L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006.[L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to comba	206361-99-1
FEJVSJIALLTFRP-LJQANCHMSA-N	DB04883	Darusentan	investigational	nan	Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.	171714-84-4
ZBNZXTGUTAYRHI-UHFFFAOYSA-N	DB01254	Dasatinib	approved;investigational	L01EA02	Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the path	302962-49-8
JYRJOQGKGMHTOO-VURMDHGXSA-N	DB04367	Debromohymenialdisine	experimental	nan	nan	125118-55-0
MTCUAOILFDZKCO-UHFFFAOYSA-N	DB01245	Decamethonium	approved	nan	Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.	156-74-1
ASUGUQWIHMTFJL-QGZVFWFLSA-N	DB12566	Decernotinib	investigational	nan	Decernotinib has been used in trials studying the treatment of Drug Interactions and Rheumatoid Arthritis.	944842-54-0
FWLMVFUGMHIOAA-UHFFFAOYSA-N	DB12282	Defactinib	approved;investigational	nan	Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases.[L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in	1073154-85-4
SJFBTAPEPRWNKH-CCKFTAQKSA-N	DB11956	Delanzomib	investigational	nan	Delanzomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.	847499-27-8
WHBIGIKBNXZKFE-UHFFFAOYSA-N	DB00705	Delavirdine	approved;withdrawn	J05AG02	A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.	136817-59-9
LOWWYYZBZNSPDT-ZBEGNZNMSA-N	DB16133	Delgocitinib	approved;investigational	D11AH11	Delgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.[L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]	1263774-59-9
CHIFCDOIPRCHCF-UHFFFAOYSA-N	DB01511	Delorazepam	illicit;investigational	nan	Delorazepam is a benzodiazepine which, like other drugs in its class, possesses anxiolytic, skeletal muscle relaxant, hypnotic and anticonvulsant properties. It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolit	2894-67-9
HJPRDDKCXVCFOH-UHFFFAOYSA-N	DB19482	Denbufylline	experimental	nan	Denbufylline is a small molecule drug. The usage of the INN stem '-fylline' in the name indicates that Denbufylline is a N-methylated xanthine derivative. Denbufylline has a monoisotopic molecular weight of 320.18 Da.	57076-71-8
SXWMIXPJPNCXQQ-UHFFFAOYSA-N	DB17159	Denfivontinib	investigational	nan	nan	1457983-28-6
HCYAFALTSJYZDH-UHFFFAOYSA-N	DB01151	Desipramine	approved	N06AA01	Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as des	50-47-5
JAUOIFJMECXRGI-UHFFFAOYSA-N	DB00967	Desloratadine	approved;investigational	R06AX27	Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.	100643-71-8
SRPXSILJHWNFMK-ZBEGNZNMSA-N	DB14071	Desmethylsertraline	experimental	nan	Desmethylsertraline is a metabolite of sertraline.	87857-41-8
NFLWUMRGJYTJIN-PNIOQBSNSA-N	DB00035	Desmopressin	approved;investigational	H01BA02	Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubule	16679-58-6
KYYIDSXMWOZKMP-UHFFFAOYSA-N	DB06700	Desvenlafaxine	approved;investigational	N06AX23	Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Eu	93413-62-8
AUTOLBMXDDTRRT-JGVFFNPUSA-N	DB03775	Dethiobiotin	experimental	nan	nan	533-48-2
BZZKEPGENYLQSC-FIBGUPNXSA-N	DB16650	Deucravacitinib	approved;investigational	L04AF07	Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as 	1609392-27-9
NFHRQQKPEBFUJK-HSZRJFAPSA-N	DB20841	Devazepide	experimental	nan	Devazepide is a small molecule drug. Devazepide has a monoisotopic molecular weight of 408.16 Da.	103420-77-5
UREBDLICKHMUKA-CXSFZGCWSA-N	DB01234	Dexamethasone	approved;investigational;vet_approved	R01AD53;D07XB05;R01AD03;D10AA03;S01CB01;S02CA06;S03CA01;C05AA09;S01CA01;D07CB04;H02AB02;S01BA01;A01AC02;S03BA01;D07AB19;S02BA06	Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19	50-02-2
SSQJFGMEZBFMNV-PMACEKPBSA-N	DB06444	Dexanabinol	investigational	nan	nan	112924-45-5
SOYKEARSMXGVTM-HNNXBMFYSA-N	DB13679	Dexchlorpheniramine	investigational	R06AB52;R06AB02	Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.	25523-97-1
CLPFFLWZZBQMAO-CQSZACIVSA-N	DB21746	Dexfadrostat	investigational	nan	Dexfadrostat is under investigation in clinical trial NCT04007406 (DP13 - a Phase II Study in Patients With Primary Aldosteronism).	102676-87-9
HEFNNWSXXWATRW-JTQLQIEISA-N	DB09213	Dexibuprofen	approved;withdrawn	M01AE14	Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a slower dissolution rate in the simulated gastric and enteric juices compared with the racemic ibuprofen and displays improved o	51146-56-6
DKYWVDODHFEZIM-NSHDSACASA-N	DB09214	Dexketoprofen	approved;investigational;withdrawn	M02AA27;N02AJ14;M01AE17	Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties [L1298].	22161-81-5
IMYZQPCYWPFTAG-NGZCFLSTSA-N	DB11807	Dexmecamylamine	investigational	nan	Dexmecamylamine has been used in trials studying the basic science and treatment of Patients, Depression, Drug Abuse, Pharmacokinetics, and Renal Impairment, among others.	107538-05-6
CUHVIMMYOGQXCV-NSHDSACASA-N	DB00633	Dexmedetomidine	approved;investigational;vet_approved	N05CM18	An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.	113775-47-6
SVJMLYUFVDMUHP-MGBGTMOVSA-N	DB14068	Dexniguldipine	experimental	nan	nan	120054-86-6
HGKAMARNFGKMLC-RBUKOAKNSA-N	DB20847	Dexoxadrol	experimental	nan	Dexoxadrol is a small molecule drug. Dexoxadrol has a monoisotopic molecular weight of 309.17 Da.	4741-41-7
FASDKYOPVNHBLU-SSDOTTSWSA-N	DB15130	Dexpramipexole	investigational	nan	Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).	104632-28-2
AQHHHDLHHXJYJD-CQSZACIVSA-N	DB03322	Dexpropranolol	experimental	nan	nan	5051-22-9
KWTSXDURSIMDCE-QMMMGPOBSA-N	DB01576	Dextroamphetamine	approved;illicit;investigational	N06BA02	Dextroamphetamine is the dextrorotatory enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.[L6010,L52145]	51-64-9
MKXZASYAUGDDCJ-NJAFHUGGSA-N	DB00514	Dextromethorphan	approved;investigational	N06AX62;R05DA09;N07XX59	Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse.[A215412] Although similar in structure to other opioids, it has minimal interaction with opioid receptors.[A215412] Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997]	125-71-3
JAQUASYNZVUNQP-PVAVHDDUSA-N	DB14682	Dextrorphan	experimental	nan	nan	125-73-5
SGTNSNPWRIOYBX-HHHXNRCGSA-N	DB14063	Dexverapamil	experimental	nan	nan	38321-02-7
SUPRUPHAEXPGPF-QWHCGFSZSA-N	DB12125	Dianicline	investigational	nan	Dianicline has been used in trials studying the treatment of Smoking, Smoking Cessation, and Tobacco Use Cessation.	292634-27-6
AAOVKJBEBIDNHE-UHFFFAOYSA-N	DB00829	Diazepam	approved;illicit;investigational;vet_approved	N05BA01	A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam	439-14-5
GMJFVGRUYJHMCO-UHFFFAOYSA-N	DB13548	Dibrompropamidine	experimental	D08AC01;S01AX14	nan	496-00-4
XHSQDZXAVJRBMX-DDHJBXDOSA-N	DB08473	Dichlororibofuranosylbenzimidazole	experimental	nan	nan	53-85-0
DCOPUUMXTXDBNB-UHFFFAOYSA-N	DB00586	Diclofenac	approved;investigational;vet_approved	S01CC01;S01BC03;M01AB55;M02AA15;M01AB05;D11AX18	Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], 	15307-86-5
GJQPMPFPNINLKP-UHFFFAOYSA-N	DB01144	Diclofenamide	approved	G01AE10;S01EC02	A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.	120-97-8
DOBMPNYZJYQDGZ-UHFFFAOYSA-N	DB00266	Dicoumarol	approved	B01AA01	Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.	66-76-2
CURUTKGFNZGFSE-UHFFFAOYSA-N	DB00804	Dicyclomine	approved	A03AA07	Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]	77-19-0
RGLYKWWBQGJZGM-ISLYRVAYSA-N	DB00255	Diethylstilbestrol	approved;withdrawn	L02AA04;L02AA01;G03CC05;G03CB02	A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]	56-53-1
LSSUMOWDTKZHHT-UHFFFAOYSA-N	DB01460	Diethyltryptamine	experimental;illicit	nan	Diethyltryptamine (DET) is an orally active hallucinogenic agent and a substituted form of tryptamine.	61-51-8
HUPFGZXOMWLGNK-UHFFFAOYSA-N	DB00861	Diflunisal	approved	N02BA11	Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomati	22494-42-4
XZTUSOXSLKTKJQ-CESUGQOBSA-N	DB04177	Digitoxigenin	experimental	nan	Digitoxigenin is a cardenolide which is the aglycon of digitoxin.	143-62-4
WDJUZGPOPHTGOT-XUDUSOBPSA-N	DB01396	Digitoxin	approved;withdrawn	C01AA04	A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)	71-63-6
SHIBSTMRCDJXLN-KCZCNTNESA-N	DB03671	Digoxigenin	experimental	nan	Digoxigenin is a cardenolide which is the aglycon of digoxin. Can be obtained by hydrolysis of digoxin or from Digitalis orientalis L. and Digitalis lanata Ehrh.	1672-46-4
LTMHDMANZUZIPE-PUGKRICDSA-N	DB00390	Digoxin	approved;investigational	C01AA05	Digoxin is one of the oldest cardiovascular medications used today.[A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure.[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.[L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historica	20830-75-5
DEQITUUQPICUMR-HJPBWRTMSA-N	DB13345	Dihydroergocristine	approved	C04AE54;C04AE04	Dihydroergocristine is part of the ergoloid mixture products.[L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.[A32879] To know more about ergoloid mixtures, please visit [DB01049].	17479-19-5
LUZRJRNZXALNLM-JGRZULCMSA-N	DB00320	Dihydroergotamine	approved	N02CA51;N02CA01	A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines.[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.[A239569] The recently approved Precision Olfactor	511-12-6
OZRNSSUDZOLUSN-LBPRGKRZSA-N	DB02015	Dihydrofolic Acid	investigational	nan	nan	4033-27-6
UXZFQZANDVDGMM-UHFFFAOYSA-N	DB09115	Diiodohydroxyquinoline	approved	G01AC01	Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.	83-73-8
QVZCXCJXTMIDME-UHFFFAOYSA-N	DB13715	Dilazep	experimental	C01DX10	nan	35898-87-4
HSUGRBWQSSZJOP-RTWAWAEBSA-N	DB00343	Diltiazem	approved;investigational	C08DB01;C05AE03	Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization.[L10556] Compared to dihydropyridine drugs, such as [nifedipine], that preferentially act on vascular smooth muscle and [verapamil] th	42399-41-7
DMULVCHRPCFFGV-UHFFFAOYSA-N	DB01488	Dimethyltryptamine	illicit;investigational	nan	An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.	61-50-7
MVMQESMQSYOVGV-UHFFFAOYSA-N	DB08801	Dimetindene	approved;investigational	R06AB03;D04AA13	Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.	5636-83-9
PIMQWRZWLQKKBJ-SFHVURJKSA-N	DB12021	Dinaciclib	investigational	nan	Dinaciclib has been used in trials studying the treatment of rrMM, rrCLL, rrDLBCL, Solid Tumors, and Solid Neoplasm, among others.	779353-01-4
PXGPLTODNUVGFL-YNNPMVKQSA-N	DB12789	Dinoprost	approved;withdrawn	G02AD01	Dinoprost has been investigated in Headache.	551-11-1
XEYBRNLFEZDVAW-ARSRFYASSA-N	DB00917	Dinoprostone	approved;investigational	G02AD02	Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.	363-24-6
MBNGWHIJMBWFHU-UHFFFAOYSA-N	DB11259	Diosmetin	approved	nan	Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231]. Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflamatory activities [A27231]. It also acts as a weak TrkB receptor agonist [A27230].	520-34-3
KNBRWWCHBRQLNY-UHFFFAOYSA-N	DB14174	Dipentamethylenethiuram disulfide	approved	nan	nan	94-37-1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N	DB01075	Diphenhydramine	approved;investigational	D04AA32;R06AA02;M01AE57;D04AA33;R06AA52	Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation d	58-73-1
OGAKLTJNUQRZJU-UHFFFAOYSA-N	DB01231	Diphenidol	approved;withdrawn	nan	Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.	972-02-1
QFXKXRXFBRLLPQ-UHFFFAOYSA-N	DB17025	Diphenyleneiodonium	experimental	nan	An NADPH oxidase 2 (NOX2) inhibitor.[A252987]	244-54-2
OIJXLIIMXHRJJH-KNLIIKEYSA-N	DB01548	Diprenorphine	illicit;investigational;vet_approved	nan	A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]	14357-78-9
IZEKFCXSFNUWAM-UHFFFAOYSA-N	DB00975	Dipyridamole	approved;investigational	B01AC07	A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)	58-32-2
AUZONCFQVSMFAP-UHFFFAOYSA-N	DB00822	Disulfiram	approved;investigational	P03AA04;P03AA54;N07BB01	A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.	97-77-8
LMBWSYZSUOEYSN-UHFFFAOYSA-N	DB02520	Ditiocarb	investigational	nan	A chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental animals. It is the main metabolite of DISULFIRAM.	147-84-2
LBOJYSIDWZQNJS-CVEARBPZSA-N	DB20240	Dizocilpine	experimental	nan	Dizocilpine is a small molecule drug. Dizocilpine has a monoisotopic molecular weight of 221.12 Da.	77086-21-6
ZDZOTLJHXYCWBA-VCVYQWHSSA-N	DB01248	Docetaxel	approved;investigational	L01CD02	Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of [paclitaxel].[A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death.[A259676] Compared to paclitaxel, docetaxel is	114977-28-5
LJODJUIHONTDMR-UHFFFAOYSA-N	DB21606	Docirbrutinib	investigational	nan	Docirbrutinib is a small molecule drug. The usage of the INN stem '-brutinib' in the name indicates that Docirbrutinib is a agammaglobulinaemia tyrosine kinase (Bruton tyrosine kinase) inhibitor. Docirbrutinib is under investigation in clinical trial NCT05602363 (AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma). Docirbrutinib has a monoisotopic molecular weight of 578.24 Da.	2227211-00-7
OFDNQWIFNXBECV-VFSYNPLYSA-N	DB12730	Dolastatin 10	investigational	nan	Dolastatin 10 has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Liver Cancer, and Kidney Cancer, among others.	110417-88-4
RHWKPHLQXYSBKR-BMIGLBTASA-N	DB08930	Dolutegravir	approved;investigational	J05AR29;J05AR27;J05AJ03;J05AR13;J05AR25;J05AR21	Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI).[A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.[A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.[L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment reg	1051375-16-6
PRXXYMVLYKJITB-IZZDOVSWSA-N	DB17521	Domatinostat	investigational	nan	nan	910462-43-0
VZFRNCSOCOPNDB-AOKDLOFSSA-N	DB02852	Domoic Acid	experimental	nan	nan	14277-97-5
FGXWKSZFVQUSTL-UHFFFAOYSA-N	DB01184	Domperidone	approved;investigational;vet_approved	A03FA03	A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.	57808-66-9
ADEBPBSSDYVVLD-UHFFFAOYSA-N	DB00843	Donepezil	approved;investigational	N06DA52;N06DA53;N06DA02	In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990.[A182411] Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [M	120014-06-4
MVCOAUNKQVWQHZ-UHFFFAOYSA-N	DB03044	Doramapimod	investigational	nan	Doramapimod is a P38 MAP kinase inhibitor.	285983-48-4
ZIAOVIPSKUPPQW-UHFFFAOYSA-N	DB12301	Doravirine	approved;investigational	J05AR24;J05AG06	Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).[L4562] Doravirine is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibili	1338225-97-0
XHBVYDAKJHETMP-UHFFFAOYSA-N	DB08597	Dorsomorphin	experimental	nan	nan	866405-64-3
IAVUPMFITXYVAF-XPUUQOCRSA-N	DB00869	Dorzolamide	approved;investigational	G01AE10;S01EE52;S01EC03	Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] Firs	120279-96-1
QVFLVLMYXXNJDT-CSBVGUNJSA-N	DB14554	Dotatate	approved;investigational	nan	nan	177943-88-3
VOFLAIHEELWYGO-UHFFFAOYSA-N	DB16145	Dotinurad	investigational	nan	Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).	1285572-51-1
PIQCTGMSNWUMAF-UHFFFAOYSA-N	DB05928	Dovitinib	investigational	nan	Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.	405169-16-6
RUZYUOTYCVRMRZ-UHFFFAOYSA-N	DB00590	Doxazosin	approved;investigational	C02CA04;G04CA55	Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]	74191-85-8
ODQWQRRAPPTVAG-UHFFFAOYSA-N	DB01142	Doxepin	approved	N06AA12;D04AX01	Doxepin is a psychotropic agent with antidepressant and anxiolytic properties.[T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.[T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desip	1668-19-5
CYQFCXCEBYINGO-IAGOWNOFSA-N	DB00470	Dronabinol	approved;illicit;investigational	A04AD10	Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant,	1972-08-3
RMEDXOLNCUSCGS-UHFFFAOYSA-N	DB00450	Droperidol	approved;investigational;vet_approved	N05AD08	A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)	548-73-2
METQSPRSQINEEU-HXCATZOESA-N	DB01395	Drospirenone	approved;investigational	G03AA18;G03AC10;G03FA17;G03AA12	Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol].[L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibi	67392-87-4
YUAALFPUEOYPNX-UHFFFAOYSA-N	DB15187	Dubermatinib	investigational	nan	Dubermatinib is under investigation in clinical trial NCT03572634 (Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL).	1341200-45-0
ZEUITGRIYCTCEM-KRWDZBQOSA-N	DB00476	Duloxetine	approved;investigational	N06AX21	Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continu	116539-59-4
DVJAMEIQRSHVKC-BDAKNGLRSA-N	DB11723	Dutogliptin	investigational	nan	Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.	852329-66-9
SJVQHLPISAIATJ-ZDUSSCGKSA-N	DB11952	Duvelisib	approved;investigational	L01EM04	Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]	1201438-56-3
LXBIFEVIBLOUGU-JGWLITMVSA-N	DB03206	Duvoglustat	investigational	nan	An alpha-glucosidase inhibitor with antiviral action. Derivatives of deoxynojirimycin may have anti-HIV activity.	19130-96-2
JMNJYGMAUMANNW-FIXZTSJVSA-N	DB16146	Dynorphin	investigational	nan	Dynorphin is under investigation in clinical trial NCT00000244 (Effects of Dynorphin 1-13 on Heroin Addiction - 1).	80448-90-4
PUOAETJYKQITMO-LANLRWRYSA-N	DB05171	E-2012	experimental	nan	E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.	870843-42-8
DGPGXHRHNRYVDH-UHFFFAOYSA-N	DB16881	E-52862	experimental	nan	nan	878141-96-9
MWUFVYLAWAXDHQ-HMNLTAHHSA-N	DB11687	E-6201	investigational	nan	E6201 has been investigated for the treatment of Chronic Plaque Psoriasis.	603987-35-5
BLQYVHBZHAISJM-CMDGGOBGSA-N	DB16891	ENMD-981693	investigational	nan	nan	934353-76-1
AKJBLKUZXRMECW-UHFFFAOYSA-N	DB18120	EP-0042	investigational	nan	nan	1402709-93-6
NSSOSHDCWCMNDM-UHFFFAOYSA-N	DB06875	ERB-196	experimental	nan	nan	550997-55-2
YQEYLCGMINXDBN-UHFFFAOYSA-N	DB07306	ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	experimental	nan	nan	nan
MJJALKDDGIKVBE-UHFFFAOYSA-N	DB11742	Ebastine	approved;investigational;withdrawn	R06AX22	Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.	90729-43-4
DYEFUKCXAQOFHX-UHFFFAOYSA-N	DB12610	Ebselen	investigational	nan	Ebselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.	60940-34-3
QIEKHLDZKRQLLN-FOIQADDNSA-N	DB18967	Ebvaciclib	investigational	nan	Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).	2185857-97-8
RLRQXKXWZNPYRB-UHFFFAOYSA-N	DB21597	Eciruciclib	experimental	nan	Eciruciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Eciruciclib is a cyclin dependant kinase inhibitor. Eciruciclib has a monoisotopic molecular weight of 488.28 Da.	1868086-40-1
LEZWWPYKPKIXLL-UHFFFAOYSA-N	DB01127	Econazole	approved	G01AF05;D01AC03;G01AF20;G01AF55	A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.	27220-47-9
DMJWENQHWZZWDF-PKOBYXMFSA-N	DB12273	Ecopipam	investigational	nan	Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.	112108-01-7
BNVPFDRNGHMRJS-UHFFFAOYSA-N	DB12504	Edicotinib	investigational	nan	JNJ-40346527 has been used in trials studying the treatment of Health and Arthritis, Rheumatoid.	1142363-52-7
HGVDHZBSSITLCT-JLJPHGGASA-N	DB09075	Edoxaban	approved;investigational	B01AF03	Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary emboli	480449-70-5
XPOQHMRABVBWPR-ZDUSSCGKSA-N	DB00625	Efavirenz	approved;investigational	J05AR06;J05AG03;J05AR11	Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded pos	154598-52-4
KAGLWQUWUNBAOO-KSZLIROESA-N	DB21303	Efegatran	experimental	nan	Efegatran is a small molecule drug. Efegatran has a monoisotopic molecular weight of 416.25 Da.	105806-65-3
ZXEIEKDGPVTZLD-NDEPHWFRSA-N	DB19825	Eflucimibe	experimental	nan	Eflucimibe is a small molecule drug. Eflucimibe has a monoisotopic molecular weight of 469.3 Da.	202340-45-2
VTAARTQTOOYTES-RGDLXGNYSA-N	DB21031	Eglumetad	experimental	nan	Eglumetad is a small molecule drug. Eglumetad has a monoisotopic molecular weight of 185.07 Da.	176199-48-7
SIFNOOUKXBRGGB-AREMUKBSSA-N	DB06374	Elacestrant	approved;investigational	L02BA04	Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.[L44918,L44948] It received a similar approval in the EU in September 2023.[L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its ability to block the transcriptional activity 	722533-56-4
OSFCMRGOZNQUSW-UHFFFAOYSA-N	DB04881	Elacridar	investigational	nan	Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.	143664-11-3
ABNXKGFLZFSILK-MOPGFXCFSA-N	DB21212	Elarofiban anhydrous	experimental	nan	Elarofiban anhydrous is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Elarofiban anhydrous is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Elarofiban anhydrous has a monoisotopic molecular weight of 416.24 Da.	198958-88-2
JERXUPDBWDWFCF-UHFFFAOYSA-N	DB20663	Elbimilast	investigational	nan	Elbimilast is a small molecule drug. The usage of the INN stem '-milast' in the name indicates that Elbimilast is a Phosphodiesterase-4 (PDE4) inhibitor. Elbimilast is under investigation in clinical trial NCT00977886 (Safety and Pharmacokinetics of ELB353 in Healthy Men). Elbimilast has a monoisotopic molecular weight of 442.04 Da.	418794-42-0
YNUAEEJQYHYLMS-UHFFFAOYSA-N	DB12394	Eleclazine	investigational	nan	Eleclazine has been used in trials studying the treatment of LQT2 Syndrome, Long QT Syndrome, Ischemic Heart Disease, Ventricular Arrhythmia, and Long QT Syndrome Type 3, among others.	1443211-72-0
BKJIXTWSNXCKJH-UHFFFAOYSA-N	DB05719	Elesclomol	investigational	nan	Elesclomol is a novel, injectable, drug candidate that kills cancer cells by elevating oxidative stress levels beyond a breaking point, triggering programmed cell death. In preclinical models elesclomol showed potent killing of a broad range of cancer cell types at high doses, and an ability to strongly enhance the efficacy of certain chemotherapy agents, with minimal additional toxicity, at moderate doses. It is being developed by Synta Pharmaceuticals.	488832-69-5
GTQPEQGDLVSFJO-CXAGYDPISA-N	DB21465	Eliapixant	investigational	nan	Eliapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist. Eliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside o	1948229-21-7
YBXRSCXGRPSTMW-CYBMUJFWSA-N	DB19041	Elimusertib	investigational	nan	Elimusertib is under investigation in clinical trial NCT05071209 (Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors).	1876467-74-1
GGUSQTSTQSHJAH-UHFFFAOYSA-N	DB12869	Eliprodil	investigational	nan	Eliprodil has been used in trials studying the treatment of Parkinson Disease and Movement Disorders.	119431-25-3
CTSPAMFJBXKSOY-UHFFFAOYSA-N	DB17026	Ellipticine	experimental	nan	Ellipticine is a potent antineoplastic agent.[A252992]	519-23-3
XFLQIRAKKLNXRQ-UUWRZZSWSA-N	DB12486	Elobixibat	investigational	A06AX09	Elobixibat has been used in trials studying the treatment and basic science of Dyslipidemia, Constipation, Chronic Constipation, Functional Constipation, and Chronic Idiopathic Constipation.	439087-18-0
PGNHBJGIQAEIHD-UHFFFAOYSA-N	DB19875	Elopiprazole	experimental	nan	Elopiprazole is a small molecule drug. The usage of the INN stem '-prazole' in the name indicates that Elopiprazole is a benzimidazole derivative antiulcer medication. Elopiprazole has a monoisotopic molecular weight of 375.17 Da.	115464-77-2
JUZYLCPPVHEVSV-LJQANCHMSA-N	DB09101	Elvitegravir	approved;investigational	J05AJ02;J05AR09;J05AR18	Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the HIV-1 provirus and resulting propagation of the viral infection. Although available as a single dose tablet, elvitegravir must be used in co	697761-98-1
UUDPUQDMSHQSKH-NSHDSACASA-N	DB18918	Elzovantinib	investigational	nan	Elzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).	2271119-26-5
AUVVAXYIELKVAI-CKBKHPSWSA-N	DB13393	Emetine	investigational	P01AX02;P01AX52	nan	483-18-1
MLILORUFDVLTSP-UHFFFAOYSA-N	DB08188	Emivirine	investigational	nan	Emivirine has been used in trials studying the treatment of HIV Infections.	149950-60-7
NRJKIOCCERLIDG-GOSISDBHSA-N	DB19473	Empesertib	investigational	nan	Empesertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Empesertib is a serine/threonine kinase inhibitor. Empesertib is under investigation in clinical trial NCT02138812 (Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel). Empesertib has a monoisotopic molecular weight of 559.17 Da.	1443763-60-7
JMBYBVLCYODBJQ-HFMPRLQTSA-N	DB16967	Enadoline	experimental	nan	nan	124378-77-4
GBXSMTUPTTWBMN-XIRDDKMYSA-N	DB00584	Enalapril	approved;investigational;vet_approved	C09BA02;C09BB06;C09BB02;C09AA02	Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling.[A1845	75847-73-3
LZFZMUMEGBBDTC-QEJZJMRPSA-N	DB09477	Enalaprilat	approved;investigational	nan	Enalaprilat is the active metabolite of the orally available pro-drug, [enalapril]. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to 	76420-72-9
DYLUUSLLRIQKOE-UHFFFAOYSA-N	DB13874	Enasidenib	approved;investigational	L01XM01	Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to 	1446502-11-9
KORCWPOBTZTAFI-YVTYUBGGSA-N	DB18970	Enavogliflozin	investigational	A10BK09	Enavogliflozin is under investigation in clinical trial NCT06399835 (Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis).	1415472-28-4
SSRDSYXGYPJKRR-ZDUSSCGKSA-N	DB11726	Encenicline	investigational	nan	Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.	550999-75-2
GKIRPKYJQBWNGO-OCEACIFDSA-N	DB06735	Enclomiphene	investigational	nan	nan	15690-57-0
CMJCXYNUCSMDBY-ZDUSSCGKSA-N	DB11718	Encorafenib	approved;investigational	L01EC03	Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.[L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in vari	1269440-17-6
YZCUMZWULWOUMD-NDEPHWFRSA-N	DB17297	Enitociclib	investigational	nan	nan	1610408-97-3
HJGJDFXTHQBVNV-ONEGZZNKSA-N	DB19852	Enofelast	experimental	nan	Enofelast is a small molecule drug. Enofelast has a monoisotopic molecular weight of 242.11 Da.	127035-60-3
MPDGHEJMBKOTSU-YKLVYJNSSA-N	DB13089	Enoxolone	investigational	D03AX10	Enoxolone (glycyrrhetic acid) has been investigated for the basic science of Apparent Mineralocorticoid Excess (AME).	471-53-4
GLCKXJLCYIJMRB-UPRLRBBYSA-N	DB06460	Enrasentan	experimental	nan	nan	167256-08-8
QMPBBNUOBOFBFS-UHFFFAOYSA-N	DB18834	Ensitrelvir	investigational	J05AE16	Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).	2647530-73-0
INVTYAOGFAGBOE-UHFFFAOYSA-N	DB11841	Entinostat	investigational	L01XH05	Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.	209783-80-2
HAYYBYPASCDWEQ-UHFFFAOYSA-N	DB11986	Entrectinib	approved;investigational	L01EX14	Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit 	1108743-60-7
BVGDAZBTIVRTGO-UONOGXRCSA-N	DB21585	Envonalkib	experimental	nan	Envonalkib is a small molecule drug. The usage of the INN stem '-alkib' in the name indicates that Envonalkib is a ALK (anaplastic lymphoma kinase) inhibitor. Envonalkib has a monoisotopic molecular weight of 505.14 Da.	1621519-26-3
WXCXUHSOUPDCQV-UHFFFAOYSA-N	DB08899	Enzalutamide	approved;investigational	L02BB04	Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic.[L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer.[A252667] Until recently, doceta	915087-33-1
AXRCEOKUDYDWLF-UHFFFAOYSA-N	DB06486	Enzastaurin	investigational	nan	Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.	170364-57-5
FBKMWOJEPMPVTQ-UHFFFAOYSA-N	DB11717	Epacadostat	investigational	L01XX58	Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.	1204669-58-8
SQUNAWUMZGQQJD-UHFFFAOYSA-N	DB08992	Eperisone	investigational	M03BX09	Eperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.	64840-90-0
NLPRAJRHRHZCQQ-IVZWLZJFSA-N	DB07720	Epibatidine	experimental	nan	nan	140111-52-0
NMARPFMJVCXSAV-UHFFFAOYSA-N	DB20422	Epiroprim	experimental	nan	Epiroprim is a small molecule drug. Epiroprim has a monoisotopic molecular weight of 353.19 Da.	73090-70-7
VAIOZOCLKVMIMN-PRJWTAEASA-N	DB12177	Eplivanserin	investigational	nan	Eplivanserin has been used in trials studying the treatment of Sleep, Insomnia, Chronic Pain, Fibromyalgia, and Primary Insomnia, among others.	130579-75-8
VAPSMQAHNAZRKC-PQWRYPMOSA-N	DB19810	Epristeride	experimental	nan	Epristeride is a small molecule drug. The usage of the INN stem '-steride' in the name indicates that Epristeride is a androgen/anabolic steroid. Epristeride has a monoisotopic molecular weight of 399.28 Da.	119169-78-7
VPCSYAVXDAUHLT-UHFFFAOYSA-N	DB05035	Eprotirome	investigational	nan	Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and blood glucose.	355129-15-6
PWBHUSLMHZLGRN-UHFFFAOYSA-N	DB19242	Eragidomide	investigational	nan	Eragidomide is under investigation in clinical trial NCT04297124 (A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects).	1860875-51-9
HLFSMUUOKPBTSM-ISIOAQNYSA-N	DB12329	Eravacycline	approved;investigational	J01AA13;J01AA20	Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens [A38683]. It was first ap	1207283-85-9
YQQZZYYQTCPEAS-OYLFLEFRSA-N	DB18019	Erbumine	investigational	nan	nan	1919888-06-4
OLAHOMJCDNXHFI-UHFFFAOYSA-N	DB12147	Erdafitinib	approved;investigational	L01EN01	In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] A	1346242-81-6
WVVSZNPYNCNODU-XTQGRXLLSA-N	DB01253	Ergometrine	approved;investigational	G02AB03	An ergot alkaloid with uterine and vascular smooth muscle contractile properties.	60-79-7
XCGSFFUVFURLIX-VFGNJEKYSA-N	DB00696	Ergotamine	approved	N02CA02;N02CA52;N02CA72	A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.	113-15-5
AAKJLRGGTJKAMG-UHFFFAOYSA-N	DB00530	Erlotinib	approved;investigational	L01EB02	Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of J	183321-74-6
XIESSJVMWNJCGZ-VKJFTORMSA-N	DB07933	Erteberel	investigational	nan	Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.	533884-09-2
FONCZICQWCUXEB-RUZDIDTESA-N	DB06521	Ertiprotafib	experimental	nan	Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.	251303-04-5
MCIACXAZCBVDEE-CUUWFGFTSA-N	DB11827	Ertugliflozin	approved;investigational	A10BD23;A10BK04;A10BD24	Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.[A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]	1210344-57-2
ULGZDMOVFRHVEP-RWJQBGPGSA-N	DB00199	Erythromycin	approved;investigational;vet_approved	J01FA01;D10AF02;S01AA17;D10AF52	Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of [Azithromycin], [Clarithromycin], [Spiramycin] and others. It was originally discovered in 1952.[L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria.[L5245,L7261] It is available for administration in various	114-07-8
WSEQXVZVJXJVFP-FQEVSTJZSA-N	DB01175	Escitalopram	approved;investigational	N06AB10	Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escital	128196-01-0
YQEZLKZALYSWHR-ZDUSSCGKSA-N	DB11823	Esketamine	approved;investigational	N06AX27;N01AX14	Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use	33643-46-8
CBQGYUDMJHNJBX-OALUTQOASA-N	DB12395	Esreboxetine	investigational	nan	Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia.	98819-76-2
AJIPIJNNOJSSQC-NYLIRDPKSA-N	DB12235	Estetrol	approved;investigational	G03AA18	Naturally or synthetically produced steroid estrogens have a wide range of pharmaceutical uses ranging from hormonal contraception to the treatment of menopausal symptoms.[L33184] Estetrol (E4) is a native estrogen occurring naturally during pregnancy, but can be synthesized from a plant source and used for contraception.[L33179] It is more potent and is safer than the synthetic estrogen ethinylestradiol (EE2) found in 97% of oral contraceptive pills, reducing the environmental accumulation of u	15183-37-6
VOXZDWNPVJITMN-ZBRFXRBCSA-N	DB00783	Estradiol	approved;investigational;vet_approved	G03FA16;G03FA06;G03FA09;G03FA14;G03CA53;G03FA12;G03FB12;G03FB03;G03FA15;G03FB02;G03FB10;G03FA10;G03EA01;G03FA04;G03FB11;G03FA01;G03FB09;G03FB08;G03EA03;G03AA14;G03AB08;G03FB01;G03FA03;H01CC54;G03FA08;G03FB06;G03EA02;G03AA17;G03FA11;G03FB07;G03FA17;G03FA07;G03FA02;G03HB01;G03FB04;H01CC53;G03FA13;G02BB01;G03CA03;G03FA05;G03FB05	Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays, gels, and creams.[L11485,L11488,L11491, L11494,L11497,L11500,L11503] When used for oral or IM administration, estradiol is commonly synthes	50-28-2
PROQIPRRNZUXQM-ZXXIGWHRSA-N	DB04573	Estriol	approved;investigational;vet_approved	G03CC06;G03CA04	A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however avail	50-27-1
DNXHEGUUPJUMQT-CBZIJGRNSA-N	DB00655	Estrone	approved	G03CC04;G03CA07	Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.	53-16-7
JKKFKPJIXZFSSB-CBZIJGRNSA-N	DB04574	Estrone sulfate	approved	nan	Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.	481-97-0
GBBSUAFBMRNDJC-INIZCTEOSA-N	DB00402	Eszopiclone	approved;investigational	N05CF04	Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity[A179827], offering a safer alternative to other drugs used for insomnia. One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets i	138729-47-2
YFIZRWPXUYFCSN-UHFFFAOYSA-N	DB12850	Etalocib	investigational	nan	Etalocib has been used in trials studying the treatment of Pancreatic Cancer, Carcinoma, Non-Small-Cell Lung, and Unspecified Adult Solid Tumor, Protocol Specific.	161172-51-6
BFPYWIDHMRZLRN-SLHNCBLASA-N	DB00977	Ethinylestradiol	approved;investigational	G03AA15;G03AA11;L02AA03;G03AA12;G03AA16;G03AB02;G03CA01;G03AA03;G03AA10;G03AB04;G03AB01;G03AB07;G03AA13;G03AA06;G03AA08;G03AA02;G03AA04;G03AA09;G03AB09;G03AA07;G03AB03;G03AA05;G03AB05;G03AB06;G03AA01	Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability.[A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.[A191107] Ethinylestradiol was granted FDA approval on 25 June 1943.[L11884]	57-63-6
OUZWUKMCLIBBOG-UHFFFAOYSA-N	DB00311	Ethoxzolamide	approved;withdrawn	G01AE10	Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. Its pharmacological activity thus confers the risk for hypokalemia.	452-35-7
AOXRBFRFYPMWLR-XGXHKTLJSA-N	DB01493	Ethylestrenol	approved;withdrawn	A14AB02	An anabolic steroid with some progestational activity and little androgenic effect. [PubChem]	965-90-2
AADCDMQTJNYOSS-LBPRGKRZSA-N	DB15492	Eticlopride	experimental	nan	nan	84226-12-0
NNYBQONXHNTVIJ-UHFFFAOYSA-N	DB00749	Etodolac	approved;investigational;vet_approved	M01AB08	Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.	41340-25-4
NPUKDXXFDDZOKR-LLVKDONJSA-N	DB00292	Etomidate	approved;investigational	N01AX07	Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.	33125-97-2
PXDBZSCGSQSKST-UHFFFAOYSA-N	DB01462	Etonitazene	experimental;illicit	nan	nan	911-65-9
IZBNNCFOBMGTQX-UHFFFAOYSA-N	DB09194	Etoperidone	approved;withdrawn	N06AB09	Etoperidone is an atypical antidepressant introduced in Europe in 1977. It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.[T45] Etoperidone was developed by Angelini Francesco ACRAF.[A4909]	52942-31-1
VJJPUSNTGOMMGY-MRVIYFEKSA-N	DB00773	Etoposide	approved;investigational	L01CB01	A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.	33419-42-0
MNJVRJDLRVPLFE-UHFFFAOYSA-N	DB01628	Etoricoxib	approved;investigational;withdrawn	M01AH05	Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.	202409-33-4
INOYCBNLWYEPSB-XHSDSOJGSA-N	DB21188	Etoxadrol	experimental	nan	Etoxadrol is a small molecule drug. Etoxadrol has a monoisotopic molecular weight of 261.17 Da.	28189-85-7
PYGWGZALEOIKDF-UHFFFAOYSA-N	DB06414	Etravirine	approved;investigational	J05AG04	Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended fo	269055-15-4
BUXIAWLTBSXYSW-UHFFFAOYSA-N	DB17506	Etrumadenant	investigational	nan	nan	2239273-34-6
UPADRKHAIMTUCC-OWALTSPQSA-N	DB06431	Evernimicin	experimental	nan	nan	109545-84-8
HKVAMNSJSFKALM-GKUWKFKPSA-N	DB01590	Everolimus	approved;investigational	L01EG02;L04AH02	Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.	159351-69-6
IQFZADSTVFSHDX-UHFFFAOYSA-N	DB21510	Evifacotrep	experimental	nan	Evifacotrep is a small molecule drug. The usage of the INN stem '-cotrep' in the name indicates that Evifacotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist. Evifacotrep has a monoisotopic molecular weight of 441.06 Da.	2413739-88-3
OIIOPWHTJZYKIL-PMACEKPBSA-N	DB21520	Evixapodlin	investigational	nan	Evixapodlin is a small molecule drug. Evixapodlin is under investigation in clinical trial NCT04049617 (Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors). Evixapodlin has a monoisotopic molecular weight of 690.22 Da.	2374856-75-2
QUIWHXQETADMGN-UHFFFAOYSA-N	DB15170	Evobrutinib	investigational	nan	Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).	1415823-73-2
GZMYLSJUNSCMTD-MOPGFXCFSA-N	DB17582	Exarafenib	investigational	nan	nan	2639957-39-2
KSGCNXAZROJSNW-UHFFFAOYSA-N	DB12888	Ezutromid	investigational	nan	Ezutromid has been investigated for the treatment of Muscular Dystrophy, Duchenne.	945531-77-1
OUQVKRKGTAUJQA-UHFFFAOYSA-N	DB08687	FG-2216	investigational	nan	A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability. [A14422]	223387-75-5
RWVIMCIPOAXUDG-UHFFFAOYSA-N	DB03759	FG-9041	experimental	nan	nan	2379-57-9
VXLAKHWYGRKCGI-UHFFFAOYSA-N	DB17383	FN-1501	investigational	nan	nan	1429515-59-2
RYCBSFIKWACFBY-UHFFFAOYSA-N	DB31834	FRAX1036	experimental	nan	FRAX1036 is a p21-activated kinase (PAK) inhibitor.	1432908-05-8
TXCYUSKWBHUVEP-CYBMUJFWSA-N	DB05586	Facinicline	investigational	nan	nan	677306-35-3
DLPIYBKBHMZCJI-WBVHZDCISA-N	DB15425	Fadraciclib	investigational	nan	CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).	1070790-89-4
CLPFFLWZZBQMAO-UHFFFAOYSA-N	DB16832	Fadrozole	experimental	nan	nan	102676-47-1
LLGDPTDZOVKFDU-XUHJSTDZSA-N	DB11808	Faldaprevir	investigational	J05AP04	Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.	801283-95-4
OABRYNHZQBZDMG-INIZCTEOSA-N	DB15167	Fallypride	investigational	nan	Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).	166173-78-0
FTFRZXFNZVCRSK-UHFFFAOYSA-N	DB12966	Falnidamol	investigational	nan	Falnidamol has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.	196612-93-8
GKEYKDOLBLYGRB-LGMDPLHJSA-N	DB11741	Famitinib	investigational	nan	Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.	1044040-56-3
XUFQPHANEAPEMJ-UHFFFAOYSA-N	DB00927	Famotidine	approved;investigational	A02BA03;A02BA53	Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children.[L11166] Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disea	76824-35-6
VGIGHGMPMUCLIQ-UHFFFAOYSA-N	DB19807	Fananserin	experimental	nan	Fananserin is a small molecule drug. The usage of the INN stem '-anserin' in the name indicates that Fananserin is a serotonin receptor antagonist. Fananserin has a monoisotopic molecular weight of 425.16 Da.	127625-29-0
GUZBZPCNAJDYMO-UHFFFAOYSA-N	DB21485	Fanotaprim	experimental	nan	Fanotaprim is a small molecule drug. Fanotaprim has a monoisotopic molecular weight of 378.19 Da.	2120282-75-7
VWFJDQUYCIWHTN-YFVJMOTDSA-N	DB07780	Farnesyl diphosphate	experimental	nan	nan	13058-04-3
HGGAKXAHAYOLDJ-FHZUQPTBSA-N	DB12190	Faropenem	investigational	J01DI03	Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.	106560-14-9
NGOGFTYYXHNFQH-UHFFFAOYSA-N	DB08162	Fasudil	investigational	C04AX32	Fasudil has been investigated in Carotid Stenosis.	103745-39-7
BQSJTQLCZDPROO-UHFFFAOYSA-N	DB04854	Febuxostat	approved;investigational	M04AA03	Febuxostat is a non-purine xanthine oxidase (XO) inhibitor.[A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout.[A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol].[L32238] Gout is a form of arthritis that is caused by the accumulation of uric aci	144060-53-7
JOOXLOJCABQBSG-UHFFFAOYSA-N	DB12500	Fedratinib	approved;investigational	G01AE10;L01EJ02	Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]	936091-26-8
CLSJNXXMIVKULC-MUUNZHRXSA-N	DB20151	Feloprentan	experimental	nan	Feloprentan is a small molecule drug. The usage of the INN stem '-entan' in the name indicates that Feloprentan is a endothelin receptor antagonist. Feloprentan has a monoisotopic molecular weight of 528.23 Da.	204267-34-5
OJSFTALXCYKKFQ-YLJYHZDGSA-N	DB20364	Femoxetine	experimental	nan	Femoxetine is a small molecule drug. Femoxetine has a monoisotopic molecular weight of 311.19 Da.	59859-58-4
ZPAKPRAICRBAOD-UHFFFAOYSA-N	DB08981	Fenbufen	approved	M01AE05	Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.	36330-85-5
DWPQODZAOSWNHB-UHFFFAOYSA-N	DB12931	Fenobam	investigational	nan	Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome).	57653-26-6
YMTINGFKWWXKFG-UHFFFAOYSA-N	DB01039	Fenofibrate	approved;investigational	C10BA03;C10BA12;C10AB05;C10BA09;C10BA04	Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]	49562-28-9
MQOBSOSZFYZQOK-UHFFFAOYSA-N	DB13873	Fenofibric acid	approved;investigational	C10AB11	Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have	42017-89-0
AKJHMTWEGVYYSE-FXILSDISSA-N	DB05076	Fenretinide	investigational	nan	A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.	65646-68-6
PJMPHNIQZUBGLI-UHFFFAOYSA-N	DB00813	Fentanyl	approved;illicit;investigational;vet_approved	N01AH01;N02AB03;N01AH51	Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.[A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.[A179542] In 2017, 47600 overdose deaths in the United State	437-38-7
KSEBMYQBYZTDHS-HWKANZROSA-N	DB07767	Ferulic acid	investigational	nan	nan	1135-24-6
VRQMAABPASPXMW-HDICACEKSA-N	DB12247	Fexagratinib	investigational	nan	AZD4547 has been used in trials studying the treatment of Cancer, LYMPHOMA, Gastric Cancer, Adenocarcinoma, and Solid Neoplasm, among others.	1035270-39-3
STTRYQAGHGJXJJ-LICLKQGHSA-N	DB02660	Filaminast	experimental	nan	Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	141184-34-1
MROBUJILSMBILX-FOIQADDNSA-N	DB21467	Filapixant	experimental	nan	Filapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Filapixant is a purinoreceptor (P2X) antagonist. Filapixant has a monoisotopic molecular weight of 521.17 Da.	1948232-63-0
RIJLVEAXPNLDTC-UHFFFAOYSA-N	DB14845	Filgotinib	approved;investigational	L04AF04	Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.[A221451,A221456] The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders.[A189165] 50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-m	1206161-97-8
NPFDWHQSDBWQLH-QZTJIDSGSA-N	DB12158	Filorexant	investigational	nan	Filorexant has been used in trials studying the prevention and treatment of Migraine, Headache, Polysomnography, Diabetic Neuropathy, Painful, and Major Depressive Disorder, Recurrent.	1088991-73-4
JOWXJLIFIIOYMS-UHFFFAOYSA-N	DB11891	Fimepinostat	investigational	nan	Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.	1339928-25-4
DBEPLOCGEIEOCV-WSBQPABSSA-N	DB01216	Finasteride	approved;investigational	D11AX10;G04CA55;G04CA51;G04CB51;G04CB01	Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptom	98319-26-7
KXSUAWAUCNFBQJ-UHFFFAOYSA-N	DB06585	Fipamezole	investigational	nan	nan	150586-58-6
ZZWWXIBKLBMSCS-FQEVSTJZSA-N	DB16166	Firsocostat	investigational	nan	Firsocostat is under investigation in clinical trial NCT02781584 (Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)).	1434635-54-7
MGZKYOAQVGSSGC-DLBZAZTESA-N	DB16167	Fisogatinib	investigational	nan	Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).	1707289-21-1
VHBFFQKBGNRLFZ-UHFFFAOYSA-N	DB07776	Flavone	approved;investigational	nan	nan	525-82-6
RFHAOTPXVQNOHP-UHFFFAOYSA-N	DB00196	Fluconazole	approved;investigational	J01RA07;J02AC01;D01AC15	Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an eff	86386-73-4
LPEPZBJOKDYZAD-UHFFFAOYSA-N	DB02266	Flufenamic acid	approved	M01AG03	An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)	530-78-9
BJCJYEYYYGBROF-UHFFFAOYSA-N	DB11904	Flumatinib	investigational	nan	Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic.	895519-90-1
OFBIFZUFASYYRE-UHFFFAOYSA-N	DB01205	Flumazenil	approved;investigational	V03AB25	Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.	78755-81-4
SMANXXCATUTDDT-QPJJXVBHSA-N	DB04841	Flunarizine	approved;investigational	N07CA03	Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.	52468-60-7
PPTYJKAXVCCBDU-UHFFFAOYSA-N	DB01544	Flunitrazepam	approved;illicit	N05CD03	Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.	1622-62-4
NOOCSNJCXJYGPE-UHFFFAOYSA-N	DB11518	Flunixin	experimental;vet_approved	nan	Flunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian. Flunixin may be also referred to as _Banamine_, and other trade names.	38677-85-9
DBWPFHJYSTVBCZ-BYPYZUCNSA-N	DB02966	Fluoro-Willardiine	experimental	nan	nan	nan
GHASVSINZRGABV-UHFFFAOYSA-N	DB00544	Fluorouracil	approved;investigational	L01BC52;L01BC02	A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.	51-21-8
RTHCYVBBDHJXIQ-UHFFFAOYSA-N	DB00472	Fluoxetine	approved;investigational;vet_approved	N06CA03;N06AB03	Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI).[A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.[L7721]	54910-89-3
WPYGCZCMGMVGNO-UHFFFAOYSA-N	DB20128	Fluperamide	experimental	nan	Fluperamide is a small molecule drug. Fluperamide has a monoisotopic molecular weight of 544.21 Da.	53179-10-5
OBWGMKKHCLHVIE-UHFFFAOYSA-N	DB20643	Fluperlapine	experimental	nan	Fluperlapine is a small molecule drug. Fluperlapine has a monoisotopic molecular weight of 309.16 Da.	67121-76-0
PLDUPXSUYLZYBN-UHFFFAOYSA-N	DB00623	Fluphenazine	approved	N05AB02	A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.	69-23-8
SYTBZMRGLBWNTM-UHFFFAOYSA-N	DB00712	Flurbiprofen	approved;investigational	M02AA19;M01AE09;R02AX01;S01BC04	Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.	5104-49-4
QOYHHIBFXOOADH-UHFFFAOYSA-N	DB04842	Fluspirilene	approved;withdrawn	N05AG01	A long-acting injectable antipsychotic agent used for chronic schizophrenia.	1841-19-6
MKXKFYHWDHIYRV-UHFFFAOYSA-N	DB00499	Flutamide	approved;investigational	L02BB01	An antiandrogen with about the same potency as cyproterone in rodent and canine species.	13311-84-7
XTULMSXFIHGYFS-VLSRWLAYSA-N	DB08906	Fluticasone furoate	approved;investigational	R03AL08;R01AD12;R03AK10;R03BA09	Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].	397864-44-7
WMWTYOKRWGGJOA-CENSZEJFSA-N	DB00588	Fluticasone propionate	approved;investigational	nan	Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].	80474-14-2
FJLGEFLZQAZZCD-VAWYXSNFSA-N	DB01095	Fluvastatin	approved;investigational	C10AA04	Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal	93957-54-1
CJOFXWAVKWHTFT-XSFVSMFZSA-N	DB00176	Fluvoxamine	approved;investigational	N06AB08	Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide hav	54739-18-3
OVBPIULPVIDEAO-LBPRGKRZSA-N	DB00158	Folic acid	approved;investigational;nutraceutical;vet_approved	B03AE02;B03AD04;V04CX02;B03AD01;B03BB51;B03AD03;B03BB01;B03AE01;B03AD05;B03AD02	Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As hum	59-30-3
YONOBYIBNBCDSJ-UHFFFAOYSA-N	DB01342	Forasartan	experimental	nan	Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.	145216-43-9
CXQHYVUVSFXTMY-UHFFFAOYSA-N	DB12307	Foretinib	investigational	nan	Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of MET, RON, ERK and AKT, decreased proliferation and increased apoptosis.	849217-64-7
HKQYGTCOTHHOMP-UHFFFAOYSA-N	DB15335	Formononetin	experimental	nan	Formononetin is under investigation in clinical trial NCT02174666 (Isoflavone Treatment for Postmenopausal Osteopenia.).	485-72-3
BPZSYCZIITTYBL-UHFFFAOYSA-N	DB00983	Formoterol	approved;investigational	R03AL09;R03AL05;R03AK09;R03AL10;R03CC15;R03AL11;R03AL07;R03AK08;R03AC13;R03AK07;R03AK11	Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001.[L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers.[A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined w	73573-87-2
IWKXDMQDITUYRK-KUBHLMPHSA-N	DB06185	Forodesine	investigational	nan	Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic leukemia and cutaneous T-cell lymphoma. Additional preliminary findings support its use for the management of some B-cell malignancies.	209799-67-7
ZJAOAACCNHFJAH-UHFFFAOYSA-N	DB00529	Foscarnet	approved;investigational	J05AD01	An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.	4428-95-9
VHOZWHQPEJGPCC-AZXNYEMZSA-N	DB15034	Foscenvivint	investigational	nan	PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).	1198780-38-9
BVXLAHSJXXSWFF-KEKPKEOLSA-N	DB12198	Fosdagrocorat	investigational	nan	Fosdagrocorat has been used in trials studying the treatment and basic science of Rheumatoid Arthritis.	1044535-58-1
GKDRMWXFWHEQQT-UHFFFAOYSA-N	DB12010	Fostamatinib	approved;investigational	B02BX09	Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modul	901119-35-5
IKZACQMAVUIGPY-HOTGVXAUSA-N	DB06472	Fradafiban	experimental	nan	nan	148396-36-5
PGBHMTALBVVCIT-VCIWKGPPSA-N	DB00452	Framycetin	approved;investigational	D09AA01;R01AX08;S01AA07	A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)	119-04-0
BAFUFNSAYGCZIC-VWLOTQADSA-N	DB21683	Frespaciguat	investigational	nan	Frespaciguat is a small molecule drug. The usage of the INN stem '-ciguat' in the name indicates that Frespaciguat is a guanylate cyclase activator and stimulator. Frespaciguat is under investigation in clinical trial NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD). Frespaciguat has a monoisotopic molecular weight of 608.14 Da.	2101645-33-2
BALLNEJQLSTPIO-UHFFFAOYSA-N	DB11679	Fruquintinib	approved;investigational	L01EK04	Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation, loss of tumor suppressor function, and hypoxia, usually facilitated by cancer cells, are known to upregulate VEGF.[A262097] There are 	1194506-26-7
JDARDSVOVYVQST-MRXNPFEDSA-N	DB15085	Fulacimstat	investigational	nan	Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction).	1488354-15-9
VWUXBMIQPBEWFH-WCCTWKNTSA-N	DB00947	Fulvestrant	approved;investigational	L02BA03	Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor recept	129453-61-8
NEBUOXBYNAHKFV-NRFANRHFSA-N	DB11769	Funapide	investigational	nan	Funapide has been used in trials studying the treatment of Pharmacokinetics, Postherpetic Neuralgia, and Osteoarthritis of the Knee.	1259933-16-8
HMZQULPVMKITSP-UHFFFAOYSA-N	DB14029	Furafylline	experimental	nan	Furafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for [theophylline].	80288-49-9
WXINNGCGSCFUCR-ZDUSSCGKSA-N	DB02026	Furo[2,3d]Pyrimidine Antifolate	experimental	nan	nan	nan
ZZUFCTLCJUWOSV-UHFFFAOYSA-N	DB00695	Furosemide	approved;investigational;vet_approved	C03EB01;C03CA01;G01AE10;C03CB01	Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative.[L7958] Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure.[L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short du	54-31-9
KEIPNCCJPRMIAX-HNNXBMFYSA-N	DB15149	Futibatinib	approved;investigational	L01EN04	Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies.[A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first appro	1448169-71-8
DASHZBBQOARCMQ-QPJJXVBHSA-N	DB17028	GBR-12879	experimental	nan	nan	67469-43-6
BSPZFJDYQHDZNR-ASPXRTSYSA-N	DB15796	GC-376 free acid	experimental	nan	GC-376 is a 3C-like protease (3CL<sup>pro</sup> or M<sup>pro</sup>) inhibitor that stops the cleavage and activation of functional viral proteins required for replication and transcription in host cells[A219036]. The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056]. In addition, GC-376 displays potent activity against various coronaviruses such as feline, ferret, and mi	1417031-79-8
SKMKJBYBPYBDMN-RYUDHWBXSA-N	DB17079	GDC-0134	investigational	nan	nan	1637394-01-4
WZRFLSDVFPIXOV-LRQRDZAKSA-N	DB12380	GDC-0152	investigational	nan	GDC-0152 has been used in trials studying the treatment of Solid Cancers.	873652-48-3
KJAAPZIFCQQQKX-NDEPHWFRSA-N	DB14934	GDC-0927	investigational	nan	GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).	2100830-77-9
CABBMMXFOOZVMS-PMERELPUSA-N	DB12309	GI-181771X	experimental	nan	Gski181771 X is under investigation in clinical trial NCT00600743 (Effect of a CCK-1R Agonist on Food Intake in Humans).	305366-98-7
CXHCNOMGODVIKB-VWLOTQADSA-N	DB12297	GLPG-0187	investigational	nan	GLPG0187 has been used in trials studying the treatment of Solid Tumors.	1320346-97-1
YANGEESWIGIKOP-UUWRZZSWSA-N	DB12806	GSK-1004723	investigational	nan	Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.	955359-72-5
QDITZBLZQQZVEE-YBEGLDIGSA-N	DB11962	GSK-1059615	investigational	nan	GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.	958852-01-2
XTKLTGBKIDQGQL-UHFFFAOYSA-N	DB11795	GSK-2636771	investigational	nan	GSK2636771 has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others.	1372540-25-4
YOVNFNXUCOWYSG-UHFFFAOYSA-N	DB17030	GSK-269962A	experimental	nan	GSK-269962A is a Rho kinase (ROCK) inhibitor with both ROCK1 and ROCK2 affinity.[A253012]	850664-21-0
SKDVMPZQJMZEAC-SECBINFHSA-N	DB16888	GSK-2881078	investigational	nan	nan	1539314-06-1
AWDJJMXJUOHGLC-UHFFFAOYSA-N	DB12542	GSK-356278	investigational	nan	Gsk356278 has been used in trials studying the treatment and basic science of Anxiety Disorders, Huntington Disease, Depressive Disorder, Huntingtons Disease, and Depressive Disorder, Major, among others.	720704-34-7
QWLNINWUBHHOLU-UHFFFAOYSA-N	DB13119	GSK-364735	investigational	nan	GSK-364735 (Naphthyridinone) has been used in trials studying the treatment of HIV-1 Infection and Infection, Human Immunodeficiency Virus.	863434-13-3
KGPGFQWBCSZGEL-ZDUSSCGKSA-N	DB12745	GSK-690693	investigational	nan	GSK690693 has been used in trials studying the treatment of Tumor, CANCER, and Lymphoma.	937174-76-0
RPYWXZCFYPVCNQ-RVDMUPIBSA-N	DB05708	GTS-21	investigational	nan	GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in s	148372-04-7
FBCQEUMZZNVQKD-UHFFFAOYSA-N	DB14969	GTX-758	investigational	nan	GTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).	938067-78-8
NAXSRXHZFIBFMI-UHFFFAOYSA-N	DB03791	GW-3965	experimental	nan	GW-3965 is a liver X receptor ligand.	405911-09-3
ACEFOQMQINFMRW-DYCFVMESSA-N	DB07278	GW-813893	investigational	nan	nan	478644-12-1
HFHDGHOGHWXXDT-ZSOIEALJSA-N	DB16032	GW810781	investigational	nan	GW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 Versus Placebo in Hiv-infected Patients).	280571-30-4
HVRWZFQFSQUILC-UHFFFAOYSA-N	DB16056	GZ-389988	investigational	nan	GZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee).	1788906-96-6
YKGYIDJEEQRWQH-UHFFFAOYSA-N	DB12831	Gabexate	investigational	nan	Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]	39492-01-8
ZXRVKCBLGJOCEE-UHFFFAOYSA-N	DB06554	Gaboxadol	investigational	nan	Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing effects of benzodiazepines. Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.	64603-91-4
ASUTZQLVASHGKV-JDFRZJQESA-N	DB00674	Galantamine	approved;investigational	N06DA04	Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease.[A1018] First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_.[A201968] Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and 	357-70-0
PAFKTGFSEFKSQG-PAASFTFBSA-N	DB12415	Galeterone	investigational	nan	Galeterone has been used in trials studying the treatment of Prostate Cancer.	851983-85-2
XQLWNAFCTODIRK-UHFFFAOYSA-N	DB12923	Gallopamil	investigational	C08DA02	Gallopamil has been used in trials studying the treatment of Asthma.	16662-47-8
IVRXNBXKWIJUQB-UHFFFAOYSA-N	DB11911	Galunisertib	investigational	nan	Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.	700874-72-2
VZCCETWTMQHEPK-QNEBEIHSSA-N	DB13854	Gamolenic acid	approved;withdrawn	D11AX02;D11AX52	Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds [F27] that is most commonly found in human milk and other botanical sources [A32848]. It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6; 6,9,12-octadecatrienoic acid; and cis-6, cis-9, cis-12- octadecatrienoic acid [F27]. Gamolenic acid is produced minimally in the body as the delta 6-desaturase metabolite of [DB0013	506-26-3
PGTVWKLGGCQMBR-FLBATMFCSA-N	DB05087	Ganaxolone	approved;investigational	N03AX27	Ganaxolone is the 3β-methylated synthetic analog of [allopregnanolone],[L41130] a metabolite of [progesterone].[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids.[A3197] Endogenous neurosteroids, which comprise certain metabolites of progesterone and deoxycorticosterone, bind potently and specifically to GABA<sub>A</sub> receptors to enhance their inhibitory effects, and are thus known to have anxiolytic, analgesic, anticonvulsant, sedative, hypnotic, and anesthetic 	38398-32-2
SQSZANZGUXWJEA-UHFFFAOYSA-N	DB13040	Gandotinib	investigational	nan	Gandotinib has been used in trials studying the treatment of Myelofibrosis, Polycythemia Vera, Primary Myelofibrosis, Thrombocythemia, Essential, and Myeloproliferative Disorders, among others.	1229236-86-5
RVAQIUULWULRNW-UHFFFAOYSA-N	DB12047	Ganetespib	investigational	nan	Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.	888216-25-9
ZOBDWFRKFSPCRB-UNMCSNQZSA-N	DB06525	Ganstigmine	experimental	nan	Ganstigmine is an orally active, geneserine derived, carbamate-based acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease.	457075-21-7
YNBHAPKHWDNTMZ-QGZVFWFLSA-N	DB20951	Gantofiban	experimental	nan	Gantofiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Gantofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Gantofiban has a monoisotopic molecular weight of 447.21 Da.	183547-57-1
QAYHKBLKSXWOEO-UHFFFAOYSA-N	DB18770	Gartisertib	investigational	nan	nan	1613191-99-3
XUBOMFCQGDBHNK-UHFFFAOYSA-N	DB01044	Gatifloxacin	approved;investigational;withdrawn	S01AE06;J01MA16	Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA w	112811-59-3
DWZAEMINVBZMHQ-UHFFFAOYSA-N	DB11896	Gedatolisib	investigational	nan	Gedatolisib has been used in trials studying the basic science and treatment of Neoplasm, Ovary Cancer, Breast Cancer, Advanced Cancer, and Endometrial Cancer, among others.	1197160-78-3
HLWURFKMDLAKOD-UHFFFAOYSA-N	DB15097	Gefapixant	approved;investigational	R05DB29;G01AE10	It has been estimated that 5-10% of adults globally suffer from chronic cough, which is defined as a cough lasting longer than eight weeks.[L48601] A subset of these patients remain symptomatic despite thorough investigation and treatment, termed refractory chronic cough (RCC) if they have a cough that does not respond to conventional treatment or unexplained chronic cough (UCC) when no diagnosable cause for the cough can be determined.[L48596] Existing treatments for chronic cough have been ass	1015787-98-0
XGALLCVXEZPNRQ-UHFFFAOYSA-N	DB00317	Gefitinib	approved;investigational	L01EB01	Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.	184475-35-2
ZRCVYEYHRGVLOC-HYARGMPZSA-N	DB01155	Gemifloxacin	approved;investigational	J01MA15	Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.	175463-14-6
SILHYVDKGHXGBL-UHFFFAOYSA-N	DB19882	Gemilukast	investigational	nan	Gemilukast is a small molecule drug. The usage of the INN stem '-lukast' in the name indicates that Gemilukast is a leukotriene receptor antagonist. Gemilukast is under investigation in clinical trial NCT01536041 (A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients). Gemilukast has a monoisotopic molecular weight of 601.26 Da.	1232861-58-3
BRZYSWJRSDMWLG-DJWUNRQOSA-N	DB04263	Geneticin	experimental	nan	Geneticin (also known as G418) is an aminoglycoside antibiotic similar in structure to gentamicin B1, produced by Micromonospora rhodorangea. Geneticin blocks polypeptide synthesis by inhibiting the elongation step in both prokaryotic and eukaryotic cells and is commonly used in laboratory research to select genetically engineered cells. Resistance to Geneticin is conferred by the neo gene from Tn5 encoding an aminoglycoside 3‘-phosphotransferase, APH 3‘ II.	49863-47-0
TZBJGXHYKVUXJN-UHFFFAOYSA-N	DB01645	Genistein	investigational	nan	An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms. It has shown to be effective in 	446-72-0
QOIGKGMMAGJZNZ-UHFFFAOYSA-N	DB12184	Gepirone	approved	N06AX19	Gepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors. Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives. It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.[A261670,A261675,A1823	83928-76-1
PZFAZQUREQIODZ-LJQANCHMSA-N	DB12134	Gepotidacin	approved;investigational	J01XX13	Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g. [ciprofloxacin] - while being structurally and pharmacologically distinct.[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicat	1075236-89-3
YALNUENQHAQXEA-UHFFFAOYSA-N	DB12645	Givinostat	approved;investigational	M09AX14	Givinostat is a small molecule histone deacetylase (HDAC) inhibitor. It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies. In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.[L50316,A263446] Givinostat was granted FDA a	497833-27-9
MLSQGNCUYAMAHD-ITNVBOSISA-N	DB13879	Glecaprevir	approved;investigational	J05AP57	Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance mutations of the virus. In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV g	1365970-03-1
YRCHYHRCBXNYNU-UHFFFAOYSA-N	DB06302	Glesatinib	investigational	nan	nan	936694-12-1
WHUUTDBJXJRKMK-VKHMYHEASA-N	DB00142	Glutamic acid	approved;investigational;nutraceutical	A09AB01	A peptide that is a homopolymer of glutamic acid.	56-86-0
ZNNLBTZKUZBEKO-UHFFFAOYSA-N	DB01016	Glyburide	approved;investigational	A10BB01	Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin].[L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was grant	10238-21-8
ANGKOCUUWGHLCE-UHFFFAOYSA-N	DB00986	Glycopyrronium	approved;investigational;vet_approved	R03AL09;R03AL04;R03BB06;D11AA01;A03AB02;R03AL11;R03AL07;A03CA05;R03AL12	Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers.[L33110] They are both quaternary ammonium compounds and long acting muscarinic antagonists.[L33110] It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic rece	740028-90-4
LPLVUJXQOOQHMX-QWBHMCJMSA-N	DB13751	Glycyrrhizic acid	approved;investigational	A05BA08	Glycyrrhizic acid is extracted from the root of the licorice plant; _Glycyrrhiza glabra_.[F79] It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. When extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin.[T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.[A33062] From January 2014, glycyrrhizi	1405-86-3
VWVYILCFSYNJHF-UHFFFAOYSA-N	DB17029	Go-6976	experimental	nan	An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]	136194-77-9
UQRCJCNVNUFYDX-UHFFFAOYSA-N	DB11977	Golvatinib	investigational	nan	Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.	928037-13-2
OQAHHWOPVDDWHD-INIZCTEOSA-N	DB01951	Gpi-1046	experimental	nan	nan	nan
OBMNJSNZOWALQB-NCQNOWPTSA-N	DB11575	Grazoprevir	approved	J05AP11;J05AP54	Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of	1350514-68-9
WDZVGELJXXEGPV-YIXHJXPBSA-N	DB00629	Guanabenz	approved;withdrawn	nan	Guanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.	5051-62-7
INJOMKTZOLKMBF-UHFFFAOYSA-N	DB01018	Guanfacine	approved;investigational	C02AC02	Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]	29110-47-2
ZKZXNDJNWUTGDK-NSCUHMNNSA-N	DB07995	H-89	experimental	nan	nan	127243-85-0
MBWRLLRCTIYXDW-UHFFFAOYSA-N	DB15169	H3B-6527	investigational	nan	H3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).	1702259-66-2
NERXPXBELDBEPZ-RMKNXTFCSA-N	DB13002	HKI-357	investigational	nan	Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).	848133-17-5
TZKBVRDEOITLRB-UHFFFAOYSA-N	DB16185	HQP1351	investigational	nan	HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).	1257628-77-5
NBHPRWLFLUBAIE-UHFFFAOYSA-N	DB20096	Halopemide	experimental	nan	Halopemide is a small molecule drug. Halopemide has a monoisotopic molecular weight of 416.14 Da.	59831-65-1
LNEPOXFFQSENCJ-UHFFFAOYSA-N	DB00502	Haloperidol	approved;investigational	N05AD01	Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide.[A180616] While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain,[A27477] it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestat	52-86-8
CTETYYAZBPJBHE-UHFFFAOYSA-N	DB00793	Haloprogin	approved;withdrawn	D01AE11	Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet). Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infection	777-11-7
BXNJHAXVSOCGBA-UHFFFAOYSA-N	DB07919	Harmine	investigational	nan	nan	442-51-3
KKJYVDXDZURHMA-UHFFFAOYSA-N	DB01767	Hemi-Babim	experimental	nan	nan	nan
MCTXSDCWFQAGFS-UEXNTNOUSA-N	DB13019	Henatinib	investigational	nan	Henatinib has been used in trials studying the treatment of Advanced Solid Cancer.	1239269-51-2
AIONOLUJZLIMTK-AWEZNQCLSA-N	DB01094	Hesperetin	investigational	nan	Hesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.	520-33-2
ACGUYXCXAPNIKK-UHFFFAOYSA-N	DB00756	Hexachlorophene	approved;withdrawn	D08AE01	A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)	70-30-4
NAQMVNRVTILPCV-UHFFFAOYSA-N	DB03260	Hexamethylene diamine	experimental	nan	nan	124-09-4
OQLKNTOKMBVBKV-UHFFFAOYSA-N	DB03808	Hexamidine	approved;investigational	S03AA05;D08AC04;R02AA18;R01AX07;S01AX08	nan	3811-75-4
ZRYHPQCHHOKSMD-UHFFFAOYSA-N	DB06787	Hexocyclium	approved	A03AB10	Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more favorable side effect profiles.	6004-98-4
IHFBPDAQLQOCBX-UHFFFAOYSA-N	DB14008	Hispidulin	experimental	nan	Hispidulin (4',5,7-trihydroxy-6-methoxyflavone) is a potent benzodiazepine (BZD) receptor ligand with positive allosteric properties [A32513].	1447-88-7
NTYJJOPFIAHURM-UHFFFAOYSA-N	DB05381	Histamine	approved;investigational	L03AX14;V04CG03	A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.	51-45-6
ZTVIKZXZYLEVOL-MCOXGKPRSA-N	DB11181	Homatropine	approved	S01FA05	Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions. Homatropine is included in subtherapeutic amounts as homatropine methylbromide to discourage deliberate overdosage. Homatropine hydrobromide has been administered as ophthalmic solutions as a cycl	87-00-3
FVYXIJYOAGAUQK-UHFFFAOYSA-N	DB19283	Honokiol	investigational	nan	Honokiol is under investigation in clinical trial NCT00966953 (Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.).	35354-74-6
ZRJBHWIHUMBLCN-YQEJDHNASA-N	DB04864	Huperzine A	approved;investigational;withdrawn	nan	Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss _Huperzia serrata_. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.	102518-79-6
RPTUSVTUFVMDQK-UHFFFAOYSA-N	DB01275	Hydralazine	approved;investigational	C02DB02;C02LG02	Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was	86-54-4
JZUFKLXOESDKRF-UHFFFAOYSA-N	DB00999	Hydrochlorothiazide	approved;investigational;vet_approved	C09BX03;C03AX01;C03AB03;C09DX03;C03EA01;C09DX06;C09XA52;G01AE10;C09DX01;C03AA03;C09XA54;C09DX08;C09DX07	Hydrochlorothiazide is the most commonly prescribed thiazide diuretic.[A185138] It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors.[A185138] Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February	58-93-5
LLPOLZWFYMWNKH-CMKMFDCUSA-N	DB00956	Hydrocodone	approved;illicit;investigational	R05DA03;N02AJ22;N02AJ23	Hydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations. Hydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain. The FDA first approved Hydrocodone for	125-29-1
JYGXADMDTFJGBT-VWUMJDOOSA-N	DB00741	Hydrocortisone	approved;investigational;vet_approved	S01CB03;A01AC03;S01BA02;S01CA03;D07AA02;S01BB01;D07XA01;D07BA04;S02CA03;A07EA02;S02BA01;R01AD60;H02AB09;D07CA01;S03CA04;C05AA01	Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex.[A188387] Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone.[A188420] Hydrocortisone was granted FDA approval on 5 August 1952.[L10574]	50-23-7
DMDGGSIALPNSEE-UHFFFAOYSA-N	DB00774	Hydroflumethiazide	approved;withdrawn	C03AA02;G01AE10;C03AH02;C03AB02	A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)	135-09-1
WVLOADHCBXTIJK-YNHQPCIGSA-N	DB00327	Hydromorphone	approved;illicit;investigational	N02AA53;N02AA03;N02AG04	Hydromorphone is a pure opioid,[A176468] a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound.[A176471] Even though hydromorphone does not pr	466-99-9
QIGBRXMKCJKVMJ-UHFFFAOYSA-N	DB09526	Hydroquinone	approved;investigational	D11AX11	Hydroquinone is a topical lightening product found in OTC products, and is used to correct skin discoloration associated with disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention, sunspots, and freckles. It can be used alone, but is more frequently found in combination with other agents such as alpha-hydroxy acids, corticosteroids, retinoids, or sunscreen. Hydroquinone has come under scrutiny due to several complications associated with its use, including dermal ir	123-31-9
XXSMGPRMXLTPCZ-UHFFFAOYSA-N	DB01611	Hydroxychloroquine	approved;investigational	P01BA02	Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.[A183047] Hydroxychloroquine is an aminoquinoline like [chloroquine].[L8072] It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus.[L8072] Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely.[L8072] It was developed during World War II as a 	118-42-3
ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	DB04707	Hydroxyfasudil	experimental	nan	nan	105628-72-6
DBPWSSGDRRHUNT-CEGNMAFCSA-N	DB14570	Hydroxyprogesterone	investigational	G03FA02;G03DA03	nan	68-96-2
ZQDWXGKKHFNSQK-UHFFFAOYSA-N	DB00557	Hydroxyzine	approved;investigational	N05BB01;N05BB51	Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus.[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in al	68-88-2
HSHNITRMYYLLCV-UHFFFAOYSA-N	DB07118	Hymecromone	investigational	A05AX02	nan	90-33-5
IWBJJCOKGLUQIZ-HQKKAZOISA-N	DB01892	Hyperforin	investigational;nutraceutical	nan	Hyperforin is a phytochemical generated by the plants of the Hypericum family. One of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.	11079-53-1
BTXNYTINYBABQR-UHFFFAOYSA-N	DB13014	Hypericin	investigational	nan	Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.	548-04-9
SSNQAUBBJYCSMY-KNTMUCJRSA-N	DB07905	Hypothemycin	experimental	nan	nan	76958-67-3
JBJYTZXCZDNOJW-JLHYYAGUSA-N	DB03083	IC261	experimental	nan	nan	nan
BVVFOLSZMQVDKV-KXQIQQEYSA-N	DB03860	ICI-164384	experimental	nan	nan	98007-99-9
LVMAULGVWBINFP-UHFFFAOYSA-N	DB18087	IDRX-42	investigational	nan	nan	2590556-80-0
QARLNMDDSQMINK-BVRKHOPBSA-N	DB18901	INCB-086550	investigational	nan	INCB-086550 is under investigation in clinical trial NCT04629339 (Study of INCB086550 in Select Solid Tumors).	2230911-59-6
HFLCERPZYCWLSZ-VKONIRKNSA-N	DB04609	INHIBITOR Q8467 OF DUPONT MERCK	experimental	nan	nan	nan
XUMALORDVCFWKV-IBGZPJMESA-N	DB16296	IPI-549	investigational	nan	IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma).	1693758-51-8
QVRVXSZKCXFBTE-KPVNRNJOSA-N	DB14900	ISO-1 F-18	investigational	nan	ISO-1 F-18 is under investigation in clinical trial NCT00968656 (Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1).	945992-47-2
AUHWQSZMVMMRLM-UHFFFAOYSA-N	DB07947	ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE	experimental	nan	nan	nan
UILYPHAKDBTKQV-UFYCRDLUSA-N	DB08003	ISOTHIAZOLIDINONE ANALOG	experimental	nan	nan	nan
IXZOHGPZAQLIBH-NRFANRHFSA-N	DB12101	Iberdomide	investigational	nan	Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.	1323403-33-3
XYFPWWZEPKGCCK-GOSISDBHSA-N	DB09053	Ibrutinib	approved;investigational	L01EL01	Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials.[A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in April 2023, the drug manufacturer withdrew the accelerated approvals 	936563-96-1
ZJVFLBOZORBYFE-UHFFFAOYSA-N	DB05266	Ibudilast	investigational	R03DC04	Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.	50847-11-5
HEFNNWSXXWATRW-UHFFFAOYSA-N	DB01050	Ibuprofen	approved;investigational	C01EB16;R02AX02;N02AJ19;M01AE51;G02CC01;M01AE01;M02AA13;N02AJ08;N02AJ23	Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics.[A39074] The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin.[A39075] Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID.[	15687-27-1
WGNWEPPRWQKSKI-AIEDFZFUSA-N	DB19451	Ibuzatrelvir	investigational	nan	Ibuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but Are at Risk for Severe Disease).	2755812-39-4
HWJPWWYTGBZDEG-UHFFFAOYSA-N	DB06358	Iclaprim	investigational	J01EA03	nan	192314-93-5
QQLKULDARVNMAL-UHFFFAOYSA-N	DB11737	Icotinib	investigational	L01EB08	Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).	610798-31-7
YBAWYTYNMZWMMJ-UHFFFAOYSA-N	DB11957	Idalopirdine	investigational	nan	Idalopirdine has been used in trials studying the treatment of Cognition, Schizophrenia, and Alzheimer's Disease.	467459-31-0
TVTXCJFHQKSQQM-LJQIRTBHSA-N	DB12325	Idasanutlin	investigational	nan	Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia.	1229705-06-9
HPMRFMKYPGXPEP-UHFFFAOYSA-N	DB12551	Idazoxan	investigational	nan	Idazoxan has been used in trials studying the basic science of Molecular Imaging, Alzheimer Disease, and Major Depressive Disorder.	79944-58-4
IFSDAJWBUCMOAH-HNNXBMFYSA-N	DB09054	Idelalisib	approved;investigational	L01EM01	Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be use	870281-82-6
JJKOTMDDZAJTGQ-DQSJHHFOSA-N	DB19895	Idoxifene	experimental	nan	Idoxifene is a small molecule drug. Idoxifene has a monoisotopic molecular weight of 523.14 Da.	116057-75-1
UYNVMODNBIQBMV-UHFFFAOYSA-N	DB08954	Ifenprodil	approved;investigational;withdrawn	C04AX28	N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. Binding at the LBD of the agonists glycine (or D-seri	23210-56-2
OYFMQDVLFYKOPZ-UHFFFAOYSA-N	DB16191	Ifidancitinib	investigational	nan	Ifidancitinib is under investigation in clinical trial NCT03585296 (A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis).	1236667-40-5
UQTPDWDAYHAZNT-AWEZNQCLSA-N	DB12784	Ilginatinib	investigational	nan	NS-018 has been used in trials studying the treatment of Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, and Post-Essential Thrombocythemia Myelofibrosis.	1239358-86-1
NITYDPDXAAFEIT-DYVFJYSZSA-N	DB02255	Ilomastat	experimental	nan	Ilomastat is a broad-spectrum matrix metalloproteinase inhibitor.	142880-36-2
XMXHEBAFVSFQEX-UHFFFAOYSA-N	DB04946	Iloperidone	approved;investigational	N05AX14	Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.[A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors.[A263547] Iloperidone is currently used to treat schizophrenia and manic or mixed episodes associated with bipolar disorder.[L50527]	133454-47-4
HIFJCPQKFCZDDL-ACWOEMLNSA-N	DB01088	Iloprost	approved;investigational	B01AC11	Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived.[A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47.[L50146] It is a potent vasodilator with reported anti-thrombotic properties.[A263316] Iloprost is available as an inhaled solution and intravenous formulations. It is used to treat pulmonary arterial hy	78919-13-8
WPHKIQPVPYJNAX-UHFFFAOYSA-N	DB11694	Ilorasertib	investigational	nan	Ilorasertib has been used in trials studying the treatment of Myelodysplasia, Solid Neoplasm, Advanced Cancers, Advanced Solid Tumors, and Acute Myelogenous Leukemia, among others.	1227939-82-3
NCWQLHHDGDXIJN-UHFFFAOYSA-N	DB16192	Imaradenant	investigational	nan	Imaradenant is under investigation in clinical trial NCT03381274 (Oleclumab (MEDI9447) Egfrm NSCLC Novel Combination Study).	1321514-06-0
KTUFNOKKBVMGRW-UHFFFAOYSA-N	DB00619	Imatinib	approved;investigational	L01EA01	"Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001.[A249305] It was deemed a ""miracle drug"" due to its clinical success, as oncologist Dr. Brian noted that ""complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy"".[A249315]. The discovery of imatinib also established a new group of therapy"	152459-95-5
VXMYWVMXSWJFCV-UHFFFAOYSA-N	DB20144	Imazodan	experimental	nan	Imazodan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Imazodan is a cardiac stimulant, pimobendan derivative. Imazodan has a monoisotopic molecular weight of 240.1 Da.	84243-58-3
YWTYJOPNNQFBPC-UHFFFAOYSA-N	DB11421	Imidacloprid	experimental;vet_approved	nan	Imidacloprid is a neonicotinoid, which is a class of neuro-active insecticides modeled after nicotine. Imidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise, Prothor, and Winner. It is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, and a systemic insecticide.	105827-78-9
ZSKVGTPCRGIANV-ZXFLCMHBSA-N	DB01598	Imipenem	approved;investigational	J01DH51;J01DH56	Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins.[A15389] Imipenem is commonly used in combin	64221-86-9
BCGWQEUPMDMJNV-UHFFFAOYSA-N	DB00458	Imipramine	approved;investigational	N06AA02	Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such a	50-49-7
QCCHBHSAIQIQGO-UHFFFAOYSA-N	DB19544	Imirestat	experimental	nan	Imirestat is a small molecule drug. The usage of the INN stem '-restat' in the name indicates that Imirestat is a aldose reductase inhibitor. Imirestat has a monoisotopic molecular weight of 286.06 Da.	89391-50-4
MURRAGMMNAYLNA-UHFFFAOYSA-N	DB20379	Impromidine	experimental	nan	Impromidine is a small molecule drug. Impromidine has a monoisotopic molecular weight of 321.17 Da.	55273-05-7
SGEUNORSOZVTOL-CABZTGNLSA-N	DB15275	Inavolisib	approved;investigational	nan	_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation.[A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor tyrosine kinase signaling, ree	2060571-02-8
QZZUEBNBZAPZLX-QFIPXVFZSA-N	DB05039	Indacaterol	approved;investigational	R03AC18;R03AL04;R03AL12;R03AK14	Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.	312753-06-3
SADQVAVFGNTEOD-UHFFFAOYSA-N	DB08953	Indalpine	approved;withdrawn	nan	Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.	63758-79-2
NDDAHWYSQHTHNT-UHFFFAOYSA-N	DB00808	Indapamide	approved;investigational	C03BA11;C09BX01;G01AE10;C10BX13;C09BX06	The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension.[A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally.[A204155] Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be 	26807-65-8
SVFXPTLYMIXFRX-XJKSGUPXSA-N	DB17032	Indatraline	experimental	nan	Indatraline is a nonselective monoamine reuptake inhibitor.[A253022]	86939-10-8
SOLIIYNRSAWTSQ-UHFFFAOYSA-N	DB06169	Indibulin	investigational	nan	nan	204205-90-3
CBVCZFGXHXORBI-PXQQMZJSSA-N	DB00224	Indinavir	approved	J05AE02	A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]	150378-17-9
CRDNMYFJWFXOCH-BUHFOSPRSA-N	DB12379	Indirubin	investigational	nan	Indirubin is under investigation in clinical trial NCT01735864 (Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment).	479-41-4
HBDSHCUSXQATPO-BGBJRWHRSA-N	DB02052	Indirubin-3'-monoxime	experimental	nan	nan	nan
IHBOEHLUIBMBMY-YPKPFQOOSA-N	DB02519	Indirubin-5-sulphonate	experimental	nan	nan	244021-67-8
SETFNECMODOHTO-UHFFFAOYSA-N	DB06370	Indisulam	investigational	nan	nan	165668-41-7
LZCQFJKUAIWHRW-UHFFFAOYSA-N	DB19499	Indolidan	experimental	nan	Indolidan is a small molecule drug. The usage of the INN stem '-dan' in the name indicates that Indolidan is a cardiac stimulant, pimobendan derivative. Indolidan has a monoisotopic molecular weight of 257.12 Da.	100643-96-7
CGIGDMFJXJATDK-UHFFFAOYSA-N	DB00328	Indomethacin	approved;investigational	S01CC02;M01AB51;S01BC01;M02AA23;M01AB01;C01EB03	Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid.[A177871] The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent a	53-86-1
QSQQQURBVYWZKJ-UHFFFAOYSA-N	DB01446	Indopan	experimental;illicit	nan	Indopan (alpha-methyltryptamine) is a stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar. It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.	299-26-3
RJMIEHBSYVWVIN-UHFFFAOYSA-N	DB08951	Indoprofen	approved;withdrawn	M01AE10	A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.	31842-01-0
JXZZEXZZKAWDSP-UHFFFAOYSA-N	DB08950	Indoramin	approved;withdrawn	C02CA02	Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.	26844-12-2
VZNNJZGVQVNHCM-CDNLURBZSA-N	DB04255	Inhibitor BEA388	experimental	nan	nan	nan
AJZAPEZJWWQJHC-UWNKZCSISA-N	DB04547	Inhibitor BEA409	experimental	nan	nan	nan
FOBRXMROTNVGST-CXPJILFNSA-N	DB02683	Inhibitor Bea428	experimental	nan	nan	nan
YZSCPLGKKMSBMV-UHFFFAOYSA-N	DB21584	Inixaciclib	experimental	nan	Inixaciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Inixaciclib is a cyclin dependant kinase inhibitor. Inixaciclib has a monoisotopic molecular weight of 480.24 Da.	2370913-42-9
CDPROXZBMHOBTQ-SJORKVTESA-N	DB19880	Inogatran	experimental	nan	Inogatran is a small molecule drug. Inogatran has a monoisotopic molecular weight of 438.3 Da.	155415-08-0
GRSZFWQUAKGDAV-KQYNXXCUSA-N	DB04566	Inosinic Acid	investigational	nan	Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety.	131-99-7
JJZFWROHYSMCMU-UHFFFAOYSA-N	DB12680	Intepirdine	investigational	nan	Intepirdine has been used in trials studying the treatment of Alzheimer's Disease.	607742-69-8
AXXYLTBQIQBTES-BYPYZUCNSA-N	DB02818	Iodo-Willardiine	experimental	nan	nan	nan
GRZXWCHAXNAUHY-NSISKUIASA-N	DB11743	Ipatasertib	investigational	nan	Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.	1001264-89-6
YBBUGSYNPXTSGW-UHFFFAOYSA-N	DB21479	Ipivivint	experimental	nan	Ipivivint is a small molecule drug. The usage of the INN stem '-vivint' in the name indicates that Ipivivint is a Wnt signaling inhibitor. Ipivivint has a monoisotopic molecular weight of 464.19 Da.	1481617-15-5
OEXHQOGQTVQTAT-BHIXFJMTSA-N	DB00332	Ipratropium	approved;investigational	R03BB01;R01AX03;R03AL01;R03AL02	Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.[A176939] It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption.[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891]	60205-81-4
NYMGNSNKLVNMIA-UHFFFAOYSA-N	DB04818	Iproniazid	approved;withdrawn	N06AF05	Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.	54-92-2
TZJUVVIWVWFLCD-UHFFFAOYSA-N	DB20133	Ipsapirone	experimental	nan	Ipsapirone is a small molecule drug. The usage of the INN stem '-pirone' in the name indicates that Ipsapirone is a anxiolytic, buspirone derivative. Ipsapirone has a monoisotopic molecular weight of 401.15 Da.	95847-70-4
RENRQMCACQEWFC-UGKGYDQZSA-N	DB16200	Iptacopan	approved;investigational	L04AJ08	Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B.[A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase.[A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene. Due to this mutation, all pro	1644670-37-0
YOSHYTLCDANDAN-UHFFFAOYSA-N	DB01029	Irbesartan	approved;investigational	C09CA04;C09DB05;C09DA04;C09DX07	Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.[L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459] Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]	138402-11-6
XUKROCVZGZNGSI-CQSZACIVSA-N	DB12900	Irdabisant	investigational	nan	Irdabisant has been used in trials studying Cognitive Impairment.	1005402-19-6
UWKQSNNFCGGAFS-XIFFEERXSA-N	DB00762	Irinotecan	approved;investigational	L01CE02	Irinotecan is a topoisomerase inhibitor used for chemotherapy. It is a water-soluble analogue of [camptothecin], which is extracted from the Chinese tree _Camptotheca acuminate_.[A263376] The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility.[A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer.[A263376] Approved by the FDA in 1996,[A263366] irinotec	97682-44-5
DSLPMJSGSBLWRE-UHFFFAOYSA-N	DB02292	Irosustat	investigational	nan	Irosustat has been investigated for the treatment of Metastatic Breast Cancer and Locally Advanced Breast Cancer.	288628-05-7
MUCZHBLJLSDCSD-UHFFFAOYSA-N	DB00677	Isoflurophate	approved;withdrawn	nan	An irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)	55-91-4
DXDRHHKMWQZJHT-FPYGCLRLSA-N	DB03285	Isoliquiritigenin	experimental	nan	Isoliquiritigenin is a precursor to several flavonones in many plants.	961-29-5
QRXWMOHMRWLFEY-UHFFFAOYSA-N	DB00951	Isoniazid	approved;investigational	J04AM04;J04AM01;J04AM03;J04AM02;J04AM09;J04AM06;J04AC01;J04AM05;J04AM07;J04AM08;J04AM12;J04AC51	Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.	54-85-3
IZQSVPBOUDKVDZ-UHFFFAOYSA-N	DB16767	Isorhamnetin	experimental	nan	nan	480-19-3
SHGAZHPCJJPHSC-XFYACQKRSA-N	DB00982	Isotretinoin	approved;investigational	D10AD04;D10AD54;D10BA01	Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued.[L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States.[L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]	4759-48-2
VYKCLMALANGCDF-STQMWFEESA-N	DB21703	Istisociclib	investigational	nan	Istisociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Istisociclib is a cyclin dependant kinase inhibitor. Istisociclib is under investigation in clinical trial NCT04718675 (A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)). Istisociclib has a monoisotopic molecular weight of 287.21 Da.	2416873-83-9
IQVRBWUUXZMOPW-PKNBQFBNSA-N	DB11757	Istradefylline	approved;investigational	N04CX01	Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.[A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.[A184067] This region of the brain is highly involved in motor control.[A184067] Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease.[L8237] This drug was 	155270-99-8
LQKQLKMTJOMCMJ-UHFFFAOYSA-N	DB19109	Isuzinaxib	investigational	nan	Isuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI).	1270084-92-8
KTBSXLIQKWEBRB-UHFFFAOYSA-N	DB12154	Itacitinib	investigational	L04AF05	Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.	1334298-90-6
DNBCBAXDWNDRNO-GDNZZTSVSA-N	DB16756	Ivarmacitinib	investigational	nan	Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis,[L40584] rheumatoid arthritis,[L40589] psoriatic arthritis,[L40594] graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcera	1445987-21-2
MXAYKZJJDUDWDS-LBPRGKRZSA-N	DB09570	Ixazomib	approved;investigational	L01XG03	Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.[A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.[A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.[L51244] It was also	1072833-77-2
DADAEARVGOQWHV-OSYLJGHBSA-N	DB16660	Izencitinib	investigational	nan	Izencitinib is under investigation in clinical trial NCT03920254 (TD-1473 Long-term Safety (LTS) Ulcerative Colitis (UC) Study).	2051918-33-1
CUFQBQOBLVLKRF-RZDMPUFOSA-N	DB02668	JE-2147	experimental	nan	nan	186538-00-1
GUBJNPWVIUFSTR-UHFFFAOYSA-N	DB17140	JNJ-28312141	experimental	nan	nan	885692-52-4
JRWCBEOAFGHNNU-UHFFFAOYSA-N	DB13113	JNJ-38877605	investigational	nan	JNJ-38877605 has been used in trials studying the treatment of Neoplasms.	943540-75-8
DNVXATUJJDPFDM-KRWDZBQOSA-N	DB17021	JQ1	experimental	nan	First-in-class potent and selective inhibitor of the BRD4 signaling pathway.[A252967]	1268524-70-4
VTGBZWHPJFMTKS-UHFFFAOYSA-N	DB17033	JTC-801 free base	experimental	nan	An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]	244218-93-7
KNPYQCPWTWANOG-RUZDIDTESA-N	DB18174	JTT-251	investigational	nan	nan	1627957-25-8
ARIOBGGRZJITQX-UHFFFAOYSA-N	DB07664	K-00546	experimental	nan	nan	443798-47-8
KOZFSFOOLUUIGY-SOLYNIJKSA-N	DB02152	K-252a	experimental	nan	nan	97161-97-2
RHJLQMVZXQKJKB-FPHSVDBKSA-N	DB17760	K-777	experimental	nan	nan	502960-90-9
ZMQSLMZOWVGBSM-GXTWGEPZSA-N	DB16511	KAND567	investigational	nan	KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908]. Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].	911715-90-7
OZYQIQVPUZANTM-UHFFFAOYSA-N	DB03176	KB-141	experimental	nan	An anticholesteremic agent.	219691-94-8
HHCSNTXVZDWIGT-CMDGGOBGSA-N	DB16637	KW-2450 free base	investigational	nan	nan	904899-25-8
IYRMWMYZSQPJKC-UHFFFAOYSA-N	DB01852	Kaempherol	experimental	nan	nan	520-18-3
VLSMHEGGTFMBBZ-OOZYFLPDSA-N	DB21189	Kainic acid	experimental	nan	Kainic acid is a small molecule drug. Kainic acid has a monoisotopic molecular weight of 213.1 Da.	487-79-6
OJCFZTVYDSKXNM-GXSJLCMTSA-N	DB08040	Kelatorphan	experimental	nan	nan	92175-57-0
YQEZLKZALYSWHR-UHFFFAOYSA-N	DB01221	Ketamine	approved;investigational;vet_approved	N01AX03	Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surge	6740-88-1
FPCCSQOGAWCVBH-UHFFFAOYSA-N	DB12465	Ketanserin	investigational	C02KD01	Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.	74050-98-9
HQBZLVPZOGIAIQ-SDDDUWNISA-N	DB20132	Ketazocine	experimental	nan	Ketazocine is a small molecule drug. The usage of the INN stem '-azocine' in the name indicates that Ketazocine is a narcotic antagonist/agonist related to 6,7-benzomorphan. Ketazocine has a monoisotopic molecular weight of 285.17 Da.	36292-69-0
DKYWVDODHFEZIM-UHFFFAOYSA-N	DB01009	Ketoprofen	approved;investigational;vet_approved	M01AE03;M02AA10;M01AE53	Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.	22071-15-4
OZWKMVRBQXNZKK-UHFFFAOYSA-N	DB00465	Ketorolac	approved;investigational	M01AB15;S01FB51;S01BC05	Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.[L6358][L6508][L11055][L3674][L11070] It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis.[L6520] Impressively, ketorolac has a similar efficacy to 	74103-06-3
ZCVMWBYGMWKGHF-UHFFFAOYSA-N	DB00920	Ketotifen	approved;investigational	S01GX08;R06AX17	Ketotifen is a benzocycloheptathiophene derivative[A231204] with potent antihistaminic and mast cell stabilizing properties. It has a similar structure to some other first-generation antihistamines such as [cyproheptadine] and [azatadine].[A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.[A231204] In the US, it is now used in an over-the-counter ophthalmic formulation for the treatment of itchy eye	34580-13-7
IEMDOFXTVAPVLX-YWQHLDGFSA-N	DB09309	Kitasamycin	experimental	nan	Kitasamycin is a macrolide antibiotic derived from <em>Streptomyces kitasatoensis</em>.	1392-21-8
AOMZDQMIOCTPQP-CFSTZTOESA-N	DB02009	L-756423	investigational	nan	nan	216863-66-0
JNUGFGAVPBYSHF-UHFFFAOYSA-N	DB07227	L-778123	experimental	nan	nan	183499-57-2
GTOFKXZQQDSVFH-SECBINFHSA-N	DB07506	L-BENZYLSUCCINIC ACID	experimental	nan	nan	nan
KUZKVXUOMSVPOA-BQBZGAKWSA-N	DB01821	L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide	experimental	nan	nan	nan
IUFRDGFKAVLPFZ-CSMHCCOUSA-N	DB02077	L-N(omega)-nitroarginine-(4R)-amino-L-proline amide	experimental	nan	nan	nan
QUMWKKVIZAIAHU-LBPRGKRZSA-N	DB17816	LAS-191954	experimental	nan	nan	1403947-26-1
UFPFGVNKHCLJJO-SSKFGXFMSA-N	DB12085	LCL-161	investigational	nan	LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.	1005342-46-0
CDOVNWNANFFLFJ-UHFFFAOYSA-N	DB18051	LDN-193189	experimental	nan	nan	1062368-24-4
SLXTWXQUEZSSTJ-UHFFFAOYSA-N	DB01941	LG-100268	experimental	nan	LG-100268 is a retinoid X receptor (RXR) selective compound.	153559-76-3
JMPZTWDLOGTBPM-OUQSKUGOSA-N	DB05785	LGD-1550	experimental	nan	LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.	178600-20-9
VRQXRVAKPDCRCI-ZNMIVQPWSA-N	DB14943	LGH-447	investigational	nan	LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies).	1210608-43-7
JQUBXCDDRXAMLF-IXPVHAAZSA-N	DB18018	LJ-2698	experimental	nan	nan	945457-84-1
PWPNYABQEOGNNC-UHFFFAOYSA-N	DB16009	LX-7101	investigational	nan	LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).	1192189-69-7
HRJWTAWVFDCTGO-UHFFFAOYSA-N	DB11913	LY-2090314	investigational	nan	Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.	603288-22-8
GZNIYOXWFCDBBJ-UHFFFAOYSA-N	DB17035	LY-2183240	experimental	nan	LY-2183240 is an inhibitor of endocannabinoid reuptake/breakdown.[A253037]	874902-19-9
FYXRSVDHGLUMHB-UHFFFAOYSA-N	DB12690	LY-2584702	investigational	nan	LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.	1082949-67-4
MJQMRGWYPNIERM-HNNXBMFYSA-N	DB13065	LY-2811376	investigational	nan	LY2811376 has been used in trials studying the basic science of Alzheimer's Disease.	1194044-20-6
GKJCVYLDJWTWQU-CXLRFSCWSA-N	DB13022	LY-2874455	investigational	nan	LY2874455 has been used in trials studying the treatment of Advanced Cancer.	1254473-64-7
NIDRNVHMMDAAIK-YPMLDQLKSA-N	DB12547	LY-2886721	investigational	nan	LY2886721 has been used in trials studying the basic science of Alzheimer's Disease.	1262036-50-9
CZQHHVNHHHRRDU-UHFFFAOYSA-N	DB02656	LY-294002	experimental	nan	Specific inhibitor of phosphatidylinositol 3-kinase.	154447-36-6
ACCFLVVUVBJNGT-AWEZNQCLSA-N	DB12167	LY-3023414	investigational	nan	LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.	1386874-06-1
RBSGUQYXRDKPAE-QFIPXVFZSA-N	DB12858	LY-377604	investigational	nan	Ly377604 has been used in trials studying the treatment of Obesity.	204592-94-9
SGUAFYQXFOLMHL-UHFFFAOYSA-N	DB00598	Labetalol	approved;investigational	C07BG01;C07CG01;C07AG01	Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture.[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]	36894-69-6
VPPJLAIAVCUEMN-GFCCVEGCSA-N	DB06218	Lacosamide	approved;investigational	N03AX18	Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels.[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.[A262681] It was granted approval by Health Canada in September 2010.[L49206]	175481-36-4
AQGNHMOJWBZFQQ-UHFFFAOYSA-N	DB19676	Laduviglusib	experimental	nan	Laduviglusib is a small molecule drug. Laduviglusib has a monoisotopic molecular weight of 464.1 Da.	252917-06-9
FPKOGTAFKSLZLD-FQEVSTJZSA-N	DB20451	Lamifiban	experimental	nan	Lamifiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Lamifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Lamifiban has a monoisotopic molecular weight of 468.2 Da.	144412-49-7
WKDNQONLGXOZRG-HRNNMHKYSA-N	DB14814	Lanabecestat	investigational	nan	Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).	1383982-64-6
FWUQWDCOOWEXRY-ZDUSSCGKSA-N	DB11889	Lanicemine	investigational	nan	Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.	153322-05-5
MJIHNNLFOKEZEW-UHFFFAOYSA-N	DB00448	Lansoprazole	approved;investigational	A02BC03;A02BD02;A02BD07;A02BD09;A02BD10;A02BD03;A02BC53	Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.[A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.[A177053]	103577-45-3
BCFGMOOMADDAQU-UHFFFAOYSA-N	DB01259	Lapatinib	approved;investigational	L01EH01	Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation dom	231277-92-2
NXFFJDQHYLNEJK-CYBMUJFWSA-N	DB11629	Laropiprant	approved;withdrawn	nan	Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.	571170-77-9
NYNZQNWKBKUAII-KBXCAEBGSA-N	DB14723	Larotrectinib	approved;investigational	L01EX12	Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.[L49821] Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress 	1223403-58-4
XEDHVZKDSYZQBF-UHFFFAOYSA-N	DB11732	Lasmiditan	approved;investigational	N02CC08	Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022.[L43997] Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety. Their use is not devoid of concerns, however, and their vaso	439239-90-4
GXESHMAMLJKROZ-IAPPQJPRSA-N	DB06202	Lasofoxifene	approved;investigational;withdrawn	G03XC03	Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. Later Fablyn was developed as a result of a research c	180916-16-9
QMMMGQKKOKYDMN-UHFFFAOYSA-N	DB20829	Lauroguadine	experimental	nan	Lauroguadine is a small molecule drug. Lauroguadine has a monoisotopic molecular weight of 376.3 Da.	135-43-3
KKVZONPEMODBBG-UHFFFAOYSA-N	DB07873	Lauryl alcohol diphosphonic acid	experimental	nan	nan	16610-63-2
RRMJMHOQSALEJJ-UHFFFAOYSA-N	DB16216	Lazertinib	approved;investigational	L01EB09	Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).[A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]	1903008-80-9
NRPQELCNMADTOZ-OAQYLSRUSA-N	DB12540	Lecozotan	investigational	nan	Lecozotan has been used in trials studying the treatment of Alzheimer Disease.	434283-16-6
VHOGYURTWQBHIL-UHFFFAOYSA-N	DB01097	Leflunomide	approved;investigational	L04AK01	Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.	75706-12-6
MUGXRYIUWFITCP-PGRDOPGGSA-N	DB11951	Lemborexant	approved;investigational	N05CJ02	"Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to ""switch on"" sleep-related circuits, but rather an inability to ""switch-off"" wake-promoting circuits.[A189006,A189030] Whereas historically popular pharmacologic treatments for insomnia (e.g. [zopiclone"	1369764-02-2
YCHYFHOSGQABSW-RTBURBONSA-N	DB12193	Lenabasum	investigational	nan	Ajulemic acid has been used in trials studying the treatment of Cystic Fibrosis, Dermatomyositis, and Diffuse Cutaneous Systemic Sclerosis.	137945-48-3
GOTYRUGSSMKFNF-UHFFFAOYSA-N	DB00480	Lenalidomide	approved;investigational	L04AX04	Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.[A228553] It is a 4-amino-glutamyl analogue of [thalidomide] [A228543] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms.[A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including len	191732-72-6
MWKYMZXCGYXLPL-ZDUSSCGKSA-N	DB16217	Leniolisib	approved;investigational	L03AX22	Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections.[A258473,A258463] Leniolisib works to inhibit hyperactive PI3Kδ.[L45	1354690-24-6
BBIPVJCGIASXJB-PKTZIBPZSA-N	DB15039	Lenrispodun	investigational	nan	ITI-214 is under investigation in clinical trial NCT03489772 (Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement).	1160521-50-5
SDAMYSWGWHXMRT-MRXNPFEDSA-N	DB20964	Lensiprazine	experimental	nan	Lensiprazine is a small molecule drug. Lensiprazine has a monoisotopic molecular weight of 422.21 Da.	327026-93-7
WOSKHXYHFSIKNG-UHFFFAOYSA-N	DB09078	Lenvatinib	approved;investigational	L01EX08	Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα)	417716-92-8
QQOPOYMFJLUSBI-GFCCVEGCSA-N	DB21646	Lepzacitinib	investigational	nan	Lepzacitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Lepzacitinib is a Janus kinase inhibitor. Lepzacitinib is under investigation in clinical trial NCT05432596 (Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis). Lepzacitinib has a monoisotopic molecular weight of 355.16 Da.	2321488-47-3
YPJRHEKCFKOVRT-UHFFFAOYSA-N	DB16218	Lerociclib	investigational	nan	Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer).	1628256-23-4
MCPUZZJBAHRIPO-UHFFFAOYSA-N	DB11649	Lersivirine	investigational	nan	Lersivirine has been used in trials studying the treatment of HIV-1.	473921-12-9
HGCAUCAWEADMPM-RXMQYKEDSA-N	DB02386	Leucine Phosphonic Acid	experimental	nan	nan	nan
VNYSSYRCGWBHLG-AMOLWHMGSA-N	DB12961	Leukotriene B4	investigational	nan	Leukotriene B4 has been used in trials studying the treatment of HIV Infections.	71160-24-2
YEESKJGWJFYOOK-IJHYULJSSA-N	DB11858	Leukotriene D4	investigational	nan	Leukotriene D4 has been used in trials studying the diagnostic of Asthma and Allergic Rhinitis.	73836-78-9
GDBQQVLCIARPGH-ULQDDVLXSA-N	DB16961	Leupeptin	experimental	nan	nan	55123-66-5
OZYUPQUCAUTOBP-QXAKKESOSA-N	DB00504	Levallorphan	approved	nan	An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)	152-02-3
NWIUTZDMDHAVTP-KRWDZBQOSA-N	DB09351	Levobetaxolol	approved	nan	Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.	93221-48-8
IXHBTMCLRNMKHZ-LBPRGKRZSA-N	DB01210	Levobunolol	approved	S01ED03	A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.	47141-42-4
GJJFMKBJSRMPLA-DZGCQCFKSA-N	DB08918	Levomilnacipran	approved	N06AX28	Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans.[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressi	96847-54-0
JAQUASYNZVUNQP-USXIJHARSA-N	DB00854	Levorphanol	approved	nan	A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	77-07-6
BGRJTUBHPOOWDU-NSHDSACASA-N	DB16021	Levosulpiride	investigational	N05AL07	nan	23672-07-3
XUIIKFGFIJCVMT-LBPRGKRZSA-N	DB00451	Levothyroxine	approved;investigational	H03AA01;H03AA51	Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland.[F4633] Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T<sub>4</sub> (tetraiodothyronine or thyroxine) and T<sub>3</sub> (triiodothyronine or [DB00279]), resulting in diminished down-stream effects 	51-48-9
VCIBGDSRPUOBOG-QFIPXVFZSA-N	DB14878	Liafensine	investigational	nan	Liafensine is under investigation in clinical trial NCT00892840 (Multiple-Ascending Dose Study).	1198790-53-2
UGFHIPBXIWJXNA-UHFFFAOYSA-N	DB13066	Liarozole	investigational	nan	Liarozole has been used in trials studying the treatment of Ichthyosis, Lamellar.	115575-11-6
KAZSKMJFUPEHHW-DHZHZOJOSA-N	DB19281	Licochalcone A	experimental	nan	nan	58749-22-7
UAWXGRJVZSAUSZ-UHFFFAOYSA-N	DB04725	Licofelone	experimental	nan	Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.	156897-06-2
XFJAMQQAAMJFGB-ZQGJOIPISA-N	DB15048	Licogliflozin	investigational	nan	Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity).	1291094-73-9
CHFSOFHQIZKQCR-UHFFFAOYSA-N	DB19864	Licostinel	experimental	nan	Licostinel is a small molecule drug. The usage of the INN stem '-stinel' in the name indicates that Licostinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. Licostinel has a monoisotopic molecular weight of 274.95 Da.	153504-81-5
ZBIAKUMOEKILTF-UHFFFAOYSA-N	DB13766	Lidoflazine	approved	C08EX01	nan	3416-26-0
NGFFVZQXSRKHBM-FKBYEOEOSA-N	DB14773	Lifirafenib	investigational	nan	Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).	1446090-79-4
JFOZKMSJYSPYLN-QHCPKHFHSA-N	DB11611	Lifitegrast	approved;investigational	S01XA25	Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both l	1025967-78-5
LTXREWYXXSTFRX-QGZVFWFLSA-N	DB08882	Linagliptin	approved;investigational	A10BH05;A10BD19;A10BD11;A10BD27	Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050]. Linagliptin was approved by the FDA on May 2, 2011[L9557].	668270-12-0
JLYXXMFPNIAWKQ-GNIYUCBRSA-N	DB00431	Lindane	approved;withdrawn	P03AB02	An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head l	58-89-9
MPVGZUGXCQEXTM-UHFFFAOYSA-N	DB06080	Linifanib	investigational	nan	Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.	796967-16-3
OYHQOLUKZRVURQ-HZJYTTRNSA-N	DB14104	Linoleic acid	approved	nan	nan	60-33-3
NVWKNQGHVMMAJW-UHFFFAOYSA-N	DB17235	Linperlisib	investigational	nan	nan	1702816-75-8
KRTIYQIPSAGSBP-ZACQAIPSSA-N	DB14986	Linrodostat	investigational	nan	Linrodostat is under investigation in clinical trial NCT03247283 (Pharmacokinetics and Metabolism Study in Healthy Male Participants).	1923833-60-6
PKCDDUHJAFVJJB-VLZXCDOPSA-N	DB06075	Linsitinib	investigational	nan	An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.	867160-71-2
AUYYCJSJGJYCDS-LBPRGKRZSA-N	DB00279	Liothyronine	approved;investigational;vet_approved	H03AA03;H03AA02	Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine.[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]	6893-02-3
AGBQKNBQESQNJD-SSDOTTSWSA-N	DB00166	Lipoic acid	approved;investigational;nutraceutical	A16AX01	A vitamin-like antioxidant.	1200-22-2
XOQVZSSDIQQUGO-UHFFFAOYSA-N	DB18300	Lirafugratinib	investigational	nan	nan	2549174-42-5
HPODOLXTMDHLLC-QGZVFWFLSA-N	DB14581	Lirametostat	investigational	nan	Potent and selective histone methyltransferase EZH2 inhibitor.	1621862-70-1
FNBXDBIYRAPDPI-BHVANESWSA-N	DB18054	Lisaftoclax	investigational	nan	Lisaftoclax is a novel, orally active, selective and potent BCL-2 inhibitor	2180923-05-9
BKRGVLQUQGGVSM-KBXCAEBGSA-N	DB00589	Lisuride	approved	G02CB02;N02CA07	An ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).	18016-80-3
MJJDYOLPMGIWND-UHFFFAOYSA-N	DB15038	Litoxetine	investigational	nan	Litoxetine is under investigation in clinical trial NCT03397771 (DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence).	86811-09-8
WUECXCBONAGRSA-UHFFFAOYSA-N	DB19521	Lixazinone	experimental	nan	Lixazinone is a small molecule drug. Lixazinone has a monoisotopic molecular weight of 384.22 Da.	94192-59-3
PPHTXRNHTVLQED-UHFFFAOYSA-N	DB06666	Lixivaptan	investigational	nan	nan	168079-32-1
CHHXEZSCHQVSRE-UHFFFAOYSA-N	DB09198	Lobeglitazone	investigational	A10BG04;A10BD26	Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles [A19748]. Unlike [DB01132], which is a dual PP	607723-33-1
MXYUKLILVYORSK-HBMCJLEFSA-N	DB05137	Lobeline	investigational	nan	An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]	90-69-7
IMYHGORQCPYVBZ-NLFFAJNJSA-N	DB09174	Lofentanil	experimental;illicit	nan	Lofentanil is an analog of fentanyl and is one of the most potent opioids available today. It displays most similarity to carfentanil (4-carbomethoxyfentanyl) and is considered to be slightly more potent than this drug.	61380-40-3
SAPNXPWPAUFAJU-UHFFFAOYSA-N	DB13411	Lofepramine	experimental	N06AA07	nan	23047-25-8
KSMAGQUYOIHWFS-UHFFFAOYSA-N	DB04948	Lofexidine	approved;investigational	N07BC04	Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine.[T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than	31036-80-3
ZUQBAQVRAURMCL-DOMZBBRYSA-N	DB12769	Lometrexol	investigational	nan	Lometrexol has been used in trials studying the treatment of Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, and Unspecified Adult Solid Tumor, Protocol Specific.	106400-81-1
MBBCVAKAJPKAKM-UHFFFAOYSA-N	DB08827	Lomitapide	approved;investigational	C10AX12	Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).	182431-12-5
DHMTURDWPRKSOA-RUZDIDTESA-N	DB06448	Lonafarnib	approved	A16AX20	Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by	193275-84-2
VHZPUDNSVGRVMB-RXDLHWJPSA-N	DB16221	Lonaprisan	investigational	nan	Lonaprisan is under investigation in clinical trial NCT00555919 (ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer).	211254-73-8
JNUZADQZHYFJGW-JOCHJYFZSA-N	DB19190	Londamocitinib	investigational	nan	Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high Dose ICS-LABA).	2241039-81-4
RDOIQAHITMMDAJ-UHFFFAOYSA-N	DB00836	Loperamide	approved;investigational	A07DA53;A07DA03	Loperamide is an anti-diarrheal agent that is available as an over-the-counter product for treating diarrhea.[L42785] The drug was first synthesized in 1969 and used medically in 1976.[A251610] It is a highly lipophilic synthetic phenylpiperidine opioid that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and electrolyte loss.[A251610] Loperamide has a chemical structure that is similar to diphenoxylate and haloperidol;[A6249] however, loperamide wor	53179-11-6
KJHKTHWMRKYKJE-SUGCFTRWSA-N	DB01601	Lopinavir	approved;investigational	J05AR10	Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection.[L11163] Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-admin	192725-17-0
JCCNYMKQOSZNPW-UHFFFAOYSA-N	DB00455	Loratadine	approved;investigational	R06AX13	Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis.[A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.[A176441]	79794-75-5
XTTZERNUQAFMOF-QMMMGPOBSA-N	DB04871	Lorcaserin	approved;withdrawn	A08AA11	Lorcaserin (previously APD-356), a highly selective 5HT2C receptor agonist, is used for the treatment of obesity. It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydro	616202-92-7
AQDWDWAYVBQMAM-UHFFFAOYSA-N	DB14883	Lorecivivint	investigational	nan	Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).	1467093-03-3
IIXWYSCJSQVBQM-LLVKDONJSA-N	DB12130	Lorlatinib	approved;investigational	L01ED05	Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. [L13580	1454846-35-5
PSIFNNKUMBGKDQ-UHFFFAOYSA-N	DB00678	Losartan	approved;investigational	C09CA01;C09DA01;C09DB06	Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydro	114798-26-4
KKYABQBFGDZVNQ-UHFFFAOYSA-N	DB12270	Losmapimod	investigational	nan	Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.	585543-15-3
BBTFKAOFCSOZMB-UHFFFAOYSA-N	DB12776	Lotamilast	investigational	nan	E6005 has been used in trials studying the treatment of Atopic Dermatitis.	947620-48-6
PYZOVVQJTLOHDG-FQEVSTJZSA-N	DB20872	Lotrafiban	experimental	nan	Lotrafiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Lotrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Lotrafiban has a monoisotopic molecular weight of 428.24 Da.	171049-14-2
XJGVXQDUIWGIRW-UHFFFAOYSA-N	DB00408	Loxapine	approved;investigational	N05AH01	An antipsychotic agent used in schizophrenia. [PubChem]	1977-10-2
HTODIQZHVCHVGM-JTQLQIEISA-N	DB09196	Lubazodone	experimental	nan	Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was discontinued. It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.	161178-07-0
UQRORFVVSGFNRO-XFWSIPNHSA-N	DB14872	Lucerastat	investigational	nan	Lucerastat is under investigation in clinical trial NCT03425539 (Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease).	141206-42-0
CUDVHEFYRIWYQD-UHFFFAOYSA-N	DB11845	Lucitanib	investigational	nan	Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.	1058137-23-7
HOIIHACBCFLJET-SFTDATJTSA-N	DB06077	Lumateperone	approved;investigational	N05AD10	Schizophrenia is a complex mental illness and impacts approximately 1% of the population.[L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects.[A189093] Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia.[A189093] It has a unique receptor binding profile and d	313368-91-1
KHPKQFYUPIUARC-UHFFFAOYSA-N	DB01283	Lumiracoxib	approved;withdrawn	M01AH06	Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.	220991-20-8
ARBRHWRTXPWZGN-UHFFFAOYSA-N	DB19241	Lunresertib	investigational	nan	nan	2719793-90-3
MQYXUWHLBZFQQO-QGTGJCAVSA-N	DB12622	Lupeol	investigational	nan	Lupeol has been investigated for the treatment of Acne.	545-47-1
PQXKDMSYBGKCJA-CVTJIBDQSA-N	DB08815	Lurasidone	approved;investigational	N05AE05	Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.	367514-87-2
PMQUGSPFUBGJCZ-CHOKWEPUSA-N	DB19200	Luvixasertib	investigational	nan	Luvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer).	1610759-22-2
VAYOSLLFUXYJDT-RDTXWAMCSA-N	DB04829	Lysergic acid diethylamide	illicit;investigational	nan	Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is rem	50-37-3
HXAUJHZZPCBFPN-QGZVFWFLSA-N	DB15431	M-2698	investigational	nan	M-2698 is under investigation in clinical trial NCT01971515 (First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies).	1379545-95-5
XLIBABIFOBYHSV-UHFFFAOYSA-N	DB19205	MAK-683	investigational	nan	nan	1951408-58-4
UKCFUFHREWUXJJ-UHFFFAOYSA-N	DB07765	METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL](METHYL)AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE	experimental	nan	nan	nan
NYNAFINLHQEHKU-UHFFFAOYSA-N	DB07689	METHYL 1-(4-{[(2,4-DIAMINOPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)PIPERIDINE-4-CARBOXYLATE	experimental	nan	nan	nan
MOPRTFSMCQNUCT-CABCVRRESA-N	DB08403	METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID	experimental	nan	nan	nan
USYYNLPEWBGIMJ-ICTDUYRTSA-N	DB15791	MK-0668	experimental	nan	nan	865110-07-2
XCGJIFAKUZNNOR-QCKZDCLWSA-N	DB12852	MK-0752	investigational	nan	Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).	471905-41-6
QKIWQBLNTSQOLY-UHFFFAOYSA-N	DB12238	MK-0777	investigational	nan	MK-0777 has been used in trials studying the treatment of Schizophrenia, Anxiety Disorder, and Generalized Anxiety Disorder.	252977-51-8
JJWKQXNHYDJXKF-UHFFFAOYSA-N	DB13029	MK-0873	investigational	nan	MK-0873 has been used in trials studying the treatment of Rheumatoid Arthritis.	500355-52-2
CJAWPFJGFFNXQI-UHFFFAOYSA-N	DB12111	MK-212	investigational	nan	MK-212 has been used in trials studying the treatment of Alcoholism.	64022-27-1
ULDXWLCXEDXJGE-UHFFFAOYSA-N	DB16828	MK-2206	investigational	nan	nan	1032349-93-1
AZAANWYREOQRFB-SETSBSEESA-N	DB12424	MK-3207	investigational	nan	Mk3207 has been used in trials studying the treatment of Migraine and Migraine Disorders.	957118-49-9
KXDIHAQCVNNLIB-UHFFFAOYSA-N	DB08460	MK-4965	experimental	nan	MK-4965 is an HIV-1 reverse transcriptase inhibitor.	920035-77-4
LCVIRAZGMYMNNT-VVONHTQRSA-N	DB12556	MK-5108	investigational	nan	MK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.	1010085-13-8
FZBAOOQVQXATRL-UHFFFAOYSA-N	DB12999	MK-6186	investigational	nan	MK6186 has been used in trials studying the treatment of HIV-1 Infection.	1034474-19-5
OCKGFTQIICXDQW-ZEQRLZLVSA-N	DB11968	MK-7145	investigational	nan	MK-7145 has been used in trials studying the treatment of Hypertension and Renal Insufficiency.	1255204-84-2
GMIZZEXBPRLVIV-SECBINFHSA-N	DB11899	MK-8776	investigational	nan	Sch 900776 has been used in trials studying the treatment of Neoplasms, Hodgkin Disease, Adult Erythroleukemia, Lymphoma, Non-Hodgkin, and Myelogenous Leukemia, Acute, among others.	891494-63-6
QAOAOVKBIIKRNL-UHFFFAOYSA-N	DB16739	MK-886	experimental	nan	MK-886 is an experimental inhibitor of leukotriene synthesis.	118414-82-7
HHFBDROWDBDFBR-UHFFFAOYSA-N	DB13061	MLN8054	investigational	nan	MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.	869363-13-3
QJAPFAZHNSZLJE-CWURXVSKSA-N	DB02378	MMI-175	experimental	nan	nan	nan
NKHUILHBYOOZDF-NCOIWELASA-N	DB17015	MRK-003	experimental	nan	MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]	623165-93-5
GOIFCXRIFSYPFG-UHFFFAOYSA-N	DB13993	MRK-409	experimental	nan	MRK-409 is a GABA-A receptor agonist [A31972].	233275-76-8
BZKIOORWZAXIBA-UHFFFAOYSA-N	DB18016	MRTX-1719	investigational	nan	nan	2630904-44-6
JGCMEBMXRHSZKX-UHFFFAOYSA-N	DB08932	Macitentan	approved;investigational	C02KX04;C02KX54	Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.[L50622]	441798-33-0
TYMRLRRVMHJFTF-UHFFFAOYSA-N	DB06795	Mafenide	approved;vet_approved;withdrawn	G01AE10;D06BA03	Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.[L36773] In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations. In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements.[L44251]	138-39-6
QSLMDECMDJKHMQ-UHFFFAOYSA-N	DB00934	Maprotiline	approved	N06AA21	Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive diso	10262-69-8
GSNHKUDZZFZSJB-QYOOZWMWSA-N	DB04835	Maraviroc	approved;investigational	J05AX09	Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.	376348-65-1
AZEXWHKOMMASPA-UHFFFAOYSA-N	DB08387	Mardepodect	investigational	nan	nan	898562-94-2
OCSMOTCMPXTDND-OUAUKWLOSA-N	DB00786	Marimastat	investigational	nan	Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.	154039-60-8
NGWSFRIPKNWYAO-SHTIJGAHSA-N	DB11762	Marizomib	investigational	nan	Marizomib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Malignant Glioma, among others.	437742-34-2
WNIDBXBLQFPAJA-VOTSOKGWSA-N	DB14979	Martinostat	investigational	nan	Martinostat is under investigation in clinical trial NCT03721211 (Imaging With [11C]Martinostat in Breast Cancer).	1629052-58-9
WJEOLQLKVOPQFV-UHFFFAOYSA-N	DB11526	Masitinib	investigational;vet_approved	L01EX06	Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.	790299-79-5
JYIUNVOCEFIUIU-GHMZBOCLSA-N	DB16228	Mavelertinib	investigational	nan	Mavelertinib is under investigation in clinical trial NCT02349633 (Study for Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)).	1776112-90-3
ZKZFPRUSWCYSGT-UHFFFAOYSA-N	DB20960	Mazapertine	experimental	nan	Mazapertine is a small molecule drug. Mazapertine has a monoisotopic molecular weight of 421.27 Da.	134208-17-6
ZPXSCAKFGYXMGA-UHFFFAOYSA-N	DB00579	Mazindol	approved	A08AA05	Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than [amphetamine], but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.	22232-71-9
IMYZQPCYWPFTAG-UHFFFAOYSA-N	DB00657	Mecamylamine	approved;investigational	C02BB01	A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	60-40-2
DYLJVOXRWLXDIG-UHFFFAOYSA-N	DB06455	Meclinertant	investigational	nan	nan	146362-70-1
SBDNJUWAMKYJOX-UHFFFAOYSA-N	DB00939	Meclofenamic acid	approved;investigational;vet_approved	M01AG04;M02AA18	A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.	644-62-2
OCCZJXAHSUCJSA-UHFFFAOYSA-N	DB20263	Medorinone	experimental	nan	Medorinone is a small molecule drug. Medorinone has a monoisotopic molecular weight of 160.06 Da.	88296-61-1
PSGAAPLEWMOORI-PEINSRQWSA-N	DB00603	Medroxyprogesterone acetate	approved;investigational	G03AA08;G03DA02;G03FB06;G03FA12;L02AB02;G03AA17;G03AC06	Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties.[A14848] MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medr	71-58-9
HYYBABOKPJLUIN-UHFFFAOYSA-N	DB00784	Mefenamic acid	approved	M01AG01	A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.	61-68-7
ROBJKLPZIPNAMV-UHFFFAOYSA-N	DB18248	Mefuparib	experimental	nan	nan	1392502-82-7
DKWNMCUOEDMMIN-PKOBYXMFSA-N	DB13616	Melagatran	investigational	B01AE04	nan	159776-70-2
DRLFMBDRBRZALE-UHFFFAOYSA-N	DB01065	Melatonin	approved;investigational;nutraceutical;vet_approved	N05CH01	Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The se	73-31-4
ZRVUJXDFFKFLMG-UHFFFAOYSA-N	DB00814	Meloxicam	approved;investigational;vet_approved	N01BB59;M01AC56;M01AC06	Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.[A190189] With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects	71125-38-7
DKMFBWQBDIGMHM-UHFFFAOYSA-N	DB09224	Melperone	investigational	N05AD03	Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union [L1316]. It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. Recently, it has been studied as a treatment of psychosis re	3575-80-2
BUGYDGFZZOZRHP-UHFFFAOYSA-N	DB01043	Memantine	approved;investigational	N06DA52;N06DX01;N06DA53	Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulat	19982-08-2
GKNPSSNBBWDAGH-UHFFFAOYSA-N	DB04843	Mepenzolate	approved;withdrawn	A03AB12	Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complicat	25990-43-6
XADCESSVHJOZHK-UHFFFAOYSA-N	DB00454	Meperidine	approved;investigational	N02AB02;N02AB72;N02AB52;N02AG03	A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.	57-42-1
YECBIJXISLIIDS-UHFFFAOYSA-N	DB06691	Mepyramine	approved;vet_approved	D04AA02;R06AC01	Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.	91-84-9
QHADVLVFMKEIIP-UHFFFAOYSA-N	DB12381	Merestinib	investigational	nan	Merestinib has been used in trials studying the treatment of Cancer, Solid Tumor, Advanced cancer, ColoRectal Cancer, and Metastatic Cancer, among others.	1206799-15-6
JBPUGFODGPKTDW-SFHVURJKSA-N	DB04862	Merimepodib	investigational	nan	Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.	198821-22-6
KBOPZPXVLCULAV-UHFFFAOYSA-N	DB00244	Mesalazine	approved;investigational	A07EC02	An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022]. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent [A174019]. Throughout the late seventies and the eighties, important research initiatives developed s	89-57-6
RHCSKNNOAZULRK-UHFFFAOYSA-N	DB19083	Mescaline	investigational	nan	Mescaline is under investigation in clinical trial NCT05933213 (Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis).	54-04-6
SLVMESMUVMCQIY-UHFFFAOYSA-N	DB00933	Mesoridazine	approved;withdrawn	N05AC03	A phenothiazine antipsychotic with effects similar to chlorpromazine.	5588-33-0
IMSSROKUHAOUJS-MJCUULBUSA-N	DB01357	Mestranol	approved;withdrawn	nan	The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.	72-33-3
MYWUZJCMWCOHBA-VIFPVBQESA-N	DB01577	Metamfetamine	approved;illicit;investigational;withdrawn	N06BA03	Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.[L43942]	537-46-2
YFGBQHOOROIVKG-FKBYEOEOSA-N	DB12668	Metenkefalin	investigational	nan	Metenkefalin is an endogenous opioid and beta-endorphin.[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis.[A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]	58569-55-4
NZWOPGCLSHLLPA-UHFFFAOYSA-N	DB06709	Methacholine	approved;investigational	V04CX03	Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction.[A229603, A229618, A	55-92-5
USSIQXCVUWKGNF-UHFFFAOYSA-N	DB00333	Methadone	approved;investigational	N07BC02;N02AC52	Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain transmission. It also has a number of unique characteristics that have led to its increased use in the last two decades; in particular, methadone has a lower risk of neuropsychiatric 	76-99-3
HNJJXZKZRAWDPF-UHFFFAOYSA-N	DB04819	Methapyrilene	approved;withdrawn	R06AC05	Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.	91-80-5
FLOSMHQXBMRNHR-QPJJXVBHSA-N	DB00703	Methazolamide	approved	G01AE10;S01EC05	A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	554-57-4
LPLLVINFLBSFRP-UHFFFAOYSA-N	DB15339	Methcathinone	experimental	nan	Methcathinone is under investigation in clinical trial NCT02617862 (PCI Imaging System in Pediatric Ophthalmology).	5650-44-2
FBOZXECLQNJBKD-ZDUSSCGKSA-N	DB00563	Methotrexate	approved;investigational	L04AX03;L01BA01	Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.[A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicate	59-05-2
QXKHYNVANLEOEG-UHFFFAOYSA-N	DB00553	Methoxsalen	approved;investigational	D05BA02;D05AD02	A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.	298-81-7
KWKZCGMJGHHOKJ-WTIHWRCNSA-N	DB02465	Methoxy arachidonyl fluorophosphonate	experimental	nan	Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases. It inhibits phospholipase A2 and fatty acid amide hydrolase with special potency, displaying IC50 values in the low-nanomolar range.	180509-15-3
LZCOQTDXKCNBEE-IKIFYQGPSA-N	DB11315	Methscopolamine	approved	A03CB01;S01FA03;A03BB03	Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.	13265-10-6
AMKFOVYTEUFMCU-HCGLCNNCSA-N	DB03748	Methyl-[4-(4-Piperidine-1-Ylmethyl-Phenyl)-Cyclohexyl]-Carbaminic Acid-(4-Chlorophenyl)-Ester	experimental	nan	nan	nan
HDAMOICMOAXFLJ-UHFFFAOYSA-N	DB13181	Methylbenactyzium	experimental	nan	nan	13473-61-5
UNBRKDKAWYKMIV-QWQRMKEZSA-N	DB00353	Methylergometrine	approved;investigational	G02AC01;G02AB01	A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)	113-42-8
LXCFILQKKLGQFO-UHFFFAOYSA-N	DB14212	Methylparaben	approved;investigational	nan	Methylparaben is used in allergenic testing.	99-76-3
DUGOZIWVEXMGBE-UHFFFAOYSA-N	DB00422	Methylphenidate	approved;investigational	N06BA04	Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span	113-45-1
GCKMFJBGXUYNAG-HLXURNFRSA-N	DB06710	Methyltestosterone	approved;investigational	G03BA02;G03EA01;G03EK01	A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.	58-18-4
RBTBFTRPCNLSDE-UHFFFAOYSA-N	DB08167	Methylthioninium	investigational	nan	nan	7060-82-4
TTWJBBZEZQICBI-UHFFFAOYSA-N	DB01233	Metoclopramide	approved;investigational	A03FA01	Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system.[A184934] Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures.[L8	364-62-5
AQCHWTWZEMGIFD-UHFFFAOYSA-N	DB00524	Metolazone	approved;investigational	C03EA12;G01AE10;C03BA08	A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.	17560-51-9
BQDBKDMTIJBJLA-UHFFFAOYSA-N	DB13591	Metopimazine	investigational	A04AD05	nan	14008-44-7
IUBSYMUCCVWXPE-UHFFFAOYSA-N	DB00264	Metoprolol	approved;investigational	C07FB02;C07FX05;C07FX03;C07FB13;C07AB02;C07BB52;C07CB02;C07BB02	Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative.[T274] To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US	51384-51-1
CCCIJQPRIXGQOE-XWSJACJDSA-N	DB02998	Metribolone	experimental	nan	A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.	965-93-5
OOEMZCZWZXHBKW-SCFUHWHPSA-N	DB20226	Metrifudil	experimental	nan	Metrifudil is a small molecule drug. The usage of the INN stem '-dil' in the name indicates that Metrifudil is a vasodilator. Metrifudil has a monoisotopic molecular weight of 371.16 Da.	23707-33-7
FJLBFSROUSIWMA-UHFFFAOYSA-N	DB01011	Metyrapone	approved;investigational	V04CD01	An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.	54-36-4
SCJNYBYSTCRPAO-LXBQGUBHSA-N	DB21454	Mevociclib	investigational	nan	Mevociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Mevociclib is a cyclin dependant kinase inhibitor. Mevociclib is under investigation in clinical trial NCT03134638 (A Study of SY-1365 in Adult Patients With Advanced Solid Tumors). Mevociclib has a monoisotopic molecular weight of 586.26 Da.	1816989-16-8
YTINZZFBHWSAGL-NDEPHWFRSA-N	DB17584	Mezigdomide	investigational	nan	Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).	2259648-80-9
ITYXRJDDBZMFAY-UHFFFAOYSA-N	DB21271	Mezilamine	experimental	nan	Mezilamine is a small molecule drug. Mezilamine has a monoisotopic molecular weight of 287.1 Da.	50335-55-2
UEQUQVLFIPOEMF-UHFFFAOYSA-N	DB06148	Mianserin	approved;withdrawn	N06AX03	A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of [mirtazapine].	24219-97-4
HBNPJJILLOYFJU-VMPREFPWSA-N	DB01388	Mibefradil	approved;investigational;withdrawn	C08CX01	Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.	116644-53-2
PIEUQSKUWLMALL-YABMTYFHSA-N	DB01141	Micafungin	approved;investigational	J02AX05	Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.	235114-32-6
BYBLEWFAAKGYCD-UHFFFAOYSA-N	DB01110	Miconazole	approved;investigational;vet_approved	A07AC01;J02AB01;D01AC52;G01AF20;A01AB09;D01AC02;S02AA13;G01AF04	Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well.[A203636] It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethyla	22916-47-8
DDLIGBOFAVUZHB-UHFFFAOYSA-N	DB00683	Midazolam	approved;illicit;investigational	N05CD08	Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties.[A173842] It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action.[A173842] Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentis	59467-70-8
SHXWCVYOXRDMCX-UHFFFAOYSA-N	DB01454	Midomafetamine	illicit;investigational	nan	An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.	42542-10-9
BMGQWWVMWDBQGC-IIFHNQTCSA-N	DB06595	Midostaurin	approved;investigational	L01EX10	Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherape	120685-11-2
LXBIFEVIBLOUGU-DPYQTVNSSA-N	DB05018	Migalastat	approved;investigational	A16AX14	Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other organs.[L47036,L47057,L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and a	108147-54-2
IBAQFPQHRJAVAV-ULAWRXDQSA-N	DB00491	Miglitol	approved	A10BF02	Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glu	72432-03-2
UQRORFVVSGFNRO-UTINFBMNSA-N	DB00419	Miglustat	approved;investigational	A16AX06	Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological sym	72599-27-0
RYAYYVTWKAOAJF-QISPRATLSA-N	DB15257	Milademetan	investigational	nan	Milademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)).	1398568-47-2
GJJFMKBJSRMPLA-UHFFFAOYSA-N	DB04896	Milnacipran	approved;investigational	N06AX17	Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia [F3925], although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment	92623-85-3
PZRHRDRVRGEVNW-UHFFFAOYSA-N	DB00235	Milrinone	approved;investigational	C01CE02	Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart failure is underpinned by numerous physiological changes, including alteration in β-adrenergic signalling and cyclic adenosine monophosphate	78415-72-2
FSWFYCYPTDLKON-CMJOXMDJSA-N	DB16233	Milvexian	investigational	nan	Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).	1802425-99-5
VMMKGHQPQIEGSQ-UHFFFAOYSA-N	DB06548	Minodronic acid	investigational	nan	nan	180064-38-4
HNFMVVHMKGFCMB-UHFFFAOYSA-N	DB14982	Miransertib	investigational	nan	Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).	1313881-70-7
SUDAHWBOROXANE-SECBINFHSA-N	DB07101	Mirdametinib	approved;investigational	L01EE05	Mirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).[L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation of the mitogen-activated protein kinase (MAPK) pathway.[A265065] Mirdametinib selectively and potent	391210-10-9
RONZAEMNMFQXRA-UHFFFAOYSA-N	DB00370	Mirtazapine	approved;investigational	N06AX11	Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994.[A177946] This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine h	85650-52-8
OJLOPKGSLYJEMD-URPKTTJQSA-N	DB00929	Misoprostol	approved;investigational	G02AD06;A02BB01;M01AE56	Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.[L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.[A181586] Misoprostol was granted FDA approval on 2	59122-46-2
BHKKSKOHRFHHIN-MRVPVSSYSA-N	DB18963	Mitiperstat	investigational	nan	Mitiperstat is under investigation in clinical trial NCT05492877 (An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.).	1933460-19-5
JWBOIMRXGHLCPP-UHFFFAOYSA-N	DB00648	Mitotane	approved;investigational	L01XX23	Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma[A263010] and is used off-label for the management of Cushing's syndrome.[A263016]	53-19-0
MJHOMTRKVMKCNE-NWDGAFQWSA-N	DB16849	Mivavotinib	investigational	nan	nan	1312691-33-0
RDONXGFGWSSFMY-UHFFFAOYSA-N	DB21300	Mivebresib	investigational	nan	Mivebresib is a small molecule drug. The usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic. Mivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis). Mivebresib has a monoisotopic molecular wei	1445993-26-9
ZQFNDBISEYQVRR-LOSJGSFVSA-N	DB21458	Mizacorat	investigational	nan	Mizacorat is a small molecule drug. The usage of the INN stem '-corat' in the name indicates that Mizacorat is a glucocorticoid receptor agonist. Mizacorat is under investigation in clinical trial NCT04556760 (Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes). Mizacorat has a monoisotopic molecular weight of 494.21 Da.	1893415-00-3
PVLJETXTTWAYEW-UHFFFAOYSA-N	DB12523	Mizolastine	approved	R06AX25	Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).	108612-45-9
AZSRSNUQCUDCGG-UHFFFAOYSA-N	DB16390	Mobocertinib	approved;investigational;withdrawn	L01EB10	"Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (as compared to ""classical"" _EGFR_ mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors.[A238828] Mobocertinib appears to be an effective means of treating thi"	1847461-43-1
HRNLUBSXIHFDHP-UHFFFAOYSA-N	DB11830	Mocetinostat	investigational	nan	Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.	726169-73-9
VXLBSYHAEKDUSU-JXMROGBWSA-N	DB19621	Mofegiline	experimental	nan	Mofegiline is a small molecule drug. The usage of the INN stem '-giline' in the name indicates that Mofegiline is a monoamine oxydase (MAO)-inhibitor type B. Mofegiline has a monoisotopic molecular weight of 197.1 Da.	119386-96-8
DJEIHHYCDCTAAH-UHFFFAOYSA-N	DB21153	Mofezolac	experimental	nan	Mofezolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Mofezolac is a anti-inflammatory agent, ibufenac derivative. Mofezolac has a monoisotopic molecular weight of 339.11 Da.	78967-07-4
AAAQFGUYHFJNHI-SFHVURJKSA-N	DB16239	Molibresib	investigational	nan	Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).	1260907-17-2
IJMBOKOTALXLKS-UHFFFAOYSA-N	DB15642	Molidustat	investigational	B03XA09	Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).	1154028-82-6
KLPWJLBORRMFGK-UHFFFAOYSA-N	DB01618	Molindone	approved	N05AE02	An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of	7416-34-4
WOFMFGQZHJDGCX-ZULDAHANSA-N	DB14512	Mometasone furoate	approved;investigational;vet_approved	D07AC13;R03BA07;D07XC03;R01AD09;R03AK09	Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label][F4292,F4295]. It has a glucocorticoid receptor binding affinity 22 times stronger than [dexamethasone] and higher than many other corticosteroids as well[A176906]. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications[FDA Label][F4292,F4295].	83919-23-7
UCHDWCPVSPXUMX-TZIWLTJVSA-N	DB00471	Montelukast	approved;investigational	R03DC03;R03DC53	Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair.[L6301] The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy.[A178645] Regardless, in 2008-2009, there w	158966-92-8
DNTVXDZWVOVLOD-GDNBJRDFSA-N	DB21619	Monzosertib	experimental	nan	Monzosertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Monzosertib is a serine/threonine kinase inhibitor. Monzosertib has a monoisotopic molecular weight of 465.16 Da.	1402057-88-8
AGAHNABIDCTLHW-UHFFFAOYSA-N	DB13554	Moperone	experimental	N05AD04	nan	1050-79-9
YXOLAZRVSSWPPT-UHFFFAOYSA-N	DB16770	Morin	experimental	nan	nan	480-16-0
BQJCRHHNABKAKU-KBQPJGBKSA-N	DB00295	Morphine	approved;investigational	A07DA52;N02AA51;N02AA01;N02AG01	Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]	57-27-2
YUMYYTORLYHUFW-ZUDLOMHPSA-N	DB03837	Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide	experimental	nan	nan	nan
YPELFRMCRYSPKZ-UHFFFAOYSA-N	DB11675	Mosapride	investigational	A03FA09	Mosapride is under investigation for the treatment and prevention of Postoperative Ileus and Gastric Peroral Endoscopic Pyloromyotomy (G-POEM). Mosapride has been investigated for the treatment and diagnostic of Constipation, Type 2 Diabetes, Functional Dyspepsia, Functional Constipation, and Epigastric Pain Syndrome, among others.	112885-41-3
ZUXPFTYMSHPRQX-GFCCVEGCSA-N	DB21673	Mosperafenib	experimental	nan	Mosperafenib is a small molecule drug. The usage of the INN stem '-rafenib' in the name indicates that Mosperafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. Mosperafenib has a monoisotopic molecular weight of 461.1 Da.	2649372-20-1
RAHBGWKEPAQNFF-UHFFFAOYSA-N	DB05575	Motesanib	investigational	nan	nan	453562-69-1
MTMZZIPTQITGCY-OLGWUGKESA-N	DB13418	Moxestrol	experimental	G03CB04	nan	34816-55-2
FABPRXSRWADJSP-MEDUHNTESA-N	DB00218	Moxifloxacin	approved;investigational	S01AE07;J01MA14	Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.	151096-09-2
VAYJLOGCWOXMAS-UHFFFAOYSA-N	DB19718	Moxilubant	experimental	nan	Moxilubant is a small molecule drug. The usage of the INN stem '-lubant' in the name indicates that Moxilubant is a leukotriene B4​ receptor antagonist. Moxilubant has a monoisotopic molecular weight of 455.28 Da.	146978-48-5
VRYMTAVOXVTQEF-UHFFFAOYSA-N	DB09205	Moxisylyte	approved	C04AX10;G04BE06	Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist.[T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA.[L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.	54-32-0
WPNJAUFVNXKLIM-UHFFFAOYSA-N	DB09242	Moxonidine	approved;investigational;withdrawn	C02AC05;C02LC05	Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.	75438-57-2
KYRSNWPSSXSNEP-ZRTHHSRSSA-N	DB02102	Mozenavir	experimental	nan	nan	174391-92-5
MINDHVHHQZYEEK-HBBNESRFSA-N	DB00410	Mupirocin	approved;investigational;vet_approved	R01AX06;D06AX09	Mupirocin, formerly termed pseudomonic acid A,[A178531] is a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents. Produced by fermentation using the organism _Pseudomonas fluorescens_, mupirocin is a naturally-occurring antibiotic that displays a broad-specturm activity against many gram-positive bacteria and certain gram-negative bacteria _in vitro_.[L10580] It primarily works by inhibiting bacterial protein synthesis. Due to its uniq	12650-69-0
IRLWJILLXJGJTD-UHFFFAOYSA-N	DB06510	Muraglitazar	investigational	nan	Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease in LDL-C levels.	331741-94-7
ZJQHPWUVQPJPQT-UHFFFAOYSA-N	DB12458	Muscimol	investigational	nan	Muscimol has been used in trials studying the treatment of Epilepsy and Parkinson's Disease.	2763-96-4
HPNSFSBZBAHARI-RUDMXATFSA-N	DB01024	Mycophenolic acid	approved;investigational	L04AA06	Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.[L42165] It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.[A249170]. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone.[A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to	24280-93-1
QTFCKBFCXDAZIU-UHFFFAOYSA-N	DB07253	N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine	experimental	nan	nan	nan
CLEGTVIMOPPIBR-UHFFFAOYSA-N	DB07537	N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide	experimental	nan	nan	nan
KLVYMYQTRZCMLE-CYBMUJFWSA-N	DB04186	N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea	experimental	nan	nan	nan
UYZFAUAYFLEHRC-LURJTMIESA-N	DB03305	N(G)-Iminoethylornithine	experimental	nan	nan	36889-13-1
KKYYLKPGILUPOA-UHFFFAOYSA-N	DB08056	N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	experimental	nan	nan	nan
LDXLQEXLXZCYSR-UHFFFAOYSA-N	DB07790	N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE	experimental	nan	nan	nan
JKEJEOJPJVRHMQ-JTQLQIEISA-N	DB07928	N-(2-OXOTETRAHYDROFURAN-3-YL)OCTANAMIDE	experimental	nan	nan	nan
RIGZCVNCFXYBEG-UHFFFAOYSA-N	DB06944	N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide	experimental	nan	N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. The proteins that N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide targets include cyclin-A2 and cyclin-dependent kinase 2.	nan
UZUCFTPPULEGQO-UHFFFAOYSA-N	DB18299	N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo(d)imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-amine	investigational	nan	nan	2102887-41-0
BTTFXKUTBNGQTP-UHFFFAOYSA-N	DB06956	N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE	experimental	nan	nan	nan
GKODDLYLEKSDJL-UHFFFAOYSA-N	DB07272	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	experimental	nan	nan	nan
JGWHILNNHLDARR-UHFFFAOYSA-N	DB08462	N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE	experimental	nan	nan	nan
GGPZCOONYBPZEW-UHFFFAOYSA-N	DB07288	N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide	experimental	nan	nan	nan
BACSZMCLZIDTIO-IBGZPJMESA-N	DB07936	N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine	experimental	nan	nan	nan
LUCORKWTQSQFFU-UHFFFAOYSA-N	DB02647	N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide	experimental	nan	nan	nan
JYCUVOXSZBECAY-UHFFFAOYSA-N	DB08454	N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE	experimental	nan	nan	nan
QHIMVPIOWKYPSO-UHFFFAOYSA-N	DB07249	N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine	experimental	nan	nan	nan
JFVNFXCESCXMBC-UHFFFAOYSA-N	DB06836	N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide	experimental	nan	nan	593960-11-3
UCIDPJLYUKNYFZ-UHFFFAOYSA-N	DB02544	N-(6-{[3-(4-Bromophenyl)-1,2-Benzisothiazol-6-Yl]Oxy}Hexyl)-N-Methylprop-2-En-1-Amine	experimental	nan	nan	nan
JJVQUUYZGJWBPW-UHFFFAOYSA-N	DB02505	N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl)	experimental	nan	nan	nan
FOHZGCHKLPIBBX-UHFFFAOYSA-N	DB07834	N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	experimental	nan	nan	nan
WHLPIOSHBKQGHA-KYJUHHDHSA-N	DB02477	N-({4-[4-(2-Methyl-1H-imidazol-1-yl)butyl]phenyl}acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide	experimental	nan	nan	164931-25-3
HDCXQTPVTAIPNZ-UHFFFAOYSA-N	DB08301	N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE	experimental	nan	nan	nan
DRHXTSWSUAJOJZ-FMDGEEDCSA-N	DB03747	N-Acetyl-glucosamine thiazoline	experimental	nan	N-Acetyl-glucosamine thiazoline (NAG-thiazoline) is an analog of the oxazolinium bicyclic intermediate leading from N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid.	179030-22-9
FNZKIJOTNKEJBF-UHFFFAOYSA-N	DB03888	N-Allyl-6-{[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yl]oxy}-N-methyl-1-hexanamine	experimental	nan	nan	nan
PDJZASCRQRBYQS-UHFFFAOYSA-N	DB07010	N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE	experimental	nan	nan	nan
AQTBUVAFYDVTFD-UHFFFAOYSA-N	DB02029	N-Cyclohexyl-N'-(4-Iodophenyl)Urea	experimental	nan	nan	nan
LPXYBLIRYGCMPQ-UHFFFAOYSA-N	DB03677	N-Cyclohexyl-N'-Decylurea	experimental	nan	nan	nan
YAUHDTOEJHVKJO-UHFFFAOYSA-N	DB04105	N-Heptylformamide	experimental	nan	nan	nan
DNGGPLKVDUPXFN-GOSISDBHSA-N	DB04232	N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide	experimental	nan	nan	nan
JIRXORZYIXSWOB-UHFFFAOYSA-N	DB08271	N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID	experimental	nan	nan	nan
IKASAFLVQIJQOK-UVTDQMKNSA-N	DB08122	N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide	experimental	nan	nan	nan
APLJSSOXDWUNGV-GOSISDBHSA-N	DB07991	N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE	experimental	nan	nan	nan
HHOVRZGUSBMKKU-ZDUSSCGKSA-N	DB07235	N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE	experimental	nan	nan	nan
IRSOCWQJNYLTDD-SFHVURJKSA-N	DB08752	N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide	experimental	nan	nan	nan
XBYJCVDSFWJBSM-OAHLLOKOSA-N	DB07048	N-[(2R)-5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-2-propylpentanamide	experimental	nan	nan	nan
VBPPNJCVXGAZDD-PMACEKPBSA-N	DB03642	N-[(2S)-4-Methyl-1-oxo-1-{[(4S)-3-oxo-1-(2-pyridinylsulfonyl)-4-azepanyl]amino}-2-pentanyl]-1-benzofuran-2-carboxamide	experimental	nan	nan	nan
XIWRCSVXKPGGAJ-UHFFFAOYSA-N	DB01807	N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea	experimental	nan	nan	nan
FJDDSMSDZHURBJ-UHFFFAOYSA-N	DB08190	N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide	experimental	nan	nan	nan
QINCZVSBLITNRD-UHFFFAOYSA-N	DB07389	N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE	experimental	nan	nan	nan
WRUVOSYKHXGAQN-GKRYNVPLSA-N	DB03768	N-[2-Hydroxy-2-(8-Isopropyl-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-11-Yl)-Ethyl]-N-(3-Methyl-Butyl)-Benzenesulfonamide,Inhibitor 3	experimental	nan	nan	nan
OYOUIHFZUAKCEF-LLVKDONJSA-N	DB06991	N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide	experimental	nan	nan	nan
FPKSFXFWECAIBR-UHFFFAOYSA-N	DB08066	N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE	experimental	nan	nan	nan
QYZPDCGWIJYZMN-ZBFHGGJFSA-N	DB07926	N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE	experimental	nan	nan	nan
ZCRPPLDDHBLUES-UHFFFAOYSA-N	DB02538	N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide	experimental	nan	nan	nan
OOHYJGNSESWEFT-UHFFFAOYSA-N	DB04588	N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE	experimental	nan	nan	nan
MRLVIVXGUGNENL-UHFFFAOYSA-N	DB07476	N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE	experimental	nan	nan	nan
HTIZPBXCJPQDEM-UHFFFAOYSA-N	DB07334	N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE	experimental	nan	nan	nan
KGUVBHLPMGERAT-NIYFSFCBSA-N	DB08507	N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID	experimental	nan	nan	nan
MVAWJSIDNICKHF-UHFFFAOYSA-N	DB04275	N-acetylserotonin	experimental	nan	nan	1210-83-9
OXYDLVAOXASTMW-UHFFFAOYSA-N	DB08006	N-anthracen-2-yl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	experimental	nan	nan	nan
HYNNWLVWJXWXFO-UHFFFAOYSA-N	DB08023	N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine	experimental	nan	nan	nan
MNEXDVSJIUQQRH-UHFFFAOYSA-N	DB08351	N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide	experimental	nan	nan	nan
CAGHIASAHLPQMS-UHFFFAOYSA-N	DB07164	N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine	experimental	nan	nan	nan
ZATGFXTWDKIEKC-UHFFFAOYSA-N	DB07274	N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide	experimental	nan	nan	nan
ZZTMFGIGOADCFX-UHFFFAOYSA-N	DB06940	N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide	experimental	nan	N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide is a solid. This compound belongs to the pyrrolotriazines. These are compounds containing a pyrrolotriazine moiety, which consists of a pyrrole ring fused to a triazine ring. N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide is known to target mitogen-activated protein kinase 14.	nan
FOSWRYKPHVPIDJ-UHFFFAOYSA-N	DB06945	N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide	experimental	nan	N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide is a solid. This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.	nan
KCWZGJVSDFYRIX-YFKPBYRVSA-N	DB12750	N-omega-nitro-L-arginine methyl ester	investigational	nan	L-NAME has been investigated for the treatment of Hypotension and Spinal Cord Injury.	50903-99-6
VWCMAGONQJHIJZ-LPHOPBHVSA-N	DB08019	N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine	experimental	nan	nan	nan
JDRSQGJWTVRNGM-QFBILLFUSA-N	DB08018	N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE	experimental	nan	nan	nan
RMSWBHUVFNFNIZ-ZETCQYMHSA-N	DB02027	N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine	experimental	nan	nan	357965-98-1
RDTDWGQDFJPTPD-UHFFFAOYSA-N	DB07545	N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE	experimental	nan	nan	nan
NESXBRNDMQUVNG-UHFFFAOYSA-N	DB08221	N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE	experimental	nan	nan	nan
SFVPXERGVLDWIS-OAQYLSRUSA-N	DB07233	N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophan	experimental	nan	nan	nan
GCBPAPVOMPJQHK-NQIIRXRSSA-N	DB08489	N4-HYDROXY-2-ISOBUTYL-N1-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.013,18]NONADECA-12(19),13,15,17-TETRAEN-10-YL)-SUCCINAMIDE	experimental	nan	nan	nan
XCUAIINAJCDIPM-XVFCMESISA-N	DB15660	N4-Hydroxycytidine	experimental	nan	N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.[A193023] It has shown antiviral activity against Venezuelan equine encephalitis virus,[A193008] and the human coronavirus HCoV-NL63 _in vitro_.[A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human air	3258-02-4
HZTFNSCZLJLPEO-UHFFFAOYSA-N	DB02583	N6-(2,5-Dimethoxy-Benzyl)-N6-Methyl-Pyrido[2,3-D]Pyrimidine-2,4,6-Triamine	experimental	nan	nan	175354-76-4
PZUJQWHTIRWCID-HXUWFJFHSA-N	DB05695	NPS-2143	experimental	nan	nan	284035-33-2
KTDZCOWXCWUPEO-UHFFFAOYSA-N	DB14060	NS-398	experimental	nan	NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.	123653-11-2
GECBBEABIDMGGL-RTBURBONSA-N	DB00486	Nabilone	approved;investigational	A04AD11	Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with 	51022-71-0
RSBPYSTVZQAADE-RQJHMYQMSA-N	DB15353	Nacubactam	investigational	nan	Nacubactam is under investigation in clinical trial NCT03174795 (A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection).	1452458-86-4
VWPOSFSPZNDTMJ-UCWKZMIHSA-N	DB01203	Nadolol	approved;investigational	C07BA12;C07AA12	Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]	42200-33-9
MQQNFDZXWVTQEH-UHFFFAOYSA-N	DB12598	Nafamostat	investigational	nan	Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.	81525-10-2
JEYWNNAZDLFBFF-UHFFFAOYSA-N	DB19957	Nafoxidine	experimental	nan	Nafoxidine is a small molecule drug. Nafoxidine has a monoisotopic molecular weight of 425.24 Da.	1845-11-0
OZGNYLLQHRPOBR-DHZHZOJOSA-N	DB00735	Naftifine	approved	D01AE22	Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.	65472-88-0
HRRBJVNMSRJFHQ-UHFFFAOYSA-N	DB12092	Naftopidil	investigational	nan	Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.	57149-07-2
NETZHAKZCGBWSS-CEDHKZHLSA-N	DB00844	Nalbuphine	approved;investigational	N02AF02	A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.	20594-83-6
AXQACEQYCPKDMV-RZAWKFBISA-N	DB11691	Naldemedine	approved;investigational	A06AH05	Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.	916072-89-4
XGZZHZMWIXFATA-UEZBDDGYSA-N	DB13471	Nalfurafine	investigational	V03AX02	nan	152657-84-6
WJBLNOPPDWQMCH-MBPVOVBZSA-N	DB06230	Nalmefene	approved;investigational;withdrawn	N07BB05	Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.[L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.[L1024] In Europe, nalmefene oral tablets are used to reduce alcohol consumption in adults with alcohol dependence.[L1024] Nalmefene was approved in the United States in 1995 as an antidote for opioid overdose.[A245839] Nalmefene injection is used to manage known or suspecte	55096-26-9
UIQMVEYFGZJHCZ-SSTWWWIQSA-N	DB11490	Nalorphine	experimental;vet_approved	V03AB02	Nalorphine is a mixed opioid agonist–antagonist. It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.	62-67-9
UZHSEJADLWPNLE-GRGSLBFTSA-N	DB01183	Naloxone	approved;investigational;vet_approved	A06AH04;N02AA53;N02AD51;V03AB15;N02AA55;N02AX51	Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide.[A234594] More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors.[A234594] When taken in large quantities, opioid medications such as [morphine], [hydromorphone], [me	465-65-6
DQCKKXVULJGBQN-XFWGSAIBSA-N	DB00704	Naltrexone	approved;investigational;vet_approved	N02AA56;N07BB04;A08AA62	Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.	16590-41-3
SPWZXWDPAWDKQE-UHFFFAOYSA-N	DB05562	Naluzotan	investigational	nan	nan	740873-06-7
IPSYPUKKXMNCNQ-PFHKOEEOSA-N	DB12885	Namodenoson	investigational	nan	Namodenoson has been used in trials studying the treatment of Chronic Hepatitis C and Hepatocellular Carcinoma.	163042-96-4
QRGHOAATPOLDPF-VQFNDLOPSA-N	DB15419	Nanatinostat	investigational	nan	Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).	1256448-47-1
NPAGDVCDWIYMMC-IZPLOLCNSA-N	DB13169	Nandrolone	investigational	S01XA11;A14AB01	Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone.	434-22-0
CNIIGCLFLJGOGP-UHFFFAOYSA-N	DB06711	Naphazoline	approved	R01AB02;S01GA01;S01GA51;R01AA08	Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles[L5804,L5807]. It acts to decrease congestion and is found in many over the counter (OTC) eye drops and nasal preparations[L5804,L5807]. Naphazoline was first developed in 1942 as a nasal formulation for congestion[A176609].	835-31-4
UEPXBTCUIIGYCY-UHFFFAOYSA-N	DB18865	Naporafenib	investigational	nan	Naporafenib is under investigation in clinical trial NCT06346067 (A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With Nras-mutant Melanoma (SEACRAFT-2)).	1800398-38-2
CMWTZPSULFXXJA-VIFPVBQESA-N	DB00788	Naproxen	approved;investigational;vet_approved	M01AE02;M01AE57;G02CC02;M02AA12;M01AE56;M01AE52;N02CC51	Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994.[A178975] It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile.[A179098] Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia.[A179098] Naproxen	22204-53-1
AMKVXSZCKVJAGH-UHFFFAOYSA-N	DB00952	Naratriptan	approved	N02CC02	Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.	121679-13-8
FTVWIRXFELQLPI-ZDUSSCGKSA-N	DB03467	Naringenin	experimental	nan	nan	480-41-1
AWJVIOYPZZZYAX-UHFFFAOYSA-N	DB18463	Narmafotinib	investigational	nan	nan	1393653-34-3
CQOJHAJWCDJEAT-UHFFFAOYSA-N	DB16068	Navacaprant	investigational	nan	BTRX-335140 is under investigation in clinical trial NCT04221230 (Study in Major Depressive Disorder With BTRX-335140 vs Placebo).	2244614-14-8
JLYAXFNOILIKPP-KXQOOQHDSA-N	DB12340	Navitoclax	investigational	L01XX78	Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others. Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. It blocks some of the enzymes that keep cancer cells from dying.	923564-51-6
YGACXVRLDHEXKY-WXRXAMBDSA-N	DB15439	Navoximod	investigational	nan	Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).	1402837-78-8
DRLCSJFKKILATL-YWCVFVGNSA-N	DB15299	Navtemadlin	investigational	nan	Navtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia).	1352066-68-2
IOMMMLWIABWRKL-WUTDNEBXSA-N	DB16250	Nazartinib	investigational	nan	Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations).	1508250-71-2
KOHIRBRYDXPAMZ-UHFFFAOYSA-N	DB04861	Nebivolol	approved;investigational	C07FB12;C09DX05;C09BX07;C10BX22;C07BB12;C07AB12	Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].[A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.[A182594] Nebivolol was granted FDA approva	118457-14-0
CCRUCMHMQXUZAT-LBPRGKRZSA-N	DB21700	Nedemelteon	experimental	nan	Nedemelteon is a small molecule drug. The usage of the INN stem '-melteon' in the name indicates that Nedemelteon is a melatonin receptor agonist. Nedemelteon has a monoisotopic molecular weight of 258.14 Da.	1000334-38-2
MOWXJLUYGFNTAL-DEOSSOPVSA-N	DB16252	Nedisertib	investigational	nan	Nedisertib is under investigation in clinical trial NCT03770689 (Study of M3814 in Combination With Capecitabine and Radiotherapy in Rectal Cancer).	1637542-33-6
VRBKIVRKKCLPHA-UHFFFAOYSA-N	DB01149	Nefazodone	approved;withdrawn	N06AX06	Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale	83366-66-9
VEPKQEUBKLEPRA-UHFFFAOYSA-N	DB07138	Neflamapimod	investigational	nan	Neflamapimod has been used in trials studying the treatment of Alzheimer's Disease and Mild Cognitive Impairment.	209410-46-8
QAGYKUNXZHXKMR-HKWSIXNMSA-N	DB00220	Nelfinavir	approved;investigational	J05AE04	Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.[L36485]	159989-64-7
NJXZWIIMWNEOGJ-WEWKHQNJSA-N	DB12643	Nelivaptan	investigational	nan	Nelivaptan has been used in trials studying the treatment of Anxiety Disorders, Depressive Disorder, and Major Depressive Disorder.	439687-69-1
COSPVUFTLGQDQL-UHFFFAOYSA-N	DB12555	Nelotanserin	investigational	nan	Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM or dream sleep. Nelotanserin works through a mechanism of action that is different from currently marketed drugs.	839713-36-9
KRVOJOCLBAAKSJ-RDTXWAMCSA-N	DB19314	Nemonapride	experimental	nan	nan	75272-39-8
ALWKGYPQUAPLQC-UHFFFAOYSA-N	DB01400	Neostigmine	approved;investigational;vet_approved	N07AA01;S01EB06;N07AA51	A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.	59-99-4
JWNPDZNEKVCWMY-VQHVLOKHSA-N	DB11828	Neratinib	approved;investigational	L01EH02	Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.	698387-09-6
GRPXLKXGJAGYSD-UHFFFAOYSA-N	DB18110	Nesuparib	investigational	nan	nan	2055357-64-5
IGUVQCZYMKVWFL-SFHVURJKSA-N	DB19337	Nesvategrast	investigational	nan	Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).	1621332-91-9
OURRXQUGYQRVML-AREMUKBSSA-N	DB13931	Netarsudil	approved;investigational	S01EE51;S01EX05	A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the	1254032-66-0
YDZYKNJZCVIKPP-VWLOTQADSA-N	DB12355	Netazepide	investigational	nan	Netazepide has been used in trials studying the prevention and treatment of Dyspepsia, Hypergastrinaemia, Barrett's Esophagus, ECL-cell Hyperplasia, and Rebound Hyperacidity, among others.	155488-25-8
CIDUJQMULVCIBT-MQDUPKMGSA-N	DB00955	Netilmicin	approved	S01AA23;J01GB07	Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.	56391-56-1
PKKNCEXEVUFFFI-UHFFFAOYSA-N	DB16254	Nevanimibe	investigational	nan	Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).	133825-80-6
NQDJXKOVJZTUJA-UHFFFAOYSA-N	DB00238	Nevirapine	approved;investigational	J05AG01;J05AR05;J05AR07	A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.	129618-40-2
ZBBHBTPTTSWHBA-UHFFFAOYSA-N	DB00622	Nicardipine	approved;investigational	C08CA04	A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]	55985-32-5
RJMUSRYZPJIFPJ-UHFFFAOYSA-N	DB06803	Niclosamide	approved;investigational;vet_approved	P02DA01	Niclosamide is an antihelminthic used for the treatment of tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from m	50-65-7
DFPAKSUCGFBDDF-UHFFFAOYSA-N	DB02701	Nicotinamide	approved;investigational	A11HA01	An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.	98-92-0
SNICXCGAKADSCV-JTQLQIEISA-N	DB00184	Nicotine	approved;investigational	N07BA01	Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.	54-11-5
HYIMSNHJOBLJNT-UHFFFAOYSA-N	DB01115	Nifedipine	approved;investigational	C08CA55;C08GA01;C08CA05;C07FB03	Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridi	21829-25-4
JZFPYUNJRRFVQU-UHFFFAOYSA-N	DB04552	Niflumic acid	investigational	M02AA17;M01AX02	Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.	4394-00-7
SVJMLYUFVDMUHP-XIFFEERXSA-N	DB09239	Niguldipine	experimental	nan	Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.	113165-32-5
HHZIURLSWUIHRB-UHFFFAOYSA-N	DB04868	Nilotinib	approved;investigational	L01EA03	Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.	641571-10-0
HYWYRSMBCFDLJT-UHFFFAOYSA-N	DB04743	Nimesulide	approved;withdrawn	M01AX17;M02AA26	Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.	51803-78-2
UIAGMCDKSXEBJQ-UHFFFAOYSA-N	DB00393	Nimodipine	approved;investigational	C08CA06	Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimo	66085-59-4
VQYYQSZNRVQLIS-UHFFFAOYSA-N	DB16256	Ningetinib	investigational	nan	Ningetinib is under investigation in clinical trial NCT03758287 (Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).	1394820-69-9
XZXHXSATPCNXJR-ZIADKAODSA-N	DB09079	Nintedanib	approved;investigational	L01EX09	Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014.[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is u	656247-17-5
XJLSEXAGTJCILF-UHFFFAOYSA-N	DB08849	Nipecotic acid	experimental	nan	nan	498-95-3
PCHKPVIQAHNQLW-CQSZACIVSA-N	DB11793	Niraparib	approved;investigational	L01XK02;L01XK52	Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada 	1038915-60-4
LIENCHBZNNMNKG-OJFNHCPVSA-N	DB16691	Nirmatrelvir	approved;investigational	J05AE30	Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL<sup>PRO</sup>) inhibitor that is the subject of clinical trial NCT04756531.[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.[A234224] Without the activity of the SARS-CoV-2 3CL<sup>PRO</sup>, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.[A234224,A234229,A234234] In 2020, Pfizer was investigating another 	2628280-40-8
VFCRKLWBYMDAED-REWPJTCUSA-N	DB12005	Nirogacestat	approved;investigational	L01XX81	Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling.[A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling and thus impede the growth of desmoid tumors.[A262561] Nirogacestat was approved unde	1290543-63-3
VKQFCGNPDRICFG-UHFFFAOYSA-N	DB00401	Nisoldipine	approved	C08CA07	Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.	63675-72-9
ITJNARMNRKSWTA-UHFFFAOYSA-N	DB09186	Nisoxetine	experimental	nan	Nisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. It has been used to research obesity and energy balance, and exerts some local analgesia effects.	53179-07-0
YQNQNVDNTFHQSW-UHFFFAOYSA-N	DB00507	Nitazoxanide	approved;investigational;vet_approved	P01AX11;J01RA17	Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nit	55981-09-4
GNWCRBFQZDJFTI-UHFFFAOYSA-N	DB19659	Nitraquazone	experimental	nan	Nitraquazone is a small molecule drug. The usage of the INN stem '-azone' in the name indicates that Nitraquazone is a anti-inflammatory analgesic, phenylbutazone derivative. Nitraquazone has a monoisotopic molecular weight of 311.09 Da.	56739-21-0
PVHUJELLJLJGLN-UHFFFAOYSA-N	DB01054	Nitrendipine	approved;investigational;withdrawn	C08CA08;C09BB06	Nitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.	39562-70-4
MRAUNPAHJZDYCK-BYPYZUCNSA-N	DB04223	Nitroarginine	investigational	nan	An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity. Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6)	2149-70-4
ASPOIVQEUUCDQT-UHFFFAOYSA-N	DB00325	Nitroprusside	approved;investigational	C02DD01	Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.	15078-28-1
RJIWZDNTCBHXAL-UHFFFAOYSA-N	DB01422	Nitroxoline	experimental	J01XX07	Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.	4008-48-4
GKPHAIOJCHBZCT-HXUWFJFHSA-N	DB21506	Nivasorexant	experimental	nan	Nivasorexant is a small molecule drug. The usage of the INN stem '-orexant' in the name indicates that Nivasorexant is a orexin receptor antagonist. Nivasorexant has a monoisotopic molecular weight of 429.19 Da.	1435480-40-2
IRIRASPSMMWZOM-CJRSTVEYSA-N	DB21603	Nizubaglustat	investigational	nan	Nizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor. Nizubaglustat is under investigation in clinical trial NCT07054515 (A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis). Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.	1633666-49-5
KYRVNWMVYQXFEU-UHFFFAOYSA-N	DB08313	Nocodazole	experimental	nan	Nocodazole is an antineoplastic agent which exerts its effect by depolymerizing microtubules.	31430-18-9
OLUJSZLBWZWGJT-HGBKYHTQSA-N	DB16259	Nolasiban	investigational	nan	Nolasiban is under investigation in clinical trial NCT03081208 (Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI).	1477482-19-1
XHWRWCSCBDLOLM-UHFFFAOYSA-N	DB12912	Nolatrexed	experimental	nan	Nolatrexed is under investigation in clinical trial NCT00012324 (Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer).	147149-76-6
XXPANQJNYNUNES-UHFFFAOYSA-N	DB04821	Nomifensine	approved;withdrawn	N06AX04	Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 	24526-64-5
JNNOSTQEZICQQP-UHFFFAOYSA-N	DB05766	Norclozapine	investigational	nan	ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.	6104-71-8
VIKNJXKGJWUCNN-XGXHKTLJSA-N	DB00717	Norethisterone	approved;investigational	H01CC53;H01CC54;G03AA05;G03DC02;G03AB04;G03AC01;G03FA01;G03FB05	Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins.[A10367] It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol].[A10367] Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency,[A188075] and is used on its own or in	68-22-4
OGJPXUAPXNRGGI-UHFFFAOYSA-N	DB01059	Norfloxacin	approved;investigational	J01RA14;J01RA13;S01AE02;J01MA06	A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.	70458-96-7
AKNNEGZIBPJZJG-MSOLQXFVSA-N	DB06174	Noscapine	approved	R05DA07	nan	128-62-1
YJQPYGGHQPGBLI-KGSXXDOSSA-N	DB01051	Novobiocin	approved;investigational;vet_approved;withdrawn	nan	Novobiocin is an antibiotic compound derived from _Streptomyces niveus_. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious infections due to susceptible strains of _Staphylococcus aureus_ when other less toxic anti	303-81-1
ZZJLMZYUGLJBSO-LAEOZQHASA-N	DB15286	Numidargistat	investigational	nan	CB-1158 is under investigation in clinical trial NCT03910530 (A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors).	2095732-06-0
BDUHCSBCVGXTJM-WUFINQPMSA-N	DB17039	Nutlin-3	experimental	nan	Nutlin-3 is a small molecule inhibitor that targets p53-Mdm2 interaction.[A253057]	548472-68-0
PTGXAUBQBSGPKF-UHFFFAOYSA-N	DB06152	Nylidrin	approved;withdrawn	C04AA02;G02CA02	Nylidrin, also known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment [L2279]. Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain m	447-41-6
UYJZZVDLGDDTCL-UHFFFAOYSA-N	DB08348	N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE	experimental	nan	nan	nan
QQDWEVONJRXVDB-UHFFFAOYSA-N	DB08029	N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide	experimental	nan	nan	nan
BOPSUAHGQHFKGG-UHFFFAOYSA-N	DB07835	N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide	experimental	nan	nan	nan
YQEMFOGNUTYMTJ-JNBVYXHXSA-N	DB04318	Nα-[(2S)-2-{[(S)-[(1S)-1-{[(Benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl]methyl}-5-phenylpentanoyl]-L-tryptophanamide	experimental	nan	nan	nan
OWXORKPNCHJYOF-UHFFFAOYSA-N	DB07126	O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE	experimental	nan	nan	nan
ZJFCBQXPTQSTCZ-UHFFFAOYSA-N	DB16843	ODM-203	investigational	nan	nan	1430723-35-5
INGXCNVWWKKWOO-LJQANCHMSA-N	DB05838	OPC-51803	experimental	nan	OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.	nan
VGIYMYGMVXPMKV-GWDMYEQXSA-N	DB15324	ORM-13070 C-11	investigational	nan	ORM-13070 C-11 is under investigation in clinical trial NCT00735774 (Suitability of 11C-ORM-13070 as a PET Tracer).	1227170-74-2
JROFGZPOBKIAEW-HAQNSBGRSA-N	DB12387	OSI-027	investigational	nan	OSI-027 has been used in trials studying the treatment of Any Solid Tumor or Lymphoma.	936890-98-1
FGTCROZDHDSNIO-UHFFFAOYSA-N	DB05913	OSI-930	investigational	nan	OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers.	728033-96-3
RFTSSZJZXOSICM-GRSHGNNSSA-N	DB12191	Obatoclax	investigational	nan	Obatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.	803712-67-6
ZZQNEJILGNNOEP-UHFFFAOYSA-N	DB06229	Ocaperidone	experimental	nan	nan	129029-23-8
DADASRPKWOGKCU-FVTQAUBDSA-N	DB18746	Ocifisertib	investigational	nan	nan	1338806-73-7
FWIVDMJALNEADT-SFTDATJTSA-N	DB06670	Odanacatib	investigational	nan	Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. The drug made it to phase III trials before abandoned due to increased stroke.	603139-19-1
XULSCZPZVQIMFM-IPZQJPLYSA-N	DB16261	Odevixibat	approved;investigational	A05AX05	Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC).[A236808,L34793] Odevixibat is the first approved non-surgical treatment option for PFIC.[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].[A236808] Odevixibat was granted FDA and Health Canada approval on 20 July 2021 and 13 November 2023 res	501692-44-0
KVWDHTXUZHCGIO-UHFFFAOYSA-N	DB00334	Olanzapine	approved;investigational	N05AH53;N05AH03	Olanzapine is a thienobenzodiazepine derivative and an atypical or second-generation antipsychotic agent.[A176996] Its chemical structure contains a thieno[2,3-b][1,5]benzodiazepine core, and has a methyl group attached to the piperazine ring. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions.[A177011] Olanzapine was discove	132539-06-1
FDLYAMZZIXQODN-UHFFFAOYSA-N	DB09074	Olaparib	approved;investigational	L01XK01	Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.[A246015] Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It wa	763113-22-0
ITIXDWVDFFXNEG-JHOUSYSJSA-N	DB04869	Olcegepant	investigational	nan	Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.	204697-65-4
YGIDGBAHDZEYMT-MQFIMZJJSA-N	DB12895	Olitigaltin	investigational	nan	Olitigaltin has been investigated for the treatment of Idiopathic Pulmonary Fibrosis.	1450824-22-2
GHBCIXGRCZIPNQ-MHZLTWQESA-N	DB16266	Olodanrigan	investigational	nan	Olodanrigan is under investigation in clinical trial NCT03297294 (Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)).	1316755-16-4
GTVPOLSIJWJJNY-UHFFFAOYSA-N	DB02116	Olomoucine	experimental	nan	nan	101622-51-9
LVRLSYPNFFBYCZ-VGWMRTNUSA-N	DB00886	Omapatrilat	experimental	nan	Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns.	167305-00-2
SUBDBMMJDZJVOS-UHFFFAOYSA-N	DB00338	Omeprazole	approved;investigational;vet_approved	A02BC51;A02BC01;A02BD05;A02BD16;A02BD01	Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs [A174232]. Omeprazole is generally effective and well-tolerate	73590-58-6
CGBJSGAELGCMKE-UHFFFAOYSA-N	DB12703	Omipalisib	investigational	nan	Omipalisib has been used in trials studying the treatment of CANCER, Solid Tumours, and Idiopathic Pulmonary Fibrosis.	1086062-66-9
IFRGXKKQHBVPCQ-UHFFFAOYSA-N	DB06306	Onalespib	investigational	nan	nan	912999-49-6
DBSMLQTUDJVICQ-CJODITQLSA-N	DB21480	Onametostat	investigational	nan	Onametostat is a small molecule drug. The usage of the INN stem '-metostat' in the name indicates that Onametostat is a histone N-methyltransferase inhibitor. Onametostat is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring). Onametostat has a monoisotopic molecular weight of 482.11 Da.	2086772-26-9
UFKLYTOEMRFKAD-SHTZXODSSA-N	DB12570	Onatasertib	investigational	nan	Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among others.	1228013-30-6
FELGMEQIXOGIFQ-UHFFFAOYSA-N	DB00904	Ondansetron	approved;investigational;withdrawn	A04AA01	A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as ge	99614-02-5
KELNNWMENBUHNS-NSHDSACASA-N	DB07884	Opaviraline	experimental	nan	nan	178040-94-3
YNZFUWZUGRBMHL-UHFFFAOYSA-N	DB12930	Opipramol	investigational	N06AA05	Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.	315-72-0
JQUVQWMHZSYCRQ-UHFFFAOYSA-N	DB16271	Opiranserin	investigational	nan	Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).	1441000-45-8
SWZXEVABPLUDIO-WSZYKNRRSA-N	DB11991	Oprozomib	investigational	nan	Oprozomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, Waldenstrom Macroglobulinemia, Advanced Hepatocellular Carcinoma, and Advanced Non-Central Nervous System (CNS) Malignancies.	935888-69-0
NHFDRBXTEDBWCZ-ZROIWOOFSA-N	DB12072	Orantinib	investigational	nan	Orantinib has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Kidney Cancer, Gastric Cancer, and Prostate Cancer, among others.	252916-29-3
VJDOPFARMOLELX-ZDUSSCGKSA-N	DB20676	Orbofiban	experimental	nan	Orbofiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Orbofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Orbofiban has a monoisotopic molecular weight of 361.18 Da.	163250-90-6
MZPVEMOYADUARK-UHFFFAOYSA-N	DB16272	Orelabrutinib	investigational	L01EL04	Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).	1655504-04-3
ZININGNRPUGNSL-UHFFFAOYSA-N	DB19042	Orismilast	investigational	nan	Orismilast is under investigation in clinical trial NCT05190419 (Study to Assess the Efficacy and Safety of Orismilast in Psoriasis).	1353546-86-7
AHLBNYSZXLDEJQ-FWEHEUNISA-N	DB01083	Orlistat	approved;investigational	A08AB01	The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.[A229928] Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use 	96829-58-2
XZEUAXYWNKYKPL-WDYNHAJCSA-N	DB13310	Ormeloxifene	experimental	G03XC04	Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week,[A251450] and it was later introduced for the treatment of dysfunctional uterine bleeding.[A251470] Similar to other selective estrogen receptor modulators (SERMs), ormeloxifene has estrogenic activity in the vagina, bone, cardiovascular, and central nervous system tissues, and anti-estrogenic	31477-60-8
QVYRGXJJSLMXQH-UHFFFAOYSA-N	DB01173	Orphenadrine	approved;investigational	M03BC51;N04AB02;M03BC01	A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.	83-98-7
OZPFIJIOIVJZMN-SFHVURJKSA-N	DB12066	Orteronel	investigational	nan	Orteronel has been investigated for the treatment of Prostate Cancer.	566939-85-3
XWNBGDJPEXZSQM-VZOBGQTKSA-N	DB12427	Orvepitant	investigational	nan	Orvepitant has been used in trials studying the treatment of Depressive Disorder, Depressive Disorder, Major, Post-Traumatic Stress Disorder, and Posttraumatic Stress Disorder (PTSD).	579475-18-6
DZOJBGLFWINFBF-UMSFTDKQSA-N	DB04872	Osanetant	investigational	nan	Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.	160492-56-8
VSZGPKBBMSAYNT-RRFJBIMHSA-N	DB00198	Oseltamivir	approved;investigational	J05AH02	Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding from the host cell, viral replication, and infectivity. The clinical benefit of use of oseltamivir is greatest when administered within 48 ho	196618-13-0
NENPYTRHICXVCS-YNEHKIRRSA-N	DB02600	Oseltamivir acid	experimental	nan	nan	187227-45-8
USUZGMWDZDXMDG-CYBMUJFWSA-N	DB11837	Osilodrostat	approved;investigational	H02CA02	Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol.[L12123] It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatme	928134-65-0
DUYJMQONPNNFPI-UHFFFAOYSA-N	DB09330	Osimertinib	approved;investigational	L01EB04	Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients 	1421373-65-0
DVFCRTGTEXUFIN-GFCCVEGCSA-N	DB21547	Osunprotafib	investigational	nan	Osunprotafib is a small molecule drug. The usage of the INN stem '-protafib' in the name indicates that Osunprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor. Osunprotafib is under investigation in clinical trial NCT04777994 (Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors). Osunprotafib has a monoisotopic molecular weight of 385.15 Da.	2489404-97-7
PFGVNLZDWRZPJW-OPAMFIHVSA-N	DB06635	Otamixaban	investigational	nan	Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.	193153-04-7
LPMXVESGRSUGHW-HBYQJFLCSA-N	DB01092	Ouabain	approved	C01AC01	A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.	630-60-4
OFPXSFXSNFPTHF-UHFFFAOYSA-N	DB00991	Oxaprozin	approved	M01AE12	Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.	21256-18-8
BAINIUMDFURPJM-UHFFFAOYSA-N	DB12877	Oxatomide	approved	R06AE06	Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.	60607-34-3
QRJJEGAJXVEBNE-HKOYGPOVSA-N	DB00239	Oxiconazole	approved	D01AC11;G01AF17;G01AF20	Oxiconazole is an antifungal agent that is commonly found in topical formulations. It is marketed under the brand names Oxistat and Oxistat, and is used in the treatment of various skin infections such as athlete's foot, jock itch and ringworm.	64211-45-6
LDCYZAJDBXYCGN-VIFPVBQESA-N	DB02959	Oxitriptan	approved;investigational;nutraceutical;withdrawn	N06AX01	5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication of major depression under trade names like Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, T	4350-09-8
XIQVNETUBQGFHX-UHFFFAOYSA-N	DB01062	Oxybutynin	approved;investigational	G04BD04	Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.	5633-20-5
WYWIFABBXFUGLM-UHFFFAOYSA-N	DB00935	Oxymetazoline	approved;investigational	S01GA04;D11AX27;R01AB07;R01AA05	Oxymetazoline is an imidazole derivative and a potent, direct-acting alpha (α)-adrenergic agonist with affinity to both α<sub>1</sub>- and α<sub>2</sub>-adrenoceptors.[A215542] Oxymetazoline is available in various formulations with a wide variety of clinical implications. The topical formulation of the drug is used to treat persistent facial redness in adults.[L15062] As an effective decongestant, oxymetazoline is available in over-the-counter intranasal sprays used to relieve nasal and sinus c	1491-59-4
UQCNKQCJZOAFTQ-ISWURRPUSA-N	DB01192	Oxymorphone	approved;vet_approved	N02AA11	An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulat	76-41-5
MCJGNVYPOGVAJF-UHFFFAOYSA-N	DB11145	Oxyquinoline	approved;investigational;vet_approved	R02AA14;A01AB07;D08AH03;G01AC30	Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.	148-24-3
ZIQFYVPVJZEOFS-UHFFFAOYSA-N	DB08339	PD-166326	experimental	nan	nan	185039-91-2
HTUBKQUPEREOGA-UHFFFAOYSA-N	DB07662	PD-168393	experimental	nan	PD-168393 is an epidermal growth factor receptor inhibitor.	194423-15-9
BGIYKDUASORTBB-UHFFFAOYSA-N	DB17040	PD-169316	experimental	nan	PD-169316 is a p38 MAP kinase inhibitor.[A253062]	152121-53-4
VAARYSWULJUGST-UHFFFAOYSA-N	DB02567	PD173955	experimental	nan	nan	nan
QGNOXTFZOLDODX-UHFFFAOYSA-N	DB12998	PF-00217830	investigational	nan	PF-00217830 has been used in trials studying the treatment of Schizophrenia.	846032-02-8
VMTJQZUZINLEKC-JOCHJYFZSA-N	DB03367	PF-00356231	experimental	nan	nan	766536-21-4
WGOJWDWKHJHXSV-UHFFFAOYSA-N	DB12408	PF-03635659	investigational	nan	Pf03635659 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.	931409-24-4
VGEXRDWWPSGZDH-UHFFFAOYSA-N	DB12138	PF-03715455	investigational	nan	PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and Chronic Obstructive Pulmonary Disease (COPD).	1056164-52-3
AYCPARAPKDAOEN-LJQANCHMSA-N	DB11775	PF-03758309	investigational	nan	PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.	898044-15-0
RYYNGWLOYLRZLK-RBUKOAKNSA-N	DB13059	PF-03814735	investigational	nan	PF-03814735 has been used in trials studying the treatment of Solid Tumors.	942487-16-3
XNULRSOGWPFPBL-REWPJTCUSA-N	DB11814	PF-03882845	investigational	nan	PF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.	1023650-66-9
LWJGMYMNSNVCEM-UHFFFAOYSA-N	DB12024	PF-04418948	investigational	nan	Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).	1078166-57-0
BATCTBJIJJEPHM-UHFFFAOYSA-N	DB12012	PF-04457845	investigational	nan	PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.	1020315-31-4
XDLYKKIQACFMJG-WKILWMFISA-N	DB11974	PF-04691502	investigational	nan	PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).	1013101-36-4
ZYSCOUXLBXGGIM-UHFFFAOYSA-N	DB14856	PF-05089771	investigational	nan	PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).	1235403-62-9
BDXXSFOJPYSYOC-UHFFFAOYSA-N	DB12096	PF-05175157	investigational	nan	PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among others.	1301214-47-0
BPIWZDNVMQQBQX-UHFFFAOYSA-N	DB12269	PF-06273340	investigational	nan	Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).	1402438-74-7
ICYNYWFGIDGBRD-UHFFFAOYSA-N	DB11683	PF-06282999	investigational	nan	Pf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).	1435467-37-0
ODMXWZROLKITMS-RISCZKNCSA-N	DB14768	PF-06459988	investigational	nan	PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).	1428774-45-1
ZLZUHACSRMOLLV-RAALSFIWSA-N	DB15105	PF-06751979	investigational	nan	PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).	1818339-66-0
RXCVUHMIWHRLDF-HXUWFJFHSA-N	DB14799	PF-06821497	investigational	nan	PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).	1844849-10-0
PITORJXKOJWMTN-SJLPKXTDSA-N	DB18039	PF-06842874	investigational	nan	nan	2516247-98-4
KXVKOYCGACSUPP-INIZCTEOSA-N	DB19143	PF-07038124	investigational	nan	PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).	2415085-44-6
NDEXUOWTGYUVGA-LJQANCHMSA-N	DB12611	PF-477736	investigational	nan	PF-00477736 has been used in trials studying the treatment of Neoplasms.	952021-60-2
KCAJXIDMCNPGHZ-UHFFFAOYSA-N	DB07941	PH-797804	investigational	nan	PH-797804 has been investigated for the treatment of Osteoarthritis.	586379-66-0
DKXHSOUZPMHNIZ-UHFFFAOYSA-N	DB17043	PHA-767491	experimental	nan	PHA-767491 is a Cdc7/CDK9 inhibitor.[A253077]	845714-00-3
HUXYBQXJVXOMKX-UHFFFAOYSA-N	DB12686	PHA-793887	investigational	nan	PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.	718630-59-2
UQAWGIKJINAKIZ-UHFFFAOYSA-N	DB04607	PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE	experimental	nan	nan	nan
TUVCWJQQGGETHL-UHFFFAOYSA-N	DB17046	PI-103	experimental	nan	PI-103 is an inhibitor of p110α of class I PI3K.[A253092]	371935-74-9
QTHCAAFKVUWAFI-DJKKODMXSA-N	DB17047	PIK-75	experimental	nan	PIK-75 is a preferential p110 alpha/gamma PI3K inhibitor.[A253097]	945619-31-8
YZDJQTHVDDOVHR-UHFFFAOYSA-N	DB06999	PLX-4720	experimental	nan	nan	918505-84-7
NVRXTLZYXZNATH-UHFFFAOYSA-N	DB08052	PP-121	experimental	nan	nan	1092788-83-4
QAHLFXYLXBBCPS-IZEXYCQBSA-N	DB05961	PPL-100	investigational	nan	nan	612547-11-2
UBIIFKJMNRPNMT-CQSZACIVSA-N	DB08391	PQ-10	experimental	nan	nan	927691-21-2
ONBSHRSJOPSEGS-INIZCTEOSA-N	DB16055	PT-2385	investigational	nan	PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).	1672665-49-4
COLCNDRDBCLVOC-ICSRJNTNSA-N	DB18125	PTX-100	investigational	nan	nan	501010-06-6
MEDBIJOVZJEMBI-YOEHRIQHSA-N	DB14030	PZM21	experimental	nan	PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine. [A33051]	1997387-43-5
RCINICONZNJXQF-MZXODVADSA-N	DB01229	Paclitaxel	approved;investigational;vet_approved	L01CD01;L01CD51	Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.	33069-62-4
HWXVIOGONBBTBY-ONEGZZNKSA-N	DB11697	Pacritinib	approved;investigational	L01EJ03	Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.[L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia.[L40793] While some patients may remain asymptomatic, typical symptoms of MF arise from abnormalities in blood cell production and may therefore include various cytopenias, infections, splenomegaly, and general systemic s	937272-79-2
MRFOPLWJZULAQD-SWGQDTFXSA-N	DB19243	Padnarsertib	investigational	nan	nan	1643913-93-2
AHJRHEGDXFFMBM-UHFFFAOYSA-N	DB09073	Palbociclib	approved;investigational	L01EF01	Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.[A176810] Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth.[L5867] It was originally FDA approved on March 2015 for the treatment of HR-p	571190-30-2
RXBWRFDZXRAEJT-SZNOJMITSA-N	DB20083	Palinavir	experimental	nan	Palinavir is a small molecule drug. The usage of the INN stem '-vir' in the name indicates that Palinavir is a antiviral. Palinavir has a monoisotopic molecular weight of 708.4 Da.	154612-39-2
PMXMIIMHBWHSKN-UHFFFAOYSA-N	DB01267	Paliperidone	approved;investigational	N05AX13	Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the	144598-75-4
IPCSVZSSVZVIGE-UHFFFAOYSA-N	DB03796	Palmitic Acid	approved;investigational	nan	A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.	57-10-3
CPZBLNMUGSZIPR-NVXWUHKLSA-N	DB00377	Palonosetron	approved;investigational	A04AA55;A04AA05	Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagoni	135729-56-5
WYJCYXOCHXWTHG-UHFFFAOYSA-N	DB21258	Palosuran	experimental	nan	Palosuran is a small molecule drug. The usage of the INN stem '-osuran' in the name indicates that Palosuran is a urotensin receptor antagonist. Palosuran has a monoisotopic molecular weight of 418.24 Da.	540769-28-6
MKLKAQMPKHNQPR-NSHDSACASA-N	DB21421	Palupiprant	investigational	nan	Palupiprant is a small molecule drug. Palupiprant has a monoisotopic molecular weight of 483.12 Da.	1369489-71-3
JYYLVUFNAHSSFE-UHFFFAOYSA-N	DB19169	Pamapimod	investigational	nan	Pamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2).	449811-01-2
WRUUGTRCQOWXEG-UHFFFAOYSA-N	DB00282	Pamidronic acid	approved;investigational	M05BA03	Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.[A203267] The second generation bisphosphonates are less common as third generation bisphosphonates, such as [ibandronic acid], [zoledronic acid], [minodronic acid], and [risedronic acid] are becoming more popular.[A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]	40391-99-9
DENYZIUJOTUUNY-MRXNPFEDSA-N	DB14769	Pamiparib	investigational	L01XK06	Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).	1446261-44-4
ORRNXRYWGDUDOG-UHFFFAOYSA-N	DB20752	Pamufetinib	investigational	nan	Pamufetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Pamufetinib is a tyrosine kinase inhibitor. Pamufetinib is under investigation in clinical trial NCT04999761 (AB122 Platform Study). Pamufetinib has a monoisotopic molecular weight of 518.14 Da.	1190836-34-0
ZGEGOFCLSWVVKG-UHFFFAOYSA-N	DB21275	Panadiplon	experimental	nan	Panadiplon is a small molecule drug. Panadiplon has a monoisotopic molecular weight of 335.14 Da.	124423-84-3
IQPSEEYGBUAQFF-UHFFFAOYSA-N	DB00213	Pantoprazole	approved;investigational	A02BD04;A02BD11;A02BC02	Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromyc	102625-70-7
XQYZDYMELSJDRZ-UHFFFAOYSA-N	DB01113	Papaverine	approved;investigational	G04BE02;A03AD01;G04BE52	An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.	58-74-2
WYMSBXTXOHUIGT-UHFFFAOYSA-N	DB13495	Paraoxon	experimental	S01EB10	nan	311-45-5
DPWPWRLQFGFJFI-UHFFFAOYSA-N	DB01626	Pargyline	approved	C02LL01;C02KC01	Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.	555-57-7
UOZODPSAJZTQNH-LSWIJEOBSA-N	DB01421	Paromomycin	approved;investigational	A07AA06	An oligosaccharide antibiotic produced by various streptomyces. [PubChem]	7542-37-2
AHOUBRCZNHFOSL-YOEHRIQHSA-N	DB00715	Paroxetine	approved;investigational	N06AB05	Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other ne	61869-08-7
VMZMNAABQBOLAK-DBILLSOUSA-N	DB06663	Pasireotide	approved;investigational	H01CB05	Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.	396091-73-9
QXRSDHAAWVKZLJ-PVYNADRNSA-N	DB03010	Patupilone	investigational	nan	Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.	152044-54-7
LGWACEZVCMBSKW-UHFFFAOYSA-N	DB15186	Paxalisib	investigational	nan	GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).	1382979-44-3
CUIHSIWYWATEQL-UHFFFAOYSA-N	DB06589	Pazopanib	approved;investigational	L01EX03	Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.	444731-52-6
AZXOTZCWQDJCLY-SJCJKPOMSA-N	DB16279	Pecavaptan	investigational	nan	Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).	1914998-56-3
WVUNYSQLFKLYNI-AATRIKPKSA-N	DB05524	Pelitinib	investigational	nan	Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.	257933-82-7
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	DB00642	Pemetrexed	approved;investigational	L01BA04	Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.[A253907]	137281-23-3
HCDMJFOHIXMBOV-UHFFFAOYSA-N	DB15102	Pemigatinib	approved;investigational	L01EN02	Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.[A193719] FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach.[A198984] Deregulated	1513857-77-6
JLCCNYVTIWRPIZ-NRFANRHFSA-N	DB19170	Pemrametostat	investigational	nan	Pemrametostat is under investigation in clinical trial NCT03614728 (Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)).	1616392-22-3
MDLAAYDRRZXJIF-UHFFFAOYSA-N	DB13791	Penfluridol	investigational	N05AG03	nan	26864-56-2
XDRYMKDFEDOLFX-UHFFFAOYSA-N	DB00738	Pentamidine	approved;investigational	P01CX01	Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.	100-33-4
VOKSWYLNZZRQPF-UHFFFAOYSA-N	DB00652	Pentazocine	approved;vet_approved	N02AD51;N02AD01	The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)	359-83-1
FPVKHBSQESCIEP-JQCXWYLXSA-N	DB00552	Pentostatin	approved;investigational	L01XX08	A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.	53910-25-1
CFJMRBQWBDQYMK-UHFFFAOYSA-N	DB11186	Pentoxyverine	approved;withdrawn	R05DB05	Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160]. Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate.[L43942] Other forms	77-23-6
FAXGPCHRFPCXOO-LXTPJMTPSA-N	DB21282	Pepstatin	experimental	nan	Pepstatin is a small molecule drug. Pepstatin has a monoisotopic molecular weight of 685.46 Da.	26305-03-3
YEHCICAEULNIGD-MZMPZRCHSA-N	DB01186	Pergolide	approved;vet_approved;withdrawn	N04BC02	Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the	66104-22-1
CYXKNKQEMFBLER-UHFFFAOYSA-N	DB01074	Perhexiline	approved	C08EX02	Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	6621-47-2
SZFPYBIJACMNJV-UHFFFAOYSA-N	DB06641	Perifosine	investigational	nan	Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.	157716-52-4
PWRPUAKXMQAFCJ-UHFFFAOYSA-N	DB19952	Perlapine	experimental	nan	Perlapine is a small molecule drug. Perlapine has a monoisotopic molecular weight of 291.17 Da.	1977-11-3
RGCVKNLCSQQDEP-UHFFFAOYSA-N	DB00850	Perphenazine	approved;investigational	N05AB03	An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.	58-39-9
BDABGOLMYNHHTR-UHFFFAOYSA-N	DB12365	Perzinfotel	investigational	nan	Perzinfotel has been used in trials studying the treatment of Diabetes Mellitus and Diabetic Neuropathy, Painful.	144912-63-0
MPUQHZXIXSTTDU-QXGSTGNESA-N	DB11759	Pevonedistat	investigational	nan	Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.	905579-51-3
JGWRKYUXBBNENE-UHFFFAOYSA-N	DB12978	Pexidartinib	approved;investigational	L01EX15	Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor.[L7901] Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to d	1029044-16-3
LNMRSSIMGCDUTP-UHFFFAOYSA-N	DB16294	Pexmetinib	investigational	nan	Pexmetinib is under investigation in clinical trial NCT04074967 (Study of ARRY-614 Plus Either Nivolumab or Ipilimumab).	945614-12-0
FPZTYKLEJPXTKD-UHFFFAOYSA-N	DB19509	Phenamazoline	experimental	nan	Phenamazoline is a small molecule drug. The usage of the INN stem '-azoline' in the name indicates that Phenamazoline is a antihistaminic or local vasoconstrictor, antazoline derivative. Phenamazoline has a monoisotopic molecular weight of 175.11 Da.	501-62-2
CGMJQQJSWIRRRL-UHFFFAOYSA-N	DB19164	Phenazepam	investigational	nan	Phenazepam is under investigation in clinical trial NCT03017430 (Pregabalin for Opiate Withdrawal Syndrome).	51753-57-2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N	DB03575	Phencyclidine	experimental;illicit	nan	A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to ketamine in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (receptors, N-methyl-D-aspartate). As a drug of abuse, it is known as PCP and Angel Dust.	77-10-1
RMUCZJUITONUFY-UHFFFAOYSA-N	DB00780	Phenelzine	approved;investigational	N06AF03	Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.	51-71-8
DQDAYGNAKTZFIW-UHFFFAOYSA-N	DB00946	Phenprocoumon	approved;investigational;withdrawn	B01AA04	Coumarin derivative that acts as a long-acting oral anticoagulant.	435-97-2
MRBDMNSDAVCSSF-UHFFFAOYSA-N	DB00692	Phentolamine	approved;investigational	V03AB36;C04AB01	Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocyto	50-60-2
HXITXNWTGFUOAU-UHFFFAOYSA-N	DB01795	Phenylboronic acid	experimental	nan	nan	98-80-6
SONNWYBIRXJNDC-VIFPVBQESA-N	DB00388	Phenylephrine	approved;investigational	S01FB01;R01AB01;C01CA06;R01AA04;C05AX06;S01FB51;S01GA05;R01BA53;S01GA55;R01BA03	Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413]	59-42-7
DLNKOYKMWOXYQA-UHFFFAOYSA-N	DB00397	Phenylpropanolamine	approved;vet_approved;withdrawn	R01BA51;R01BA01	Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.	14838-15-4
IZRPKIZLIFYYKR-UHFFFAOYSA-N	DB11160	Phenyltoloxamine	approved	nan	Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as a	92-12-6
IOUVKUPGCMBWBT-QNDFHXLGSA-N	DB16771	Phlorizin	experimental	nan	nan	60-81-1
PHEDXBVPIONUQT-RGYGYFBISA-N	DB17045	Phorbol 12-myristate 13-acetate diester	investigational	nan	Phorbol 12-myristate 13-acetate diester is an inducer of neutrophil extracellular traps (NETs).[A253087]	16561-29-8
UQABYHGXWYXDTK-UUOKFMHZSA-N	DB02082	Phosphoaminophosphonic acid guanylate ester	experimental	nan	A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of adenylate cyclase.	34273-04-6
LDKRAXXVBWHMRH-UHFFFAOYSA-N	DB03645	Phosphonoacetohydroxamic Acid	experimental	nan	nan	nan
ZPHBZEQOLSRPAK-XLCYBJAPSA-N	DB02557	Phosphoramidon	experimental	nan	nan	36357-77-4
PIJVFDBKTWXHHD-HIFRSBDPSA-N	DB00981	Physostigmine	approved	S01EB05;V03AB19	A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	57-47-6
RRRUXBQSQLKHEL-UHFFFAOYSA-N	DB01791	Piclamilast	experimental	nan	Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast.	144035-83-6
HUJXGQILHAUCCV-MOROJQBDSA-N	DB05511	Piclidenoson	investigational	nan	CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.	152918-18-8
LHNIIDJUOCFXAP-UHFFFAOYSA-N	DB11663	Pictilisib	investigational	nan	Pictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and Non-Hodgkin's Lymphoma, Solid Cancers, among others.	957054-30-7
QINPEPAQOBZPOF-UHFFFAOYSA-N	DB11772	Pilaralisib	investigational	nan	Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.	934526-89-3
RKAHOQATMSONTM-IBGZPJMESA-N	DB21552	Pilavapadin	investigational	nan	Pilavapadin is a small molecule drug. Pilavapadin is under investigation in clinical trial NCT06203002 (A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)). Pilavapadin has a monoisotopic molecular weight of 385.18 Da.	1815613-42-3
VIUAUNHCRHHYNE-JTQLQIEISA-N	DB14904	Pimasertib	investigational	nan	Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).	1236699-92-5
RKEWSXXUOLRFBX-UHFFFAOYSA-N	DB05316	Pimavanserin	approved;investigational	N05AX17	Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.[L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors.[L48236] Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pima	706779-91-1
NXFPMDWYDKHFMM-UHFFFAOYSA-N	DB18972	Pimicotinib	investigational	nan	Pimicotinib is under investigation in clinical trial NCT05804045 (Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)). It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]	2253123-16-7
NVVPMZUGELHVMH-UHFFFAOYSA-N	DB14876	Pimitespib	investigational	nan	TAS-116 is under investigation in clinical trial NCT02965885 (A Study of TAS-116 in Patients With Solid Tumors).	1260533-36-5
GLBJJMFZWDBELO-UHFFFAOYSA-N	DB11450	Pimobendan	experimental;vet_approved	nan	nan	74150-27-9
YVUQSNJEYSNKRX-UHFFFAOYSA-N	DB01100	Pimozide	approved	N05AG02	A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)	2062-78-4
IVVNZDGDKPTYHK-UHFFFAOYSA-N	DB06762	Pinacidil	approved	C02DG01;C02LX01	Pinacidil is a cyanoguanidine drug that acts by opening ATP-sensitive potassium channels, leading to peripheral vasodilatation of arterioles and decreasing peripheral vascular resistance. The above processes result in reduced blood pressure. This drug has been discontinued by the FDA.	60560-33-0
JZQKKSLKJUAGIC-UHFFFAOYSA-N	DB00960	Pindolol	approved;investigational	C07CA03;C07AA03	Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.[L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.[A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]	13523-86-9
HYAFETHFCAUJAY-UHFFFAOYSA-N	DB01132	Pioglitazone	approved;investigational	A10BD09;A10BG03;A10BD05;A10BD06;A10BD12	Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primari	111025-46-8
OSJJYEUEJRVVOD-UHFFFAOYSA-N	DB20091	Pipamazine	experimental	nan	Pipamazine is a small molecule drug. Pipamazine has a monoisotopic molecular weight of 401.13 Da.	84-04-8
AXKPFOAXAHJUAG-UHFFFAOYSA-N	DB09286	Pipamperone	investigational	N05AD05	Pipamperone is a typical antipsychotic of the _butyrophenone_ family used in the treatment of schizophrenia. It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic drugs at this time, had significant anti-tryptamine activity. Som	1893-33-0
JICOGKJOQXTAIP-UHFFFAOYSA-N	DB05414	Pipendoxifene	investigational	nan	ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.	198480-55-6
MXXWOMGUGJBKIW-YPCIICBESA-N	DB12582	Piperine	investigational	nan	Bioperine has been used in trials studying the treatment of Multiple Myeloma and Deglutition Disorders.	94-62-2
JOMHSQGEWSNUKU-UHFFFAOYSA-N	DB01621	Pipotiazine	approved;investigational;withdrawn	N05AC04	Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, l	39860-99-6
HXCNRYXBZNHDNE-UHFFFAOYSA-N	DB21405	Pirenperone	experimental	nan	Pirenperone is a small molecule drug. The usage of the INN stem '-perone' in the name indicates that Pirenperone is a tranquillizer, neuroleptic, 4'-fluoro-4-piperidinobutyrophenone derivative. Pirenperone has a monoisotopic molecular weight of 393.19 Da.	75444-65-4
RMHMFHUVIITRHF-UHFFFAOYSA-N	DB00670	Pirenzepine	approved;withdrawn	A02BX03	An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients.	28797-61-7
OQDPVLVUJFGPGQ-UHFFFAOYSA-N	DB12478	Piribedil	investigational	N04BC08	Piribedil has been investigated in Parkinson's Disease.	3605-01-4
VJXSSYDSOJBUAV-UHFFFAOYSA-N	DB03695	Piritrexim	investigational	nan	Piritrexim has been used in trials studying the treatment of Bladder Cancer, Urethral Cancer, and Transitional Cell Cancer of the Renal Pelvis and Ureter.	72732-56-0
QYSPLQLAKJAUJT-UHFFFAOYSA-N	DB00554	Piroxicam	approved;investigational	M01AC01;M02AA07;S01BC06	A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.	36322-90-4
NNACHAUCXXVJSP-UHFFFAOYSA-N	DB11642	Pitolisant	approved;investigational	N07XX11	Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy.[L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations.[A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions.	362665-56-3
FIADGNVRKBPQEU-UHFFFAOYSA-N	DB06153	Pizotifen	approved	N02CX01	Pizotifen belongs to the class of antamines and is related to [cyproheptadine].[A32532] It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years. It exhibits weak anticholinergic, antihistamine, and antikinin actions in addition to sedative and appetite-stimulating properties [L2292]. Some patients receiving pizotifen treatment developed tolerance with the prolonged use of the drug [L2292]. Numerous studies have revealed the potential antidepre	15574-96-6
YIQPUIGJQJDJOS-UHFFFAOYSA-N	DB06809	Plerixafor	approved;investigational	L03AX16	Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.[A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.[A7118,L45678] As an in	110078-46-1
YJGVMLPVUAXIQN-XVVDYKMHSA-N	DB01179	Podofilox	approved	D06BB04	A lignan found in podophyllin resin from the roots of podophyllum plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.	518-28-5
UVSMNLNDYGZFPF-UHFFFAOYSA-N	DB08910	Pomalidomide	approved;investigational	L04AX06	Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.	19171-19-8
PHXJVRSECIGDHY-UHFFFAOYSA-N	DB08901	Ponatinib	approved;investigational	L01EA05	Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.	943319-70-8
MSGYSFWCPOBHEV-AWEZNQCLSA-N	DB18855	Povorcitinib	investigational	nan	Povorcitinib is under investigation in clinical trial NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)).	1637677-22-5
YRVIKLBSVVNSHF-JTQLQIEISA-N	DB05458	Pozanicline	investigational	nan	ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity Disorder and Schizophrenia/Schizoaffective disorders. In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes. Neuronal nicotinic acetylcholine receptors (nAChRs) modulate the release of s	161417-03-4
LPFWVDIFUFFKJU-UHFFFAOYSA-N	DB12114	Poziotinib	investigational	nan	Poziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB, among others.	1092364-38-9
JHDKZFFAIZKUCU-ZRDIBKRKSA-N	DB05223	Pracinostat	investigational	nan	Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.	929016-96-6
DURULFYMVIFBIR-UHFFFAOYSA-N	DB01297	Practolol	approved	C07AB01	A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.	6673-35-4
OGSBUKJUDHAQEA-WMCAAGNKSA-N	DB06813	Pralatrexate	approved;investigational	L01BA05	Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma [L37674]. Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.[A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.[A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulate	146464-95-1
CXAGHAZMQSCAKJ-WAHHBDPQSA-N	DB04875	Pralnacasan	experimental	nan	Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).	192755-52-5
GBLBJPZSROAGMF-RWYJCYHVSA-N	DB15822	Pralsetinib	approved;investigational	L01EX23	Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, th	2097132-94-8
FASDKYOPVNHBLU-ZETCQYMHSA-N	DB00413	Pramipexole	approved;investigational	N04BC05	Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) [A176867]. It was first approved by the FDA in 1997 [L5882]. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients [A176855], leading to increased difficulty in performing activities of dail	104632-26-0
TZIRZGBAFTZREM-MKAGXXMWSA-N	DB01278	Pramlintide	approved;investigational	A10BX05	Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.	151126-32-8
NBQKINXMPLXUET-UHFFFAOYSA-N	DB01411	Pranlukast	investigational	R03DC02	Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.	103177-37-3
KCTFTBCZZUBAKN-UHFFFAOYSA-N	DB20100	Pratosartan	experimental	nan	Pratosartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Pratosartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). Pratosartan has a monoisotopic molecular weight of 426.22 Da.	153804-05-8
IENZQIKPVFGBNW-UHFFFAOYSA-N	DB00457	Prazosin	approved;investigational	C02LE01;C02CA01	Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.[A176618, A176621, A176624]	19216-56-9
HTSNFXAICLXZMA-CYBMUJFWSA-N	DB20444	Preclamol	experimental	nan	Preclamol is a small molecule drug. Preclamol has a monoisotopic molecular weight of 219.16 Da.	85966-89-8
OIGNJSKKLXVSLS-VWUMJDOOSA-N	DB00860	Prednisolone	approved;investigational;vet_approved	D07AA03;S01CA02;D07XA02;A01AC54;R01AD02;S01BB02;S01CB02;R01AD52;V03AB05;S03BA02;D07BA01;D07CA03;S01BA04;S02BA03;A01AC04;A07EA01;H02AB06;S02CA01;C05AA04;S03CA02	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]	50-24-8
AYXYPKUFHZROOJ-ZETCQYMHSA-N	DB00230	Pregabalin	approved;investigational	N02BF02	Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.[A173995] It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions.[A187190] Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190,L7066] Pregabalin is marketed by Pfizer under 	148553-50-8
IFFPICMESYHZPQ-UHFFFAOYSA-N	DB04825	Prenylamine	approved;withdrawn	C01DX52;C01DX02	Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.	390-64-7
DOTGPNHGTYJDEP-UHFFFAOYSA-N	DB12008	Prexasertib	investigational	nan	Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.	1234015-52-1
WAAVMZLJRXYRMA-UHFFFAOYSA-N	DB19479	Prifelone	experimental	nan	Prifelone is a small molecule drug. Prifelone has a monoisotopic molecular weight of 316.15 Da.	69425-13-4
INDBQLZJXZLFIT-UHFFFAOYSA-N	DB01087	Primaquine	approved;investigational	P01BA03	An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)	90-34-6
MQIMZDXIAHJKQP-UHFFFAOYSA-N	DB06832	Prinaberel	investigational	nan	Prinaberel is an estrogen receptor beta agonist.	524684-52-4
YKPYIPVDTNNYCN-INIZCTEOSA-N	DB05100	Prinomastat	investigational	nan	Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.	192329-42-3
JFACETXYABVHFD-WXPPGMDDSA-N	DB17049	Pristimerin	experimental	nan	Pristimerin is a quinone methide triterpenoid researched for its anti-cancer potential.[A253107]	1258-84-0
IVZKZONQVYTCKC-UHFFFAOYSA-N	DB11844	Pritelivir	investigational	nan	Pritelivir has been used in trials studying the prevention of HSV-2 and Genital Herpes.	348086-71-5
DBABZHXKTCFAPX-UHFFFAOYSA-N	DB01032	Probenecid	approved;investigational	M04AB01;G01AE10;M04AC51	The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.	57-66-9
REQCZEXYDRLIBE-UHFFFAOYSA-N	DB01035	Procainamide	approved	C01BA02	A derivative of procaine with less CNS action.	51-06-9
WIKYUJGCLQQFNW-UHFFFAOYSA-N	DB00433	Prochlorperazine	approved;investigational;vet_approved	N05AB04	Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.[L6637] P	58-38-8
WYDUSKDSKCASEF-UHFFFAOYSA-N	DB00387	Procyclidine	approved	N04AA04	A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.	77-37-2
RJKFOVLPORLFTN-LEKSSAKUSA-N	DB00396	Progesterone	approved;investigational;vet_approved	G03FA04;G03DA04	Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss [A175609]. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization [T481], [A175612] as well as in other formulations to promote and support pregnancy. Please see [Me	57-83-0
JWHAUXFOSRPERK-UHFFFAOYSA-N	DB01182	Propafenone	approved;investigational	C01BC03	An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.	54063-53-5
ZDWVWKDAWBGPDN-UHFFFAOYSA-O	DB02166	Propidium	experimental	nan	Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits. [PubChem]	36015-30-2
AQHHHDLHHXJYJD-UHFFFAOYSA-N	DB00571	Propranolol	approved;investigational	C07FX01;C07AA05;C07BA05	Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]	525-66-6
BWPIARFWQZKAIA-UHFFFAOYSA-N	DB00344	Protriptyline	approved	N06AA11	Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs dow	438-60-8
AQRLDDAFYYAIJP-UHFFFAOYSA-N	DB13094	Pruvanserin	investigational	nan	Pruvanserin has been used in trials studying the treatment of Sleep Initiation and Maintenance Disorders.	443144-26-1
VLEUZFDZJKSGMX-ONEGZZNKSA-N	DB17939	Pterostilbene	investigational	nan	nan	18259-15-9
HKEAFJYKMMKDOR-VPRICQMDSA-N	DB12290	Puerarin	investigational	nan	Puerarin has been investigated for the treatment of Alcohol Abuse.	3681-99-0
RXWNCPJZOCPEPQ-NVWDDTSBSA-N	DB08437	Puromycin	experimental	nan	Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.	53-79-2
ZKDXRFMOHZVXSG-HNNXBMFYSA-N	DB02733	Purvalanol	experimental	nan	nan	nan
PMXCMJLOPOFPBT-HNNXBMFYSA-N	DB04751	Purvalanol A	experimental	nan	nan	212844-53-6
BGRWSFIQQPVEML-UHFFFAOYSA-N	DB14718	Pyrazolam	experimental	nan	nan	39243-02-2
ACPOUJIDANTYHO-UHFFFAOYSA-N	DB01782	Pyrazolanthrone	experimental	nan	nan	129-56-6
RVOLLAQWKVFTGE-UHFFFAOYSA-N	DB00545	Pyridostigmine	approved;investigational	N07AA02	Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue.[A231004] Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. By inhibiting the breakdown of acetylcholine in the neuromuscular junc	155-97-5
RADKZDMFGJYCBB-UHFFFAOYSA-N	DB00147	Pyridoxal	experimental;nutraceutical	nan	The 4-carboxyaldehyde form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. [PubChem]	66-72-8
WKSAUQYGYAYLPV-UHFFFAOYSA-N	DB00205	Pyrimethamine	approved;investigational;vet_approved	P01BF09;P01BD01;P01BD51;P01BF04	One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.	58-14-0
FGVVTMRZYROCTH-UHFFFAOYSA-N	DB06815	Pyrithione	approved	D11AX12	Pyrithione zinc, or zinc pyrithione or zinc pyridinethione, is a coordination complex consisted of pyrithione ligands chelated to zinc (2+) ions via oxygen and sulfur centers. In the crystalline state, it exists as a centrosymmetric dimer. Due to its dynamic fungistatic and bacteriostatic properties, pyrithione zinc is used to treat dandruff and seborrheic dermatitis. Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia	1121-31-9
SADXACCFNXBCFY-IYNHSRRRSA-N	DB14993	Pyrotinib	investigational	nan	Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).	1269662-73-8
PTJGLFIIZFVFJV-UHFFFAOYSA-N	DB12847	Pyroxamide	investigational	nan	Pyroxamide has been used in trials studying the treatment of Leukemia, Lymphoma, Small Intestine Cancer, Precancerous Condition, and Myelodysplastic Syndromes, among others.	382180-17-8
BHZFZYLBVSWUMT-ZCFIWIBFSA-N	DB20571	Quazinone	experimental	nan	Quazinone is a small molecule drug. Quazinone has a monoisotopic molecular weight of 235.05 Da.	70018-51-8
URKOMYMAXPYINW-UHFFFAOYSA-N	DB01224	Quetiapine	approved;investigational	N05AH04	Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.[L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].[A2189]	111974-69-7
NZOONKHCNQFYCI-UHFFFAOYSA-N	DB20376	Quiflapon	experimental	nan	Quiflapon is a small molecule drug. The usage of the INN stem '-flapon' in the name indicates that Quiflapon is a 5-lipoxygenase-activating protein (FLAP) inhibitor. Quiflapon has a monoisotopic molecular weight of 586.21 Da.	136668-42-3
TUFADSGTJUOBEH-ZWNOBZJWSA-N	DB21425	Quinelorane	experimental	nan	Quinelorane is a small molecule drug. Quinelorane has a monoisotopic molecular weight of 246.18 Da.	97466-90-5
LOUPRKONTZGTKE-LHHVKLHASA-N	DB00908	Quinidine	approved	C01BA01;C01BA51;C01BA71	Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm.[A38016] It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “qui	56-54-2
FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	DB19663	Quinpirole	experimental	nan	Quinpirole is a small molecule drug. Quinpirole has a monoisotopic molecular weight of 219.17 Da.	80373-22-4
XRXDAJYKGWNHTQ-UHFFFAOYSA-N	DB19963	Quipazine	experimental	nan	Quipazine is a small molecule drug. Quipazine has a monoisotopic molecular weight of 213.13 Da.	4774-24-7
PAWIYAYFNXQGAP-UHFFFAOYSA-N	DB12985	Quisinostat	investigational	nan	Quisinostat has been used in trials studying the treatment of Lymphoma, Neoplasms, Myelodysplastic Syndromes, and Advanced or Refractory Leukemia.	875320-29-9
ASNFTDCKZKHJSW-REOHCLBHSA-N	DB02999	Quisqualic acid	experimental	nan	Quisqualic acid is an agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of _Quisqualis chinensis_.	52809-07-1
CVWXJKQAOSCOAB-UHFFFAOYSA-N	DB12874	Quizartinib	approved;investigational	L01EX11	Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind.[A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.[L47426] FLT3-ITD mutation is present in 75% of FLT3-mutated AML, leading	950769-58-1
KKKRKRMVJRHDMG-UHFFFAOYSA-N	DB06518	R-1487	experimental	nan	nan	449811-92-1
GARXJOUQUSNOGK-UHFFFAOYSA-N	DB09179	R-30490	experimental	nan	R-30490 is an opioid related to carfentanil used as an animal tranquilizer. It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives. R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely related drug sufentanil is widely used for analgesia and anesthesia during major surgery.	60618-49-7
MUTBJZVSRNUIHA-UHFFFAOYSA-N	DB12382	R-306465	investigational	nan	R306465 has been used in trials studying the treatment of Neoplasms.	604769-01-9
RCSLUNOLLUVOOG-NSHDSACASA-N	DB08598	R-82913	experimental	nan	nan	126347-69-1
CMYCCJYVZIMDFU-UHFFFAOYSA-N	DB02016	R048-8071	experimental	nan	nan	161582-11-2
ZYXHQIPQIKTEDI-UHFFFAOYSA-N	DB06553	R107474	experimental	nan	nan	214548-46-6
MOXXQFNQDDSJHT-UHFFFAOYSA-N	DB06316	R343	investigational	nan	R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.	575484-78-5
YABJJWZLRMPFSI-UHFFFAOYSA-N	DB05984	RAF-265	investigational	nan	nan	927880-90-8
OTPNDVKVEAIXTI-IYBDPMFKSA-N	DB08683	REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE	experimental	nan	nan	nan
VOPDXHFYDJAYNS-UHFFFAOYSA-N	DB16955	RG-2833	experimental	nan	nan	1215493-56-3
OJPLJFIFUQPSJR-INIZCTEOSA-N	DB11870	RG-4733	investigational	nan	Ro4929097 has been used in trials studying the treatment of Sarcoma, LYMPHOMA, Neoplasms, Wilm's Tumor, and OSTEOSARCOMA, among others.	847925-91-1
JRNJNYBQQYBCLE-UHFFFAOYSA-N	DB08094	RO-4584820	investigational	nan	nan	741713-40-6
FIMYFEGKMOCQKT-UHFFFAOYSA-N	DB12933	RO-4987655	investigational	nan	RO4987655 has been used in trials studying the treatment of Neoplasms.	874101-00-5
XFKVLKLCLYJKNF-MZNJEOGPSA-N	DB04424	RPR128515	experimental	nan	nan	nan
BKVIWGRFRKLFIO-UHFFFAOYSA-N	DB17050	RS-39604	experimental	nan	RS-39604 is a selective 5-HT4 receptor antagonist.[A253112]	161362-65-8
NQABUEUFRXDDFI-AWEZNQCLSA-N	DB03251	RWJ-51084	experimental	nan	nan	nan
VXDAVYUFYPFGDX-SNPRPXQTSA-N	DB02812	RWJ-56423	experimental	nan	nan	nan
YREYEVIYCVEVJK-UHFFFAOYSA-N	DB01129	Rabeprazole	approved;investigational	A02BD12;A02BD13;A02BC54;A02BC04	Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.	117976-89-3
WAOQONBSWFLFPE-VIFPVBQESA-N	DB12518	Raclopride	investigational	nan	Raclopride has been used in trials studying Parkinson Disease.	84225-95-6
RCOBKSKAZMVBHT-TVQRCGJNSA-N	DB11790	Radafaxine	investigational	nan	Radafaxine has been used in trials studying the treatment of Depressive Disorder, Major.	192374-14-4
WYZWZEOGROVVHK-GTMNPGAYSA-N	DB03758	Radicicol	experimental	nan	nan	12772-57-5
GKGRZLGAQZPEHO-UHFFFAOYSA-N	DB12260	Radiprodil	investigational	nan	Radiprodil has been used in trials studying the treatment of Infantile Spasms (IS) and Diabetic Peripheral Neuropathic Pain.	496054-87-6
DUPWHXBITIZIKZ-UHFFFAOYSA-N	DB12323	Radotinib	investigational	nan	Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.	926037-48-1
NPDKXVKJRHPDQT-IYARVYRRSA-N	DB12462	Ralinepag	investigational	nan	Ralinepag has been used in trials studying the treatment of Pulmonary Arterial Hypertension.	1187856-49-0
GZUITABIAKMVPG-UHFFFAOYSA-N	DB00481	Raloxifene	approved;investigational	G03XC01	Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM.[A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under	84449-90-1
CZFFBEXEKNGXKS-UHFFFAOYSA-N	DB06817	Raltegravir	approved;investigational	J05AR16;J05AJ01	Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.	518048-05-0
IVTVGDXNLFLDRM-HNNXBMFYSA-N	DB00293	Raltitrexed	approved;investigational	L01BA03	Raltitrexed (brand name Tomudex&reg;) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.	112887-68-0
YLXDSYKOBKBWJQ-LBPRGKRZSA-N	DB00980	Ramelteon	approved;investigational	N05CH02	Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.	196597-26-9
VMXUWOKSQNHOCA-UHFFFAOYSA-N	DB00863	Ranitidine	approved;investigational;withdrawn	A02BA07;A02BA02	Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GE	66357-35-5
RUOKEQAAGRXIBM-GFCCVEGCSA-N	DB01367	Rasagiline	approved;investigational	N04BD02	Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.	136236-51-6
RZUOCXOYPYGSKL-GOSISDBHSA-N	DB15281	Ravoxertinib	investigational	nan	Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).	1453848-26-4
OFJRNBWSFXEHSA-UHFFFAOYSA-N	DB19834	Razaxaban	experimental	nan	Razaxaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Razaxaban is a blood coagulation factor XA​ inhibitor, antithrombotic. Razaxaban has a monoisotopic molecular weight of 528.16 Da.	218298-21-6
WVXNSAVVKYZVOE-UHFFFAOYSA-N	DB13005	Rebastinib	investigational	nan	Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia. It is an inhibitor of Tie2 tyrosine kinase receptor and an antineoplastic agent.	1020172-07-9
GTXSRFUZSLTDFX-HRCADAONSA-N	DB06573	Rebimastat	investigational	nan	nan	259188-38-0
CBQGYUDMJHNJBX-RTBURBONSA-N	DB00234	Reboxetine	approved;investigational;withdrawn	N06AX18	Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.	71620-89-8
RDSACQWTXKSHJT-NSHDSACASA-N	DB06309	Refametinib	investigational	nan	nan	923032-37-5
FNHKPVJBJVTLMP-UHFFFAOYSA-N	DB08896	Regorafenib	approved;investigational	L01EX05	Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.	755037-03-7
BWYBBMQLUKXECQ-GIVPXCGWSA-N	DB06367	Relacatib	investigational	nan	nan	362505-84-8
WANIDIGFXJFFEL-SANMLTNESA-N	DB14976	Relacorilant	investigational	nan	Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).	1496510-51-0
CEBYCSRFKCEUSW-NAYZPBBASA-N	DB13929	Relcovaptan	experimental	nan	nan	150375-75-0
SMOBCLHAZXOKDQ-ZJUUUORDSA-N	DB12377	Relebactam	approved	J01DH56	Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam].[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge.[A181207] It is currently available in a combination product which includes [imipenem] and [cilastatin] to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated intra-abdominal infections in adults.[label] It is considered to be a last-line treatment op	1174018-99-5
CUABMPOJOBCXJI-UHFFFAOYSA-N	DB16852	Remibrutinib	approved;investigational	L04AA60	Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.[L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.[A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndro	1787294-07-8
GUJRSXAPGDDABA-NSHDSACASA-N	DB00409	Remoxipride	approved;withdrawn	N05AL04	Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]	80125-14-0
KQDRVXQXKZXMHP-LLVKDONJSA-N	DB12614	Reparixin	investigational	nan	Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus.	266359-83-5
FIKPXCOQUIZNHB-WDEREUQCSA-N	DB16826	Repotrectinib	approved;investigational	L01EX28	Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene.[A262056] ROS1 mutations are one of the defined oncogenic drives of NSCLC, and the solvent-front mutation ROS1 G2032R is responsible for 50 to 60% of [crizotinib]-resistant cases.[A262056] Repotrectinib possesses a compact macrocyclic structure that both limits adverse interactions wit	1802220-02-5
YXVDEILMUVTDMK-JKSUJKDBSA-N	DB21664	Resigratinib	experimental	nan	Resigratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Resigratinib is a fibroblast growth factor receptor (FGFR) inhibitor. Resigratinib has a monoisotopic molecular weight of 523.21 Da.	2750709-91-0
FECGNJPYVFEKOD-VMPITWQZSA-N	DB12392	Resminostat	investigational	L01XH07	Resminostat has been used in trials studying the treatment of Sezary Syndrome, Mycosis fungoides, Hodgkin's Lymphoma, Hepatocellular Carcinoma, and Lymphoma, T-Cell, Cutaneous, among others.	864814-88-0
LUKBXSAWLPMMSZ-OWOJBTEDSA-N	DB02709	Resveratrol	investigational	nan	Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it	501-36-0
OAKGNIRUXAZDQF-TXHRRWQRSA-N	DB05626	Retaspimycin	investigational	nan	nan	857402-23-4
PLVGDGRBPMVYPB-FDUHJNRSSA-N	DB11818	Retosiban	investigational	nan	Retosiban has been used in trials studying the treatment of Premature Labor and Obstetric Labour, Premature.	820957-38-8
IXQHNBONEVULTL-UHFFFAOYSA-N	DB11838	Revamilast	investigational	nan	Revamilast has been used in trials studying the treatment of Asthma and Rheumatoid Arthritis.	893555-90-3
RHXHGRAEPCAFML-UHFFFAOYSA-N	DB11730	Ribociclib	approved;investigational	L01EF02	Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.	1211441-98-3
QGZYDVAGYRLSKP-UHFFFAOYSA-N	DB12376	Ricolinostat	investigational	nan	Ricolinostat is under investigation for the treatment of Breast Carcinoma and Metastatic Breast Cancer.	1316214-52-4
GLLPUTYLZIKEGF-HAVVHWLPSA-N	DB01207	Ridogrel	experimental	nan	Ridogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.	110140-89-1
OWBFCJROIKNMGD-BQYQJAHWSA-N	DB12146	Rigosertib	investigational	nan	Rigosertib has been used in trials studying the treatment and basic science of MDS, RAEB, Cancer, Hepatoma, and Neoplasms, among others.	592542-59-1
CQXADFVORZEARL-UHFFFAOYSA-N	DB11738	Rilmenidine	approved;withdrawn	C02AC06	Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.	54187-04-1
YIBOMRUWOWDFLG-ONEGZZNKSA-N	DB08864	Rilpivirine	approved;investigational	J05AR19;J05AR21;J05AR08;J05AG05	Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative.[A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's.[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.[L1030] On No	500287-72-9
LCFFREMLXLZNHE-GBOLQPHISA-N	DB17709	Rilzabrutinib	approved;investigational	nan	Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP).[L53743] ITP is an autoimmune disorder characterized by low platelet count. Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.[A	1575591-66-0
UBCHPRBFMUDMNC-UHFFFAOYSA-N	DB00478	Rimantadine	approved	J05AC02	An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	13392-28-4
JZCPYUJPEARBJL-UHFFFAOYSA-N	DB06155	Rimonabant	approved;withdrawn	A08AX01	Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended t	168273-06-1
QSKQVZWVLOIIEV-NSHDSACASA-N	DB13165	Ripasudil	investigational	S01EX07;S01EA55	Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.	223645-67-8
IIDJRNMFWXDHID-UHFFFAOYSA-N	DB00884	Risedronic acid	approved;investigational	M05BB07;M05BB02;M05BB04;M05BA07	Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].	105462-24-6
KTLQDDGRBDLKMN-UHFFFAOYSA-N	DB21474	Risovalisib	investigational	nan	Risovalisib is a small molecule drug. Risovalisib is under investigation in clinical trial NCT05043922 (A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma). Risovalisib has a monoisotopic molecular weight of 598.19 Da.	1494684-28-4
RAPZEAPATHNIPO-UHFFFAOYSA-N	DB00734	Risperidone	approved;investigational	N05AX08	Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder.[L12885] It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).[L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting	106266-06-2
ADGOPPKEIZXKAZ-UHFFFAOYSA-N	DB21602	Risvodetinib	investigational	nan	Risvodetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Risvodetinib is a tyrosine kinase inhibitor. Risvodetinib is under investigation in clinical trial NCT05424276 (A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease). Risvodetinib has a monoisotopic molecular weight of 574.28 Da.	2031185-00-7
JUQLTPCYUFPYKE-UHFFFAOYSA-N	DB12693	Ritanserin	investigational	nan	Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.	87051-43-2
CBRJPFGIXUFMTM-WDEREUQCSA-N	DB14924	Ritlecitinib	approved;investigational	L04AF08	Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.[L48181] Ritlecitinib is administered orally and is the first member of its class.[A260122,A260127] Ritlecitinib binds covalently to C	1792180-81-4
IOVGROKTTNBUGK-SJKOYZFVSA-N	DB00867	Ritodrine	approved;withdrawn	G02CA01	Adrenergic beta-agonist used to control premature labor.	26652-09-5
GOHUJGMYCZDYDF-UHFFFAOYSA-N	DB19517	Ritolukast	experimental	nan	Ritolukast is a small molecule drug. The usage of the INN stem '-lukast' in the name indicates that Ritolukast is a leukotriene receptor antagonist. Ritolukast has a monoisotopic molecular weight of 382.06 Da.	111974-60-8
NCDNCNXCDXHOMX-XGKFQTDJSA-N	DB00503	Ritonavir	approved;investigational	J05AP53;J05AR10;J05AE30;J05AE03;J05AR23;J05AR26;J05AP52	Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C viru	155213-67-5
JUOSGGQXEBBCJB-GORDUTHDSA-N	DB05855	Rivanicline	experimental	nan	Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. Rivanicline also has stimulant and analgesic actions which are thought	15585-43-0
XSVMFMHYUFZWBK-NSHDSACASA-N	DB00989	Rivastigmine	approved;investigational	N06DA03	Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.	123441-03-2
WPEWQEMJFLWMLV-UHFFFAOYSA-N	DB14765	Rivoceranib	investigational	nan	Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).	811803-05-1
ULFRLSNUDGIQQP-UHFFFAOYSA-N	DB00953	Rizatriptan	approved;investigational	N02CC04	Rizatriptan is a second-generation triptan [A258918] and a selective 5-HT<sub>1B and 5-HT1D</sub> receptor agonist.[L46018] Used in the treatment of migraines, rizatriptan was first approved in the US in 1998.[L46018] Rizatriptan is available in oral tablets, orally disintegrating tablets (wafers), and oral film formulations.	144034-80-0
DAPAQENNNINUPW-IDAMAFBJSA-N	DB15495	Rocaglamide	experimental	nan	Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides.[A186760] Rocaglamides are secondary metabolites of the plant genus _Aglaia_, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties.[A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_.[A1	84573-16-0
HUFOZJXAKZVRNJ-UHFFFAOYSA-N	DB11907	Rociletinib	investigational	L01EB05	Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer.	1374640-70-6
ZNSPHKJFQDEABI-NZQKXSOJSA-N	DB18478	Rodatristat	experimental	nan	nan	1673568-73-4
RZJQGNCSTQAWON-UHFFFAOYSA-N	DB00533	Rofecoxib	approved;withdrawn	M01AH02	Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to sti	162011-90-7
MNDBXUUTURYVHR-UHFFFAOYSA-N	DB01656	Roflumilast	approved;investigational	D05AX06;R03DX07	Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor.[A251385] PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells like those of the smooth muscle or epithelium.[A251385] The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4 is thought to mediate its disease-modifying effects, although its precise mechanism	162401-32-3
HNLRRJSKGXOYNO-UHFFFAOYSA-N	DB15078	Rogaratinib	investigational	nan	Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).	1443530-05-9
NFHSJYKXENYICE-UHFFFAOYSA-N	DB18088	Roginolisib	investigational	nan	nan	1305267-37-1
HJORMJIFDVBMOB-UHFFFAOYSA-N	DB01954	Rolipram	investigational	nan	A phosphodiesterase inhibitor with antidepressant properties.	61413-54-5
RNRYULFRLCBRQS-UHFFFAOYSA-N	DB13080	Roluperidone	investigational	nan	Roluperidone has been used in trials studying the treatment of Schizophrenia.	359625-79-9
OHRURASPPZQGQM-GCCNXGTGSA-N	DB06176	Romidepsin	approved;investigational	L01XH02	Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.	128517-07-7
UELYDGOOJPRWGF-SRQXXRKNSA-N	DB12974	Roniciclib	investigational	nan	Roniciclib has been investigated for the treatment of Small Cell Lung Carcinoma.	1223498-69-8
PYSCVJMLJRHJGJ-OYNCUSHFSA-N	DB19134	Ropanicant	investigational	nan	Ropanicant is under investigation in clinical trial NCT06126497 (Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients).	2414674-70-5
UHSKFQJFRQCDBE-UHFFFAOYSA-N	DB00268	Ropinirole	approved;investigational	N04BC04	Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. In 2008, the extended-release capsules of ropinirole w	91374-21-9
XPLZTJWZDBFWDE-OYOVHJISSA-N	DB18709	Ropsacitinib	investigational	nan	nan	2127109-84-4
YASAKCUCGLMORW-UHFFFAOYSA-N	DB00412	Rosiglitazone	approved;investigational	A10BD04;A10BG02;A10BD03	Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPAR	122320-73-4
JUVIOZPCNVVQFO-HBGVWJBISA-N	DB11457	Rotenone	experimental;vet_approved	nan	Rotenone is an isoflavone compound that naturally occurs in the jicama vine plant as well as many Fabaceae plants. It has broad spectrum insecticide and pesticide activity and is also toxic to fish.	83-79-4
KFQYTPMOWPVWEJ-INIZCTEOSA-N	DB05271	Rotigotine	approved;investigational	N04BC09	Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharma	99755-59-6
IRAXRQFCCSHQDX-WBVHZDCISA-N	DB21089	Roxifiban	experimental	nan	Roxifiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Roxifiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Roxifiban has a monoisotopic molecular weight of 447.21 Da.	170902-47-3
HGEYJZMMUGWEOT-UHFFFAOYSA-N	DB19883	Roxindole	experimental	nan	Roxindole is a small molecule drug. Roxindole has a monoisotopic molecular weight of 346.2 Da.	112192-04-8
ZCBUQCWBWNUWSU-SFHVURJKSA-N	DB11829	Ruboxistaurin	investigational	nan	Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.	169939-94-0
HMABYWSNWIZPAG-UHFFFAOYSA-N	DB12332	Rucaparib	approved;investigational	L01XK03	Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair.[A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Br	283173-50-2
HFNKQEVNSGCOJV-OAHLLOKOSA-N	DB08877	Ruxolitinib	approved;investigational	D11AH09;L01EJ01	Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.[A7450] Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and 	941678-49-5
YEUSLPIIQGZHQB-UHFFFAOYSA-N	DB03910	S,S'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea	experimental	nan	nan	nan
YWCLDDLVLSQGSZ-JOCHJYFZSA-N	DB12149	S-3304	investigational	nan	S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.	203640-27-1
AREYWCZYVPSHGS-NVMNQCDNSA-N	DB16821	S-49076	experimental	nan	nan	1265965-22-7
VYXJULKGMXJVGI-XIFFEERXSA-N	DB18365	S-55746	investigational	nan	nan	1448584-12-0
LAXNJIWNBHHMDO-UHFFFAOYSA-N	DB03707	S-Ethyl-N-Phenyl-Isothiourea	experimental	nan	nan	nan
VFIZBHJTOHUOEK-UHFFFAOYSA-N	DB02234	S-Ethylisothiourea	investigational	nan	S-Ethylisothiourea is a nitric oxide synthase inhibitor.	2986-20-1
XSSNABKEYXKKMK-UHFFFAOYSA-N	DB04018	S-Isopropyl-Isothiourea	experimental	nan	nan	nan
ZIGJZZDDPXRGTL-UHFFFAOYSA-N	DB04720	S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE	experimental	nan	nan	nan
ZJUKTBDSGOFHSH-WFMPWKQPSA-N	DB01752	S-adenosyl-L-homocysteine	experimental	nan	5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.	979-92-0
AWAKIULNKVOBKE-UHFFFAOYSA-N	DB08494	S-{2-[(2-chloro-4-sulfamoylphenyl)amino]-2-oxoethyl} 6-methyl-3,4-dihydroquinoline-1(2H)-carbothioate	experimental	nan	nan	nan
IDKAKZRYYDCJDU-HBMMIIHUSA-N	DB12541	SAR-405838	investigational	nan	SAR405838 has been used in trials studying the treatment of Neoplasm Malignant.	1303607-60-4
ATQMRMGXINTJHV-UHFFFAOYSA-N	DB17052	SB 224289	experimental	nan	SB-224289 is a small molecule with a high affinity for human 5-HT1B receptors.[A253122]	180083-23-2
NNXDIGHYPZHXTR-ONEGZZNKSA-N	DB15294	SB-1578	investigational	nan	SB-1578 is under investigation in clinical trial NCT01235871 (A Single and Multiple-Dose Study of SB1578).	937273-04-6
OTPNDVKVEAIXTI-UHFFFAOYSA-N	DB17051	SB-218078	experimental	nan	SB-218078 is a specific inhibitor of CHK1.[A253117]	135897-06-2
HWKROQUZSKPIKQ-MRXNPFEDSA-N	DB13988	SB-269970	experimental	nan	SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]	201038-74-6
ONVZFCHLOZUXRP-UHFFFAOYSA-N	DB01793	SB-409513	experimental	nan	nan	nan
ZJXIUGNEAIHSBI-IBGZPJMESA-N	DB14822	SB-649868	investigational	nan	SB-649868 is under investigation in clinical trial NCT01030939 (Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers).	380899-24-1
VSPFURGQAYMVAN-UHFFFAOYSA-N	DB04338	SB220025	experimental	nan	nan	nan
ZVVCSBSDFGYRCB-UHFFFAOYSA-N	DB17101	SC 41930	experimental	nan	nan	120072-59-5
AQHMBDAHQGYLIU-XNFHFXFQSA-N	DB12451	SCY-635	investigational	nan	SCY-635 has been investigated for the treatment of Chronic Hepatitis C and Hepatitis C Infection.	210759-10-7
UWSVAGUSMAEUKO-QHQGJXSCSA-N	DB02729	SD146	experimental	nan	nan	183854-21-9
UOUBCIJIWDLRGM-UHFFFAOYSA-N	DB18082	SEL-24	investigational	nan	nan	1616359-00-2
FSBMCTDYWXIBLM-UHFFFAOYSA-N	DB18107	SEL120-34A free base	investigational	nan	nan	1609522-33-9
MHXGEROHKGDZGO-UHFFFAOYSA-N	DB12494	SGI-1776	investigational	nan	SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.	1025065-69-3
BCZUAADEACICHN-UHFFFAOYSA-N	DB06314	SGX-523	investigational	nan	A MET receptor tyrosine kinase inhibitor.	1022150-57-7
HLMBXBGDBBCYII-UHFFFAOYSA-N	DB17054	SKF-96365 free base	experimental	nan	SKF-96365 is a receptor-mediated calcium entry (RMCE) inhibitor structurally different from other calcium antagonists.[A253132]	162849-90-3
YJQZNWPYLCNRLP-UHFFFAOYSA-N	DB18815	SLC-0111	investigational	nan	nan	178606-66-1
FJHBVJOVLFPMQE-QFIPXVFZSA-N	DB05482	SN-38	investigational	nan	7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative Breast Cancer, among others.	86639-52-3
OUSFTKFNBAZUKL-UHFFFAOYSA-N	DB05969	SNS-032	investigational	nan	nan	345627-80-7
FAYAUAZLLLJJGH-UHFFFAOYSA-N	DB06134	SNS-314	investigational	nan	SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.	1057249-41-8
ZFVRYNYOPQZKDG-MQMHXKEQSA-N	DB17055	SNX-2112	experimental	nan	SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor.[A253137]	908112-43-6
AVDSOVJPJZVBTC-CTYIDZIISA-N	DB06070	SNX-5422	investigational	nan	SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.	908115-27-5
JFIBVDBTCDTBRH-REZTVBANSA-N	DB05186	SQ-109	investigational	nan	SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.	502487-67-4
MMJJNHOIVCGAAP-UHFFFAOYSA-N	DB14013	SR-9009	experimental	nan	SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues [A32628].	1379686-30-2
PPUYOYQTTWJTIU-UHFFFAOYSA-N	DB14014	SR-9011	experimental	nan	SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues [A32628].	1379686-29-9
RNZIUDLOJHVHLZ-VYIQYICTSA-N	DB02258	SR11254	experimental	nan	nan	nan
YBYYWUUUGCNAHQ-LLVKDONJSA-N	DB16876	SRA-737	experimental	nan	nan	1489389-18-5
XPLJEFSRINKZLC-ATVHPVEESA-N	DB08009	SU-11652	experimental	nan	SU-11652 is a tyrosine kinase inhibitor.	326914-10-7
QNUKRWAIZMBVCU-WCIBSUBMSA-N	DB03428	SU9516	experimental	nan	nan	nan
GWCYPEHWIZXYFZ-UHFFFAOYSA-N	DB06140	SUVN-502	investigational	nan	SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.	701205-60-9
JTQBMTFVGGUDPN-UHFFFAOYSA-N	DB18119	SXR-1096	investigational	nan	nan	1087624-28-9
JDJOUBVVSQDIRC-AWEZNQCLSA-N	DB17099	SY-5609	investigational	nan	nan	2417302-07-7
CVHZOJJKTDOEJC-UHFFFAOYSA-N	DB12418	Saccharin	investigational	nan	Saccharin has been investigated for the treatment of Hypertension and Hyperglycemia.	81-07-2
DOBNVUFHFMVMDB-BEFAXECRSA-N	DB14127	Sacubitrilat	experimental	nan	A metabolite of LCZ696 with neprilysin inhibitory activity.	149709-44-4
NEMGRZFTLSKBAP-LBPRGKRZSA-N	DB06654	Safinamide	approved;investigational	N04BD03	Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.	133865-89-1
YGSDEFSMJLZEOE-UHFFFAOYSA-N	DB00936	Salicylic acid	approved;investigational;vet_approved	D01AE12;G04BX17;N02BA04;N02BA12;S01BC08	A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.	69-72-7
GIIZNNXWQWCKIB-UHFFFAOYSA-N	DB00938	Salmeterol	approved;investigational	R03AK06;R03AK12;R03AC12	Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol].[A190459] Salmeterol was first described in the literature in 1988.[A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A18373	89365-50-4
RYIDHLJADOKWFM-MAODMQOUSA-N	DB12543	Samidorphan	approved;investigational	N05AH53	[Olanzapine] is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes.[A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability, and a longer half-life, making it an attractive candidate for oral dosing.[A235623, A235638, L34359] Althou	852626-89-2
LGHLGTHRJNIRCA-ZXKDJJQISA-N	DB20035	Samixogrel	experimental	nan	Samixogrel is a small molecule drug. Samixogrel has a monoisotopic molecular weight of 484.12 Da.	133276-80-9
LPUDGHQMOAHMMF-JBACZVJFSA-N	DB21283	Sampatrilat	experimental	nan	Sampatrilat is a small molecule drug. Sampatrilat has a monoisotopic molecular weight of 584.25 Da.	129981-36-8
YCVGLKWJKIKVBI-MJGOQNOKSA-N	DB16061	Samuraciclib	investigational	nan	Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).	1805833-75-3
GYLDXIAOMVERTK-UHFFFAOYSA-N	DB11836	Sapanisertib	investigational	nan	Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.	1224844-38-5
DFJSJLGUIXFDJP-UHFFFAOYSA-N	DB12183	Sapitinib	investigational	nan	Sapitinib has been used in trials studying the treatment and basic science of Neoplasms, Breast Cancer, Breast Neoplasms, Metastatic Cancer, and Metastatic Breast Cancer, among others.	848942-61-0
QWAXKHKRTORLEM-UGJKXSETSA-N	DB01232	Saquinavir	approved	J05AE01	Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies.[A214382] While its efficacy was initially limited by exceptionally poor oral bioavaila	127779-20-8
OUKYUETWWIPKQR-UHFFFAOYSA-N	DB11805	Saracatinib	investigational	nan	Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.	379231-04-6
PFGWGEPQIUAZME-NXSMLHPHSA-N	DB06763	Saralasin	experimental	nan	nan	34273-10-4
PGKXDIMONUAMFR-AREMUKBSSA-N	DB06660	Saredutant	investigational	nan	Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.	142001-63-6
LIFDPEORUVTOCP-UHFFFAOYSA-N	DB19528	Saripidem	experimental	nan	Saripidem is a small molecule drug. Saripidem has a monoisotopic molecular weight of 341.13 Da.	103844-86-6
GMBQZIIUCVWOCD-WWASVFFGSA-N	DB16928	Sarsagenin	experimental	nan	nan	126-19-2
WQAVGRAETZEADU-UHFFFAOYSA-N	DB18982	Saruparib	investigational	nan	Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).	2589531-76-8
XYDNMOZJKOGZLS-NSHDSACASA-N	DB12048	Savolitinib	investigational	nan	Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.	1313725-88-0
QGJUIPDUBHWZPV-SGTAVMJGSA-N	DB06335	Saxagliptin	approved;investigational	A10BD21;A10BD25;A10BH03;A10BD10	Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.	361442-04-8
STECJAGHUSJQJN-FWXGHANASA-N	DB00747	Scopolamine	approved;investigational	N05CM05;S01FA02;A04AD01;A04AD51	Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.[A228763] As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system	51-34-3
JTDYUFSDZATMKU-UHFFFAOYSA-N	DB17053	Scriptaid	experimental	nan	Scriptaid is a histone deacetylase (HDAC) inhibitor researched for its anti-tumor properties.[A253127]	287383-59-9
CYVVCTRDWISRAC-KRWDZBQOSA-N	DB21678	Segatroxaban	experimental	nan	Segatroxaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Segatroxaban is a blood coagulation factor XA​ inhibitor, antithrombotic. Segatroxaban has a monoisotopic molecular weight of 567.14 Da.	1184300-63-7
MEZLKOACVSPNER-GFCCVEGCSA-N	DB01037	Selegiline	approved;vet_approved	N04BD01	A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.	14611-51-9
SKNBJMQZTZPCPF-QZTLEVGFSA-N	DB03070	Selenazole-4-carboxyamide-adenine dinucleotide	experimental	nan	nan	nan
LNLJHGXOFYUARS-OAQYLSRUSA-N	DB12706	Seletalisib	investigational	nan	Seletalisib has been used in trials studying the treatment and basic science of Primary Sjogren's Syndrome.	1362850-20-1
BTIHMVBBUGXLCJ-OAHLLOKOSA-N	DB06195	Seliciclib	investigational	nan	R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.	186692-46-6
FUZYTVDVLBBXDL-UHFFFAOYSA-N	DB13978	Selisistat	investigational	nan	Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.	49843-98-3
OEBIHOVSAMBXIB-SJKOYZFVSA-N	DB14896	Selitrectinib	investigational	nan	Selitrectinib is under investigation in clinical trial NCT03215511 (Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers).	2097002-61-2
XIIOFHFUYBLOLW-UHFFFAOYSA-N	DB15685	Selpercatinib	approved;investigational	L01EX22	Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib 	2152628-33-4
SQOCEMCKYDVLMM-IYBDPMFKSA-N	DB14961	Seltorexant	investigational	nan	Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).	1452539-75-1
CYOHGALHFOKKQC-UHFFFAOYSA-N	DB11689	Selumetinib	approved;investigational	L01EE04	Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.[A193611] Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its contin	606143-52-6
PKXWXXPNHIWQHW-RCBQFDQVSA-N	DB12463	Semagacestat	investigational	nan	Semagacestat has been used in trials studying the treatment of Alzheimer Disease.	425386-60-3
WUWDLXZGHZSWQZ-WQLSENKSSA-N	DB06436	Semaxanib	investigational	nan	nan	194413-58-6
QMRJOIUGPCVZPH-UHFFFAOYSA-N	DB20058	Sepimostat	experimental	nan	Sepimostat is a small molecule drug. Sepimostat has a monoisotopic molecular weight of 373.15 Da.	103926-64-3
WIQRCHMSJFFONW-HNNXBMFYSA-N	DB06731	Seproxetine	experimental	nan	Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.	126924-38-7
BLGWHBSBBJNKJO-UHFFFAOYSA-N	DB14935	Serabelisib	investigational	nan	Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).	1268454-23-4
FLNYCRJBCNNHRH-OIYLJQICSA-N	DB12973	Serlopitant	investigational	nan	Serlopitant has been investigated for the treatment of Prurigo Nodularis.	860642-69-9
QZAYGJVTTNCVMB-UHFFFAOYSA-N	DB08839	Serotonin	investigational;nutraceutical	nan	For temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.	50-67-9
GZKLJWGUPQBVJQ-UHFFFAOYSA-N	DB06144	Sertindole	approved;withdrawn	N05AE03	Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.	106516-24-9
VGKDLMBJGBXTGI-SJCJKPOMSA-N	DB01104	Sertraline	approved;investigational	N06AB06	Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which freque	79617-96-2
HDHDTKMUACZDAA-PHNIDTBTSA-N	DB11700	Setmelanotide	approved;investigational	A08AA12	Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies.[L24474] It is an agonist of the melanocortin 4 receptor.[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate.[A224449] Other earlier treatments for these patients included gastric bypass surgery.[A224449] Patients taking setmelanotide experienced an averag	920014-72-8
DBCKRBGYGMVSTI-UHFFFAOYSA-N	DB20962	Sibenadet	experimental	nan	Sibenadet is a small molecule drug. Sibenadet has a monoisotopic molecular weight of 464.14 Da.	154189-40-9
WBNUCLPUOSXSNJ-ZDUSSCGKSA-N	DB21420	Sibrafiban	experimental	nan	Sibrafiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Sibrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Sibrafiban has a monoisotopic molecular weight of 420.2 Da.	170094-62-9
BNRNXUUZRGQAQC-UHFFFAOYSA-N	DB00203	Sildenafil	approved;investigational	G01AE10;G04BE03	In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood in	139755-83-2
MUOKSQABCJCOPU-UHFFFAOYSA-N	DB15408	Silmitasertib	investigational	nan	Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).	1009820-21-6
PNCPYILNMDWPEY-QGZVFWFLSA-N	DB06207	Silodosin	approved;investigational	G04CA04	Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate.[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. Silodosin is available as oral capsules	160970-54-7
JTZZSQYMACOLNN-VDWJNHBNSA-N	DB06290	Simeprevir	approved;withdrawn	G01AE10;J05AP05	Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified	923604-59-5
XGVXKJKTISMIOW-ZDUSSCGKSA-N	DB16330	Simurosertib	investigational	nan	Simurosertib is under investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors).	1330782-76-7
LMXOHSDXUQEUSF-YECHIGJVSA-N	DB01910	Sinefungin	experimental	nan	Sinefungin is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar. The proteins that adenosyl-ornithine target include RdmB, modification methylase TaqI, rRNA (adenine-N6-)-methyltransferase, and modification methylase RsrI.	58944-73-3
XWAONOGAGZNUSF-UHFFFAOYSA-N	DB06555	Siramesine	experimental	nan	nan	147817-50-3
QFJCIRLUMZQUOT-HPLJOQBZSA-N	DB00877	Sirolimus	approved;investigational	L01EG04;S01XA23;L04AH01	Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island).[A242412] It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent.[A13448] Its primar	53123-88-9
PHWXUGHIIBDVKD-UHFFFAOYSA-N	DB06268	Sitaxentan	approved;withdrawn	C02KX03	Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.	184036-34-8
WLAVZAAODLTUSW-UHFFFAOYSA-N	DB15036	Sitravatinib	investigational	L01EX26	Sitravatinib is under investigation in clinical trial NCT03680521 (Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma).	1123837-84-2
BTGNGJJLZOIYID-UHFFFAOYSA-N	DB12863	Sivelestat	investigational	nan	Sivelestat has been used in trials studying the treatment of Acute Lung Injury and Respiratory Distress Syndrome, Adult.	127373-66-4
IUDCAKKZLXFOQA-QJAPXLAMSA-N	DB04191	Skf 107457	experimental	nan	nan	144285-77-8
QNAZTOHXCZPOSA-UHFFFAOYSA-N	DB07425	Sobetirome	investigational	nan	nan	211110-63-3
MPYACSQFXVMWNO-UHFFFAOYSA-N	DB19856	Solcitinib	investigational	nan	Solcitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Solcitinib is a Janus kinase inhibitor. Solcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184). Solcitinib has a monoisotopic molecular weight of 389.19 Da.	1206163-45-2
FBOUYBDGKBSUES-VXKWHMMOSA-N	DB01591	Solifenacin	approved;investigational	G04BD08;G04CA53	Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]	242478-37-1
WORSVFBVUCBRIP-VNQPRFMTSA-N	DB19872	Solimastat	experimental	nan	Solimastat is a small molecule drug. The usage of the INN stem '-mastat' in the name indicates that Solimastat is a matrix metalloproteinase inhibitor. Solimastat has a monoisotopic molecular weight of 408.24 Da.	226072-63-5
IXXFZUPTQVDPPK-ZAWHAJPISA-N	DB09308	Solithromycin	investigational	J01FA16	Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.	760981-83-7
NHXLMOGPVYXJNR-ATOGVRKGSA-N	DB09099	Somatostatin	approved;investigational;withdrawn	H01CB01	Somatostatin, also known as growth hormone-inhibiting hormone, is a naturally-occurring peptide hormone of 14 or 28 amino acid residues [T28] that regulates the endocrine system. It is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating hormones from the anterior pituitary [T28]. Somatostatin is initially secreted as a 116 amino acid precursor, prep	38916-34-6
QIUASFSNWYMDFS-NILGECQDSA-N	DB12601	Sonolisib	investigational	nan	Sonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.	502632-66-8
ZQTKOYMWCCSKON-XKXNWSITSA-N	DB18753	Sonrotoclax	investigational	nan	nan	2383086-06-2
KNCWSXRTKLTULH-MRXNPFEDSA-N	DB18749	Soquelitinib	investigational	nan	nan	2226636-04-8
MLDQJTXFUGDVEO-UHFFFAOYSA-N	DB00398	Sorafenib	approved;investigational	L01EX02	Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.[A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.[A14794]	284461-73-0
QKDRXGFQVGOQKS-CRSSMBPESA-N	DB12713	Sotagliflozin	approved;investigational	A10BK06	Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>.[L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors.[A244499] The added inhibition 	1018899-04-1
ZBMZVLHSJCTVON-UHFFFAOYSA-N	DB00489	Sotalol	approved;investigational	C07AA07;C07BA07;C07FX02	Sotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992.[L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376]	3930-20-9
NXQKSXLFSAEQCZ-SFHVURJKSA-N	DB15569	Sotorasib	approved;investigational	L01XX73	Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.[A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.[A187547] The drug [MRTX849] is also currently being developed and has th	2252403-56-6
OAVGBZOFDPFGPJ-UHFFFAOYSA-N	DB12369	Sotrastaurin	investigational	nan	Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.	425637-18-9
NJIAKNWTIVDSDA-FQEVSTJZSA-N	DB17557	Sovleplenib	investigational	nan	Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).	1415792-84-5
WRFHGDPIDHPWIQ-UHFFFAOYSA-N	DB12548	Sparsentan	approved;investigational	C09XX01	Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub>A</sub>R and 0.8 nM for AT<sub>1</sub>R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural elements of [irbesartan], an AT<sub>1</sub>R antagonist, and biphenylsulfonamide, an ET<sub>A</sub>R antagonist.[A257330] In February 2023, the us	254740-64-2
KXBDTLQSDKGAEB-UHFFFAOYSA-N	DB11764	Spebrutinib	investigational	nan	Spebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell.	1202757-89-8
ATHGHQPFGPMSJY-UHFFFAOYSA-N	DB03566	Spermidine	investigational	nan	Spermidine is a polyamine formed from putrescine. It is found in almost all tissues in association with nucleic acids. It is found as a cation at all pH values, and is thought to help stabilize some membranes and nucleic acid structures. It is a precursor of spermine.	124-20-9
PFNFFQXMRSDOHW-UHFFFAOYSA-N	DB00127	Spermine	investigational;nutraceutical	nan	Spermine is a spermidine-derived biogenic polyamine found as a polycation at all pH values. Found in various tissues and organisms, it often acts as an essential growth factor in some bacterial species. Spermine is associated with nucleic acids, particularly in viruses, and is thought to stabilize the helical structure.	71-44-3
DKGZKTPJOSAWFA-UHFFFAOYSA-N	DB17056	Spiperone	experimental	nan	Spiperone is a dopamine antagonist that binds dopamine and serotonin receptors.[A253142]	749-02-0
NYKCGQQJNVPOLU-ONTIZHBOSA-N	DB12704	Spiradoline	investigational	nan	Spiradoline has been investigated for the basic science of Bipolar Depression.	87151-85-7
FJUKDAZEABGEIH-UHFFFAOYSA-N	DB19907	Spiramide	experimental	nan	Spiramide is a small molecule drug. Spiramide has a monoisotopic molecular weight of 383.2 Da.	510-74-7
LXMSZDCAJNLERA-ZHYRCANASA-N	DB00421	Spironolactone	approved;investigational	C03DA01	Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists.[A178192] It promotes sodium and water excretion and potassium retention.[A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension.[L44602] Off-label uses o	52-01-7
KMSATRJZEXNGDP-UHFFFAOYSA-N	DB03351	Sri-9439	experimental	nan	nan	nan
UPBAOYRENQEPJO-UHFFFAOYSA-N	DB20261	Stallimycin	experimental	nan	Stallimycin is a small molecule drug. The usage of the INN stem '-mycin' in the name indicates that Stallimycin is a antibiotic, produced by Streptomyces strain. Stallimycin has a monoisotopic molecular weight of 481.22 Da.	636-47-5
NVKAWKQGWWIWPM-ABEVXSGRSA-N	DB02901	Stanolone	illicit;investigational	A14AA01;G03BB02	A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.	521-18-6
LKAJKIOFIWVMDJ-IYRCEVNGSA-N	DB06718	Stanozolol	approved;vet_approved	A14AA02	Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.	10418-03-8
HKSZLNNOFSGOKW-FYTWVXJKSA-N	DB02010	Staurosporine	experimental	nan	An indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)	62996-74-1
XNKLLVCARDGLGL-JGVFFNPUSA-N	DB00649	Stavudine	approved;investigational	J05AR28;J05AF04;J05AR07	A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.	3056-17-5
ODSQODTUNULBHF-JGVFFNPUSA-N	DB02887	Stavudine triphosphate	experimental	nan	nan	26194-89-8
QMGVPVSNSZLJIA-FVWCLLPLSA-N	DB15954	Strychnine	experimental	nan	nan	57-24-9
LXRZVMYMQHNYJB-UNXOBOICSA-N	DB16406	Subasumstat	investigational	nan	Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)).	1858276-04-6
GGCSSNBKKAUURC-UHFFFAOYSA-N	DB00708	Sufentanil	approved;investigational	N01AH03	Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments [L4717]. Consideration	56030-54-7
AFNXATANNDIXLG-UHFFFAOYSA-N	DB06820	Sulconazole	approved	D01AC09	Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial fungal infections.[A255612]	61318-90-9
SEEPANYCNGTZFQ-UHFFFAOYSA-N	DB00359	Sulfadiazine	approved;investigational;vet_approved	J01EE06;J01EC02;G01AE10;J01EE02	One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.	68-35-9
JLKIGFTWXXRPMT-UHFFFAOYSA-N	DB01015	Sulfamethoxazole	approved;investigational	J04AM08;J01EE01;G01AE10;J01EC01	Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacte	723-46-6
FDDDEECHVMSUSB-UHFFFAOYSA-N	DB00259	Sulfanilamide	approved;withdrawn	G01AE10;J01EB06;D06BA05	Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.	63-74-1
RXXXPZYBZLDQKP-UHFFFAOYSA-N	DB20271	Sulfasuccinamide	experimental	nan	Sulfasuccinamide is a small molecule drug. Sulfasuccinamide has a monoisotopic molecular weight of 272.05 Da.	3563-14-2
MLKXDPUZXIRXEP-MFOYZWKCSA-N	DB00605	Sulindac	approved;investigational	M01AB02	Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, ex	38194-50-2
BGRJTUBHPOOWDU-UHFFFAOYSA-N	DB00391	Sulpiride	approved;withdrawn	N05AL01	Sulpiride first appeared in published literature in 1967.[A229538] Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses.[A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]	15676-16-1
HMHVCUVYZFYAJI-UHFFFAOYSA-N	DB08329	Sulthiame	approved	N03AX03;G01AE10	nan	61-56-3
UNRHXEPDKXPRTM-UHFFFAOYSA-N	DB13273	Sultopride	approved	N05AL02	Sultopride is used in Japan, Hong Kong, and Europe to treat schizophrenia. It is of the drug class atypical antipsychotics [L5626].	53583-79-2
RKZSNTNMEFVBDT-MRVPVSSYSA-N	DB06477	Sumanirole	investigational	nan	nan	179386-43-7
KQKPFRSPSRPDEB-UHFFFAOYSA-N	DB00669	Sumatriptan	approved;investigational	N02CC01;G01AE10;N02CC51	Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]	103628-46-2
WINHZLLDWRZWRT-ATVHPVEESA-N	DB01268	Sunitinib	approved;investigational	L01EX01	Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R)	557795-19-4
BTMKEDDEMKKSEF-QGZVFWFLSA-N	DB18925	Sunvozertinib	investigational	nan	Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.[L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs).[A40018] EGFR often have mutations that lead to unfavourable treatment options and prognosis.[A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung can	2370013-12-8
FIAFUQMPZJWCLV-UHFFFAOYSA-N	DB04786	Suramin	investigational	P01CX02	A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®.	145-63-1
HMXDWDSNPRNUKI-UHFFFAOYSA-N	DB13070	Surinabant	investigational	nan	Surinabant has been investigated for the treatment of Smoking Cessation.	288104-79-0
TTZSNFLLYPYKIL-UHFFFAOYSA-N	DB15106	Surufatinib	investigational	L01EX24	Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).	1308672-74-3
AWGQQZVAXXLVMT-ORYVFAGJSA-N	DB21698	Surzetoclax	experimental	nan	Surzetoclax is a small molecule drug. The usage of the INN stem '-toclax' in the name indicates that Surzetoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Surzetoclax has a monoisotopic molecular weight of 1038.41 Da.	2858632-01-4
IQIKXZMPPBEWAD-CQSZACIVSA-N	DB19139	Suvecaltamide	investigational	nan	Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).	953778-58-0
JYTNQNCOQXFQPK-MRXNPFEDSA-N	DB09034	Suvorexant	approved;investigational	N05CJ01	Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.	1030377-33-3
QZNGFWQWWSECMG-HUUCEWRRSA-N	DB16939	TAK-418 free base	investigational	nan	nan	1818252-52-6
DZFZXPPHBWCXPQ-UHFFFAOYSA-N	DB13093	TAK-593	investigational	nan	TAK-593 has been used in trials studying the treatment of Solid Tumors.	1005780-62-0
HEKAIDKUDLCBRU-UHFFFAOYSA-N	DB16108	TAK-715	investigational	nan	TAK-715 is under investigation in clinical trial NCT00760864 (Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis).	303162-79-0
RCLQNICOARASSR-SECBINFHSA-N	DB12241	TAK-733	investigational	nan	TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.	1035555-63-5
WKDACQVEJIVHMZ-UHFFFAOYSA-N	DB12756	TAK-901	investigational	nan	TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.	934541-31-8
VQIIUJSNIKEMCK-MHZLTWQESA-N	DB16463	TD-0903	investigational	nan	TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)	2412496-23-0
RXFCFGLSOUOCEA-UHFFFAOYSA-N	DB07013	TERT-BUTYL 4-({[4-(BUT-2-YN-1-YLAMINO)PHENYL]SULFONYL}METHYL)-4-[(HYDROXYAMINO)CARBONYL]PIPERIDINE-1-CARBOXYLATE	experimental	nan	nan	nan
QBMYJIFXSXKPFS-UHFFFAOYSA-N	DB07902	TERT-BUTYL {2-[(1,3-THIAZOL-2-YLAMINO)CARBONYL]PYRIDIN-3-YL}CARBAMATE	experimental	nan	nan	nan
JMGXJHWTVBGOKG-UHFFFAOYSA-N	DB05075	TG-100801	investigational	nan	TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye diseases including diabetic macular edema and proliferative diabetic retinopathy.	867331-82-6
UJIAQDJKSXQLIT-UHFFFAOYSA-N	DB05552	TG100-115	investigational	nan	An NSAID that inhibits PI-3K gamma and delta.	677297-51-7
RKHCTAKUYDTFHE-QMMMGPOBSA-N	DB16909	TIK-301	experimental	nan	nan	118702-11-7
UOBYJVFBFSLCTQ-UHFFFAOYSA-N	DB11822	TMC-647055	investigational	nan	TMC647055 has been used in trials studying the treatment of Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic, and Chronic Hepatitis C Virus.	1204416-97-6
SGIWFELWJPNFDH-UHFFFAOYSA-N	DB07080	TO-901317	experimental	nan	TO-901317 is an LXRalpha and LXRbeta agonist.	293754-55-9
FWXVGKSWZJEPQI-UHFFFAOYSA-N	DB14839	TOP-1288	investigational	nan	TOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis).	1630202-02-6
YRNFLVUMZIRYKY-BLLLJJGKSA-N	DB18104	TP-1287	investigational	nan	nan	2044686-42-0
XRNVABDYQLHODA-JCNLHEQBSA-N	DB18109	TP-3654	investigational	nan	nan	1361951-15-6
SAYGKHKXGCPTLX-UHFFFAOYSA-N	DB17058	TPCA-1	experimental	nan	TPCA-1 is a selective inhibitor of human IκB kinase 2 (IKK-2).[A253152]	507475-17-4
VAZAPHZUAVEOMC-UHFFFAOYSA-N	DB12291	Tacedinaline	investigational	nan	Tacedinaline has been used in trials studying the treatment of Lung Cancer, Multiple Myeloma, and Pancreatic Cancer.	112522-64-2
YLJREFDVOIBQDA-UHFFFAOYSA-N	DB00382	Tacrine	approved;withdrawn	N06DA01	A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.	321-64-2
QJJXYPPXXYFBGM-LFZNUXCKSA-N	DB00864	Tacrolimus	approved;investigational	D11AH01;L04AD02	Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsuk	104987-11-3
FKCMADOPPWWGNZ-YUMQZZPRSA-N	DB06182	Talabostat	investigational	nan	nan	149682-77-9
SNFYYXUGUBUECJ-UHFFFAOYSA-N	DB13083	Talarozole	investigational	nan	Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.	201410-53-9
HWGQMRYQVZSGDQ-HZPDHXFCSA-N	DB11760	Talazoparib	approved;investigational	L01XK04	Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.[L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.[L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate ca	1207456-01-6
MXFWWQICDIZSOA-UHFFFAOYSA-N	DB11770	Talinolol	investigational	C07AB13	Talinolol has been investigated for the basic science of Gastrointestinal Motility Disorder.	57460-41-0
DHSSDEDRBUKTQY-UHFFFAOYSA-N	DB20211	Talipexole	experimental	nan	Talipexole is a small molecule drug. Talipexole has a monoisotopic molecular weight of 209.1 Da.	101626-70-4
ZMELOYOKMZBMRB-DLBZAZTESA-N	DB05412	Talmapimod	investigational	nan	Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.	309913-83-5
NHHQJBCNYHBUSI-UHFFFAOYSA-N	DB07159	Tamatinib	investigational	nan	nan	841290-80-0
MUTNCGKQJGXKEM-UHFFFAOYSA-N	DB04942	Tamibarotene	investigational	nan	Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.	94497-51-5
ATFXVNUWQOXRRU-UHFFFAOYSA-N	DB18811	Taminadenant	investigational	nan	nan	1337962-47-6
WHMMKPWGWNYYFE-UHFFFAOYSA-N	DB19201	Tamnorzatinib	investigational	nan	Tamnorzatinib is under investigation in clinical trial NCT03176277 (A Study of ONO-7475 in Patients With Acute Leukemias).	1646839-59-9
NKANXQFJJICGDU-QPLCGJKRSA-N	DB00675	Tamoxifen	approved;investigational	L02BA01	Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].[A1026] Tamoxifen was granted FDA approval on 30 Dece	10540-29-1
DRHKJLXJIQTDTD-OAHLLOKOSA-N	DB00706	Tamsulosin	approved;investigational	G04CA52;G04CA02;G01AE10;G04CA54;G04CA53	Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common.[Label] It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy.[Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.[Label] Other alpha-1 adrenoceptor antagonists developed in the 1980s we	106133-20-4
CEIJFEGBUDEYSX-FZDBZEDMSA-N	DB12833	Tandospirone	investigational	nan	Tandospirone has been used in trials studying the treatment of Schizophrenia.	87760-53-0
UXXQOJXBIDBUAC-UHFFFAOYSA-N	DB05465	Tandutinib	investigational	nan	MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML pat	387867-13-2
VCFBPAOSTLMYIV-SANMLTNESA-N	DB12800	Tanimilast	investigational	nan	CHF6001 has been used in trials studying the treatment of Asthma and Chronic Obstructive Pulmonary Disease.	1239278-59-1
MAOALPSHCIBFJZ-RUZDIDTESA-N	DB21367	Tanogitran	investigational	nan	Tanogitran is a small molecule drug. Tanogitran is under investigation in clinical trial NCT02254057 (Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects). Tanogitran has a monoisotopic molecular weight of 477.25 Da.	637328-69-9
JXAGDPXECXQWBC-LJQANCHMSA-N	DB06276	Tanomastat	experimental	nan	nan	179545-77-8
IBGLGMOPHJQDJB-IHRRRGAJSA-N	DB11798	Tanzisertib	investigational	nan	Tanzisertib has been used in trials studying the treatment of Fibrosis, Discoid Lupus, Pulmonary Fibrosis, Interstitial Lung Disease, and Lung Diseases, Interstitial, among others.	899805-25-5
JQNINBDKGLWYMU-GEAQBIRJSA-N	DB17166	Tapotoclax	investigational	nan	nan	1883727-34-1
UXZDMXYRRQJIBJ-IBGZPJMESA-N	DB18810	Tarafenacin	investigational	nan	nan	385367-47-5
QLYKJCMUNUWAGO-GAJHUEQPSA-N	DB06624	Taranabant	investigational	nan	nan	701977-09-5
LGGHDPFKSSRQNS-UHFFFAOYSA-N	DB06240	Tariquidar	investigational	nan	nan	206873-63-4
BEUQXVWXFDOSAQ-UHFFFAOYSA-N	DB12108	Taselisib	investigational	nan	Taselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.	1282512-48-4
ADXGNEYLLLSOAR-UHFFFAOYSA-N	DB01349	Tasosartan	experimental	C09CA05	Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.	145733-36-4
IBHOLSBDZMIPPT-UHFFFAOYSA-N	DB21222	Tasurgratinib	investigational	nan	Tasurgratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)). Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.	1622204-21-0
LFQDNHWZDQTITF-UHFFFAOYSA-N	DB09041	Tavaborole	approved	D01AE24	Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).	174671-46-6
NSQSAUGJQHDYNO-UHFFFAOYSA-N	DB12887	Tazemetostat	approved;investigational	L01XX72	Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363] Tazemetaostat was granted FDA approval on 23 January 2020.[L11476]	1403254-99-8
LPQZKKCYTLCDGQ-WEDXCCLWSA-N	DB01606	Tazobactam	approved;investigational	J01CG02	Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with [Piperacillin] and [Ceftolozane] for the treatment of a variety of bacterial infections. Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftoloza	89786-04-9
MKTAGSRKQIGEBH-SSDOTTSWSA-N	DB20434	Tebanicline	experimental	nan	Tebanicline is a small molecule drug. Tebanicline has a monoisotopic molecular weight of 198.06 Da.	198283-73-7
ZHXUEUKVDMWSKV-UHFFFAOYSA-N	DB21002	Tebufelone	experimental	nan	Tebufelone is a small molecule drug. Tebufelone has a monoisotopic molecular weight of 300.21 Da.	112018-00-5
OESBDSFYJMDRJY-BAYCTPFLSA-N	DB04954	Tecadenoson	investigational	nan	Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.	204512-90-3
ZVQUCWXZCKWZBP-CQSZACIVSA-N	DB20329	Tecalcet	experimental	nan	Tecalcet is a small molecule drug. The usage of the INN stem '-calcet/-calcet-' in the name indicates that Tecalcet is a calcium-sensing receptor (CaSR) agonist. Tecalcet has a monoisotopic molecular weight of 303.14 Da.	148717-54-8
NTPZXHMTJGOMCJ-WDEREUQCSA-N	DB20045	Tedalinab	experimental	nan	Tedalinab is a small molecule drug. Tedalinab has a monoisotopic molecular weight of 345.17 Da.	916591-01-0
IKBKZGMPCYNSLU-RGVLZGJSSA-N	DB01079	Tegaserod	approved;withdrawn	A06AX06	Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular events in patients.[L5918,F4229] Since then, closer evaluations of the original data suggesting such cardiovascular risk have 	145158-71-0
BMZYTDRMCBZVNH-HXUWFJFHSA-N	DB20358	Teglicar	experimental	nan	Teglicar is a small molecule drug. Teglicar has a monoisotopic molecular weight of 399.35 Da.	250694-07-6
MTNBRBDFNSGQKB-GXTWGEPZSA-N	DB21635	Tegtociclib	investigational	nan	Tegtociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Tegtociclib is a cyclin dependant kinase inhibitor. Tegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors). Tegtociclib has a monoisotopic molecular weight of 404.22 Da.	2460249-19-6
PRAAPINBUWJLGA-UHFFFAOYSA-N	DB15232	Telaglenastat	investigational	nan	Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).	1439399-58-2
BBAWEDCPNXPBQM-GDEBMMAJSA-N	DB05521	Telaprevir	approved;withdrawn	J05AP02	Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of 	402957-28-2
QFCXANHHBCGMAS-UHFFFAOYSA-N	DB15393	Telatinib	investigational	nan	Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).	332012-40-5
CGDZXLJGHVKVIE-DNVCBOLYSA-N	DB12228	Telcagepant	investigational	nan	Telcagepant has been investigated for the treatment of Migraine. It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain. During migraine attacks, CGRP activates these receptors and facilitates the transmission of pain impulses.	781649-09-0
ZILOOGIOHVCEKS-HZFUHODCSA-N	DB12178	Telinavir	investigational	nan	Telinavir has been used in trials studying the treatment of HIV Infections.	143224-34-4
LJVAJPDWBABPEJ-PNUFFHFMSA-N	DB00976	Telithromycin	approved	J01FA15	Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two dom	191114-48-4
RMMXLENWKUUMAY-UHFFFAOYSA-N	DB00966	Telmisartan	approved;investigational	C09DB04;C10BX20;C09CA07;C09DX08;C09DA07	Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure.[A1489,A1490] Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentiall	144701-48-4
NCLGDOBQAWBXRA-PGRDOPGGSA-N	DB14218	Telotristat	investigational	A16AX15	A tryptophan hydroxylase inhibitor. [Telotristat ethyl] (brand name Xermelo) is a prodrug of telotristat.	1033805-28-5
MDSQOJYHHZBZKA-GBXCKJPGSA-N	DB12095	Telotristat ethyl	approved;investigational	nan	Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo.[L43342] It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment.[L43342] 	1033805-22-9
JNPRPMBJODOFEC-UHFFFAOYSA-N	DB18806	Temuterkib	investigational	nan	nan	1951483-29-6
HDXDQPRPFRKGKZ-INIZCTEOSA-N	DB15295	Tenalisib	investigational	nan	Tenalisib is under investigation in clinical trial NCT03711604 (Compassionate Use Study of Tenalisib (RP6530)).	1639417-53-0
NGBBVGZWCFBOGO-UHFFFAOYSA-N	DB01509	Tenamfetamine	illicit;investigational	nan	An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]	4764-17-4
WGRQANOPCQRCME-PMACEKPBSA-N	DB11950	Teneligliptin	investigational	A10BD28;A10BH08	Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.	760937-92-6
LXIKEPCNDFVJKC-QXMHVHEDSA-N	DB13481	Tenidap	experimental	M01AX23	nan	120210-48-2
SGOIRFVFHAKUTI-ZCFIWIBFSA-N	DB14126	Tenofovir	investigational	nan	Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate.[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to obtain oral bioavailability.[A18473, A178360]	147127-20-6
YDPWZFPXWFTXNT-UHFFFAOYSA-N	DB21475	Teplinovivint	experimental	nan	Teplinovivint is a small molecule drug. The usage of the INN stem '-vivint' in the name indicates that Teplinovivint is a Wnt signaling inhibitor. Teplinovivint has a monoisotopic molecular weight of 442.21 Da.	1428064-91-8
AHYMHWXQRWRBKT-UHFFFAOYSA-N	DB15133	Tepotinib	approved;investigational	L01EX21	Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.[A228058] It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma.[A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to pla	1100598-32-0
VCKUSRYTPJJLNI-UHFFFAOYSA-N	DB01162	Terazosin	approved;investigational	G04CA03	Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].	63590-64-7
DOMXUEMWDBAQBQ-WEVVVXLNSA-N	DB00857	Terbinafine	approved;investigational;vet_approved	D01AE15;D01BA02	Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]	91161-71-6
XUTLOCQNGLJNSA-RGVLZGJSSA-N	DB12204	Terbogrel	investigational	nan	Terbogrel has been used in trials studying the treatment of Hypertension, Pulmonary.	149979-74-8
GUGOEEXESWIERI-UHFFFAOYSA-N	DB00342	Terfenadine	approved;withdrawn	R06AX12	In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.	50679-08-8
JOAHPSVPXZTVEP-YXJHDRRASA-N	DB13399	Terguride	experimental	G02CB06	nan	37686-84-3
UTNUDOFZCWSZMS-YFHOEESVSA-N	DB08880	Teriflunomide	approved;investigational	L04AK02	Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.	163451-81-8
CXGTZJYQWSUFET-IBGZPJMESA-N	DB06536	Tesaglitazar	investigational	nan	Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.	251565-85-2
HVXKQKFEHMGHSL-QKDCVEJESA-N	DB11973	Tesevatinib	investigational	nan	Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others. Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly ex	781613-23-8
MUMGGOZAMZWBJJ-DYKIIFRCSA-N	DB00624	Testosterone	approved;investigational	G03BA03;G03EA02	Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]	58-22-0
PDMMFKSKQVNJMI-BLQWBTBKSA-N	DB01420	Testosterone propionate	approved;investigational;vet_approved;withdrawn	nan	Testosterone propionate is a slower-releasing anabolic steroid with a short half-life. It is a synthetic androstane steroid derivative of testosterone in the form of 17β propionate ester of testosterone.[T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974. Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]	57-85-2
XDBHURGONHZNJF-UHFFFAOYSA-N	DB05298	Tetomilast	investigational	nan	Tetomilast has been used in trials studying the treatment of Crohn Disease, Colitis, Ulcerative, and Chronic Obstructive Pulmonary Disease.	145739-56-6
OMZYUVOATZSGJY-UHFFFAOYSA-N	DB04462	Tetrabromo-2-Benzotriazole	experimental	nan	nan	nan
GKCBAIGFKIBETG-UHFFFAOYSA-N	DB09085	Tetracaine	approved;investigational;vet_approved	C05AD02;N01BA03;D04AB06;N01BA53;S01HA03	Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.	94-24-6
ZROLHBHDLIHEMS-HUUCEWRRSA-N	DB11755	Tetrahydrocannabivarin	investigational	nan	Tetrahydrocannabivarin (THCV) is a propyl analogue of tetrahydrocannabinol (Δ9-THC), one of the primary pharmacological components of [Medical Cannabis]. Δ9-THC is currently available in several synthetic forms, including [Dronabinol], while purified or isolated THCV is not approved for any medical uses and is not available as any marketed products. As a major phytocannabinoid, however, THCV is accessible within [Medical Cannabis] along with other identified cannabinoids including [Cannabidiol] 	31262-37-0
MSTNYGQPCMXVAQ-KIYNQFGBSA-N	DB00116	Tetrahydrofolic acid	investigational;nutraceutical	nan	Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.	135-16-0
AEQDJSLRWYMAQI-KRWDZBQOSA-N	DB12093	Tetrahydropalmatine	investigational	nan	Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).	483-14-7
PPJYSSNKSXAVDB-UHFFFAOYSA-N	DB01751	Tetraiodothyroacetic acid	experimental	nan	nan	67-30-1
QEMXHQIAXOOASZ-UHFFFAOYSA-N	DB03095	Tetramethylammonium	experimental	nan	nan	51-92-3
WVTKBKWTSCPRNU-KYJUHHDHSA-N	DB14066	Tetrandrine	investigational	nan	nan	518-34-3
WSWJIZXMAUYHOE-UHFFFAOYSA-N	DB15976	Tetroxoprim	experimental	J01EE06	nan	53808-87-0
TUYWTLTWNJOZNY-UHFFFAOYSA-N	DB06558	Tezosentan	investigational	nan	Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.	180384-57-0
UEJJHQNACJXSKW-UHFFFAOYSA-N	DB01041	Thalidomide	approved;investigational;withdrawn	L04AX02	A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start 	50-35-1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N	DB00277	Theophylline	approved;investigational	R03DA54;R03DA74;R03DA20;R03DA04;R03DB04	A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.	58-55-9
WJCNZQLZVWNLKY-UHFFFAOYSA-N	DB00730	Thiabendazole	approved;vet_approved;withdrawn	D01AC06;P02CA02	2-Substituted benzimidazole first introduced in 1962. It is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential. (From Smith and Reynard, Textbook of Pharmacology, 1992, p919)	148-79-8
JZRWCGZRTZMZEH-UHFFFAOYSA-N	DB00152	Thiamine	approved;investigational;nutraceutical;vet_approved	A11DA01	Thiamine or thiamin, also known as vitamin B1, is a colorless compound with the chemical formula C12H17N4OS. It is soluble in water and insoluble in alcohol. Thiamine decomposes if heated. Thiamine was first discovered by Umetaro Suzuki in Japan when researching how rice bran cured patients of Beriberi. Thiamine plays a key role in intracellular glucose metabolism and it is thought that thiamine inhibits the effect of glucose and insulin on arterial smooth muscle cell proliferation. Thiamine pla	70-16-6
VZYCZNZBPPHOFY-UHFFFAOYSA-N	DB01622	Thioproperazine	approved	N05AB08	Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.	316-81-4
KLBQZWRITKRQQV-UHFFFAOYSA-N	DB00679	Thioridazine	approved;withdrawn	N05AC02	A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.	50-52-2
LJJKNPQAGWVLDQ-SNVBAGLBSA-N	DB08626	Thiorphan	experimental	nan	A potent inhibitor of membrane metalloendopeptidase (enkephalinase). Thiorphan potentiates morphine-induced analgesia and attenuates naloxone-precipitated withdrawal symptoms.	76721-89-6
KUAZQDVKQLNFPE-UHFFFAOYSA-N	DB13245	Thiram	approved	P03AA05	Thiram may be used in dermatology as a scabicide [T436]. Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada [L5425].	137-26-8
IQFYYKKMVGJFEH-XLPZGREQSA-N	DB04485	Thymidine	approved;investigational	nan	Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis.[A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the toxicity of established anti-metabolite chemotherapeutic agents, such as 5-Fluorouracil (FU), Methotrexate (MTX), and Cytosine arabinoside (ara-C).[A2	50-89-5
GYOZYWVXFNDGLU-XLPZGREQSA-N	DB01643	Thymidine monophosphate	investigational	nan	5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.	365-07-1
UURAUHCOJAIIRQ-QGLSALSOSA-N	DB11468	Tiamulin	experimental;vet_approved	nan	Tiamulin is a pleuromutilin antibiotic drug that is used in veterinary medicine particularly for pigs and poultry.	55297-95-5
JTVPZMFULRWINT-UHFFFAOYSA-N	DB13025	Tiapride	investigational	N05AL03	Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.	51012-32-9
GUHPRPJDBZHYCJ-UHFFFAOYSA-N	DB01600	Tiaprofenic acid	approved	M01AE11	Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the _arylpropionic acid_ (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).	33005-95-7
WZDGZWOAQTVYBX-XOINTXKNSA-N	DB09070	Tibolone	approved;investigational	G03CX01	Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874]. Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and progestogenic properties. It has been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and the treatment of post-menopa	5630-53-5
OEKWJQXRCDYSHL-FNOIDJSQSA-N	DB08816	Ticagrelor	approved;investigational	B01AC24	Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]	274693-27-5
PHWBOXQYWZNQIN-UHFFFAOYSA-N	DB00208	Ticlopidine	approved	B01AC05	Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocy	55142-85-3
PMJIHLSCWIDGMD-UHFFFAOYSA-N	DB12129	Tideglusib	approved;investigational;withdrawn	nan	Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).[A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.	865854-05-3
KYSFUHHFTIGRJN-UHFFFAOYSA-N	DB21402	Tifenazoxide	investigational	nan	Tifenazoxide is a small molecule drug. Tifenazoxide is under investigation in clinical trial NCT04744129 (Headache Inducing Effect of NN414 in Migraine Patients). Tifenazoxide has a monoisotopic molecular weight of 290.99 Da.	279215-43-9
NTNWOCRCBQPEKQ-YFKPBYRVSA-N	DB11815	Tilarginine	approved;investigational;withdrawn	nan	Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.	17035-90-4
BLJRIMJGRPQVNF-JTQLQIEISA-N	DB00373	Timolol	approved;investigational	C07AA06;S01ED51;C07BA06;C07DA06;S01ED01	Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.	26839-75-8
HAGSLCBZFRRBLS-UHFFFAOYSA-N	DB17832	Tinlarebant	investigational	nan	nan	1821327-95-0
FWRFPHJSGLYXTD-UHFFFAOYSA-N	DB18796	Tinodasertib	investigational	nan	nan	1464151-33-4
GISXTRIGVCKQBX-UHFFFAOYSA-N	DB15147	Tinostamustine	investigational	nan	Tinostamustine is under investigation in clinical trial NCT03452930 (Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma).	1236199-60-2
WYWHKKSPHMUBEB-UHFFFAOYSA-N	DB00352	Tioguanine	approved;investigational	L01BB03	An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.	154-42-7
LERNTVKEWCAPOY-DZZGSBJMSA-N	DB01409	Tiotropium	approved;investigational	R03AL06;R03BB04;R03BB54;R03AL10	Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].[A180163] Tiotropium was granted FDA approval on	186691-13-4
PLHJCIYEEKOWNM-HHHXNRCGSA-N	DB04960	Tipifarnib	investigational	nan	Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.	192185-72-1
QQHMKNYGKVVGCZ-UHFFFAOYSA-N	DB09343	Tipiracil	approved;investigational	nan	Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.[A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF or anti-EGFR therapy.[A31254]	183204-74-2
SUJUHGSWHZTSEU-FYBSXPHGSA-N	DB00932	Tipranavir	approved	J05AE09	Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.	174484-41-4
SEJLPXCPMNSRAM-GOSISDBHSA-N	DB15227	Tirabrutinib	investigational	L01EL06	Tirabrutinib is under investigation in clinical trial NCT02626026 (Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)).	1351636-18-4
UOWZUVNAGUAEQC-UHFFFAOYSA-N	DB03604	Tiratricol	approved;investigational	H03AA04;D11AX08	Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).[L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized by chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain.[A274073] Tiratricol is currently being investigated in US clinical trials	51-24-1
HUNGUWOZPQBXGX-UHFFFAOYSA-N	DB06137	Tirbanibulin	approved;investigational	D06BX03	Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin.[A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri.[L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.[A225721,A225741] Tirbanibulin blocks the molecular pathways t	897016-82-9
RBKASMJPSJDQKY-RBFSKHHSSA-N	DB13050	Tirilazad	investigational	N07XX01	Tirilazad has been used in trials studying the treatment of Spinal Cord Injury.	110101-66-1
COKMIXFXJJXBQG-NRFANRHFSA-N	DB00775	Tirofiban	approved;investigational	B01AC17	Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.	144494-65-5
UCEQXRCJXIVODC-PMACEKPBSA-N	DB12200	Tivantinib	investigational	nan	Tivantinib has been investigated in Solid Tumors.	905854-02-6
SPMVMDHWKHCIDT-UHFFFAOYSA-N	DB11800	Tivozanib	approved;investigational	L01EK03	Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.[L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individua	475108-18-0
XFYDIVBRZNQMJC-UHFFFAOYSA-N	DB00697	Tizanidine	approved;investigational	M03BX02	Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of 	51322-75-9
HVIGNZUDBVLTLU-MRXNPFEDSA-N	DB21296	Tizaterkib	investigational	nan	Tizaterkib is a small molecule drug. The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor. Tizaterkib is under investigation in clinical trial NCT04305249 (Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies). Tizaterkib has a monoisotopic molecular weight of 494.2 Da.	2097416-76-5
UJLAWZDWDVHWOW-YPMHNXCESA-N	DB08895	Tofacitinib	approved;investigational	L04AF01	Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investi	477600-75-2
DHCOPPHTVOXDKU-UHFFFAOYSA-N	DB11681	Tofimilast	investigational	nan	Tofimilast has been used in trials studying the treatment of Asthma and Pulmonary Disease, Chronic Obstructive.	185954-27-2
KOEUOFPEZFUWRF-LJQANCHMSA-N	DB18715	Tolebrutinib	investigational	nan	nan	1971920-73-6
YEZNLOUZAIOMLT-UHFFFAOYSA-N	DB09216	Tolfenamic acid	approved	M01AG02	Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent.[A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.[L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]	13710-19-5
YCXOHEXZVKOGEV-DNRQZRRGSA-N	DB16160	Tolinapant	investigational	nan	ASTX660 is under investigation in clinical trial NCT02503423 (Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas).	1799328-86-1
UPSPUYADGBWSHF-UHFFFAOYSA-N	DB00500	Tolmetin	approved	M01AB03;M02AA21	A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.	26171-23-3
FSKFPVLPFLJRQB-UHFFFAOYSA-N	DB06264	Tolperisone	investigational	M03BX04;M02AX06	Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves. Based on existing clinical data, Tolperisone is not sedating and does not interact with alcohol.	728-88-1
LUBHDINQXIHVLS-UHFFFAOYSA-N	DB02383	Tolrestat	approved;withdrawn	A10XA01	Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename Alredase but was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death.	82964-04-3
OOGJQPCLVADCPB-HXUWFJFHSA-N	DB01036	Tolterodine	approved;investigational	G04BD07	Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.	124937-51-5
MWYHLEQJTQJHSS-UHFFFAOYSA-N	DB20018	Tomelukast	experimental	nan	Tomelukast is a small molecule drug. The usage of the INN stem '-lukast' in the name indicates that Tomelukast is a leukotriene receptor antagonist. Tomelukast has a monoisotopic molecular weight of 318.17 Da.	88107-10-2
HKTBYUWLRDZAJK-UHFFFAOYSA-N	DB15219	Tomivosertib	investigational	nan	Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).	1849590-01-7
ZWTVVWUOTJRXKM-UHFFFAOYSA-N	DB12569	Tonapofylline	investigational	nan	Tonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.	340021-17-2
KJADKKWYZYXHBB-XBWDGYHZSA-N	DB00273	Topiramate	approved;investigational	A08AA51;N03AX11	Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines.[A175249] It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults.[L10550] Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical struc	97240-79-4
UBVZQGOVTLIHLH-UHFFFAOYSA-N	DB01685	Topiroxostat	investigational	nan	Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat. While [DB00437] is considered a first-line therapy in 	577778-58-6
FWFGIHPGRQZWIW-SQNIBIBYSA-N	DB11781	Tosedostat	investigational	nan	Tosedostat has been used in trials studying the treatment and supportive care of AML, Leukemia, Pancreas Cancer, Multiple Myeloma, and Pancreatic Cancer, among others. Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel. It entered the clinical trial in patients with haematologi	238750-77-1
VWMJHAFYPMOMGF-ZCFIWIBFSA-N	DB15266	Tovorafenib	approved;investigational	nan	Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity.[A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements.[L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation.[A263602] Tovorafenib inhibits BRAF and blocks dysregulated signalling pathways related to cancer cell growth and survi	1096708-71-2
GCIKSSRWRFVXBI-UHFFFAOYSA-N	DB19675	Tozasertib	investigational	nan	Tozasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Tozasertib is a serine/threonine kinase inhibitor. Tozasertib is under investigation in clinical trial NCT02532868 (A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)). Tozasertib has a monoisotopic molecular weight of 464.21 Da.	639089-54-6
AQLVRTWKJDTWQQ-SDBHATRESA-N	DB13122	Trabodenoson	investigational	nan	Trabodenoson has been used in trials studying the treatment of Ocular Hypertension (OHT) and Primary Open-Angle Glaucoma (POAG).	871108-05-3
TVYLLZQTGLZFBW-UHFFFAOYSA-N	DB00193	Tramadol	approved;investigational	N02AJ16;N02AJ13;N02AJ14;N02AX02	Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs fr	27203-92-5
LIRYPHYGHXZJBZ-UHFFFAOYSA-N	DB08911	Trametinib	approved;investigational	L01EE01	Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.[A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.[L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy 	871700-17-3
QEMSVZNTSXPFJA-HNAYVOBHSA-N	DB18795	Traxoprodil	investigational	nan	nan	134234-12-1
PHLBKPHSAVXXEF-UHFFFAOYSA-N	DB00656	Trazodone	approved;investigational	N06AX05	Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.[A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression.[T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sex	19794-93-5
SHGAZHPCJJPHSC-YCNIQYBTSA-N	DB00755	Tretinoin	approved;investigational;nutraceutical	L01XF01;D10AD51;D10AD01	Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol).[A257474] It is an oxidation product in the physiological pathway of vitamin A metabolism.[A257689] In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L.[A257689] Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities.[A257689] It has been used in dermatology for many years to	302-79-4
XMYKNCNAZKMVQN-NYYWCZLTSA-N	DB11940	Triapine	investigational	nan	Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.	143621-35-6
JOFWLTCLBGQGBO-UHFFFAOYSA-N	DB00897	Triazolam	approved;investigational	N05CD05	Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.	28911-01-5
KVSKGMLNBAPGKH-UHFFFAOYSA-N	DB20138	Tribromsalan	approved;withdrawn	nan	Tribromsalan is a small molecule drug. Tribromsalan has a monoisotopic molecular weight of 446.81 Da.	87-10-5
LMJSLTNSBFUCMU-UHFFFAOYSA-N	DB01021	Trichlormethiazide	approved;vet_approved	G01AE10;C03AA06;C03EA02;C03AB06	A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)	133-67-5
RTKIYFITIVXBLE-QEQCGCAPSA-N	DB04297	Trichostatin A	investigational	nan	nan	58880-19-6
ICUTUKXCWQYESQ-UHFFFAOYSA-N	DB11155	Triclocarban	approved	nan	Triclocarban, with the chemical formula C13H9Cl3N2O [L2675] is an antibacterial agent that is particularly effective against Gram-positive bacteria such as *Staphylococcus aureus*. It is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal effects [	101-20-2
XEFQLINVKFYRCS-UHFFFAOYSA-N	DB08604	Triclosan	approved	D08AE04;D09AA06	An aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, toothpaste and deodorants as well as in household items such as plastic chopping boards, sports equipment and shoes.	3380-34-5
VGBVAARMQYYITG-DESRROFGSA-N	DB15687	Tridecactide	investigational	nan	Tridecactide, also known as alpha-corticotropin 1-13, is a deacetylated and deaminated alpha-melanocyte stimulating hormone, which may have antipyretic, anti-inflammatory, and antimicrobial effects.[A203210] Tridecactide, along with [metenkefalin], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]	22006-64-0
FXUAIOOAOAVCGD-WCTZXXKLSA-N	DB02034	Tridolgosir	experimental	nan	An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.	72741-87-8
MFBCDACCJCDGBA-UHFFFAOYSA-N	DB12808	Trifarotene	approved;investigational	D10AD06	"Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019.[L9013] Retinoids are a class of medications structurally and functionally analogous to [vitamin A], though later generation retinoids such as trifarotene and [adapalene] bear little structural resemblance to vitamin A and are analogous only in function.[A187081] Trifarotene is considered the first of the ""fourth-generation"" retinoids due to its uniq"	895542-09-3
ZEWQUBUPAILYHI-UHFFFAOYSA-N	DB00831	Trifluoperazine	approved;investigational	N05AB06	A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.	117-89-5
GPMXUUPHFNMNDH-UHFFFAOYSA-N	DB13552	Trifluperidol	experimental	N05AD02	nan	749-13-3
HWHLPVGTWGOCJO-UHFFFAOYSA-N	DB00376	Trihexyphenidyl	approved;investigational	N04AA01	Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.[A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.[L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA app	144-11-6
PDGKHKMBHVFCMG-UHFFFAOYSA-N	DB15442	Trilaciclib	approved;investigational	V03AF12	Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.[A229313] Trilaciclib was granted FDA approval	1374743-00-6
IEDVJHCEMCRBQM-UHFFFAOYSA-N	DB00440	Trimethoprim	approved;investigational;vet_approved	J04AM08;J01EE03;J01EA01;J01EE01;J01EE04;J01EE02;J01EE05;J01EE07	Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival.[L11893] Trimethoprim is often used in combination with [sulfamethoxazole] due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract 	738-70-5
ZSCDBOWYZJWBIY-UHFFFAOYSA-N	DB00726	Trimipramine	approved;investigational	N06AA06	Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.	739-71-9
FMHHVULEAZTJMA-UHFFFAOYSA-N	DB04571	Trioxsalen	approved;withdrawn	D05BA01;D05AD01	Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative obtained from several plants, mainly Psoralea corylifolia. Like other psoralens it causes photosensitization of the skin. It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. The photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. In researc	3902-71-4
DFBIRQPKNDILPW-CIVMWXNOSA-N	DB12025	Triptolide	investigational	nan	Triptolide has been used in trials studying the treatment of HIV, Crohn's Disease, Intestinal Diseases, Gastrointestinal Diseases, and Digestive System Diseases, among others.	38748-32-2
GXPHKUHSUJUWKP-UHFFFAOYSA-N	DB00197	Troglitazone	approved;withdrawn	A10BG01	Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].	97322-87-7
BGDKAVGWHJFAGW-UHFFFAOYSA-N	DB00809	Tropicamide	approved;investigational	S01FA06;S01FA56	Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.[A230103] Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia for eye exams or ocular procedures.[A229958] It is also used in combination with [hydroxyamphetamine] for the same indication.[L32178] Oral tropicamide has been investigated as a potential drug to relieve sialorrhea in patients with Parkinson's Dis	1508-75-4
ZNRGQMMCGHDTEI-ITGUQSILSA-N	DB11699	Tropisetron	approved;investigational;withdrawn	A04AA03	Tropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Tropisetron appears to be well tolerated with the most frequently reported adverse effect being headache. Extrapyramidal side effects are rare upon using tropisetron.	89565-68-4
OYYDSUSKLWTMMQ-JKHIJQBDSA-N	DB00209	Trospium	approved;investigational	A03DA06;G04BD09	Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]	47608-32-2
HOCFDYZWQYGULA-UHFFFAOYSA-N	DB21440	Trovirdine	experimental	nan	Trovirdine is a small molecule drug. Trovirdine has a monoisotopic molecular weight of 336.0 Da.	149488-17-5
APJYDQYYACXCRM-UHFFFAOYSA-N	DB08653	Tryptamine	investigational	nan	nan	61-54-1
SDEAXTCZPQIFQM-UHFFFAOYSA-N	DB11652	Tucatinib	approved;investigational	L01EH03	Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.[L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]	937263-43-9
SZMJVTADHFNAIS-BJMVGYQFSA-N	DB06334	Tucidinostat	investigational	L01XH06	nan	1616493-44-7
INASOKQDNHHMRE-UHFFFAOYSA-N	DB12719	Turofexorate isopropyl	investigational	nan	Fxr 450 is under investigation in clinical trial NCT00509756 (Study Evaluating Turofexorate isopropyl in Healthy Japanese Men).	629664-81-9
DVEXZJFMOKTQEZ-JYFOCSDGSA-N	DB17060	U-0126	experimental	nan	U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.[A253162]	218601-62-8
AWSRDDSRQUJMAJ-LCAJTWGOSA-N	DB17096	UCB7362	experimental	nan	UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.[A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion.[A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites. It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogen	nan
OTDGPKRCQXSTPV-JTQLQIEISA-N	DB12099	UK-396,082	investigational	nan	UK-396,082 has been used in trials studying the basic science of Safety, Phase 1, Toleration, Multiple Dose, and Pharmacokinetic.	400044-47-5
OHIUQAZROSYCMC-CALCHBBNSA-N	DB12837	UK-500001	investigational	nan	UK-500,001 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.	582332-31-8
VGGGPCQERPFHOB-RDBSUJKOSA-N	DB03424	Ubenimex	investigational	nan	Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.	58970-76-6
DDOOFTLHJSMHLN-ZQHRPCGSSA-N	DB15328	Ubrogepant	approved;investigational	N02CD04	"Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.[L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as ""gepants"", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clin"	1374248-77-7
POFVJRKJJBFPII-UHFFFAOYSA-N	DB21595	Ulecaciclib	experimental	nan	Ulecaciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Ulecaciclib is a cyclin dependant kinase inhibitor. Ulecaciclib has a monoisotopic molecular weight of 496.25 Da.	2075750-05-7
WGYPAJVJMXQXTR-ABNZCKJZSA-N	DB12128	Ulimorelin	investigational	nan	Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the GI tract is severely impaired.	842131-33-3
JOCLITFYIMJMNK-UHFFFAOYSA-N	DB18788	Ulixacaltamide	investigational	nan	nan	1199236-64-0
KSERXGMCDHOLSS-LJQANCHMSA-N	DB13930	Ulixertinib	investigational	nan	Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity [A31474]. It is currently in clinical trials for the treatment of a wide range of tumors.	869886-67-9
FVTWTVQXNAJTQP-UHFFFAOYSA-N	DB09076	Umeclidinium	approved;investigational	R03AL08;R03AL03;R03BB07	Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%.[A7715] Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subt	869185-19-3
PSBBWFNMHDUTRH-DLBZAZTESA-N	DB19898	Umibecestat	experimental	nan	Umibecestat is a small molecule drug. The usage of the INN stem '-becestat' in the name indicates that Umibecestat is a beta secretase inhibitor. Umibecestat has a monoisotopic molecular weight of 513.08 Da.	1387560-01-1
WYQFJHHDOKWSHR-MNOVXSKESA-N	DB15091	Upadacitinib	approved;investigational	L04AF03	Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.[A189165] Despite a variety of therapeutic agents avai	1310726-60-3
DUCNHKDCVVSJLG-UHFFFAOYSA-N	DB21230	Upidosin	experimental	nan	Upidosin is a small molecule drug. Upidosin has a monoisotopic molecular weight of 511.25 Da.	152735-23-4
AXTAPYRUEKNRBA-JTQLQIEISA-N	DB11969	Uprosertib	investigational	nan	Uprosertib has been used in trials studying the treatment of Cancer, Melanoma, Solid Tumours, Cervical Cancer, and HER2/Neu Negative, among others.	1047634-65-0
WCGUUGGRBIKTOS-GPOJBZKASA-N	DB15588	Ursolic acid	investigational	nan	nan	77-52-1
HAMGPBKPACGWND-ZOXUKVPXSA-N	DB18184	Usnoflast	investigational	nan	nan	2455519-86-3
IGUBBWJDMLCRIK-UHFFFAOYSA-N	DB15273	VS-4718	investigational	nan	VS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).	1061353-68-1
QYBGBLQCOOISAR-UHFFFAOYSA-N	DB12986	VS-5584	investigational	nan	VS-5584 has been used in trials studying the treatment of Lymphoma, Metastatic Cancer, and Non Hematologic Cancers.	1246560-33-7
BOOOLEGQBVUTKC-NVQSDHBMSA-N	DB11806	VTP-194204	investigational	nan	Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung Cancer.	220619-73-8
FYSRKRZDBHOFAY-UHFFFAOYSA-N	DB05470	VX-702	investigational	nan	VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.	745833-23-2
IOOWNWLVCOUUEX-WPRPVWTQSA-N	DB12107	Vaborbactam	approved;investigational	J01DH52	Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.[A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of vaborbactam and [Meropenem] for intravenous administratio	1360457-46-0
FJCDSQATIJKQKA-UHFFFAOYSA-N	DB15310	Vactosertib	investigational	nan	Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).	1352608-82-2
JGRXMPYUTJLTKT-UHFFFAOYSA-N	DB12255	Vadadustat	approved;investigational	B03XA08	One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO) production.[A244165] The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa], to counter the decrease in endogenous EPO production. While efficacious, the	1000025-07-9
XBBRLCXCBCZIOI-DLBZAZTESA-N	DB16446	Vafidemstat	investigational	nan	Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).	1357362-02-7
LNPDTQAFDNKSHK-UHFFFAOYSA-N	DB00580	Valdecoxib	approved;withdrawn	M01AH03;G01AE10	Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.	181695-72-7
SSDRNUPMYCFXGM-UYPAYLBCSA-N	DB18314	Valemetostat	investigational	nan	nan	1809336-39-7
UPPMZCXMQRVMME-UHFFFAOYSA-N	DB13497	Valethamate	investigational	A03AX14	nan	16376-74-2
ZYTXTXAMMDTYDQ-DGEXFFLYSA-N	DB15114	Vamorolone	approved;investigational	H02AB18	Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function and the most common form of muscular dystrophy in the United States.[L48676] Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects.[L48676] Va	13209-41-1
UHTHHESEBZOYNR-UHFFFAOYSA-N	DB05294	Vandetanib	approved	L01EX04	Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.	443913-73-3
KUQWGLQLLVFLSM-ONAXAZCASA-N	DB11929	Vaniprevir	investigational	nan	Vaniprevir has been used in trials studying the treatment and diagnostic of Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C Infection, and Chronic Genotype 1 Hepatitis C Virus Infection.	923590-37-8
NAUWTFJOPJWYOT-UHFFFAOYSA-N	DB03701	Vanoxerine	investigational	nan	Vanoxerine is a highly selective dopamine transporter antagonist. It was synthesized in the late 1970s and developed as a potential treatment for depression.[A19824] Vanoxerine was later evaluated as a potential treatment for cocaine addiction due to its ability to block dopamine reuptake with a slower dissociation rate than cocaine.[A37914] Although several studies have suggested that the profile of vanoxerine is safer than that of cocaine,[A19824,A248550] other studies have found that vanoxeri	67469-69-6
SECKRCOLJRRGGV-UHFFFAOYSA-N	DB00862	Vardenafil	approved	G04BE09	Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis of cGMP in the smooth muscle cells of the corpus cavernosum. PDE5 inhibitors, such as vardenafil, inhibit the d	224785-90-4
SRJNRAQUSAVENA-GSHUGGBRSA-N	DB13126	Varegacestat	investigational	nan	BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.	1584647-27-7
JQSHBVHOMNKWFT-UHFFFAOYSA-N	DB01273	Varenicline	approved;investigational	S01XA28;N07BA03	Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the for	249296-44-4
BHLXTPHDSZUFHR-UHFFFAOYSA-N	DB11909	Varespladib	investigational	nan	Varespladib has been investigated for the treatment and prevention of Sickle Cell Disease, Vaso-occlusive Crisis, and Acute Coronary Syndrome.	172732-68-2
RTHKPHCVZVYDFN-UHFFFAOYSA-N	DB08694	Variolin B	experimental	nan	nan	nan
UWXSAYUXVSFDBQ-CYBMUJFWSA-N	DB05944	Varlitinib	investigational	nan	Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.	845272-21-1
XHIKZWOEFZENIX-GOSISDBHSA-N	DB18785	Varoglutamstat	investigational	nan	nan	1276021-65-8
YCOYDOIWSSHVCK-UHFFFAOYSA-N	DB04879	Vatalanib	investigational	nan	Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.	212141-54-3
QLRRJMOBVVGXEJ-XHSDSOJGSA-N	DB16657	Vecabrutinib	investigational	nan	Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).	1510829-06-7
ZEYYDOLCHFETHQ-JOCHJYFZSA-N	DB16346	Veliflapon	investigational	nan	Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).	128253-31-6
JNAHVYVRKWKWKQ-CYBMUJFWSA-N	DB07232	Veliparib	investigational	L01XK05	nan	912444-00-9
GPXBXXGIAQBQNI-UHFFFAOYSA-N	DB08881	Vemurafenib	approved;investigational	G01AE10;L01EC01	Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]	918504-65-1
YNBQAYKYNYRCCA-UHFFFAOYSA-N	DB17105	Venadaparib	investigational	nan	nan	1681017-83-3
LQBVNQSMGBZMKD-UHFFFAOYSA-N	DB11581	Venetoclax	approved;investigational	L01XX52	Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process [A18565], [A18566]. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022]. Venetoclax was developed through reverse engineering of	1257044-40-8
YFHRCLAKZBDRHN-MRXNPFEDSA-N	DB14966	Venglustat	investigational	nan	Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).	1401090-53-6
PNVNVHUZROJLTJ-UHFFFAOYSA-N	DB00285	Venlafaxine	approved;investigational	N06AX16	Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults.[L43030] The immediate formulation of the drug, marketed as Effexor, was first ap	93413-69-5
SGTNSNPWRIOYBX-UHFFFAOYSA-N	DB00661	Verapamil	approved;investigational	C09BB10;C08DA51;C08DA01	Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications.[L8791] Verapamil is administered as a racemic mixture conta	52-53-9
YHYKUSGACIYRML-KRWDZBQOSA-N	DB12285	Verubecestat	investigational	nan	Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the level	1286770-55-5
SNHCRNMVYDHVDT-UHFFFAOYSA-N	DB05585	Verubulin	investigational	nan	Antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.	827031-83-4
NZDSLYATTDIDPH-UHFFFAOYSA-N	DB21481	Vevorisertib	investigational	nan	Vevorisertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Vevorisertib is a serine/threonine kinase inhibitor. Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)). Vevorisertib has a monoisotopic molecular weight of 586.32 Da.	1416775-46-6
XPRDUGXOWVXZLL-UHFFFAOYSA-N	DB15446	Vidofludimus	investigational	nan	Vidofludimus is under investigation in clinical trial NCT03722576 (Vidofludimus Calcium for Primary Sclerosing Cholangitis).	717824-30-1
PFWVGKROPKKEDW-UHFFFAOYSA-N	DB12272	Vidupiprant	investigational	nan	Vidupiprant has been used in trials studying the treatment and basic science of Asthma.	1169483-24-2
SGEGOXDYSFKCPT-UHFFFAOYSA-N	DB06684	Vilazodone	approved;investigational	N06AX24	Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain[A6947]. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].	163521-12-8
SYOKIDBDQMKNDQ-XWTIBIIYSA-N	DB04876	Vildagliptin	approved;investigational	A10BH02;A10BD08	Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired.[A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels. E	274901-16-5
YWPHCCPCQOJSGZ-UHFFFAOYSA-N	DB09185	Viloxazine	approved;investigational;withdrawn	N06AX09	Viloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narco	46817-91-8
TVGAHWWPABTBCX-UHFFFAOYSA-N	DB17520	Vimseltinib	approved;investigational	nan	Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R).[L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.[A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in a lower risk of off-target effects, including hepatotoxicity.[L52230,A265035] Vim	1628606-05-2
JXLYSJRDGCGARV-CFWMRBGOSA-N	DB00570	Vinblastine	approved;investigational	L01CA01	Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)	865-21-4
GBABOYUKABKIAF-IELIFDKJSA-N	DB00361	Vinorelbine	approved;investigational	L01CA04	Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the va	71486-22-1
DDNCQMVWWZOMLN-IRLDBZIGSA-N	DB12131	Vinpocetine	investigational	N06BX18	Vinpocetine has been investigated for the treatment of Epilepsy.	42971-09-5
HQSBCDPYXDGTCL-UHFFFAOYSA-N	DB06625	Vipadenant	investigational	nan	nan	442908-10-3
USGHRRVFKSLEJT-WVBUVRCRSA-N	DB19549	Viquidacin	experimental	nan	Viquidacin is a small molecule drug. The usage of the INN stem '-dacin' in the name indicates that Viquidacin is a antibiotic, DNA gyrase and topoisomerase IV inhibitor. Viquidacin has a monoisotopic molecular weight of 504.16 Da.	904302-98-3
BPQMGSKTAYIVFO-UHFFFAOYSA-N	DB08828	Vismodegib	approved;investigational	L01XJ01	Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry.[A7369] Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an i	879085-55-9
JUSFANSTBFGBAF-IRXDYDNUSA-N	DB11925	Vistusertib	investigational	nan	Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma.	1009298-59-2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N	DB00162	Vitamin A	approved;investigational;nutraceutical;vet_approved	S01XA02;V04CB01;D10AD02;R01AX02;A11CA01	Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of carotenoids found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.	68-26-8
ZQOBVMHBVWNVBG-UHFFFAOYSA-N	DB17141	Vodobatinib	investigational	nan	nan	1388803-90-4
SXNJFOWDRLKDSF-STROYTFGSA-N	DB12062	Volasertib	investigational	nan	Volasertib has been used in trials studying the treatment of Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Monocytic, Acute, among others.	755038-65-4
HXTGXYRHXAGCFP-OAQYLSRUSA-N	DB16351	Volinanserin	investigational	nan	Volinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study).	139290-65-6
QCZAWDGAVJMPTA-RNFRBKRXSA-N	DB17097	Vorasidenib	approved;investigational	L01XM04	Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.[L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib].[A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment o	1644545-52-7
BCEHBSKCWLPMDN-MGPLVRAMSA-N	DB00582	Voriconazole	approved;investigational	J02AC03	Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections.[L15571] It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms.[A236050] Voriconazole was approved by the FDA und	137234-62-9
WAEXFXRVDQXREF-UHFFFAOYSA-N	DB02546	Vorinostat	approved;investigational	L01XH01	Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a	149647-78-9
AEZZJXJIJFSUEM-QFIPXVFZSA-N	DB21483	Vornorexant	experimental	nan	Vornorexant is a small molecule drug. The usage of the INN stem '-orexant' in the name indicates that Vornorexant is a orexin receptor antagonist. Vornorexant has a monoisotopic molecular weight of 447.18 Da.	2265899-49-6
YQNWZWMKLDQSAC-UHFFFAOYSA-N	DB09068	Vortioxetine	approved;investigational	N06AX26	Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhib	508233-74-7
MRPGRAKIAJJGMM-OCCSQVGLSA-N	DB15157	Voruciclib	investigational	nan	Voruciclib is under investigation in clinical trial NCT03547115 (A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML).	1000023-04-0
XMBUPPIEVAFYHO-KPZWWZAWSA-N	DB13939	Vosilasarm	investigational	nan	RAD140 is an investigational selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and breast cancer.	1182367-47-0
RGHYDLZMTYDBDT-UHFFFAOYSA-N	DB12400	Voxtalisib	investigational	nan	Voxtalisib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Breast Cancer, among others.	934493-76-2
AINJYWXKBKRQSX-UHFFFAOYSA-N	DB02071	WAY-151693	experimental	nan	nan	nan
HQVHOQAKMCMIIM-HXUWFJFHSA-N	DB13950	WIN 55212-2	experimental	nan	WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical structure. It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling.	131543-22-1
XXYGTCZJJLTAGH-UHFFFAOYSA-N	DB12561	WNT-974	investigational	nan	WNT974 has been used in trials studying the treatment of Metastatic Colorectal Cancer and Squamous Cell Carcinoma, Head And Neck.	1243244-14-5
QUMCIHKVKQYNPA-RUZDIDTESA-N	DB23606	WNY0824	experimental	nan	WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC). [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]	2412707-81-2
FACUYWPMDKTVFU-BYPYZUCNSA-N	DB04129	Willardiine	experimental	nan	Willardiine is a compound isolated from seeds of _Acacia willariana_.	21416-43-3
QDLHCMPXEPAAMD-QAIWCSMKSA-N	DB08059	Wortmannin	experimental	nan	Wortmannin is a steroid metabolite of _Penicillium funiculosum_ and _Talaromyces wortmannii_ fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).	19545-26-7
ONPGOSVDVDPBCY-CQSZACIVSA-N	DB13104	X-376	investigational	nan	X-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]	1365267-27-1
AEJACXAFHXBVHF-UHFFFAOYSA-N	DB18780	XP-102	investigational	nan	nan	1392429-79-6
JDALSSGOBMTZEP-NWJWHWDBSA-N	DB02702	XV638	experimental	nan	nan	183854-11-7
DXPOSRCHIDYWHW-UHFFFAOYSA-N	DB13781	Xamoterol	approved	C01CX07	Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.	81801-12-9
JOLJIIDDOBNFHW-UHFFFAOYSA-N	DB15357	Xanomeline	approved;investigational	nan	Schizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine.[A264509] Positive symptoms (e.g. hallucinations, delusions) have traditionally been attributed to increased dopaminergic activity in mesolimbic pathways, whereas negative symptoms (e.g. apathy, anhedonia) and cognitive impairment have been attributed to decreased dopaminergic activity in mesocortical pathways.[A264509] Positive symptoms of schizophrenia are more	131986-45-3
ZHCINJQZDFCSEL-CYBMUJFWSA-N	DB21058	Xemilofiban	experimental	nan	Xemilofiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Xemilofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist). Xemilofiban has a monoisotopic molecular weight of 358.16 Da.	149820-74-6
KOHUFVUIYUCFNG-PHDIDXHHSA-N	DB21512	Xeruborbactam	investigational	nan	Xeruborbactam is a small molecule drug. The usage of the INN stem '-bactam' in the name indicates that Xeruborbactam is a ẞ-lactamase inhibitor. Xeruborbactam is under investigation in clinical trial NCT07104162 (A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment). Xeruborbactam has a monoisotopic molecular weight of 222.05 Da.	2170834-63-4
LSXUTRRVVSPWDZ-MKKUMYSQSA-N	DB16305	Xevinapant	investigational	nan	nan	1071992-99-8
HUCJFAOMUPXHDK-UHFFFAOYSA-N	DB06694	Xylometazoline	approved;investigational	R01AB06;R01AA07;S01GA53;S01GA03	Xylometazoline is an imidazoline derivative [A228523] with sympathomimetic and nasal decongestant activity. Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels.[A228508] Xylometazoline is available in over-the-counter (OTC) nasal sprays or drops to temporarily relieve nasal congestion due to cold, hay fever or other respiratory allergies. In some countries, it is available as combination products with [ipratropium], [domiphen], or [d	526-36-3
IYOZTVGMEWJPKR-IJLUTSLNSA-N	DB08756	Y-27632	investigational	nan	Y-27632 is an inhibitor of Rho-associated protein kinase. It inhibits calcium sensitization to affect smooth muscle relaxation.	146986-50-7
VCPMZDWBEWTGNW-UHFFFAOYSA-N	DB12743	Z-160	investigational	nan	Z160 has been used in trials studying the treatment of Postherpetic Neuralgia and Lumbosacral Radiculopathy.	41332-24-5
ORZXYSPOAVJYRU-HOTGVXAUSA-N	DB03535	Z-Pro-Prolinal	experimental	nan	nan	nan
SUUHZYLYARUNIA-YEWWUXTCSA-N	DB07744	Z-Val-Ala-Asp fluoromethyl ketone	experimental	nan	Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which can be used directly with purified enzymes. It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.	161401-82-7
ALBKMJDFBZVHAK-UHFFFAOYSA-N	DB17063	ZK-93423	experimental	nan	ZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.[A253172]	83910-44-5
JSASWRWALCMOQP-UHFFFAOYSA-N	DB17064	ZM-39923	experimental	nan	ZM-39923 is a small molecule that inhibits Janus kinase and human tissue transglutaminase (TGM2).[A253177]	273727-89-2
HGVNLRPZOWWDKD-UHFFFAOYSA-N	DB12904	ZSTK-474	investigational	nan	ZSTK474 has been used in trials studying the treatment of Neoplasms.	475110-96-4
YEEZWCHGZNKEEK-UHFFFAOYSA-N	DB00549	Zafirlukast	approved;investigational	R03DC01	Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mu	107753-78-6
ARAIBEBZBOPLMB-UFGQHTETSA-N	DB00558	Zanamivir	approved;investigational	J05AH01	A guanido-neuraminic acid that is used to inhibit neuraminidase.	139110-80-8
RNOAOAWBMHREKO-QFIPXVFZSA-N	DB15035	Zanubrutinib	approved;investigational	L01EL03	Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.[L10163] Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival.[A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells.[A187985] Compar	1691249-45-2
REZGGXNDEMKIQB-UHFFFAOYSA-N	DB20746	Zaprinast	experimental	nan	Zaprinast is a small molecule drug. Zaprinast has a monoisotopic molecular weight of 271.11 Da.	37762-06-4
HJMQDJPMQIHLPB-UHFFFAOYSA-N	DB02918	Zardaverine	experimental	nan	nan	101975-10-4
SUPVGFZUWFMATN-UHFFFAOYSA-N	DB12638	Zelavespib	investigational	nan	Zelavespib (PU-H71) has been used in trials studying the treatment of LYMPHOMA, Solid Tumors, Metastatic Solid Tumor, and Myeloproliferative Neoplasms (MPN).	873436-91-0
WKTSLVQYGBHNRV-UHFFFAOYSA-N	DB15567	Zelenirstat	investigational	nan	Zelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https://pacylex.com). Current studies have shown that zelenirstat works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.[L9470]	1215011-08-7
AVIWDYSJSPOOAR-LSDHHAIUSA-N	DB18823	Zemirciclib	investigational	nan	nan	2057509-72-3
PRJHEJGMSOBHTO-UHFFFAOYSA-N	DB21710	Zerencotrep	experimental	nan	Zerencotrep is a small molecule drug. The usage of the INN stem '-cotrep' in the name indicates that Zerencotrep is a transient receptor potential canonical channel 5 (TRPC5) antagonist. Zerencotrep has a monoisotopic molecular weight of 524.11 Da.	1628287-16-0
GHYOCDFICYLMRF-UTIIJYGPSA-N	DB16070	Zetomipzomib	investigational	nan	Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).	1629677-75-3
BYPMJBXPNZMNQD-PZJWPPBQSA-N	DB12188	Zicronapine	investigational	nan	Zicronapine has been used in trials studying the treatment of Schizophrenia.	170381-16-5
MWLSOWXNZPKENC-UHFFFAOYSA-N	DB00744	Zileuton	approved;withdrawn	nan	Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the forma	111406-87-2
KPRPFTOLWQQUAV-OCVAFRRMSA-N	DB18152	Zilurgisertib	investigational	nan	nan	2173389-57-4
JKDGKIBAOAFRPJ-ZBINZKHDSA-N	DB15143	Zimlovisertib	investigational	nan	PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).	1817626-54-2
MVWVFYHBGMAFLY-UHFFFAOYSA-N	DB00246	Ziprasidone	approved;investigational	N05AE04	Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generatio	146939-27-7
DZLGSWPXZYDHBD-UHFFFAOYSA-N	DB02112	Zk-806450	experimental	nan	nan	nan
XRASPMIURGNCCH-UHFFFAOYSA-N	DB00399	Zoledronic acid	approved;investigational	M05BB08;M05BA08	Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approv	118072-93-8
BEMNJULZEQTDJY-UHFFFAOYSA-N	DB12903	Zoligratinib	investigational	nan	Ch5183284 has been used in trials studying the treatment of Solid Tumours.	1265229-25-1
ULSDMUVEXKOYBU-ZDUSSCGKSA-N	DB00315	Zolmitriptan	approved;investigational	N02CC03	Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAI	139264-17-8
ZAFYATHCZYHLPB-UHFFFAOYSA-N	DB00425	Zolpidem	approved;investigational	N05CF02	Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA 	82626-48-0
ZXVNMYWKKDOREA-UHFFFAOYSA-N	DB04828	Zomepirac	approved;withdrawn	M01AB04	Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.	33369-31-2
GDXBRVCQGGKXJY-UHFFFAOYSA-N	DB20312	Zoniporide	experimental	nan	Zoniporide is a small molecule drug. The usage of the INN stem '-poride' in the name indicates that Zoniporide is a Na+/H+ antiport inhibitor. Zoniporide has a monoisotopic molecular weight of 320.14 Da.	241800-98-6
UBQNRHZMVUUOMG-UHFFFAOYSA-N	DB00909	Zonisamide	approved;investigational	N03AX15;G01AE10	Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.[L42530,L42535] Zonisamide rep	68291-97-4
BCSVCWVQNOXFGL-UHFFFAOYSA-N	DB08772	Zopolrestat	experimental	nan	nan	110703-94-1
MXDSJQHFFDGFDK-CYBMUJFWSA-N	DB14795	Zorifertinib	investigational	nan	AZD-3759 is under investigation in clinical trial NCT03360929 (Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759).	1626387-80-1
HDOZVRUNCMBHFH-UHFFFAOYSA-N	DB09225	Zotepine	approved;withdrawn	N05AX11	Zotepine, with the formula (2-chloro-11-(2-dimethyl-amino-ethoxy)-dibenzo thiepin, is a neuroleptic drug. It was designed and synthesized by Fujisawa Pharmaceutical Co Ltd.[A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA. In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germ	26615-21-4
VXBAJLGYBMTJCY-NSCUHMNNSA-N	DB16656	Zotiraciclib	investigational	nan	Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).	1204918-72-8
FQPQMJULRZINPV-UHFFFAOYSA-N	DB16502	Zunsemetinib	investigational	nan	ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.	1640282-42-3
RNOYCNIZOAIUSV-LSWMGQQCSA-N	DB04107	[(1-{2[(4-Carbamimidoyl-Phenylamino)-Methyl]-1-Methyl-1h-Benzoimidazol-5-Yl}-Cyclopropyl)-Pyridin-2-Yl-Methyleneaminooxy]-Acetic Acid Ethyl Ester	experimental	nan	nan	nan
QTPYRNAKLBXKNP-SFHVURJKSA-N	DB01858	[1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate	experimental	nan	nan	nan
BBYRUZKRFAIQSR-UHFFFAOYSA-N	DB07546	[1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid	experimental	nan	nan	nan
NWIARQRYIRVYCM-UHFFFAOYSA-N	DB07426	[1-HYDROXY-2-(1,1':3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)	experimental	nan	nan	nan
WATXEHGLYJKXOF-NDEPHWFRSA-N	DB04172	[2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine	experimental	nan	nan	nan
BYVXAUZOTGITQZ-UHFFFAOYSA-N	DB07410	[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID	experimental	nan	nan	nan
WUGJIPFLBOATGL-UHFFFAOYSA-N	DB04006	[2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone	experimental	nan	nan	nan
DYTKVFHLKPDNRW-UHFFFAOYSA-N	DB02833	[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine	experimental	nan	nan	nan
IWJSQELMWLOYSO-LWSSLDFYSA-N	DB06910	[4-R-(4-ALPHA,6-BETA,7-BETA]-HEXAHYDRO-5,6-DI(HYDROXY)-1,3-DI(ALLYL)-4,7-BISPHENYLMETHYL)-2H-1,3-DIAZEPINONE	experimental	nan	nan	nan
IJDQETGUEUJVTB-HNNXBMFYSA-N	DB08424	[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE	experimental	nan	nan	nan
ZKJVCUXZMYKTLT-UHFFFAOYSA-N	DB06927	[5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE	experimental	nan	nan	nan
NXCCIJQEAKMFGW-UHFFFAOYSA-N	DB08406	[N-(2,4-DIAMINOPTERIDIN-6-YL)-METHYL]-DIBENZ[B,F]AZEPINE	experimental	nan	nan	nan
BNMYZGAZFGNKTH-UHFFFAOYSA-N	DB03649	[{(5-Chloro-2-Pyridinyl)Amino} Methylene]-1,1-Bisphosphonate	experimental	nan	nan	nan
WDTMVBQZDFMOIK-GOSISDBHSA-N	DB07263	[{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid	experimental	nan	nan	nan
FMYKJLXRRQTBOR-BZSNNMDCSA-N	DB07558	acetylleucyl-leucyl-norleucinal	experimental	nan	nan	110044-82-1
CAWZRIXWFRFUQB-IOSLPCCCSA-N	DB02596	alpha,beta-Methyleneadenosine 5'-triphosphate	experimental	nan	nan	7292-42-4
KJQOYUHYAZGPIZ-PIJHVLQJSA-N	DB05724	alpha-Conotoxin VC 1.1	experimental	nan	nan	467428-30-4
OHWCAVRRXKJCRB-CXNFULCWSA-N	DB03879	alpha-L-methyl-fucose	experimental	nan	nan	14687-15-1
VFMMPHCGEFXGIP-UHFFFAOYSA-N	DB07453	alpha-Naphthoflavone	experimental	nan	nan	604-59-1
OUGIDAPQYNCXRA-UHFFFAOYSA-N	DB06732	beta-Naphthoflavone	experimental	nan	β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs). It may be a chemopreventive agent.	6051-87-2
SUYVUBYJARFZHO-RRKCRQDMSA-N	DB03222	dATP	experimental	nan	nan	1927-31-7
CXJCGSPAPOTTSF-VURMDHGXSA-N	DB08691	ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate	experimental	nan	nan	nan
BTCSSZJGUNDROE-UHFFFAOYSA-N	DB02530	gamma-Aminobutyric acid	approved;investigational	nan	The most common inhibitory neurotransmitter in the central nervous system.	56-12-2
XVQJTFMKKZBBSX-UHFFFAOYSA-N	DB08165	indane-5-sulfonamide	experimental	nan	nan	nan
VHFVKMTVMIZMIK-UHFFFAOYSA-N	DB12110	m-Chlorophenylpiperazine	investigational	nan	m-Chlorophenylpiperazine has been used in trials studying the treatment of Alcoholism.	6640-24-0
KOBHCUDVWOTEKO-VKHMYHEASA-N	DB02381	nor-NOHA	investigational	nan	N-Hydroxy-nor-L-arginine (nor-NOHA) is under investigation in clinical trial NCT02009527 (Arginase Inhibition in Ischemia-reperfusion Injury).	189302-40-7
NGSWKAQJJWESNS-ZZXKWVIFSA-N	DB04066	p-Coumaric acid	experimental	nan	nan	501-98-4
LMYRWZFENFIFIT-UHFFFAOYSA-N	DB17299	p-Toluenesulfonamide	investigational	L01XX83	nan	70-55-3
PMOWTIHVNWZYFI-AATRIKPKSA-N	DB01650	trans-2-hydroxycinnamic acid	experimental	nan	nan	614-60-8
SUACYXRSGYYBGT-UHFFFAOYSA-N	DB06989	{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID	experimental	nan	nan	nan
BDRDBXXWQDFXEC-UHFFFAOYSA-N	DB08138	{[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide	experimental	nan	nan	nan
BTAGTGWPDROBMG-UHFFFAOYSA-N	DB02651	{[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)	experimental	nan	nan	nan